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1.1 Introduction
Carbohydrates, also referred to as sugars, saccharides or glycans, are the 
most abundant class of organic compounds in nature. They play a key role 
as food source (e.g. sucrose and starch) and are subsequently used in 
metabolic processes such as energy generation and storage. Carbohydrates 
are also important for structural purposes. For example, the rigidity of plants 
is based on the carbohydrate polymer cellulose, and many invertebrates 
have protective shells made of another carbohydrate polymer called chitin. In 
addition, the carbohydrate, (deoxy-)ribose is an integral part of the structural 
framework of DNA and RNA.[1] Essential however for the studies described in 
this thesis, a dense layer of carbohydrates can also be found on the surface 
of almost all cells. There they are often linked to proteins and lipids to form 
so-called glycoconjugates that, among other things,[2] play a vital role in cell-
to-cell interactions, communication processes and protein activity regulation. 
The complex, macromolecular, network of these glycoconjugates and other 
carbohydrate derivatives on the periphery of cells is called the glycocalyx, and 
is actually visible on a microscopic level (Figure 1). The collection of all glycan 
(macro)structures found in an organism is called the glycome and it is thought 
to be involved in, and lie at the root of, many of such crucial biological events. 
An increasing number of studies focuses on the so-called functional 
glycomics, i.e. mapping the glycome and its functions. The glycocalyx, and the 
proteins that interact with it, are at the center of interest in functional glycomics.[4] 
Some concrete examples of such studies are focusing on influenza (the flu) and 
cholera. At the basis of the pathogeneses of these diseases lie carbohydrates, 
found in the glycocalyx, that are recognized and targeted by pathogen-produced 
proteins, which upon binding to the carbohydrates initiate cascades of intracellular 
processes. Although research activities in the field of functional glycomics 
are continuously increasing, much still remains unresolved when it comes to 
Figure 1. Transmission electron microscopy image of the glycocalyx on a bovine aortic epithelial cell. Figure 
adapted from reference.[3]
2 μm
Glycocalyx
Bovine aortic epithelial cell
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the properties and complexity of the glycocalyx and functions of its individual 
elements. The structural complexity of carbohydrates, including their chirality, 
conformation and variable regiochemistry, makes it challenging, however not 
impossible, to investigate their biological roles.[5] In addition, complex carbohydrate 
structures and their patterns on cells are very dynamic and, importantly, not 
encoded in our genome. This makes it difficult to study them via a molecular 
biology approach (e.g. gene knock-out techniques[6] or using green fluorescent 
protein (GFP) fusions[7] for visualization). Hence, this research area is the “turf” 
of the glycochemist, who is able to design and synthesize tailor-made analogues 
of natural carbohydrate constructs so that they can be investigated in detail on a 
smaller scale, while being isolated from interference by other biological processes. 
The overall aim of the research described in this thesis is to investigate the 
interaction of several such tailor-made carbohydrate derivatives with their natural 
protein binding partners, either both completely solubilized or at an interface. 
With these functional glycomics studies, we aim for an improved understanding 
of the nature of these protein-carbohydrate binding events and their relationship 
with the pathogeneses of the associated ailments. A better understanding can in 
turn lead to improved/ cheaper/ faster medical treatments, or detection methods 
in the form of biosensors, based on these same molecules. In line with these 
Figure 2. Glycosphingolipid GM1 consists of a carbohydrate part, a sphingosine and lipid part. It belongs to the 
class of gangliosides, because of the presence of at least one Neu5Ac moiety. Both the chemical spatial and 
widely accepted abstract representation[9, 10] are depicted here and alternately used throughout this thesis.[9]
Carbohydrate
Sphingosine
Lipid
Chemical spatial representation:
Abstract representation:
Neu5Ac
Ceramide
= N-acetyl neuraminic acid (Neu5Ac)
= galactosamine (GalNAc)
= glucose (Glc)
= galactose (Gal)
Ceramide = Sphinghosine + Lipid 
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envisaged applications, the work described in this thesis formed an integral part 
of the Interreg “Unihealth” project[8] that focused on the development of a novel 
type of biosensor for the facile detection of allergens or pathogenic species.
In the following sections, topics will be highlighted that are of particular interest 
for the studies in this thesis. First, a specific group of carbohydrates, gangliosides, 
will be discussed in an attempt to create an understanding on their natural 
purpose and the roles that they play in the pathogenesis of several diseases. 
The tools that are available for glycochemists to make mimics of these natural 
carbohydrates are subsequently discussed. This includes general protective 
group strategies, glycosylations, and chemoenzymatic procedures. To study the 
biological role of the tailor-made carbohydrates, many techniques exist, some of 
them will be discussed in more detail later on in this chapter. Finally, an overview 
is presented of what can be expected in the forthcoming chapters of this thesis.
1.2 Gangliosides
Before introducing the carbohydrate family of the gangliosides it is important to 
briefly discuss the several ways that the structure of carbohydrates are depicted 
in the scientific literature and this thesis. The two most commonly used ways, 
and also in this thesis, are the chemical spatial representation and the more 
abstract representation with colored icons as shown in Figure 2. The latter, 
nowadays widely accepted, abstract representation leaves out a lot of chemical 
and structural information, but does provide a fast overview of the sequence and 
branching of poly-saccharides and oligo-carbohydrates. Herein, the galactose 
(Gal) moieties are depicted as yellow circles, galactosamine (GalNAc) as yellow 
squares, Neu5Ac as purple diamonds and glucose (Glc) as blue circles.[9]
1.2.1 Introduction on gangliosides
In 1942, a specific class of carbohydrate-rich glycosphingolipids was discovered,[11] 
following the isolation of several of these from mammalian brain tissue.[12] This 
subclass of glycosphingolipids, termed gangliosides, was found to typically 
consist of fatty acids, various carbohydrates, and sphingosine (Figure 2). 
Glycosphingolipids are only characterized as gangliosides if they contain 
the carbohydrate N-acetylneuraminic acid (Neu5Ac). When all types of brain 
gangliosides are taken into account they together account for ~ 75% of the brain’s 
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sialic acid content and they represent ~ 80% of the total carbohydrate mass.[13] In 
Figure 2, the ganglioside GM1 is depicted. It contains a pentasaccharide moiety that 
plays an important role throughout this thesis for reasons that will be clarified later.
Svennerholm[14] was the first to separate individual gangliosides by 
chromatography and distinguished several compounds that each contained 
different carbohydrate parts. The gangliosides were separately named 
according to their chromatographic separation (Figure 3). The chemical 
composition was identified by a stepwise acid degradation and isolation of 
the separate ganglioside components.[15] Their nomenclature is now widely 
accepted to begin with a G for ganglioside, followed by an M, D, T, Q, or P 
as a designation of the number of Neu5Ac residues present (one, two three, 
four, or five residues, respectively). In addition, a number was assigned to the 
gangliosides that were known at that time according to their retention on thin 
layer chromatography (TLC) plates. For example, the ganglioside that was 
least retained on the TLC plate was termed GM3, received the “3” for being the 
highest on the plate.[16] The structurally closely related gangliosides GM1, GD1a, 
GD1b, and GT1b represent the majority of the gangliosides in the adult human 
brain, i.e., ~ 97% of all gangliosides (the central four structures in Figure 4).[17]
1.2.2 Natural function of gangliosides
Even though gangliosides have also been isolated from spleen[18] and red 
Figure 3. A reproduction of Svennerholm’s original TLC plate depicting total ganglioside extracts from various 
tissues. Fet = fetal brain, New = newborn brain, T = total, adult human brain, G = grey matter of adult human brain, 
W = white matter of adult human brain, T-S = infantile amaurotic idiocy (=Tay-Sachs disease) brain, and S-V = 
juvenile amaurotic idiocy brain. Solvent: 1-propanol-water, 7 : 3 (v/v). Figure and adapted caption from reference.[16] 
17
C
hapter 1
G
eneral introduction
blood cells,[19] they are mainly characteristic components of nerve cells. For 
most gangliosides, their natural functions have not yet been (fully) determined, 
but by intense research more and more is being discovered about this class 
of glycosphingolipids.[13, 20] One way to investigate their natural function is by 
applying gene knock-out techniques on their biosynthesis machinery. In mouse 
models, genes can be switched off (knocked out) that are specifically responsible 
for the expression of, for example, GalNAc transferases.[13] These specific 
transferases facilitate the enzymatic synthesis of GM2 and GD2, from GM3 and 
GD3, respectively (Figure 4), by adding a GalNAc moiety to the terminal Gal of 
the substrates.[21] The absence of such transferases prevents the formation of the 
more complex, and in adult brains more abundant, four gangliosides GM1, GD1a, 
GD1b, and GT1b. These knockout mice that lack the GalNAc transferase, display 
an unusual amount of unmyelinated fibers in the central nervous system (CNS). 
Myelin serves as a protective sheath on a.o. muscle nerve cells (see Chapter 6 
for additional information on this topic). The absence of this protective sheath 
in the knock-out mice indicates that these gangliosides, GM2 and GD2, are, in 
part, responsible for the formation of it. On a physiological level, this translated to 
the observation that these knockout mice displayed loss of function in the lower 
extremities and loss of coordination. On the contrary, also hyperactivity was noted 
of which the origin was not established, since this could not be directly related to 
loss of motor functions or axon conductivity. This indicates possible additional 
functions of these gangliosides. When additionally also the gene responsible 
for the biosynthesis of GD3 was knocked out, the mice only displayed GM3. 
These “GM3-only mice”, additional to earlier mentioned physiological problems, 
also suffered from seizures and deadly convulsions.[22] Several additional 
such studies were performed to elucidate the natural function of gangliosides 
and taken together, these studies imply that complex brain gangliosides like 
GM1, GD1a, GD1b, and GT1b are required for axon-myelin interactions and 
long-term axon stability.[13] Other crucial functions of gangliosides include cell 
signaling for programmed cell death of white blood cells (GD3),[23] whereas 
specifically GM1 plays a modulatory role in the calcium flux from the cytosol 
to the plasma through non voltage-gated channels.[24] This is however only the 
tip of the ice berg as it comes to the natural roles that gangliosides fulfill.[13, 20] 
Aside from having these roles in healthy cellular functioning, gangliosides are 
also involved in several diseases and play evident roles in their pathogenesis.
18
1.2.3 Gangliosides and disease
Gangliosides play a role in many disrupted metabolic processes. For example, 
ganglioside GM2 (Figure 4) accumulates in the brain of patients suffering 
from Tay-Sachs disease due to a genetic disorder. A mutation in the gene that 
encodes for the enzymes that break down this ganglioside causes a lowered 
expression of this enzyme.[15] This results in abnormally high concentrations of 
the ganglioside in brain nerve cells. Subsequent accumulation in the ganglion 
lysosomes lead to nerve cell swelling and neuron distubances. The disease GM1 
gangliosidosis is quite similar, leading to severe accumulation of GM1 on the 
Figure 4. List of gangliosides and other related glycosphingolipids. The biosyntheses of these compounds 
involve a large array of glycosyltransferases and glycosidases.[25]
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periphery of cells. In many types of cancer, the expression of glycoconjugates, 
including gangliosides, on the cancer cells have been found to change with 
respect to their healthy counterparts. In these cases, the exact constitution of 
these abnormal glycoconjugate levels is often highly specific for each type of 
cancer.[26] As an example, on carcinoma cells the gangliosides GM1 is above-
normally present and therefore more easily recognized by the hemagglutinin of 
influenza viruses, making the patient more susceptible to infection.[27] Influenza A 
virus infections are initiated via hemagglutinin (a glycoprotein that can be found 
on the surface of influenza viruses) that binds to sialylated glycoconjugates 
exposed on the surface of target cells.[28] In this example, rather than the 
toxic effects of ganglioside accumulation, the disease is caused by direct 
gangliosides-targeting by an external pathogen that uses them as recognition 
and binding points. After successful protein-ganglioside recognition and 
binding, the pathogen enters the cell via endocytosis. This type of involvement 
of ganlgiosides in the pathogenesis of a disease is also seen in cholera. 
This disease is initiated by the ingestion of the Vibrio cholerae bacterium (V. 
cholerae). Once in the host, this bacterium generates the cholera toxin (CT) that 
targets intestinal epithelial cells that contain ganglioside GM1 on their periphery. 
CT plays an important role in the research discussed in Chapters 2, 3 and 5.
The gastrointestinal life-threatening disease cholera is one of the main causes 
of death by infectious diseases worldwide. In 2010 alone, almost 320 thousand 
cases of cholera were reported globally, with a little more than 7500 reported 
fatalities.[29] The infections and mortality numbers are, however, known to be 
underreported. Therefore the true total amount of global cases is estimated to 
be 10-fold higher, with around 3-5 million infections per year and around 150.000 
Figure 5. left) CT 3d model; Frontal view; depicting both the toxic CTA and the five CTB units; right) Bottom view 
of the five identical B5-subunits. (PDB: 1XTC)
[35]
]
] CTA
CTB →
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annual mortal cases.[30] Currently, patients affected by cholera are treated via oral 
and intravenous rehydration therapy. Antibiotics are also used in severe cases of 
cholera infection, but growing antibiotic resistance renders the treatment increasingly 
less effective. To this date no medical drug has been submitted for clinical trials, 
making the development of an effective treatment still a highly worthwhile goal.
The CT is a member of the AB5 toxin family, and contains a pentameric 
binding domain[31] (Figure 5). These toxins typically have an enzymatically active 
A subunit (CTA), responsible for inducing toxicity, and a pentavalent toroid-like 
B5 subunit (CTB), responsible for binding to cell surfaces. The natural ligand for 
CT is ganglioside GM1 (Figure 2), which can be found a.o. on the periphery of 
intestinal cells. Lateral mobility of the gangliosides across cell surfaces ensures 
an optimal multivalent binding for the toxin, which results in a strong adhesion 
of the CT molecule to the cell, and subsequent incorporation via endocytosis. 
This is followed by the release of the toxic A-subunit in the cytosol,[32] which 
leads to a cascade of biological processes.[33] At the end of the line, this cascade 
induces the efflux of water from the patients intestinal epithelial cells than in turn 
causes violent diarrhoea and associated severe dehydration. Preventing these 
events by capturing the toxin in the intestines would seem to be a logical way 
of cholera treatment. Natural ganglioside GM1 is however not applicable as 
such an inhibitory drug for the treatment of toxins like CT, because exogenous 
gangliosides are readily integrated in cell membranes and thereby become 
functional components thereof. This occurrence can turn cells that were initially 
unaffected by CT into more susceptible targets for the toxic agent.[34] To avoid 
this, the GM1os should be connected to an appropriately designed synthetic 
scaffold. Some examples on how the GM1os can be presented to toxins when 
attached to such a scaffold are discussed in §1.3 and in Chapters 2 and 3 of 
this thesis. Additional research regarding the binding affinity of CTB towards a 
couple of novel carbohydrate-presenting compounds is discussed in Chapter 5.
Several neurodegenerative diseases also involve gangliosides.[36] Amongst 
others, these include: amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, 
multiple sclerosis (MS), and Guillain-Barré syndrome (GBS). GBS is also initiated 
by the ingestion of a pathogen, like in the case of cholera. However, rather than the 
pathogen itself causing the pathogenesis by targeting cell surface glycans, in GBS, 
the pathogen displays glycans that resemble carbohydrates that are also displayed 
on the cell surface of human nerve cells. These glycans, presented on the bacterial 
cell wall, resemble and mimic gangliosides.[37] This phenomenon is called molecular 
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mimicry. When the patient’s immune system forms antibodies (Abs) that target the 
carbohydrate moieties that are displayed on the pathogen, these Abs will also 
target the similar ganglioside epitopes that reside on the patient’s nerve cells. As 
a result, an auto-immune response is imminent. A more extensive discussion on 
the pathogenesis of GBS will be discussed in Chapter 6. In order to investigate 
the pathogenesis of abovementioned diseases, and eventually to understand it at 
a molecular level, carbohydrate structures are needed that resemble the targeted 
gangliosides. These can be extracted from natural sources. However, natural sources 
have the disadvantage that the yield is low, purification processes are long and 
difficult (hence, expensive) and that the obtained products are still potentially (and 
in practice: regularly) contaminated with other compounds. In contrast, chemically 
synthesized compounds can be obtained completely pure in higher quantities, 
and if desired the synthetic route – in this case mainly involving carbohydrate 
chemistry – can be used to incorporate tailor-made modifications in their structure.
1.3 Carbohydrate chemistry
1.3.1 Glycosylations, glycosyl donors and protective groups
In order to investigate protein-cell or cell-cell interactions, synthetic analogues of 
the signaling carbohydrates that reside on the cell surface need to be developed. 
A glycochemist has ample choice of numerous glycosylation reactions. An 
efficient protective group strategy that is compatible with the glycosylation 
conditions is essential. In addition, various stereo-electronic effects that are 
intrinsic for carbohydrates need to be taken into account. An additional challenge 
in carbohydrate chemistry is that for a standard pyranoside, e.g. galactose, 
five reactive hydroxyl groups are presented with nearly equal reactivity. Only 
due to small effects – involving charge differences, the anomeric effect, axial 
or equatorial orientation, or the reactivity difference between primary and 
secondary hydroxyl functionalities – one can discriminate between these 
various sites (Figure 6). In order to work with compounds that display so many 
reactive groups in close proximity of one another, it is imperative to keep in mind 
the compatibility of the various protective groups and glycosylation conditions.
Over the years, many fine reviews have been published regarding glycosylation 
reactions.[38] Among the most used glycosyl donors belong the trichloroacetimidates, 
also called Schmidt imidates (Compound 1, Scheme 1),[39] which are synthesized by 
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reacting a pyranosie hemiacetal with tricholoracetonitrile. In general, nucleophiles 
of various reactivity react with these imidates in the presence of Lewis acids such as 
equimolar BF3·OEt2 or catalytic TMSOTf. Other well-known glycosyl donors include 
thioglycosides (2),[41] phosphates (3),[42] sulfoxides (4),[43] and pentyl glycosides (5).
[44] The thioglycosides (2) can be conveniently activated in at least two different ways. 
The first is a “two-step” activation, which involves first forming a glycosyl halide, 
and then activating this with a halophilic reagent. The second route, which is most 
Scheme 1. Common glycosyl donors and typical reactants used in their glycosylation with a nucleophilic alcohol 
acceptor (R-OH). See text for references.
Figure 6. Various stereo-electronic anomeric effects and physical aspects that help to distinguish between the 
quite similar reactive functionalities on carbohydrates; A) Lone-pair donation to αC-1 σ*; B)  Dipole moment; C) 
carbohydrate pyranosides consist generally of five reactive hydroxyl sites (glycosamines not taken into account) 
with slightly different reactivities.
A)
B)
C)
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commonly used nowadays, involves a one-step activation with a thiophilic reagent 
such as methyl trifluoromethanesulfonate (methyl triflate) or dimethyl(methylthio)
sulfonium trifluoromethanesulfonate (DMTST).[45] Per-acetyl 6 is a substrate for 
SnCl4-promoted glycosylation.
[40] Although the C-1 is equipped with a generally 
stable acetyl protective group, reactions with relatively low nucleophilic alcohols 
can still be performed due to the chemical distinction of the anomeric position. This 
reactivity can be ascribed to the anomeric effect(s) that are depicted in Figure 6. 
Possibly the oldest type of glycosyl donors are the glycosyl halides. Especially, 
C-1 chlorides (7) and bromides have been extensively used in Koenings-Knorr-
type glycosylations.[46] Also glycosyl iodides (8) have received a lot of attention 
in literature and are also used on several occasions in experiments described in 
this thesis. Scheme 2A shows a proposed mechanism for the formation of iodide 
donor 13.[47] The reaction may proceed via oxonium intermediates 11a - 11d, in 
which an iodine anion reacts as a nucleophile on the empty p-orbital on the 
anomeric position. This leads after equilibration to the desired α-iodo glycoside. 
Scheme 2. A) Mechanism for the stereoselective formation of glycosyl iodides by Gervay et al.[47] B) Proposed 
alternative, concerted mechanism (only shown for the β-acetate). 
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1.3.2 Protective groups 
Successful glycosylation reactions hinge on using the correct protective group 
strategy. Several good reviews have been published on this topic.[48] In glycosylation 
reactions with glycosidic halides, several nucleophilic reactions can take place. This 
may especially require attention when protective groups are used that stimulate 
anchimeric assistance, a.k.a. neigboring group participation. In the reaction of 
iodides with alcohols, the β-product is formed by either the SN2-type mechanism 
or by the SN1-type mechanism (Scheme 3A and B, respectively), wheras the 
α-product is only formed in the SN1-type reaction. In the case of a SN2 mechanism, 
the nucleophilic alcohol displaces the still intact C-I bond resulting in a new β-acetal 
bond, and iodine acts as the leaving group. Iodine promotes the SN1 reaction
[46b] 
when it is used as reactant (Lewis acid). It coordinates to the α-iodide and the 
subsequent dissociation of triiodide (I3
-) leads to the formation of an oxocarbenium 
ion (Scheme 3B, 18). This reaction is feasible because of mesomeric stabilization 
of the resulting carbocation with one of the oxygen lone-pairs. A nucleophilic 
reaction of the alcohol at the anomeric centre can now occur from both the axial 
or equatorial position, leading to α-product 20, or β-product 16, respectively.
In this reaction, also the choice of a suitable solvent is of importance to form 
the desired β-product, since polar protic solvents favor SN1, and polar aprotic 
favor SN2 reactions.
[49] In addition, when acetonitrile is used as solvent, another 
stereo-electronic effect plays an important role, and a stereoselective yield of the 
β-product is observed (Scheme 3C).[39c, 50] The solvent participation effect that 
is shown here, involves acetonitrile coordinating to the glycosyl C-1 α-position, 
effectively blocking that side for nucleophilic reaction in favor of β-product 
formation. On occasion, also C-2 deprotected glycosides are observed. In that 
case, the acetyl group on C-2 participates in the glycosylation reaction (Scheme 
3D). This C-2 anchimeric assistance works via an additional stabilization of 
oxocarbenium ion 23, which is also in equilibrium with its oxonium ion, like 
galactoside-equivalent oxocarbenium ion 18. The carbonyl oxygen lone pair of 
the C-2 acetyl protecting group interacts with the empty p-orbital at C-1, and only 
the α-position is within reach of the acetyl carbonyl. The resulting dioxolenium 
ion 24 is then prone to nucleophilic reaction with the alcohol, in two ways. First, 
direct glycosylation (Scheme 3D, route a) on the activated C-1 leading to the 
septa-O-Ac-protected β-product. Second (route b), the dioxolenium ion reacts 
with the nucleophile to form an orthoester.[51] Once the unstable orthoester is 
25
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Scheme 3. Glycosylation of α-iodo-glycosides with alcohols via A) SN2-type and B) SN1-type mechanisms,[46b] 
C) β-directing acetonitrile solvent participation,[39c, 50] and D) neighboring group-participation;[50] *route a leads to 
11-azido undecyl 2,3,4,6-tetra-O-acetyl-β-d-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-d-glucopyranoside (not 
shown) and could be considered an SN2-type mechanism.
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formed, the C-1 oxygen is displaced, deprotecting the C-2 alcohol (compound 
26), while the methyl ester 27 is expelled as byproduct. A second nucleophilic 
reaction leads to the anomeric mixture of hexa-O-acetate compound 28.
Acetyl (Ac) esters are possibly one of the most used protective groups for 
hydroxyls in carbohydrate chemistry together with benzyl (Bn) ethers. As shown 
in the previous example, an advantage of the acetyl group is that in some cases 
it also facilitates the anchimeric effect that can aid in the stereoselectivity of 
reactions. The acetyl group is base labile, and can withstand most other reaction 
conditions, including hydrogenations and mild acids.[52] The more sterically 
demanding pivaloyl (trimethylacetyl) group is even more stable than the acetyl 
group and also relatively easy to attach,[53] however, it sometimes suffers from the 
disadvantage of requiring long or harsh deprotection conditions, which may affect 
other functionalities in the compound.[54]
In an effort to distinguish between the secondary C-4 hydroxyl and the primary 
C-6 hydroxyl, acetal groups are often used in carbohydrate chemistry (Scheme 
4). Benzylidene acetals can be regioselectively opened depending on the reaction 
conditions, leading to the 4-OBn, 6-OH (compound 30)[55] or 4-OH, 6-OBn 
(compound 31)[56] glycosides.[57] The benzyl group is able to withstand both basic 
and acidic conditions and is generally cleaved by hydrogenation with catalytic Pd/C 
and hydrogen gas. As an alternative for the benzyl groups, p-methoxy benzyl is 
often employed.[58] The electron-deficient DDQ facilitates the mild deprotection of 
PMB-ethers[59] by a mechanism of multiple single electron transfers (SET) (Scheme 
5).[5] In addition, 4,6-PMB acetals can undergo regioselective ring-opening 
reactions, with NaCNBH3, similar to those described for benzylidene acetals.
[56, 58] 
This is especially useful in strategies wherein hydrogenations are unwanted, for 
example, when an azide is present in the carbohydrate and it needs to remain intact.
A different approach to carbohydrate synthesis, that also avoids protective 
groups, is to use enzymatic procedures. A fine example of (chemo)enzymatic 
synthesis of carbohydrates, or more specifically, ganglioside analogues, is 
shown in Scheme 6.[60] Ganglioside analogues 34 - 36. were synthesized by our 
group starting from acetyl protection of lactose by acetic anhydride in pyridine, 
followed by selective Lewis acid-mediated glycosylation on the lactoside C-1 
with 11-azido-undecan-1-ol. Subsequent deacetylation according to the Zemplén 
procedure[61] resulted in lactoside 33 (Scheme 6, i - iv). Next, the unprotected 
lactoside was exposed to a cascade of enzymes in which the corresponding 
transferases added the Neu5Ac, GalNAc, and terminal Gal-units, respectively. 
With this procedure, our lab acquired the ganglioside analogues that present the 
oligosaccharides of gangliosides GM3, GM2, and GM1. The azide functionality 
was required to allow for subsequent immobilizations on soluble platforms 
and surfaces. These compounds were then subjected to experiments in 
which they functioned as substrates for pathogen and antibody (Ab) detection.
1.4 Synthetic carbohydrate derivatives in pathogen detection
The focus of the studies that are described in this thesis was mainly directed 
to the interaction that proteins display with synthesized carbohydrates that 
are analogues of naturally occurring structures. One reoccurring topic is the 
interaction of the complementary set of cholera toxin and its natural substrate 
ganglioside GM1. The adhesion of CTB to GM1os on cell surfaces is the 
prerequisite for the endocytosis of CTA, and the subsequent pathogenic biological 
Scheme 5. Single electron transfer mechanism for the deprotection of PMB-ether protected carbohydrates. 
Scheme reproduced from reference.[5]
Scheme 4. Reaction conditions for the stereoselective ring opening of glycosylic 4,6-benzylidene acetals.
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groups, is to use enzymatic procedures. A fine example of (chemo)enzymatic 
synthesis of carbohydrates, or more specifically, ganglioside analogues, is 
shown in Scheme 6.[60] Ganglioside analogues 34 - 36. were synthesized by our 
group starting from acetyl protection of lactose by acetic anhydride in pyridine, 
followed by selective Lewis acid-mediated glycosylation on the lactoside C-1 
with 11-azido-undecan-1-ol. Subsequent deacetylation according to the Zemplén 
procedure[61] resulted in lactoside 33 (Scheme 6, i - iv). Next, the unprotected 
lactoside was exposed to a cascade of enzymes in which the corresponding 
transferases added the Neu5Ac, GalNAc, and terminal Gal-units, respectively. 
With this procedure, our lab acquired the ganglioside analogues that present the 
oligosaccharides of gangliosides GM3, GM2, and GM1. The azide functionality 
was required to allow for subsequent immobilizations on soluble platforms 
and surfaces. These compounds were then subjected to experiments in 
which they functioned as substrates for pathogen and antibody (Ab) detection.
1.4 Synthetic carbohydrate derivatives in pathogen detection
The focus of the studies that are described in this thesis was mainly directed 
to the interaction that proteins display with synthesized carbohydrates that 
are analogues of naturally occurring structures. One reoccurring topic is the 
interaction of the complementary set of cholera toxin and its natural substrate 
ganglioside GM1. The adhesion of CTB to GM1os on cell surfaces is the 
prerequisite for the endocytosis of CTA, and the subsequent pathogenic biological 
Scheme 5. Single electron transfer mechanism for the deprotection of PMB-ether protected carbohydrates. 
Scheme reproduced from reference.[5]
Scheme 4. Reaction conditions for the stereoselective ring opening of glycosylic 4,6-benzylidene acetals.
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cascade. To stop the pathogenesis in an early stage, several studies have been 
focused on the synthesis of new multivalent glycosylated ligands,[62] based on 
the ganglioside GM1 pentasaccharide, which can act as inhibitor by binding to 
CTB with high affinity. Both natural GM1os-containing derivatives and synthetic 
Scheme 6. Chemoenzymatic synthesis procedure for ganglioside oligosaccharides; i) Ac2O, NaOAc, Δ, 4 h; 
ii) azido-undecan-1-ol, SnCl4, DCM, rt, overnight; iii) BF3·Et2O in dry CH2Cl2, 0 °C → rt, overnight; iv) NaOMe, 
MeOH, rt, overnight.[60]
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GM1os analogues were used as inhibitor building blocks. In 1997, Thompson 
and Schengrund described dendritic structures that were functionalized with 
the GM1os, which lacked the glucose in its pyranose-form (Compound 37, 
Figure 7A).[63] With chemiluminiscent enzyme-linked immunosorbent assay 
(ELISA) experiments (for more information on ELISA see §1.5 of this Chapter), 
it was shown that IC50-values for the tetra- and octavalent dendrimers are 7 and 
3 nM, respectively. The IC50 value for the GM1os is reported to be 10 µM.
[64]
Two years later, Bernardi et al.[65] published a series of GM1-mimics (pseudo-
GM1) that present at the same time a good affinity for CTB and a simpler structure 
compared to the complex natural pentasaccharide of ganglioside GM1. The 
two-finger appearance of GM1os that in the natural occurring ganglioside is the 
combination of the terminal Gal and Neu5Ac units – which can be visualized as the 
index-finger and the thumb, respectively – is maintained in Bernardi’s pseudo-GM1 
derivatives. The terminal Gal- and the Neu5Ac-units were also identified as the major 
contributors to the binding of CT.[66] The Neu5Ac-unit, however was substituted by 
a much simpler structure, which gets around the very labor-intensive synthesis of 
the GM1 pentasaccharide,[67] or the low-yielding isolation from natural sources, and 
gives ample possibility for modification. Additionally, it makes these compounds 
accessible on a multigram scale. These mimics showed good affinity for CT, with 
dissociation constants (Kd) ranging from 190 to 10 µM, which are noteworthy 
especially in comparison to simple sugars such as galactose and lactose (Kd = 
40 and 81 mM, respectively).[64] Whereas the ganglioside GM1 oligosaccharide 
is reported to have a Kd of 43 nM.
[68] When combining these GM1 mimics with a 
multivalent presentation, a further enhancement in binding affinity was achieved. 
This was performed by connecting the pseudo-GM1 to di- or tetra-valent and 
octavalent dendritic structures,[69] and a calix[4]arene scaffold[70] (Figure 7B). The 
tetravalent dendrimer showed the best multivalency effect and an 442-fold enhanced 
binding with respect to a monovalent reference compound. Spectrofluorimetric 
analyses showed up to 4000-fold enhancement in the complexation efficiency for 
the multivalent calix[4]arene ligands compared to the monovalent pseudo-GM1.
Together with our group, Pieters reported the synthesis and the biological 
application of a series of highly effective inhibitors of CTB by using the authentic 
ganglioside GM1 pentasaccharides linked to a multivalent core (Figure 7C).[71] 
The potency of these dendritic compounds to be bound by CT was evaluated 
with ELISA experiments. The combined effect of the high binding efficiency of the 
single ligand and synergetic the multivalency effect led to inhibitors that showed 
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unprecedented high affinities. While the monovalent derivative, which was used 
as reference, showed an IC50 in the micromolar range (19 µM), the octavalent 
derivative (39) exhibited a record-low IC50-value of only 50 pM. It showed 
Figure 7. GM1os-based multivalent CTB inhibitors. See text for references.
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therefore to be 47,500-fold more potent per GM1os unit, than the monovalent 
GM1os. The tetravalent variant of compound 39 was later also successfully 
employed in GBS-related anti-ganglioside antibody binding studies.[72]
1.5 Biological binding assays with synthetic carbohydrates
Biological assays that we performed and discuss in this thesis typically refer 
to ELISA experiments. This is one way to investigate, on a molecular level, 
the pathogenesis of a disease by mimicking protein-cell interactions. Other 
techniques include, surface plasmon resonance (SPR), which is a label-
free diagnostic tool based on the variations in the surface resonance of gold-
plated chips upon the binding of a protein to antigens on the chip;[73] Western 
Blot,[74] which is a gel-based electrophoresis technique for the separation of 
proteins; and isothermal calorimetry (ITC),[75] which measures the enthalpic 
changes and equilibrium constants relevant for protein-antigen or protein-
protein binding. We limit ourselves to ELISA experiments as biological assays, 
because this is currently still the most widely used technique to measure 
binding affinity for the specific target proteins that are crucial in our research. 
An ELISA is typically performed on a 96 wells microtiter plate.[76] To be 
measured, compounds can be attached to the plates by hydrophobic interactions, 
on hydrophobic microtiter plates, or covalently on plates. An adapted version 
of “indirect ELISA” that was used on several occasions in our research has 
previously been described (Scheme 7A).[72] The indirect ELISA involves a target 
substrate (also called an antigen), in our case a carbohydrate, that is coated on 
the surface of a microtiter plate. For the covalent immobilization of antigens, 
ester-terminated microtiter plates were coated with propargylamine in the 
presence of a buffered solution. Azido-terminated carbohydrates could then be 
attached to the alkyne-terminated microtiter plates via copper-catalyzed azide-
alkyne cycloaddtion (CuAAC) reactions. This was followed by a blocking step 
to prevent aspecific adsorption of biomaterials to unreacted free sites on the 
surface of the ELISA plates. A typical protein that is used for such purposes 
is bovine serum albumin (BSA). Blocking allows for a higher signal-to-noise 
ratio by preventing aspecific adsorption to the surface of solvated elements in 
the test solution. Then, the protein, for example a toxin or an Ab, is added in 
solution to the carbohydrate monolayer. A washing step removes all compounds 
that are not attached and the ganglioside-protein complexes remain on the 
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surface. The following step requires a secondary antibody that recognizes the 
first antibody and carries a protein that is able to catalyze coloring reactions. 
An example of such a protein is horseradish peroxidase (HRP).[77] But, other 
systems exist that involve fluorescence, chemiluminiscence, and radioactivity. 
The coloring reaction is started by addition of a substrate that changes color 
by HRP-mediated oxidation. The optical density (OD) of the coloration is then 
measured. The OD is a measure for the amount of primary protein present 
on the plate. By performing binding experiments with various concentrations 
of the antigen (or the protein) across the plate, it is possible to obtain a 
binding curve, which is indicative to the protein-ganglioside binding potential. 
For a so-called direct ELISA, or “sandwich” ELISA (Scheme 7B), the roles of 
the antigen (ganglioside) and the protein are inverted. In first instance, the protein 
is coated on the surface of the microtiter plate via hydrophobic interactions, after 
which the antigen is added that binds the protein on the surface. A specific primary 
antibody is then added that “sandwiches” the antigen.
A third type of ELISA experiment is based on competition. As an example, 
the graphical representation of our competition experiments that are 
described in Chapter 3 is depicted here (Scheme 7C). It must be noted that 
technically this type of test is called enzyme-linked lectin assay (ELLA) since 
it involves interactions between carbohydrates and lectins rather than between 
carbohydrates and Abs. Nevertheless, the principle is the same. In this case, the 
native ganglioside GM1 is coated hydrophobically on a microtiter plate. The test 
antigen (GM1os-calix[5]arene) is allowed to bind with the target protein (CTB) 
in separate vials. Subsequently, the protein-antigen mixtures are added to the 
microtiter plate and the natural and synthetic antigens are allowed to compete 
for inhibition of the protein. After removing the materials that are not bound to 
the surface, a coloring substrate is added to start the oxidation reaction. Intense 
coloration indicates the presence of a high amount of CTB on the surface i.e. 
low inhibition of the test antigen, and low coloration less CTB and high inhibition.
1.6 Outline of this thesis
The main focus of this thesis is the rational design and synthesis of carbohydrates 
that resemble natural gangliosides for the purpose of studying protein-cell 
interactions in vitro. In Chapters 2 and 3, we describe ganglioside analogues 
that display the GM1os on pentavalent platforms. We test their inhibitory potency 
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towards the “equi-valent” CTB protein. In these studies we employ the highly 
effective CuAAC reaction. Since copper has, apart from its catalytic function 
in CuAAC, also detrimental biological effects, copper-free click reactions are 
of interest. Therefore, Chapter 4 deals with strain-promoted azide-alkyne 
cycloaddition (SPAAC) reactions. In an investigation on the reactivity of the various 
SPAAC substrates that are nowadays developed, we employed computational 
chemistry to find a calculable unit that predicts the reactivity of these compounds. 
SPAAC continues to be a topic in the study presented in Chapter 5, where it is 
used in parallel to CuAAC reactions in a direct comparison of their efficiency in 
immobilizing GM1os on ELISA microtiter plates. In addition, Chapter 5 describes 
the effect of residual copper from CuAAC on the carbohydrate-CTB binding 
Scheme 7. Graphical representation of A) Indirect ELISA; B) Direct “sandwich” ELISA; C) Competitive ELISA 
experiment.
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affinity. In Chapter 6, we then describe the design and synthesis of a small library 
of glycan fragments based on the GM1os epitope of GBS-associated antibodies. 
This library is immobilized on microtiter plates via the CuAAC reaction and then 
used in subsequent ELISA experiments to detect various GBS-related anti-
ganglioside Abs in patient sera. Chapter 7 provides a general discussion and future 
prospects on the research that is described in this thesis. Chapter 8 concludes 
with an extensive scientific summary in English and in the Dutch language.
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Abstract:
Eight symmetric and pentavalent corannulene derivatives were functionalized with 
galactose and the ganglioside GM1-oligosaccharide via copper-catalyzed alkyne-
azide cycloaddition reactions. The compounds were evaluated for their ability to 
inhibit the binding of the pentavalent cholera toxin to its natural ligand, ganglioside 
GM1. In this assay, all ganglioside GM1os-sym-corannulenes proved highly potent 
nanomolar inhibitors of cholera toxin.
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2.1 Introduction
The World Health Organization (WHO) estimates that annually 3-5 million people 
worldwide are infected with cholera, resulting in over a hundred thousand fatalities.[1] 
The responsible pathogen, the Vibrio cholerae bacterium, produces the cholera 
toxin (CT) protein that is responsible for the severe clinical symptoms. CT belongs 
to the protein family of AB5 bacterial toxins.
[2] The structure and activity of CT and 
other AB5 toxins have been investigated in detail.
[3] These proteins consist of two 
distinct domains with different roles. The A-subunit is an enzyme that – when 
delivered inside a host cell – is toxic and responsible for the subsequent disease 
symptoms. The cholera toxin B-subunit (CTB) is a lectin and plays a crucial role 
in the recognition and interaction with its natural ligand, ganglioside GM1 (Figure 
1a) on the periphery of intestinal cells. The crystal structure of CT[4] shows that 
the protein complex consists of five identical monomeric CTB subunits, arranged 
Figure 1. a) Structure of CTB’s natural ligand, ganglioside GM1; b) Structure of the pentavalent GM1os-
functionalized sym-corannulene, a nanomolar inhibitor of cholera toxin.
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in a pentagonal symmetry, and each of these subunits can bind the ganglioside 
GM1 in a one-to-one stoichiometry. Detailed colorimetric studies revealed that CT 
exhibits allosteric cooperativity,[5] which contributes to increasingly higher binding 
affinities to CT when more ligands are bound.[6]
One of the possible approaches for the design of CT inhibitors aims to 
prevent the receptor-recognition process.[7] Two major routes can be discerned 
in the literature to achieve this goal. The first strategy, monovalent receptor-
binding approach, focuses on strong binding interactions, and it is based on 
the design and synthesis of ligands that closely mimic the natural ligand on the 
cell surface[8] in order to obtain a strong interaction with the CTB receptor. The 
second approach, multivalent receptor-binding,[9] exploiting chelate cooperativity, 
takes advantage of the pentavalent character of the ligand-binding sites of CT. 
This approach is based on the synthesis of a functionalized branched system, in 
which each branch carries a single-site inhibitor, like galactose[10,11] or lactose,[12] 
leading to a compound that has an overall stronger interaction with the toxin 
than the sum of the independent inhibitors. The synthesis of dendritic multivalent 
inhibitors, functionalized with the GM1os, has been reported,[13] these displayed 
unprecedented high inhibitory potencies for CTB, in picomolar range.
An important improvement in the design of multivalent binders was achieved 
with symmetrical pentameric molecules based on the concept of “finger-linker-
core” systems:[12] the pentavalent “core” is connected by flexible “linkers” to 
“fingers” that include the monovalent receptor-binding ligand. Pentavalent CT 
inhibitors were synthesized using various “cores”: acylated pentacyclen,[12a] large 
cyclic peptide[12e] and calix[5]arene.[14]
This Chapter details a study that combines the two strategies to obtain an 
optimal binding by the design and synthesis of pentavalent GM1os-presenting 
compounds based on a 5-fold symmetrical sym-substituted[15] corannulene 
scaffold (Figure 1b). Binding assays allowed the determination of the interaction 
with CTB (the protein complex without the toxic A part) for these and analogous 
pentavalent galactose corannulenes. This revealed a high inhibitory potency 
towards CTB by this new class of inhibitors.
2.2 Results and Discussion
Apart from its obvious 5-fold symmetry, the corannulene scaffold is a good 
candidate to function as the “core” of pentavalent receptor-binding inhibitors for 
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AB5 toxins on the basis of the following observations: the recent development of a 
kilogram-scale synthesis of corannulene (1),[16] its further functionalization to sym-
pentachloro-corannulene (2),[17] and the growing number of robust and flexible 
procedures for the preparation of molecular pentapods displaying functional 
groups and bioconjugated moieties, by iron-catalyzed[18] cross-coupling and
Scheme 2 Synthesis of azido-linked galactoside 14. i) HgBr2, DCM, rt, 3 d; ii) (1) MeONa, MeOH, rt, 
48 h; (2) DOWEX-H+.
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Scheme 1. Synthesis route of the corannulene core and ethylene glycol spacers; i) ICl, DCM, rt, 72 h; ii) 
(1) Fe(acac)3, 1-bromo-4-trimethylsilyl-3-butyne, THF-NMP, rt, 2.5 h; (2) NaOH, MeOH-H2O, rt, 24 h; iii) Cu 
nanoparticles, DMF, microwave, 60 °C, 2 h; iv) TBAF, THF, rt, 2 h.
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Scheme 3. Microwave-assisted CuAAC-based synthesis of penta-galactose corannulenes; i) 14, Cu 
nanoparticles, DMF, microwave, 80 °C, 2 h.
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copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction.
The synthetic pathway towards PEG-corannulene systems starts from the 
conjugation of the terminal acetylene 3[18] by an efficient copper nanoparticle-
catalyzed CuAAC reaction with n-mers of α-azidoethyl-ω-propargyl diglyme (n 
= 1, 2, 4) (Figure S1 Appendix II).[19] This route gave satisfactory results for the 
preparation of other sym-bioconjugated corannulenes, and was used here to 
prepare the five-fold symmetric compounds 5, 6 and 7 in good yield and purity. The 
PEG arms function as linkers of different lengths and improve water solubility and 
flexibility of the inhibitor. The terminal TIPS-protected acetylenes were deprotected 
by reaction with TBAF[19] yielding the alkyne-terminated PEG-corannulenes 8, 
9 and 10 (Scheme 1). After preparing the three PEG-corannulenes the focus 
shifted to attaching the (oligo)saccharides. In this work, two different CTB binders 
were used: galactose, an easily obtainable but quite poor binder of CTB, and the 
oligosaccharide of ganglioside GM1 (GM1os), the natural ligand of CTB. In order 
to introduce the galactose-based “finger” to the terminal acetylenes 3, 8, 9 and 10, 
galactoside 11 was functionalized at the anomeric position with a short PEG chain 
that bears an azido group (compound 12, Scheme 2). An analogous compound 
without ethylene oxide moieties belonging to this inhibitor family was previously 
synthesized[18] by CuAAC reaction on the terminal acetylene 3 and 2-azidoethyl-
β-D-galactopyranoside.[20,21] The synthetic pathway for the synthesis of azido-
PEG-galactoside 14 starts with a Koenigs-Knorr-type glycosylation of azido-PEG 
hydroxide 12[22,23] with peracetylated galactosyl bromide 11 to afford β-galactoside 
13. The deprotected compound 14 was then obtained by treatment of 13 with 
sodium methoxide. The pentavalent Gal-functionalized sym-corannulene inhibitor 
was prepared in good yield by employing the microwave-assisted CuAAC reaction 
on the terminal acetylenes 3, 8, 9 and 10 with the azido galactose derivative 
14 affording the four galactose-based CTB inhibitors 15 - 18 (Scheme 3). 
The second family of pentavalent inhibitors displays five GM1os moieties 
(Scheme 4). The chemo-enzymatic synthesis from lactose of the azide-
terminated GM1os oligosaccharide was previously reported.[24] The pentavalent 
GM1os inhibitors 20, 21 and 22 were synthesized, in the presence of copper 
nanoparticles, by microwave-assisted CuAAC reaction of azido-pentasaccharide 
19 with the terminal acetylenes 8, 9 and 10. Because of the low solubility of the 
GM1 analog in DMF, the reactions were performed in water, allowing a complete 
dissolution of 19 in the reaction media. The inhibitory efficiency of the synthesized 
five-fold symmetric pentavalent CT ligands (15 - 18 and 20 - 22) was evaluated 
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by an enzyme-linked lectin assay experiment (ELLA) on 96-well plates.[25,26] 
Solubility issues at concentrations > 1 mM limited the experiments intended to 
find an IC50-value for galactose-based compounds 15 - 18. When compared 
to previously reported IC50-values for multivalent ligands functionalized with 
galactose,[10,11] these concentrations should not have been limiting. One hypothesis 
to account for this observation is that the supramolecular aggregation competes 
against binding to the pentad-complex. 
Further investigations by 1H NMR, UV-Vis and fluorescence spectroscopy on the 
properties of C5-symmetric galactose conjugated corannulene in aqueous solution 
suggest the formation of supramolecular aggregates of this amphiphilic molecule 
in water. If the formation of the supramolecular assemblies is thermodynamically 
and kinetically favored over the interaction with the CTB, the competition of 
these two processes might be a plausible explanation for the unexpected results 
obtained from the ELLA experiment; however, the GM1os-PEG-corannulenes 
showed high, nanomolar inhibitory potencies (Figure 2; Table 1). 
The pentavalent GM1os-functionalized inhibitors, 20, 21, and 22, bind CTB 
at lower IC50 values than monomeric GM1os (cf. Table 1). The lowest IC50 value 
measured is for 21 (Table 1, entry 2) with an inhibition potency that is nearly 4000 
times stronger than that of monomeric GM1os.[12f] The lower binding affinity for 
CTB by compounds 20 and 22 (Table 1, entries 1 and 3) is most probably due to 
the effects related to the linker length: if the linker is not long enough (compound 
20), not all of the five ligands can simultaneously bind the five binding sites of 
Figure 2. Fitted inhibition curves of compounds ● GM1os-PEG3 corannulene 20, ■ GM1os-PEG6 corannulene 
21, and ◘ GM1os-PEG12 corannulene 22.
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CTB. In the opposite case (i.e. compound 22), binding would lead to a substantial 
ordering in the chain, making it entropically less favorable, while enthalpically the 
necessary folding of the longer linkers to enable binding of CTB by the GM1os 
fingers might create sufficient steric hindrance to cause an increased IC50 value. A 
further complicating factor is the possibility that galactose and GM1os derivatives 
undergo supramolecular self-aggregation that competes with binding to CTB and 
results in apparent higher inhibitory concentrations. 
Caveats notwithstanding, compound 21 is as of yet one of the strongest 
multivalent CT inhibitors,[22,27] and displays the power of combining the natural 
valency with the natural ganglioside to reach optimal blocking of multivalent 
lectins. Design efforts to create systems that optimize spacer geometry and avoid 
self complexation will likely lead to new derivatives with inhibitory concentrations 
more favorably comparable to other previously reported GM1os-based inhibitors.
Table 1. Inhibitory potency of pentavalent GM1os-functionalized ligands towards CTB
Entry Compound IC50 (nM) RIP
a 
1 20 25 ± 4 770
2 21 5 ± 2 3700
3 22 7.3 ± 0.9 2600
aRIP = Relative inhibition potency calculated as the ratio between the IC50 value of the inhibitor and the IC50 
value of GM1os.[12f]
2.3 Conclusions
This manuscript reports a powerful method for the synthesis of a new class of 
cholera toxin inhibitors with a design based on a pentavalent sym-substituted 
corannulene as the core unit and equipped with the galactose and the GM1os 
as CTB binders. Microwave-assisted CuAAC reactions, catalyzed by copper 
nanoparticles, were employed for the conjugation of the monovalent CTB ligands 
(galactose and GM1os) to the corannulene core via azide-presenting PEG-linkers 
of various lengths. The potent CTB inhibition of 25, 5.0, and 7.3 nM observed 
for the penta-GM1os corannulenes, 20, 21, and 22, respectively, prove that 
multivalent systems functionalized with strong CTB binders represents a solid 
strategic approach for the synthesis CT inhibitors with high potency in comparison 
with previously reported monovalent inhibitors. 
The developed method allows for the use of sym-substituted corannulenes 
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as a possible core unit for the development of new multivalent binders of cholera 
toxin or other possible biological targets that rely on multivalent binding of their 
target ligand.
2.4 Representative experimental procedures
Compound 6. A mixture of 3 (9.4 mg, 18 µmol), the proper azide-functionalized 
PEG (83.0 mg, 0.14 mmol) and copper nanoparticles (11.7 mg, 0.18 mmol) in 
DMF (1.0 mL) was loaded in a microwave vessel and was heated at 80 °C in a 
microwave reactor for 2 h. The reaction mixture was filtrated over Celite® and the 
solvent evaporated. The crude mixture was purified by column chromatography 
on silica gel (DCM/ MeOH 94 : 6 → 9 : 1) to yield a reddish oil (49 mg, 79%); 1H 
NMR (500 MHz, CDCl3): δ = 7.69 (s, 5H), 7.64 (s, 5H), 7.53 (s, 5H), 4.62 (s, 10H), 
4.48 (q, 20H, J = 5.5 Hz), 4.21 (s, 10H), 3.82 (t, 20H, J = 5.0 Hz), 3.69 - 3.47 (m, 
90H), 3.26 (t, 10H, J = 8.0 Hz), 1.04 (s, 105H); 13C NMR (125 MHz, CDCl3): δ = 
147.1, 144.8, 140.4, 134.9, 129.7, 123.9, 123.1, 122.5, 103.2, 87.8, 70.6, 70.5 
70.5, 70.5, 69.7, 69.6, 69.5, 68.7, 64.6, 59.3, 50.3, 50.3, 33.4, 28.5, 18.7, 11.2; MS 
(HR-ESI+) m/z = 1163.6590 [M+3Na]3+, calcd. (C175H280N30Na3O30Si5
3+) 1163.6609. 
Compound 9. A solution of TBAF in THF (1M, 1.0 mL, 1.0 mmol) was added to 
a solution of 6 (103 mg, 30.1 µmol) in THF (1.0 mL) and the reaction mixture was 
stirred at rt for 2 h. The solution was then diluted with a saturated aqueous solution 
of NH4Cl and extracted with ethyl acetate. The collected organic phases were 
dried over NasSO4 and evaporated to yield the crude product. The crude was then 
heated at 75 °C under high vacuum for 18 h. The product was then purified by 
column chromatography on silica gel (DCM/ MeOH 9:1) to yield a reddish oil (24 
mg, 30%). 1H NMR (500 MHz, CDCl3): δ = 7.70 (s, 5H), 7.64 (s, 5H), 7.53 (s, 5H), 
4.62 (s, 10H), 4.50 - 4.46 (m, 20 H), 4.16 (d, J = 2.5 Hz, 10H), 3.82 (t, 20H, J = 5.0 
Hz), 3.64 - 3.51 (m, 90H), 3.23 (t, 10H, J = 8.0 Hz), 2.44 (d, 5H, J = 2.5 Hz); 13C 
NMR (125 MHz, CDCl3): δ = 147.1, 144.8, 140.5, 134.9, 129.8, 124.0, 123.1, 122.5, 
79.7, 74.9, 70.6, 70.6, 70.5, 69.7, 69.5, 69.1, 64.7, 58.5, 50.3, 50.2, 33.4, 28.5; 
MS (HR-ESI+) m/z = 529.2767 [M+5H]5+, calcd. (C130H185N30O305+) = 529.2769.
Compound 17. A mixture of 9 (8.5 mg, 3.2 µmol), 14 (11.3 mg, 24.1 µmol) 
and copper nanoparticles (1.5 mg, 23.6 µmol) in DMF (300 µL) was loaded 
into a microwave vessel was heated at 80 °C in a microwave reactor for 2 h. 
The mixture was filtered over Celite® and the solid was washed with water. 
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The crude was lyophilized and purified by size exclusion chromatography 
(Sephadex® G-25, water) to yield a reddish solid (9.1 mg, 57%); 1H NMR (500 
MHz, D2O/ MeOD): δ = 8.01 (s, 5H), 7.88 (s, 5H), 7.68 (s, 5H), 7.60 (s, 5H), 
4.58 - 4.39 (m, 50H), 4.08 - 4.06 (m, 5H), 3.98 - 3.12 (m, 255H); 13C NMR (125 
MHz, D2O/ MeOD): δ = 147.9, 144.8, 141.3, 134.8, 130.4, 126.3, 126.1, 124.8 
124.2, 103.9, 76.1, 73.7, 71.7, 70.7, 70.6, 70.5, 70.4, 70.4, 70.4, 70.3, 70.2, 
69.9, 69.8, 69.7, 69.7, 69.6, 69.5, 64.0, 61.9, 50.9, 50.8, 49.5, 34.0, 28.1; MS 
(HR-ESI+) m/z = 854.2378 [M+6Na]6+, calcd. (C220H355N45Na6O85
6+) = 854.2366.
Compound 21. A mixture of 9 (2.88 mg, 1.09 µmol), 19 (11.1 mg, 9.3 µmol) and 
copper nanoparticles (0.76 mg, 12.0 µmol) in water (300 µL) was loaded into 
a microwave vessel was heated at 80 °C in a microwave reactor for 2 h. The 
mixture was filtered over Celite® and the solid was washed with water. The crude 
was lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
water) to yield a colorless solid (4.8 mg, 51%); 1H NMR (500 MHz, D2O/ MeOD): 
δ = 7.96 - 7.75 (m, 20H), 4.57 - 4.54 (m, 70H), 4.18 - 4.05 (m, 45H), 3.94 - 3.34 
(m, 286H), 2.70 (d, 5H, J = 10.0 Hz), 2.06 (d, 35H, J = 15.0 Hz), 1.98 - 1.94 (t, 
5H, J = 10.0 Hz), 1.62 - 1.45 (m br, 25H), 1.28 - 1.25 (m br, 20H), 1.11 - 0.90 
(m br, 75H); 13C NMR (125 MHz, D2O/ MeOD): δ = 176.0, 175.1, 105.7, 103.6, 
103.5, 103.2, 102.7, 75.8, 75.3, 73.5, 71.7, 70.7, 70.6, 70.6, 70.5, 70.5, 70.5, 
70.5, 70.4, 69.6, 69.6, 61,9, 52.6, 52.1, 51.1, 51.1, 29.7, 26.6, 26.2, 23.6, 23.0; 
MS (HR-ESI-) m/z = 1721.1778 [M-5H]5-; calc (C370H590N55O1755-) = 1720.7797.
ELLA assays. Each well of a 96-well microtiter plate was coated with a 100 μL 
native GM1 solution (1.3 µM in ethanol) after which the solvent was evaporated. 
Unattached GM1 was removed by washing with PBS (3 × 450 µL), the remaining 
free binding sites were blocked by incubation with 100 µL of a 1% (w/v) BSA 
solution in PBS for 30 min at 37 °C. Subsequently, the wells were washed with 
PBS (3 × 450 µL). In separate vials, a logarithmic serial dilution, starting from 
2.0 mM, of 150 µL saccharide-corannulenes in 0.1% BSA, 0.05% Tween-20 in 
PBS, mixed with 150 µL of a 50 ng/mL CTB-HRP solution in the same buffer 
were incubated. This gave an initial inhibitor concentration of 1.0 mM. In the 
case of potent inhibitors, based on the logarithmic experiments, a more accurate, 
serial dilution of a factor two was performed around the expected IC50 values. 
The inhibitor-toxin mixtures were incubated at room temperature for 2 h and then 
transferred to the coated wells. After 30 min of incubation at room temperature, 
unbound CTB-HRP-corannulene complexes were removed from the wells by 
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washing with 0.1% BSA, 0.05% Tween-20 in PBS (3 x 500 µL). 100 µL of a 
freshly prepared OPD solution (25 mg OPD·2HCl, 7.5 mL 0.1M citric acid, 7.5 
mL 0.1M sodium citrate and 6 µL of a 30% H2O2 solution, pH was adjusted to 6.0 
with NaOH) was added to each well and allowed to react with HRP in absence of 
light, at room temperature, for 15 min. The oxidation reaction was quenched by 
addition of 50 µL 1M H2SO4. Within 5 min, the adsorbance was measured at 490 nm.
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Picomolar inhibition of cholera toxin by a pentavalent 
ganglioside GM1os-calix[5]arene
3
Abstract:
Cholera toxin (CT), the causative agent of cholera, displays a pentavalent binding 
domain that targets the oligosaccharide of ganglioside GM1 (GM1os) on the 
periphery of human abdominal epithelial cells. Here, we report the first GM1os-
based CT inhibitor that matches the valency of the CT binding domain (CTB). 
This pentavalent inhibitor contains five GM1os moieties linked to a calix[5]arene 
scaffold. When evaluated with an inhibition assay, it achieved a picomolar inhibition 
potency (IC50 = 450 pM) for CTB. This represents a significant multivalency effect, 
with a relative inhibitory potency of 100.000 compared to a monovalent GM1os 
derivative, making GM1os-calix[5]arene one of the most potent known CTB inhibitors.
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3.1 Introduction
Cholera still represents a serious health problem in areas of the developing world 
where there is a lack of clean water and proper sanitation. In 2012, the World Health 
Organization estimated that annually 3 - 5 million cholera cases occur that result 
in more than 100.000 deaths.[1] Although several treatments exist for cholera,[2] 
resistance development and mutations in the causative pathogen mean that efforts 
to better understand the disease pathogenesis and develop new treatments are 
crucial.[3,4] The symptoms of cholera are caused by cholera toxin (CT), which is 
produced by the Vibrio cholerae bacterium. CT is a member of the AB5 toxin family 
that contains a pentameric binding domain, the cholera toxin B-subunit (CTB), for 
recognition and binding to cell surfaces.[5] The natural target ligand for CTB is 
the glycosphingolipid ganglioside GM1, on cellular membranes of the infected 
hosts’ intestinal epithelial surface. CTB can bind five GM1 saccharide epitopes 
simultaneously with the terminal Gal- and the Neu5Ac carbohydrate units of the 
Figure 1. Developed CTB inhibitor: penta-GM1os-calix[5]arene (1).
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ganglioside as the major contributors to the binding.[6,7] The adhesion of CTB to 
ganglioside GM1 on cell surfaces is the prerequisite for endocytosis of the toxic 
enzymatically active A subunit of CT, and the ensuing severe clinical symptoms.[8] 
One avenue in cholera research is to study the binding of CTB to GM1 and 
to develop CTB inhibitors that might prevent CT from binding the hosts’ cell 
surface and thereby also the development of cholera. Here, we present the first 
example of a pentavalent GM1os-based inhibitor for CTB, GM1os-calix[5]arene 
(1; Figure 1). In Chapter 2, also a pentavalent CTB inhibitors based on a GM1os-
presenting corannulene scaffold was described. In the past, several studies have 
focused on the development of multivalent glycosylated inhibitors for CTB based 
on ganglioside GM1.[9] It is noteworthy that in none of these studies, inhibitors 
were investigated with a pentavalent structure that matches the pentavalent 
structure of CTB. On the other hand, pentavalent cyclens[10,11] and cyclic 
peptides[12] have been described as CTB inhibitors, but those contained only 
the much simpler galactose epitope, likely to get around the difficulty to obtain 
sufficient tailor-made GM1os. 
Therefore, also GM1 mimics have been used, e.g.  Thompson and Schengrund 
described poly(propylene) imine dendrimers that present the Galβ1-3GalNAcβ1-
4(Neu5Acα2-3)Galβ-epitope of GM1 (see Chapter 1 for structure),[13] with IC50 values 
for the tetravalent and octavalent dendrimer of 7 and 3 nM, respectively. Bernardi 
et al. published a series of GM1-mimics (pseudo-GM1), in which the residues in 
the GM1os that are not essential for binding were replaced by a conformationally 
restricted cyclohexane-diol and the Neu5Ac-unit was substituted by various 
α-hydroxy acids.[14,15] When attached to multivalent dendritic structures,[16] the 
relative inhibitory potency (RIP) per mimic unit of the tetravalent and octavalent 
inhibitors were 111 and 55, respectively. Interestingly, when the same mimic was 
linked to a divalent calix[4]arene scaffold,[17] a 4000-fold enhancement in binding 
efficiency was achieved compared to the monovalent pseudo-GM1. These data 
suggested to us that the calixarene macrocycle, from which the binding inhibitors 
are projected, could be a promising multivalent scaffold[18-20] to design CTB inhibitors 
with improved efficiency. In collaboration with the group of Pieters, our lab previously 
published divalent, tetravalent, and octavalent dendritic structures decorated with 
GM1os (see for structure §1.4 on p.39).[21,22] For the octavalent compound the 
unprecedentedly low IC50 value of 50 pM was observed with a relative inibititory 
potency (RIP) of 17500 per each arm compared to its monovalent counterpart. 
However, its mismatched valency compared to CTB, prompted us to investigate 
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a pentavalent scaffold as core structure that when decorated with GM1os has 
the potential to form 1 : 1 inhibitor-CTB complexes. The current paper presents 
the convergent synthesis of the first, water-soluble, pentavalent CTB inhibitor 
(1), which was made by coupling five GM1os units to a calix[5]arene scaffold.
3.2 Results and Discussion 
We designed a 5-fold symmetric calix[5]arene as a pentavalent scaffold structure. 
This calix[5]arene (Figure 1) presents small methoxy groups at the lower rim, 
which confer a high conformational flexibility to the macrocyclic structure.[23] The 
upper rim of the calixarene inhibitor is decorated with the GM1 pentasaccharide 
separated from the macrocyclic core by appropriate linkers. Fan and coworkers[12] 
have demonstrated that an optimal linker length is vital for the potency of a 
synthetic multivalent inhibitor. For the calix[5]arene, described here, a 31 atom-
containing linker was chosen. This should allow the simultaneous interaction of 
the five GM1os units with the five B-subunits of a single toxin.[5]
The route towards our target (1) started with the synthesis of the pentavalent 
scaffold that began with the preparation of the known p-tert-butyl-calix[5]arene.
[24] This product was converted into p-H-calix[5]arene 2[25] by following literature 
procedures. Next, penta-aldehyde 3 was obtained in 57% yield from 2 by exploiting 
the Duff formylation reaction.[26,27] Compound 3 was subsequently methylated at the 
Scheme 1. Synthesis of the azido-calix[5]arene (8) scaffold. Reagents and conditions: a) HMTA, CF3COOH, Δ, N2, 5 
days, 57%; b) CH 3I, K2CO
 
3 CH3CN, reflux, N2, 20 h, 68%; c) NaClO2, NH2SO3H, (CH3)2CO, CHCl3, H2O, rt, 24 h, 79%; 
d) (COCl )2, CH2 Cl2, N2, rt, 18h, quant.; e) Et3N, dry CH2Cl2, N2, rt, 20 h, 44%.
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lower rim by using CH3I and K2CO3 in acetonitrile affording the penta-methoxy-
calix[5]arene 4 in 68% yield (Scheme 1). Oxidation of compound 4 with NaClO2 and 
NH2SO3H produced the penta-carboxylic acid 5. The unsymmetrically substituted 
by ditosylation, substitution to the diazide, and finally selective Staudinger reduction 
of one azide.[28,29] Initial attempts to condense amine 7 with the carboxylic azido-
penta-(ethyleneglycol)-amine 7 was synthesized from hexa-ethylene glycol 
Scheme 2. Synthesis of GM1os-calix[5]arene (1) and GM2os-calix[5]arene (11); a) CuSO4·5H2O, sodium 
ascorbate, Triton X-100, CH3OH, H2O, MW (150W), 80 
oC, 1 h; 51% 1, 59% 11
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acids in 5 using HBTU resulted in difficult purification and low yields (~ 20%) of 
8. However, when this spacer (7) was attached to calix[5]arene 5 via penta-acyl 
chloride intermediate 6 it provided penta-azido-calix[5]arene 8 in a 44% yield. 
With the calix[5]arene (8) scaffold in hand we proceeded to the next stage, 
attaching five GM1 oligosaccharides. We chose the copper-catalyzed azide-
alkyne cycloaddition (CuAAC) reaction to achieve this, which meant a GM1os 
derivative with a terminal alkyne was required. This C11-alkyne-terminated 
GM1os 9 (Scheme 2) was made via a chemo-enzymatic procedure previously 
reported by us,[30] which allowed the production of 9 on gram scale. Compound 
9 was subsequently “clicked” to scaffold 8 under standard CuAAC conditions in 
H2O while exposed to microwave irradiation to successfully provide our crude 
target inhibitor 1. With our target pentavalent GM1os-calix[5]arene 1 in hand, in 
order to properly assess the role of the GM1os in inhibitor 1, we also set out 
to synthesize derivatives of 1 containing fragments of the GM1os to use for 
comparison in the biological assays. The first of these was penta-GM2os-calix[5]
arene (11) that lacks the terminal galactose epitope compared to the GM1os. We 
synthesized 11 using the same CuAAC reaction conditions from scaffold 8 and a 
chemo-enzymatically produced alkyne-terminated C11-linked GM2os sugar (10). 
Figure 2. LCMS trace of the purification of GM2-calix[5]arene 11. (left) Chromatogram of the purification on 
a reversed phase column (see Sup. Info. for details). (right) Mass spectra for two fractions, the pentavalent 
product 11 at RT = 12 min, and the tetravalent at 21 min. 
With both our target 1 and its derivative 11 in hand as crude products, we 
investigated what purification method would be suitable for these large complex 
60
molecules. An initial purification by size exclusion chromatography (SEC) efficiently 
removed excess of alkyne-terminated GM1os 9 and GM2os 10, respectively. 
However, the crude products both also contained a minor amount of tetravalent 
byproducts as could be clearly seen with mass spectrometry and their separation 
proved quite challenging. Initial attempts to separate these by aqueous GPC on 
HPLC failed, but after extensive optimization, reversed phase HPLC purification 
proved the most successful for this final purification step. Figure 2 shows a typical 
HPLC chromatogram for the separation for both the GM1os- and GM2os-calix[5]
arenes. Despite attempts to improve the moderate resolution, the purification 
remained quite complicated because of long elution times (up to 40 minutes per 
run) and high affinity of the products with the column material. Collecting of small 
fractions in a specific retention time window over multiple HPLC injections and 
subsequent lyophilization  resulted indeed in pure pentavalent GM1os- and GM2os-
calix[5]arenes (1 and 11) as shown by HR-MS and NMR analyses. The other 
impure fractions that also contained 1 or 11 were collected, pooled, lyophilized and 
Scheme 3. Synthesis of galactoside-calix[5]arene (16), and lactoside-calix[5]arene (17); a) CuSO4·5H2O, sodium 
ascorbate, DMF, H2O, MW (150 W), 80 
oC, 1 h; 67% 14, 57% 15; b) NaOMe/ MeOH, 4 h - 18 h, H+-resin; 90% 16, 72% 17.
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re-injected to achieve optimal yields. Attempts were made to isolate the tetravalent
byproducts, but insufficient amounts could be obtained for further analysis. 
Besides the GM2os containing calixarene (11), we also prepared two further 
derivatives of 1 that contained fragments of GM1os, a pentavalent β-galactoside- 
(16) and β-lactoside-calix[5]arene (17) (Scheme 3). These more simple 
carbohydrates enabled a modified synthesis procedure that circumvented the 
potentially challenging HPLC purification, as encountered for compounds 1 and 
11. The coupling was also performed by employing the microwave-assisted 
CuAAC reaction on penta-azido-calixarene scaffold 8, but instead of using the 
deprotected carbohydrates, acetyl-protected galactoside 12, and lactoside 13 
were reacted. The resulting products could now be purified by normal phase 
silica gel chromatograpy. The acetyl-protected 14 and 15 were deprotected by 
employing standard Zemplén[31] conditions to obtain galactoside-calix[5]arene 
16, and lactoside-calix[5]arene 17, respectively, which did not require further 
purification after work up.
Finally, in order to properly determine the multivalency effect of the interaction 
of 1 with CTB in our biological assays, we also synthesized the monovalent 
GM1os derivative 20 (Scheme 4). This was achieved by first in situ generation 
of the acyl chloride of commercially available 4-methoxybenzoic acid with oxalyl 
chloride and, subsequently, reacting this with amino-azide 7, yielding azide 19 
in 20% over two steps. Again, by employing the microwave-assisted CuAAC 
reaction on alkyne-terminated 9 and azide 19, GM1os-monomer 20 was obtained 
in reasonable yield (49%). 
The inhibitory potency of the four pentavalent compounds (1, 11, 16, and 
17), was determined by enzyme-linked lectin assay (ELLA) experiments. In the 
assays, the ability of 1, 11, 16 and 17 to compete with the natural antigen GM1 for 
binding HRP-labeled CTB was measured, which was adsorbed to the well surface 
of the microtiter plate. GM1os-calix[5]arene 1 showed a high inhibition potency, 
i.e., a very low IC50 value of 450 pM (Figure 3, Table 1). Comparing the IC50 value 
Scheme 4. Synthesis of GM1-monomer 20; a) (COCl)2, dry CH2Cl2, N2, rt, 18 h; b) 7, Et3N, dry CH2Cl2, N2, rt, 20 h; 
20% in two steps; c) 9, CuSO4·5H2O, sodium ascorbate, Triton X-100, CH3OH, H2O, MW (150 W), 80 oC, 1 h; 49%. 
OH
OMe
O
H
N
OMe
O
O
N3
5 O
OH
O
O
OH
O
O
O
O
AcHN
OH
HO
O
NHAc
HO
HO
HO
HO2C
OH
O
HO
OH
OH
HO
N
H
OMe
O
ON
N N
5
4a, b c
18 19 20
OH
OH
HO
O
62
Table 1. CTB inhibition potency for reported compounds.
Entry Saccharide Valency # IC50
1 GM1os 5 1 450 pM
2 GM1os 1 20  44 µM
3 GM2os 5 11    9 µM
4 Galactose 5 16 >1 mM
5 Lactose 5 17 >1 mM
(44 µM) of the monovalent control compound (20) to that of 1, revealed a 
100-thousand fold increase in inhibitory potency, and a RIP of 20-thousand 
per arm. Pentavalent inhibitors based on a more rigid corannulene scaffold, 
which we also report in this issue, inhibited CTB in the nanomolar range.[32] 
Assay results for the GM2os-calix[5]arene 11 confirmed the importance of 
using GM1os. Lacking only the terminal galactose compared to 1, it produced 
an IC50 of 9 μM, which is 20-thousand fold worse compared to 1. The 
galactose-terminated (16) and lactose-terminated (17) calix[5]arenes displayed 
a higher inhibition concentration than their solubility in the assay medium, 
and their IC50 could therefore only be determined as being >1 mM (Table 1).
3.3 Conclusions
In summary, the study described in this chapter dealt with the synthesis and initial 
biological evaluation of the first known example of a pentavalent GM1os-based 
Figure 3. ● GM1os-calix[5]arene ♦ GM2os-calix[5]arene ▲ GM1os-monomer; Fitted curves of the experimental 
ELLA inhibition data. For details of the inhibition assays see §3.4.
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inhibitor of cholera toxin that matches the valency of the cholera toxin B-subunit. 
With an IC50 of 450 pM, the pentavalent GM1os-calix[5]arene (1) also displays 
the highest relative inhibitory potency, 20-thousand per arm (compared to 20), 
documented thus far for CT inhibitors. We are currently using the here reported 
convergent synthetic route to further explore the structure-activity-relationship of 
1 and improve its potency. Among other issues we are interested in investigating 
the effect of the length, rigidity and hydrophobicity of the used spacer and 
restricting the flexibility of the calix[5]arene scaffold to a fixed cone structure.
3.4 Experimental section
General experimental information
All moisture sensitive reactions were carried out under nitrogen atmosphere, 
using previously oven-dried glassware. All dry solvents were prepared according 
to standard procedures, distilled before use and stored over 3 Å or 4 Å molecular 
sieves. Reagents were obtained from commercial sources and used without 
further purification unless stated otherwise. Analytical TLC was performed using 
prepared plates of silica gel (Merck 60 F-254 on aluminium) and then, according 
to the functional groups present on the molecules, revealed with UV light or using 
staining reagents: FeCl3 (1% in H2O/ CH3OH 1 : 1), H2SO4 (5% in EtOH), ninhydrin 
(5% in EtOH), basic solution of KMnO4 (0.75% in H2O). Merck silica gel 60 (70 - 
230 mesh) was used for flash chromatography and for preparative TLC plates. 
1H NMR and 13C NMR spectra were recorded on Bruker AV300, Bruker AV400, 
Bruker DPX400, and Bruker AV600 equipped with cryoprobe spectrometers 
(observation of 1H nucleus at 300 MHz, 400 MHz, 600 MHz, respectively, and of 
13C nucleus at 75 MHz, 100 MHz, and 151 MHz, respectively). Chemical shifts are 
reported in part per million (ppm), calibrated on the residual peak of the solvent, 
whose values are referred to tetramethylsilane (TMS,  δTMS = 0 ppm), as internal 
standard. 13C NMR spectra were performed with proton decoupling. Electrospray 
ionization (ESI) mass analyses were performed with a Waters spectrometer, 
while high resolution ESI mass analyses were recorded on a Thermo Scientific 
Q Exactive spectrometer. Melting points were determined on an Electrothermal 
apparatus in closed capillaries. Microwave reactions were performed on a CEM 
Discovery System reactor running on Discover Application Chemdriver Software 
v3.6.0. HPLC was performed on a HP 1100 series with a DAP 190-600 nM detector, 
equipped with a Waters Xterra 100 × 4.6 mm C18 column eluted with isocratic 
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iPrOH/ H 2O 35 :65, and a flow of 0.4 mL/min, unless stated otherwise. Materials 
for the ELLA experiments i.e. bovine serum albumin (BSA), bovine brain GM1, 
ortho-phenylenediamine (dihydrochloride salt) (OPD), cholera toxin horseradish 
peroxide (CTB-HRP) conjugate, tween-20, 30% H2O2 solution, sodium citrate, and 
citric acid were purchased at Sigma Aldrich and used without further modification, 
phosphate-buffered saline (PBS) 10 × concentrate was diluted ten times with 
demineralized water prior to use. Nunc F96 MaxisorpTM 96-wells microtiter 
plates were used as purchased at Thermo Scientific. The microtiter plates were 
washed using an automated Denville® 2 Microplate Washer. Optical density (OD) 
was measured between 1.5 and 0.5 units on a Thermo Labsystems Multiskan 
Spectrum Reader running on Skanit software version 2.4.2. Data analysis 
and curve fitting of inhibition experiments were performed on Prism Graphpad 
software v5.04. Simplified nomenclature proposed by Gutsche[33] is used to name 
the calix[5]arene compounds. Compounds 31,32,33,34,35-pentahydroxycalix[5]
arene 2,[25] 17-azide-3,6,9,12,15-pentaoxaheptadecane-1-amine 7,[29] Undec-
10-ynyl-2,3,4,6-tetra-O-acetyl-β-d-galactopyranoside 12,[30] undec-10-ynyl-
2,3,4,6-tetra-O-acetyl-β-d-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-d-
glucopyranoside 13[30] were prepared according to literature procedures.
GM1-calix[5]arene (1)
Calix[5]arene 8 (15.7 mg, 6.93 μmol) was dissolved in 0.5 mL of CH3OH in a 
microwave tube. Then the GM1os derivative 9 (59.8 mg, 52.1 μmol), previously 
synthesized by chemo-enzymatic procedures,[30,34] was combined with 
CuSO4·5H2O (0.52 mg, 2.1 μmol), sodium ascorbate (0.82 mg, 4.2 μmol), 4 mL of 
H2O and a drop of Triton X-100. The mixture was heated at 80 °C by microwave 
irradiation (150 W) for 60 min. The reaction progression was monitored via TLC 
(eluent: AcOEt/ CH3OH/ H2O/ AcOH 4 : 2 : 1 : 0.1) and ESI-MS analyses. The 
crude mixture was purified via size exclusion column chromatography (Sephadex 
G-15, eluent: H2O 100%) and HPLC purification (see General Information) giving 
product 1 as a white solid. Yield: 51%; 1H NMR (D2O, 600 MHz): δ = 7.61 (s, 5H, 
H5 triazole), 7.50 (s, 10H, Ar), 4.69 (bs, 5H, H1-GalNAc), 4.43 (d, 5H, J = 8.0 Hz, 
H1-Gal’), 4.44 - 4.41 (m, 5H, H1-Gal), 4.38 - 4.37 (m, 5H), 4.32 - 4.31 (5H, d, J = 
7.9 Hz, H1-Glc),  4.05 - 4.02 (m, 15H), 3.94 - 3.92 (m, 5H, H2-GalNAc), 3.86 - 3.60 
(m, 105H), 3.60 - 3.45 (m, 80H), 3.46 - 3.33 (m, 75H), 3.26 - 3.24 (m, 5H, H2-Gal); 
3.18 - 3.15 (m, 5H, H2-Glc), 3.10 (bs, 10H), 2.56 - 2.54 (m, 5H, H3a-Neu5Ac), 2.45 
- 2.42 (m, 10H, triazole-CH2CH2CH2), 1.92 (s, 15H, NC(O)CH3-Neu5Ac), 1.89 (s, 
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15H, NC(O)CH3-GalNAc), 1.85 - 1.80 (m, 5H, H3b-Neu5Ac), 1.44 - 1.35 (m, 20H, 
CH2 aliphatic chain), 1.14 - 1.08 (m, 10H, CH2CH2OC1-Glc), 1.03 (m, 40H, CH2 
aliphatic chain); 13C NMR (D2O, 151 MHz): δ = 175.4, 175.1, 174.5 (C(O)),169.1 
(ArC(O)NH); 159.7 (Ar-ipso); 134.8 (Ar-ortho); 129.2 (Ar-para); 128.9 (Ar-meta); 
123.7 (C5 triazole), 105.1 (C1-Gal’), 103.0 (C1-Gal), 102.8 (C1-GalNAc), 102.5 
(C1-Glc), 102.0 (C2-Neu5Ac), 80.7 (C3-GalNAc), 79.0 (C4-Glc), 77.6 (C4-Gal), 
75.2 (C5-Gal’), 75.1 (C5-Glc), 74.9 (C3-Gal), 74.7, 74.4 (C5-Gal), 73.4 (C6-
Neu5Ac), 73.1 (C2-Glc), 72.8 (C3-Gal’), 72.6 (C7-Neu5Ac), 71.0 (C2-Gal’), 70.9 
(β-COCH2), 70.4 (C2-Gal), 70.1 - 69.8, 69.4, 69.2, 69.0, 68.9, 68.4, 68.3 (C4-
GalNAc), 63.1, 61.4, 61.3, 60.9, 60.5, 52.0, 51.5 (C2-GalNAc), 50.3, 40.0, 37.2, 31.1 
(ArCH2Ar), 29.3, 29.1, 29.0, 28.9, 28.8 (CH2 aliphatic chain), 25.6 (CH2CH2OC1-
Glc), 25.0 (triazole-CH2CH2CH2), 23.0 (NHC(O)CH3-GalNAc), 22.4 (NHC(O)CH3-
Neu5Ac); MS (HR-ESI-): m/z = 1600.5013 [100% (M-5H)5-], calcd: 1600.7112.
5,11,17,23,29-Pentaformyl-31,32,33,34,35-pentahydroxycalix[5]arene (3)
Calix[5]arene 2[25] (0.41 g, 0.78 mmol) was added to a solution of HMTA (2.5 g, 
17.8 mmol) in 50 mL TFA and the mixture was refluxed for 5 days under N2. The 
solvent was then removed under reduced pressure and the residue dissolved 
in 12 mL of a 1 : 1 CH2Cl2/ HCl 1 M solution. The mixture was stirred at room 
temperature for 24 h. The aqueous phase was extracted with CH2Cl2 (5 × 5mL). 
The combined organic phases were washed with water (2 × 10mL), dried over 
anhydrous Na2SO4, filtered and the solvent removed under reduced pressure. 
The residue was purified by trituration in CHCl3/ hexane 1 : 1 to give the product 
3 as a brownish solid. Yield: 57%; 1H NMR (300 MHz, CDCl3/  CD3OD 9 : 1): 
δ = 9.75 (s, 5H, CHO), 7.70 (s, 5H, ArOH), 7.22 (s, 10H, ArH), 3.45 (s, 10H, 
ArCH2Ar); 
13C NMR (75 MHz, CDCl3/ CD3OD 9 : 1): δ = 192.1 (CHO), 150.6 
(Ar-ipso), 131.9 (Ar-para), 128.1 (Ar-meta), 127.2 (Ar-ortho), 31.4 (ArCH2Ar); 
MS(HR-ESI+): m/z = 671.1921 [100% (M+H)+], calcd: 671.1917; m.p.  > 300 °C.
5,11,17,23,29-Pentaformyl-31,32,33,34,35-pentamethoxy- calix[5]arene (4)
In a two-neck round-bottomed flask, pentaformylcalix[5]arene 3 (0.7 g, 1.1 
mmol) was dissolved in 150 mL of dry CH3CN, then K2CO3 (4.5 g, 32 mmol) and 
CH3I (2 mL, 32 mmol) were added and the mixture was refluxed for 20 h under 
nitrogen atmosphere. The solvent was removed under reduced pressure and 
the residue dissolved in 150 mL of a 1:1 solution CH2Cl2/ HCl 1 M. The mixture 
was stirred for 2 h at room temperature. The organic layer was separated, and 
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the aqueous phase extracted with CH2Cl2 (2 x 50 mL). The combined organic 
phases were washed with water (2 x 100 mL), dried over anhydrous Na2SO4, 
filtered and the solvent removed under reduced pressure. The product 4 was 
obtained as a brown solid. Yield: 68%; 1H NMR (300 MHz, CDCl3): δ = 9.72 (s, 
5H, CHO), 7.50 (s, 10H, ArH), 3.92 (s, 10H, ArCH2Ar), 3.25 (s, 15H, OCH3); 
13C 
NMR (75 MHz, CDCl3/ CD3OD 9 : 1): δ = 191.4 (CHO), 161.8 (Ar-ipso), 134.8 
(Ar-para), 132.0 (Ar-ortho), 130.8 (Ar-meta), 60.6 (OCH3), 30.7 (ArCH2Ar); MS 
(HR-ESI +): m/z = 741.2700 [100% (M+H)+], calcd: 741.2700; m.p. = 217 - 219 °C.
5,11,17,23,29-Pentacarboxy-31,32,33,34,35-pentamethoxycalix[5]arene (5)
Pentaformyl-pentamethoxycalix[5]arene 4 (0.25 g, 0.34 mmol) was dissolved in 
a two-neck round-bottomed flask in 100 mL of a mixture acetone/ CHCl3 1 : 1, 
and cooled to 0 °C with an ice-water bath. In another flask, a solution of NaClO2 
80% pure (0.47 g, 4.20 mmol) was dissolved in the minimum amount of water. 
Subsequently, sulfamic acid (0.49 mg, 5.04 mmol) was added. This solution was 
slowly poured into the reaction flask. The mixture was stirred at 0 °C for 15 min and 
gradually warmed to room temperature while it remained being stirred for 24 h. 
The solvent was then removed under reduced pressure and the residue triturated 
with 1 M HCl. After filtration on a Büchner funnel, product 5 was obtained as a 
solid. Yield: 79%; 1H NMR (300 MHz, CD3OD): δ = 7.75 (s, 10H, ArH), 3.93 (s, 10H, 
ArCH2Ar), 3.30 (s, 15H, OCH3); 
13C NMR (75 MHz, CD3OD): δ (ppm) 169.6 (CO), 
162.1 (Ar-ipso), 135.8 (Ar-ortho), 132.0 (Ar-meta), 126.8 (Ar-para), 61.3 (-OCH3), 
31.9 (ArCH2Ar); MS(HR-ESI+): m/z = 843.2269 [100% (M+Na)+], calcd: 843.2265. 
5,11,17,23,29–Pentakis[(17-azide-3,6,9,12,15-pentaoxahepta-decane-1-
amino)carbonyl]–31,32,33,34,35–pentamethoxy-calix[5]arene (8)
In a round-bottomed flask, 0.12 g of calix[5]arene 5 (0.14 mmol) and 0.51 mL of 
oxalyl chloride (5.82 mmol) were solubilized in 15 mL of dry CH2Cl2 under nitrogen 
atmosphere. The solution was stirred for 18 h at room temperature and then the 
solvent evaporated to dryness. The residual compound 6 was dissolved again in 5 
mL of dry CH2Cl2 and then added dropwise to a solution of amine compound 7 (0.29 
g, 0.87 mmol) and NEt3 (0.12 mL, 0.87 mmol) in 5 mL of dry CH2Cl2. The mixture 
was stirred for 20 h at room temperature under nitrogen atmosphere. The mixture 
was then washed with 1 M HCl, an aqueous solution of Na2CO3 and water till neutral 
pH was reached. The solvent was removed under reduced pressure and the crude 
purified by flash chromatography (eluent: CHCl3/CH3OH 95:5) to give the product 8 
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as a yellow oil. Yield: 44%; 1H NMR (400 MHz, CDCl3): δ = 7.50 (s, 10H, ArH), 7.07 
(bs, 5H, CONH), 3.89 (s, 10H, ArCH2Ar), 3.65 - 3.50 (m, 110H, OCH2, CH2NHCO), 
3.34 (t, 10H, J = 4.8 Hz, CH2N3), 3.28 (s, 15H, OCH3); 
13C NMR (100 MHz, CDCl3): 
δ = 167.3 (CO), 159.2 (Ar-ipso), 134.2 (Ar-para), 129.8 (Ar-ortho), 128.2 (Ar-meta), 
70.6, 70.5, 70.2, 70.0, (OCH2), 60.8 (OCH3), 50.6 (CH2N3), 39.7 (CH2NHCO), 30.9 
(ArCH2Ar); MS (HR-ESI+): m/z = 1131.5698 [100% (M+2H)2+], calcd: 1131.5756.
GM2-calix[5]arene (11)
Calix[5]arene 8 (15.7 mg, 6.93 μmol) was dissolved in 0.5 mL of CH3OH in a 
microwave tube. Then the GM2os derivative 10 (50.5 mg, 52.1 μmol), previously 
synthesized by chemo-enzymatic procedures,[30,34] was added together with 
samples of CuSO4·5H2O (0.52 mg, 2.1 μmol), sodium ascorbate (0.82 mg, 4.2 
μmol), 4 mL of H2O and a drop of Triton X-100. The mixture was heated at 80 °C 
by microwave irradiation (150 W) for 60 min. The reaction progress was monitored 
via TLC (eluent: AcOEt/ CH3OH/ H2O/ AcOH 4 : 2 : 1 : 0.1) and ESI-MS analyses. 
The crude material was purified via size exclusion column chromatography 
(Sephadex G-15, eluent: H2O 100%), followed by HPLC purification (see General 
Information)  giving pure product 11 as a white solid. Yield: 59%; 1H NMR (D2O/ 
CD3OD, 400 MHz): δ = 7.65 (s, 5H, H5 triazole), 7.54 (s, 10H, ArH), 4.70 (m, 
5H, H1-Gal), 4.47 - 4.42 (m, 15H, H1-GalNAc), 4.36 - 4.35 (d, 5H, H1-Glc, J = 
7.6 Hz), 4.08 - 4.06 (m, 10H), 3.89 - 3.66 (m, 95H, ArCH2Ar), 3.58 - 3.43 (m, 
150H); 3.32 - 3.30 (m, 5H, H2-Gal), 3.23 - 3.19 (m, 5H, H2-Glc), 3.14 (bs, 10H), 
2.61 - 2.58 (m, 5H, H3a-Neu5Ac), 2.48 (bs, 10H), 1.97 (s, 15H, NHC(O)CH3-
Neu5Ac), 1.95 (s, 15H, NHC(O)CH3 -GalNAc), 1.89 - 1.84 (m, 5H, H3b-Neu5Ac), 
1.51-1.36 (bs, 20H, CH2 aliphatic chain), 1.23 - 0.95 (50H, m, CH2 aliphatic 
chain); MS (HR-ESI-): m/z 1440.4670 [100% (M-5H)5-], calcd: 1438.6588.
Peracetylated-galactosylcalix[5]arene (14)
Calix[5]arene 8 (32.0 mg, 14.1 μmol) and the β-galactoside derivative 12 (52.9 mg, 
106 μmol) were dissolved in 2.5 mL of DMF in a microwave tube. CuSO4·5H2O 
(2.0 mg, 8.5 μmol), sodium ascorbate (3.3 mg, 16.9 μmol) and 0.5 mL H2O were 
then added. The mixture was heated at 80 °C by microwave irradiation (150 W) 
for 60 min. When the reaction was completed (checked via TLC, eluent: CH2Cl2/
CH3OH 20 : 1), it was quenched by addition of water (15 mL) and extracted with 
AcOEt (5 × 15 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered and the solvent removed under reduced pressure. The crude 
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material was purified on preparative TLC plates (eluent: CH2Cl2/ CH3OH 9 : 1) 
giving product 14 as a yellow oil. Yield: 67%; 1H NMR (300 MHz, CD3OD): δ = 
8.21 (bs, 5H, C(O)NH), 7.77 (s, 5H, H5 triazole), 7.61 (bs, 10H, ArH), 5.38 (d, 5H, 
J = 2.7 Hz, H-4), 5.16 - 5.02 (m, 10H, H3, H2), 4.61 (d, 5H, J = 7.3 Hz, H1), 4.51 (t, 
10H, J = 5.0 Hz, OCH2CH2-triazole), 4.20 - 4.05 (m, 15H, H5, H6a, H6b), 3.94 (bs, 
10H, ArCH2Ar), 3.88 - 3.77 (m, 15H, OCH2CH2-triazole, β-COCHa), 3.70 - 3.44 
(m, 105H, OCH2, β-COCHb, C(O)NHCH2), 3.29 (s, 15H, ArOCH3), 2.67 (t, 10H, J 
= 7.6 Hz, triazole-CH2CH2CH2), 2.13 (s, 15H, Ac), 2.02 (s, 15H, Ac), 2.01 (s, 15H, 
Ac), 1.94 (s, 15H, Ac), 1.71 - 1.59 (m, 10H, triazole-CH2CH2CH2), 1.59 - 1.47 (m, 
10H, β-COCH2CH2), 1.40 - 1.23 (m, 50H, CH2 aliphatic chain); 
13C NMR (75 MHz, 
CD3OD): δ = 172.0, 171.5, 171.2 (Ac), 169.6 (C(O)NH), 160.9 (Ar-ipso), 149.0 (C4 
triazole), 135.8 (Ar-ortho), 130.7 (Ar-para), 129.7 (Ar-meta), 123.9 (C5 triazole), 
102.2 (C1), 72.4 (C3), 71.7 (C5), 71.5, 71.4, 71.3, 70.9 (OCH2), 70.6 (OCH2CH2-
triazole), 70.5 (C2), 68.8 (C4), 62.6 (C6), 61.5 (ArOCH3), 51.3 (OCH2CH2-
triazole), 41.0 (C(O)NHCH2), 32.0 (ArCH2Ar), 30.6, 30.4, 30.2 (CH2 aliphatic 
chain), 27.0 (triazole-CH2CH2CH2), 26.3 (CH2 aliphatic chain), 20.8, 20.6, 20.5 
(CH3C(O)); MS(HR-ESI+): m/z = 1607.7872 [100% (M+3Na)3+], calcd: 1607.7813. 
Peracetylated-lactosylcalix[5]arene (15)
Calix[5]arene 8 (27.5 mg, 12.0 μmol) and the β-lactoside compound 13 (70.0 mg, 
89.0 μmol) were dissolved in 2.5 mL DMF in a microwave tube. CuSO4·5H2O (2.6 
mg, 10.4 μmol), sodium ascorbate (4.4 mg, 22.2 μmol) and 0.5 mL H2O were then 
added. The mixture was heated at 80 °C by microwave irradiation (150 W) for 60 
min. When the reaction was completed (checked via TLC, eluent: CH2Cl2/ CH3OH 
94 : 6), it was quenched by addition of water (15 mL) and extracted with AcOEt (5 × 
15 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered 
and the solvent removed in vacuo. The crude was purified by flash chromatography 
(elution in gradient: CH2Cl2/ CH3OH 96 : 4 → 95 : 5) giving product 15 as a yellow 
oil. Yield: 57%; 1H NMR (300 MHz, CDCl3): δ = 7.46 (bs, 10H, ArH), 7.40 (s, 5H, 
H5 triazole), 6.83 (bs, 5H, C(O)NH), 5.33 (d, 5H, J = 3.3 Hz, H4’), 5.17 (t, 5H, 
J = 9.3 Hz, H3), 5.09 (dd, 5H, J1’-2’ = 7.9 Hz, J2’-3’ = 10.4 Hz, H2’), 4.93 (dd, 5H, 
J2’-3’ = 10.4 Hz , J3’-4’ = 3.3 Hz, H3’), 4.86 (dd, 5H, J2-3 = 9.3 Hz, J1-2 = 8.1 Hz, H2), 
4.50 - 4.38 (m, 25H, H1’, H1, H6a, OCH2CH2-triazole), 4.15 - 4.00 (m, 15H, H6b, 
H6a’, H6b’), 3.90 - 3.71 (m, 35H, H5’, H4, β-COCHa, ArCH2Ar, OCH2CH2-triazole), 
3.65 - 3.47 (m, 105H, OCH2, H5, C(O)NHCH2), 3.42 (m, 5H, β-COCHb), 3.21 (s, 
15H, ArOCH3), 2.65 (t, 10H, J = 7.7 Hz, triazole-CH2CH2CH2), 2.12 (s, 15H, Ac), 
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2.09 (s, 15H, Ac), 2.04 - 1.98 (m, 60H, Ac), 1.94 (s, 15H, Ac), 1.65 -,1.55 (m, 10H, 
triazole-CH2CH2CH2), 1.55 - 1.44 (m, 10H, β-COCH2CH2), 1.39 - 1.15 (m, 50H, 
CH2 aliphatic chain); 
13C NMR (100 MHz, CDCl3): δ = 170.4, 170.3, 170.2, 170.1, 
169.8, 169.6, 169.1 (Ac); 167.3 (C(O)NH), 159.2 (Ar-ipso), 148.2 (C4 triazole), 134.2 
(Ar-ortho), 129.9 (Ar-para), 128.2 (Ar-meta), 121.7 (C5 triazole), 101.1 (C1’), 100.6 
(C1), 76.3 (C4), 72.8 (C3), 72.5 (C5), 71.7 (C2), 71.0 (C3’), 70.6 (C5’), 70.5 (OCH2), 
70.2 (β-COCH2), 69.8 (OCH2), 69.6 (OCH2CH2-triazole), 69.1 (C2’), 66.6 (C4’), 
62.1 (C6), 60.8 (C6’), 60.7 (ArOCH3), 50.0 (OCH2CH2-triazole), 39.7 (C(O)NHCH2), 
31.0 (ArCH2Ar), 29.5, 29.3, 25.8, 25.7 (CH2 aliphatic chain), 20.9, 20.8, 20.6, 20.5 
(CH3C(O)); MS (HR-ESI+): m/z = 1571.9445 [100% (M+4Na)4+], calcd: 1571.940. 
Galactosylcalix[5]arene (16)
The peracetylated-galactosylcalix[5]arene 14 (45.0 mg, 9.46 μmol) was dissolved 
in 5 mL of CH3OH, dropwise a freshly prepared MeONa in methanol solution 
was added till pH 8 - 9. The mixture was stirred at room temperature for 4 h. The 
progress of the reaction was monitored via ESI-MS analysis. Amberlite resin IR 
120/H+ was subsequently added to quench the reaction, and the mixture was 
gently stirred for 30 min. until neutral pH was reached. The resin was then filtered 
off and the solvent removed under reduced pressure to give pure product 16 as 
a yellow oil. Yield. 90%; 1H NMR (300 MHz, CD3OD): δ = 8.23 (bs, 5H, C(O)NH), 
7.77 (s, 5H, H5 triazole), 7.61 (s, 10H, ArH), 4.51 (t, 10H, J = 5.0 Hz , OCH2CH2-
triazole), 4.20 (d, 5H, J = 7.1 Hz, H1), 3.94 (bs, 10H, ArCH2Ar), 3.92-3.80 (m, 
20H, H4, β-COCHa, OCH2CH2-triazole), 7.77 - 7.69 (m, 10H, H6a, H6b), 3.66 - 
3.40 (m, 120H, β-COCHb, H2, H3, H5, OCH2, C(O)NHCH2), 3.29 (s, 15H, OCH3), 
2.67 (t, 10H, J = 7.6 Hz, triazole-CH2CH2CH2), 1.72 - 1.53 (m, 20H, triazole-
CH2CH2CH2, β-COCH2CH2), 1.44 - 1.24 (m, 50H, CH2 aliphatic chain); 
13C NMR 
(75 MHz, CD3OD): δ = 169.6 (C(O)NH), 160.9 (Ar-ipso), 149.0 (C4triazole), 135.8 
(Ar-ortho), 130.7 (Ar-para), 129.7 (Ar-meta), 124.0 (C5 triazole), 105.0 (C1), 76.6, 
75.1, 72.6 (C2, C3, C5), 71.5, 71.4, 71.3, 70.8, 70.6, 70.4, 70.3 (OCH2, β-COCH2, 
C4), 62.5 (C6), 61.5 (ArOCH3), 51.3 (OCH2CH2-triazole), 41.0 (C(O)NHCH2), 32.0 
(ArCH2Ar), 30.8, 30.6, 30.5, 30.4, 30.3, 27.1 (CH2 aliphatic chain), 26.3 (triazole-
CH2CH2CH2); MS (HR-ESI+): m/z = 1305.0569 [100% (M+3H)3+], calcd: 1305.0601.
Lactosylcalix[5]arene (17)
The peracetylated-lactosylcalix[5]arene 15 (42.0 mg, 6.8 μmol) was dissolved in 
5 mL of CH3OH, and drops of a freshly prepared methanol solution of MeONa 
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were added till pH 8-9. The mixture was stirred at room temperature for 18 h. 
The progress of the reaction was monitored via ESI-MS analysis. Amberlite resin 
IR 120/H+ was subsequently added for quenching, and the mixture was gently 
stirred for 30 min. till neutral pH. The resin was then filtered off and the solvent 
removed under reduced pressure to give pure product 17 as a yellow oil. Yield: 
72%; 1H NMR (300 MHz, CD3OD): δ = 7.79 (s, 5H, H5 triazole); 7.60 (s, 10H, 
ArH), 4.51 (t, 10H, J = 5.0 Hz, OCH2CH2-triazole), 4.35 (d, 5H, J = 7.3 Hz, H1’), 
4.26 (d, 5H, J = 7.8 Hz, H1), 3.93 (bs, 10H, ArCH2Ar), 3.90 - 3.65 (m, 40H, H4’, 
H6ab’, H6ab, Glc β-COCHa, OCH2CH2-triazole), 3.65 - 3.35 (m, 135H, H3, H4, 
H5, H2’, H3’, H5’, Glc β-COCHb, OCH2, C(O)NHCH2), 3.28 (s, 15H, OCH3), 3.23 
(t, 5H, J = 8.4 Hz , H2), 2.66 (t, 10H, J = 7.6 Hz, triazole-CH2CH2CH2), 1.69 - 1.53 
(m, 20H, CH2 aliphatic chain), 1.42 - 1.23 (m, 50H, CH2 aliphatic chain); 
13C NMR 
(75 MHz, CD3OD): δ ppm = 169.6 (C(O)NH), 160.9 (Ar-ipso), 148.8 (C4 triazole), 
135.7 (Ar-ortho), 130.7 (Ar-para), 129.7 (Ar-meta), 124.2 (C5 triazole), 105.1 
(C1’), 104.2 (C1), 80.7 (C4), 77.0, 76.5, 76.4, 74.8, 74.7, 72.5 (C2, C3, C5, C2’, 
C3’, C5’), 71.5, 71.4, 71.3, 70.9, 70.6, 70.4 (OCH2, β-COCH2,), 70.3 (C4’), 62.5, 
61.9 (C6, C6’), 61.5 (ArOCH3), 51.4 (OCH2CH2-triazole), 41.0 (C(O)NHCH2), 32.0 
(ArCH2Ar), 30.8, 30.6, 30.5, 30.4, 30.2, 27.1 (CH2 aliphatic chain), 26.2 (triazole-
CH2CH2CH2); MS (HR-ESI+) m/z = 1575.1475 [100% (M+3H)3+], calcd = 1575.1481.
17-Azide-3,6,9,12,15-pentaoxaheptadecane-1-aminocarbonyl-p-methoxybenzene (19)
Oxalyl chloride (1.5 mL, 16.0 mmol) was added to a solution of 4-methoxybenzoic 
acid (0.30 g, 2.0 mmol) in 15 mL of dry CH2Cl2 and the mixture was stirred at room 
temperature under N2 for 18 h. The solvent was then removed under reduced 
pressure and the residue dissolved again in 5 mL of dry CH2Cl2. This solution was 
added dropwise to a round bottomed flask containing the azidoamine compound 7 
(0.91 g, 3.0 mmol) and NEt3 (0.5 mL, 3.0 mmol ) in 10 mL of dry CH2Cl2. The mixture 
was let react for 20 h at room temperature under N2 atmosphere. The reaction was 
monitored via TLC (eluent: AcOEt). A 1 M HCl solution (20 mL) was then added 
to quench the reaction, and the product extracted with CH2Cl2 (2 × 20 mL). The 
combined organic phases were washed with NaHCO3 saturated aqueous solution 
(15 mL), brine (15 mL), water (15 mL), dried over anhydrous Na2SO4, filtered and 
the solvent evaporated under reduced pressure. The crude was purified by flash 
chromatography (eluent: AcOEt/acetone 9 : 1). Product 19 was obtained pure as a 
yellow oil. Yield: 20%; 1H NMR (300 MHz, CDCl3): δ (ppm) 7.74 (d, 2H, J = 8.9 Hz, Ar-
meta); 6.87 (d, 2H, J = 8.9 Hz, Ar-ortho); 6.78 (bs, 1H, C(O)NH); 3.80 (s, 3H, OCH3); 
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3.65 - 3.54 (m, 22H, OCH2, C(O)NHCH2); 3.32 (t, 2H, J = 5.0 Hz, CH2N3); 
13C NMR 
(75 MHz, CDCl3): δ ppm 167.0 (Ac); 162.0 (Ar-ipso); 128.8 (Ar-meta); 126.9 (Ar-para); 
113.6 (Ar-ortho); 70.6, 70.5, 70.2, 70.0, 69.9 (OCH2); 55.4 (OCH3); 50.6 (CH2N3); 39.7 
(C(O)NHCH2); MS (ESI+) m/z = 463.0 [100% (M+Na)+]; 435.0 [60% (M-N2+Na)+].
GM1os-monomer (20)
Starting from compounds 19 and 9, following the same procedure as for compound 
1, and using reversed phase column chromatography for the purification (gradient 
MeOH/ H2O/ AcOH), monomer 20 was obtained as a white solid in 49% yield. 1H 
NMR (D2O, 400 MHz): δ = 7.81 (3H, m, triazole, Ar), 6.98 (2H, d, J = 8.4 Hz, Ar), 
4.71 (1H, s, H1-GalNAc), 4.39 (1H, d, J = 8.4 Hz, H1-Gal’), 4.42 (1H, m, H1-Gal), 
4.38 (1H, m), 4.31, (1H, d, J = 8.2 Hz, H1-Glc), 4.05-4.01 (3H, m), 3.93 (1H, m, H2-
GalNAc), 3.75 - 3.40 (21H, m) , 3.60-3.47 (16H, m), 3.36-3.28 (14H, m), 3.25 (1H, 
m, H2-Gal), 3.18 (1H, m, H2-Glc), 3.10 (2H, s), 2.54 (1H, m, H3a-Neu5Ac), 2.35 
(2H, m, CH2-triazole), 1.92 (3H, s, NHC(O)CH3-Neu5Ac), 1.85 (3H, s, NHC(O)CH3-
GalNAc), 1.75 (1H, m, H3b-Neu5Ac), 1.40 (4H, m), 1.11 (2H, m, Glc β-COCH2CH2), 
1.03 (8H, m, -CH2CH2CH2-);  
13C NMR (D2O, 75 MHz): δ (ppm) 174.8, 174.5, 173.9, 
168.5, 159.2, 128.4 (2 x CH Ar), 123.1 (C4 triazole), 113.2 (2 × CH Ar) 104.6 (C1-
Gal’), 102.7 (C1-Gal), 102.4 (C1-GalNAc), 102.0 (C1-Glc), 101.5 (C2-Neu5Ac), 80.2 
(C3-GalNAc), 78.5 (C4-Glc), 77.0 (C4-Gal), 74.7, 74.6, 74.4, 74.2, 74.1, 74.0, 73.9 
(C2 Glc), 72.6 (C3 Gal’), 72.3, 72.1 (C2-Gal’), 70.6 (Glc β-COCH2), 70.4 (C2-Gal), 
70.4 - 68.5 (-OCH2-, PEG,  Glc β-COCH2), 68.4 (C4-GalNAc), 67.8, 62.7, 60.9, 60.8, 
60.4, 60.0, 51.4, 51.0 (C2 GalNAc), 49.8, 39.5, 36.7, 28.8 - 28.3 (CH2CH2CH2), 25.0 
(Glc β-COCH2CH2), 24.5 (CH2-triazole), 22.5 (NHC(O)CH3-GalNAc), 21.9 (NH(O)
CH3-Neu5Ac); MS (HR-ESI-) m/z: 1587.7009 [100% (M-H)-], calcd = 1587.7034.
CTB5 inhibition assays
Each well of a 96-well microtiter plate was coated with a 100 μL native GM1 
solution (1.3 µM in ethanol) after which the solvent was evaporated. Unattached 
GM1 was removed by washing with PBS (3 × 450 µL), the remaining free binding 
sites were blocked by incubation with 100 µL of a 1% (w/v) BSA solution in PBS 
for 30 min. at 37 °C. Detection limits were determined by placing CT-horseradish 
peroxidase conjugate (CT-HRP), without inhibitor, on the plate, which gives the 
highest response, and the lowest response was determined by the optical density 
of the blank, i.e. the native GM1-coated well with all components except the 
inhibitor and toxin. These two values represent the minimum and the maximum 
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values of optical density, 0% and 100% of binding of the CT to the GM1-coating 
of the wells. Subsequently, the wells were washed with PBS (3 × 450 µL). In 
separate vials, a logarithmic serial dilution, starting from 2.0 mM, of 150 µL 
saccharide-calixarenes in 0.1% BSA, 0.05% Tween-20 in PBS, mixed with 150 
µL of a 50 ng/mL CTB-HRP solution in the same buffer were incubated. This 
gave an initial inhibitor concentration of 1.0 mM. In the case of potent inhibitors, 
based on the logarithmic experiments, a more accurate, serial dilution of a 
factor two was performed around the expected IC50 values. The inhibitor-toxin 
mixtures were incubated at room temperature for 2 h and then transferred to 
the coated wells. After 30 min. of incubation at room temperature, unbound 
CTB-HRP-calixarene complexes were removed from the wells by washing with 
0.1% BSA, 0.05% Tween-20 in PBS (3 × 500 µL). 100 µL of a freshly prepared 
OPD solution (25 mg OPD·2HCl, 7.5 mL 0.1 M citric acid, 7.5 mL 0.1M sodium 
citrate and 6 µL of a 30% H2O2 solution, pH was adjusted to 6.0 with NaOH) was 
added to each well and allowed to react with HRP in absence of light, at room 
temperature, for 15 minutes. The oxidation reaction was quenched by addition 
of 50 µL 1 M H2SO4. Within 5 min., the absorbance was measured at 490 nm.
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Electronic effects versus distortion energies during strain-
promoted alkyne-azide cycloadditions: 
A theoretical tool to predict reaction kinetics
4
Abstract:
Second-order reaction kinetics of known strain-promoted azide-alkyne 
cycloadditions (SPAAC) were compared with theoretical data from various ab initio 
methods. This produced both detailed insight into determining the reaction rates 
and two straightforward theoretical tools to predict a priori the reaction kinetics 
of novel cyclooctynes for strain-promoted cycloadditions. Multiple structural 
and electronic effects contribute to the reactivity of cyclooctynes with azides 
in cycloaddition reactions. It is therefore hard to relate a physical or electronic 
property directly and independently to the reactivity of the cyclooctyne. However, 
we show that Hartree-Fock LUMO energies, which were acquired while calculating 
activation energies on MP2 level of theory, correlate with second-order kinetic 
rate data and are therefore usable for reactivity predictions of cyclooctynes 
towards azides. Using this correlation we developed a simple theoretical 
tool to predict reaction kinetics of (novel) cyclooctynes for SPAAC reactions.
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4.1 Introduction
The strain-promoted azide-alkyne cycloaddition (SPAAC) reaction is increasingly 
investigated for bio-orthogonal purposes. Cyclooctynes have proven valuable 
because of their relative biological inertness, their strain-induced high efficiency, 
and selectivity towards azides in cycloaddition reactions.[1] Unlike the copper-
catalyzed variant of Huisgen’s 1,3-dipolar cycloaddition,[2] – i.e. the Copper-
catalyzed azide-alkyne cycloaddition reaction, which emerged over the years 
as the prototypical “click-reaction”[3] – there is no need for toxic additives 
like Cu(I). This is advantageous, since copper ions can induce undesirable 
side-reactions such as non-specific binding to thiol groups and oxidative 
damage that both Cu(I) and Cu(II) ions are able to inflict on biomolecules.[4] 
Also, since cyclooctynes are generally not reactive towards other cellular 
components in aqueous media, they can be used in studies on cellular level.[5] 
Figure 1. Cyclooctynes under study.  See text for details.
In 1953, Blomquist,[6] and later, Wittig and Krebs[7] described the reaction of 
cyclooctyne (OCT, 1, Figure 1) with phenyl azide as an “explosive reaction”. Based 
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on work by Turner et al.[8] on ∆H of hydrogenation of unsaturated aliphatic compounds 
(including cyclooctyne), Bertozzi later assigned significant rate enhancements to 
the ring strain of 18 kcal/mol[9] for 1 compared to unstrained alkynes. Subsequently, 
the use of electron-poor cyclooctynes was shown to speed up the reaction 
significantly, specifically in 3,3-difluorocyclooct-1-yne (DIFO, 2).[5d, 10] Dommerholt et 
al. developed bicyclo[6.1.0]non-4-yne (BCN, 3)[11] with the additional advantage over 
earlier cyclooctynes that it is readily prepared and symmetrical, thus avoiding the 
formation of regioisomeric adducts upon cycloaddition with an organic azide (Figure 
2). Apart from electron-withdrawing groups, like the fluorine groups in compound 2, 
the addition of extra ring strain was also shown to be advantageous, as for example 
implied from the observed high rates for 3,7-dibenzocyclooctyne (DIBO) 4.[13] 
In 2010, difluorobenzocylooctyne (DIFBO) was described[14] that combines 
the electron-withdrawing effect of the fluorine atoms of 2 with the ring strain 
of 4. This compound was shown to be the most rapidly reacting cyclooctyne 
towards azides reported to date, but was not taken up in the current study 
because of its lack of stability outside a protective cyclodextrin shell. Based 
on the framework of 4, two endocyclic nitrogen-containing dibenzocyclooctyne 
derivatives have been published. These contain either a CH2 group and a 
nitrogen atom in the ring (DIBAC, compound 5),[15, 16] or an endocyclic amide 
(lactam) functionality and no saturated carbon atoms in the cyclooctyne ring 
(BARAC, compound 6).[17] Kinetic data are available for 2 - 6 as summarized 
in Table 1, while the kintetic data of 1 is only available for an analogue that 
contains an alkoxy moiety at the 3-position.[9] Therefore, we performed our 
own kinetic study on compound 1 (vide infra). Compound 7 was described in 
literature,[12] but not in reaction with azides. Compounds 8 - 10 are strained 
models that have not been described in literature at the time of writing.
Relatively little theoretical work has been published up to now that correlates 
experimental and calculated data of these strain-promoted cycloadditions. Various
Figure 2. SPAAC of strained cyclooctyne BCN (3) and allyl azide, yielding triazole 11.
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properties are known to influence the reaction kinetics of these cyclooctynes 
in SPAAC reactions (Figure 3). For example, Houk and co-workers performed 
B3LYP/6-31G(d) optimizations to compare the reactivity of 1 and 2,[19] which were 
more recently complimented with a more extensive series of SCS-MP2/6-311G(d) 
single-point computations on B3LYP-optimized geometries.[20] These studies 
concluded that the difference in the reactivity of various cyclooctynes is based on 
the difference in distortion energies of the alkynes, which is required to deform it 
from the reactant geometry to the geometry it has in the transition state (TS). In 
addition, the ring strain in cyclooctynes has been investigated systematically by 
Bach with B3LYP/6-311+G(3df,2p) calculations.[21] He calculated that the barrier for 
cycloaddition of benzyl azide and DIFO (2) is 2.3 kcal/mol lower than addition to OCT 
(1). This method was also used to investigate the trends in activation barriers for the 
1,3-dipolar cycloadditions of azides with various cyclooctynes, dibenzocyclooctynes 
Table 1. Experimental data of SPAAC second-order reaction kinetics of cyclooctynes with benzyl azide.
Compound k [·10-3 M-1·s-1] Solvent Reference
1 5.8 CD3CN/D2O a
2 76 CH3CN [5d]
3 140 CD3CN/D2O [11]
4 170 CD3OD [13]
120 CD3CN [18]
5 310 CD3OD [15]
6 960 CH3CN [17]
[a] Current work; see Appendix II for details.
Figure 3. Various properties of the cycloocytnes that influence their SPAAC reaction kinetics; left) Transition 
state conformation of DIFO (2); right) trans-cyclobutyl-substituted 10 with allyl azide.
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and azacyclooctynes. Subsequently, Goddard and co-workers concluded that 
proper placement (e.g. on the position next to the sp-hybridized alkyne carbons) 
of electron-withdrawing substituents leads to LUMO-lowering effects on the 
alkyne, and that this is accompanied by higher reactivity of cyclooctynes towards 
cycloaddition with azides.[22] 
Houk et al. showed an approximately 2 kcal/mol increase in reactivity of DIFO 
(2) with respect to the parent compound OCT (1). Gold et al. confirmed this finding 
and elaborated with Natural Bond Order (NBO) analyses that showed that hyper-
conjugative donation of the alkyne π-system to the σ*C−F orbital directly leads to 
the TS stabilization via assistance in alkyne bending,[23] which is the apparent drive 
for the 50-fold increase of reactivity of DIFO (2), together with the LUMO-lowering 
effect, described by Goddard earlier. Both Gold and Goddard pleaded for the strategy 
of lowering the energy of the TS to increase reactivity towards azides rather than 
reactant destabilization. In case of DIFO, increased reactivity is a direct result of 
Ea lowering. Gold and co-workers hinted at a theoretical tool to predict reactivity in 
the form of a combination of the above described calculable molecule properties. 
Recently, the reaction kinetics of BARAC (6) derivatives were shown to vary 
depending on the addition of several substituents.[24] The reaction kinetics of the 
derivatives were subsequently compared with B3LYP/6-31G(d) calculations. It was 
found that addition of fluorine groups on the aryl-groups of BARAC (6), resulted in 
an increase in reactivity of ~ 75% compared to its parent compound (6). By using 
B3LYP calculations, this was attributed to increased stabilizing interaction energy 
in the TS. In the same study, a decrease in the alkyne bond angle was correlated 
to an increase in reactivity. The authors suggested that the calculated TS distortion 
and interaction energies could be used in the design of novel cyclooctynes. 
To date, however, a generally applicable computational tool to correlate the 
structures of these cyclooctynes to their reaction kinetics, has not yet been 
described. In the current paper, we will focus in more detail on the transition 
states of SPAAC reactions, and describe tools that predict a priori the reaction 
kinetics of novel cyclooctynes for application in these cycloaddition reactions. 
Given the still growing interest in SPAAC reactions, it is highly desirable 
to have a simple theoretical tool that can predict the reactivity of novel, 
hypothetical cyclooctynes. Up till now, scientists have mainly focused on the 
development of faster reacting cyclooctynes. However, the cost of increased 
reactivity is often paid by decreased stability. This is for example seen in DIBO 
 (4)[13] that needs to be stored while deprived of light and oxygen. The decreased 
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stability of highly reactive cyclooctynes hampers the further development 
of SPAAC reactions in material sciences like, in our own experience, in the 
development of biosensors.[26] Additionally, these compounds with a high 
intrinsic energy are prone to lose their selective reactivity, by also being able 
to undergo – apart from SPAAC reactions – e.g. a thiol-yne reaction with 
cysteines, which would complicate the application of these cyclooctynes in 
biosciences. The ability to tune the reactivity of cyclooctynes by combining an 
increase in reactant stability with a high efficiency during SPAAC, is therefore 
of paramount importance in both biological and material sciences.[25] Hence, it 
would be advantageous if the design of novel cyclooctynes with, for example, 
additional groups that increase the water solubility, could be guided by 
predicting their reactivity before going through the effort of synthesizing them. 
We here present precisely this: a theoretical tool that can accurately predict 
SPAAC reaction kinetics. Furthermore, we describe an even simpler, though less 
accurate, tool to be used by non-theoreticians that only requires a ChemDraw-like 
chemical structure as input to quickly give an indication of the reactivity of new 
cyclooctynes before they are actually developed. In the here presented study, 
we further elucidate the relationship between SPAAC kinetics and cyclooctyne 
electronic properties, by investigating the SPAAC transition state structures and 
energies for a structurally diverse set of ten cyclooctynes (1 - 10; Figure 1). This 
was performed with a combination of DFT (B3LYP[27], M06-2X[28]) and SCS-MP2[29] 
calculations. Among the ten selected cyclooctynes, six (1 - 6) have been previously 
used in SPAAC reactions and four (7 - 10) have not been used yet. Finally, to 
improve the benchmarking of our calculations additional competition experiments 
and kinetic constant determinations were performed on cyclooctynes 1 - 3. 
4.2 Computational and experimental methods
Calculations were performed using the Gaussian 09 set of programs.[30] Structures 
(reactants and transition states) were optimized, and the resulting geometries 
were shown to be real minima or transition states on the potential energy 
surface via vibrational frequency computations. The standard IEFPCM dielectric 
continuum solvent model for MeOH with UA0 radii was used. Optimization was 
consistently performed using the 6-311G(d,p) basis set, at the B3LYP, M06-2X, 
and MP2 levels of theory. Following the optimization, single-point energies 
were obtained using the 6-311+G(2d,2p) basis set for all these three methods, 
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while for the MP2-optimized geometries SCS-MP2 energies were obtained.
[29b] Zero-point energies were included in all values. Geometries and vibrations 
were visualized using Gaussview 4. The syntheses of 1 and allyl azide were 
performed as described in Appendix. Determination of the reaction kinetics of 
unsubstituted cyclooctyne (1) with benzyl azide was performed according to 
literature,[11] as described in detail in the Appendix II. Competition experiments of 
1, benzyl azide and allyl azide were performed as described in the Appendix II.
4.3 Results and Discussion
4.3.1. Alkyne-azide cycloadditions
Table 2 depicts the activation energies obtained from calculations with B3LYP, 
M06-2X, and SCS-MP2 methods for the ten cyclooctynes under investigation. 
Since all compounds obviously contain strain, triple-ζ [6-311G(d,p)] basis sets 
were employed for the optimizations, while the single-point energy calculations 
involved the flexible 6-311+G(2d,2p) basis sets. From experimental studies 
on reaction kinetics, it is well-known that 3 reacts appreciably faster than 
2 and at least an order of magnitude faster than 1 (Table 1). Originally, 1 
was published including an alkoxy substituent on the 3-position.[9] The kinetic 
reaction rate was also published for this compound (k = 2.4 × 10-3 M-1·s-1) 
but considering that the 3-substituent may induce both in the comparison 
with the calculated activation energy. Therefore, 1 was synthesized (see 
Appendix II for experimental details). The rate of 1 in the SPAAC reaction with 
benzyl azide was determined to be k = 5.8 × 10-3 M-1∙s-1 in CD3CN/ D2O (3 : 1). 
All currently available kinetic data for the reaction of cyclooctynes 1 - 6 
and azides are presented in Table 1, and range over more than two orders 
of magnitude. The approximate order of experimental reactivity of these 
compounds in various media is 6 > 5 > 4 ≈ 3 > 2 > 1. This order was, however, 
not borne out by B3LYP-based calculations that yielded the relative order of 
2 > 1 > 6 > 3 > 5 > 4. To check whether this discrepancy could be remedied 
by another DFT functional, thereby keeping the computational advantage of 
the relatively fast density functional theory, Truhlar’s M06-2X functional was 
employed. However, also the M06-2X functional was unable to reproduce 
the correct qualitative trend, and yielded a rate order 6 > 5 ≈ 2 > 1 ≈ 3 > 4. 
In contrast, MP2 calculations did follow the order of reactivity (Appendix 
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II Figure S6), but produced incorrect, negative, activation energies. When, 
however, scaled to SCS-MP2 (Figure 4a), the calculations could properly 
mimic the complete experimental trend in relative reactivities and also 
produced realistic activation energies (Table 2). For example, it was clear from 
these calculations that 6 was the fastest in reacting with azides and 1 the 
slowest. Application of this method on compounds 7 - 10 confirms the role of 
ring strain in determining the height of the SPAAC activation energy barrier. 
Figure 4. Plot of the logarithm of experimental second-order rate constants (see Table 1 for references) versus 
calculated activation energies obtained from (a) SCS-MP2/6-311+G(2d,2p)//MP2/6-311G(d,p), (b) B3LYP/6- 
311+G(2d,2p)//B3LYP/6-311G(d,p), and (c) M06-2X/6-311+G(2d,2p)//M06-2X/6-311G(d,p) calculations.
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Table 2. Calculated activation energies (kcal∙mol-1) in the gas phase and in MeOH (IEFPCM 
solvent model), of the SPAAC reaction for the studied cyclooctynes with allyl azide (A) or 
benzyl azide (B) obtained via SCS-MP2, B3LYP, and M06-2X calculations (see text for details).
Compound SCS-MP2Gas   MeOH
B3LYP
Gas   MeOH
M06-2X
Gas   MeOH
1 + A 10.5  11.3 12.1  13.2 11.8   13.0
1 + B   9.6  10.5 11.9    8.2 11.1   12.7
2 + Aa   6.7    6.4 11.5  11.6 9.4       9.7
2 + Ba   6.3     6.0 11.6  11.9 9.6      9.9
3 + A   6.5    7.4 13.0   14.1 11.7  12.9
3 + B   6.2    7.1 ND ND
4 + A   6.3    7.7 16.5  17.9 12.3  13.9
4 + B   5.7    7.7 15.0  11.6 11.5  13.4
5 + A   3.5    5.2 13.7   15.4 9.4    11.2
6 + A   2.1    3.5 12.9  14.5 7.7      9.5
7 + A   5.7    6.3 12.0   12.9 10.8  11.6
7 + B   5.4     5.9 12.1    7.9 10.8  11.8
8 + A   8.6    9.5 13.8   15.1 12.6  14.1
9 + A   7.5    8.7 13.3   14.6 12.2  13.8
10 + A   9.6   10.7 15.2   16.5 12.6  14.1
[a] Only 1,4-addition (trans) transition states were calculated. ND = Not Determined.
Increasing the cyclooctyne ring strain in 7 and 8 via inclusion of sp2-hybridized 
carbon atoms predicted a significantly increased reactivity towards cycloaddition 
with azides compared to 1. Comparison of compound 7 with 4 shows that an 
increased size of the conjugated system also plays an important role in lowering 
the activation energy barrier. Both 7 and 4 have a similar ring strain, but 4 has a 
more extended π-electron system. Next to the ring strain and size of the conjugated 
system, also conformational stabilities affect the cyclooctyne reactivity. For example, 
the trans-cyclobutyl moiety in 10 restricts the eight-membered ring conformation 
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to a flattened structure (Figure 3). This impedes the formation of the chair-like 
conformation that the eight-membered ring in cyclooctynes preferentially adopts 
in the TS of SPAAC reactions, as is shown for 2. The analogous cis-cyclobutyl-
containing 9 adopts a chair conformation and is correspondingly calculated to be 
more reactive than 10 (see Table 2, and Appendix II Figure S7 for TS geometries).
4.3.2. Transition state activation energies
Figure 4 shows plots of the logarithm of experimental second-order rate constants 
against the calculated activation energies as obtained by SCS-MP2, B3LYP, and 
M06-2X calculations. Obviously, the correlations of the experimental rates with 
B3LYP data (R2= 0.118) and M06-2X data (R2 = 0.335) are insufficient to be used 
in predicting the reaction kinetics of novel cyclooctynes. Given also the significant 
differences in TS geometries (cf. Figure 6), doubts rise concerning the use of DFT-
derived geometries for single-point activation energy determinations. In contrast, 
when the experimental rate constants were plotted against SCS-MP2 calculated 
activation energies, using MP2-derived geometries in the gas phase, a clear linear 
relation with good correlation was found (R2 = 0.937). The correlation was lower 
between the SCS-MP2 activation energies in MeOH and the experimental rate 
constants (Appendix II Figure S8). The used solvent model, however, only provides 
a rough approximation of the complex interactions between MeOH and molecules 
in the TS, which probably results in less accurate calculated activation energies. 
The correlation between the experimental and computational, gas phase, data 
might even improve further if the experimental data were determined for one 
solvent system, which is currently not the case (see Table 1). For example, the 
experimental data for compounds 3, 4, and 5 were reported in protic solvents, which 
are known to speed up the reaction with respect to acetonitrile.[18] Nevertheless, 
the found high linear correlation showed that SCS-MP2 data was suitable for use 
in our evisaged predictive tool. In the remainder of this study we therefore limited 
ourselves to MP2-optimized geometries and the SCS-MP2 energies thereof. 
SPAAC rate constants found in the literature have mostly been experimentally 
determined with benzyl azide as the model compound (Table 1). The number of 
carbon atoms makes the vibrational frequency calculations on the TS of benzyl 
azide and a cyclooctyne rather time-consuming to track computationally via 
Møller-Plesset type calculations. Therefore, we studied the TS properties with 
allyl azide as well, both theoretically and experimentally. Kinetic data on benzyl
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azide and allyl azide reactivity with 1 were obtained from second-order rate 
constant experiments. A five-fold excess of a 1 : 1 mixture of allyl azide and 
benzyl azide was reacted competitively with compound 1 in CD3CN/ D2O (3 : 1), 
and in a separate experiment with compound 3. As the product ratios of the allyl 
and benzyl triazole products were 1 : 1.3 and 1 : 1.4, respectively (see Appendix 
II), it is clear that the reaction of allyl azide can be compared accurately with 
that of benzyl azide. This was confirmed computationally: for compounds 1 - 4 the 
barriers were computed for both allyl azide and benzyl azide, and the difference 
between allyl azide and benzyl azide was < 0.9 kcal∙mol-1 for all four cases, with 
the barrier of benzyl azide consistently lower than that of allyl azide (Table 2). 
Also, the TS geometries for these two systems are highly similar. For example, in 
Figure 5. left) TS geometry of compounds 1 - 4 with allyl azide; right) Structural data that was obtained from 
MP2/6-311G(d,p) optimization.
∠
∠
∠
∠
∠
∠
∠
∠
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∠
∠
OCT (1)  N3 138.0 º D Nterm-C1 2.10 Å 
 C1-C2-CH2 150.0 º d Nint-C2 2.11 Å 
 C2-C1-CH2 153.2 º d C≡C 1.25 Å 
 DIFO (2)  N3 137.5 º d Nterm-C1 2.05 Å 
 C1-C2-CH2 150.6 º d Nint-C2 2.07 Å 
 C2-C1-CF2 150.0 º d C≡C 1.26 Å 
 BCN (3)   N3 143.0 º d Nterm-C1 2.19 Å 
 C1-C2-CH2 145.8 º d Nint-C2 2.18 Å 
 C2-C1-CH2 145.2 º d C≡C 1.25 Å 
 DIBO (4)  N3  136.7 º d Nterm-C1 2.07 Å 
 C1-C2-C 147.8 º d Nint-C2 2.04 Å 
 C2-C1-C 150.0 º d C≡C 1.27 Å 
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the MP2/6-311G(d,p)-derived TS of 1 with benzyl azide r(Nterm-C) and r(Nint-C) 
are 2.100 and 2.099 Å, respectively, while for the allyl azide-derived TS these 
values are 2.102 and 2.108 Å, respectively (Figure 5). In addition, the imaginary 
frequencies that track the potential energy curve for approach of the reactants are 
near- identical: -272.2 and -273.8 cm-1, respectively. Therefore, all TS structures 
were optimized at the MP2 level of theory for the reaction with allyl azide, while 
for compounds 1 - 4 these TS structures were also optimized with benzyl azide.
4.3.3. Transition state geometries
To study the correlation of experimental and theoretical data in more detail, an 
in-depth study was made of the TS geometries. When comparing the geometrical 
features of the TS as obtained by the various methods, the TSs acquired from MP2 
calculations were consistently shown to be significantly ‘tighter’ than obtained 
from either B3LYP or M06-2X calculations. As a typical example, Figure 6 shows 
the relevant bond lengths for the cycloaddition of 1 and allyl azide. With the 
B3LYP functional, the calculations yielded asymmetric alkyne-azide distances in 
the order of 2.17 - 2.31 Å. M06-2X calculations showed near-symmetric distances 
of approximately 2.20 Å, while MP2 calculations showed ‘tighter’ and also near-
identical distances of 2.10 Å. In all three cases, 1 adopted a chair-like conformation. 
In Figure 5, the TSs of four cyclooctynes (1 - 4) with allyl azide are described 
Figure 6. TS conformations of 1 and allyl azide, calculated with MP2, B3LYP, and M06-2X, respectively.
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as optimized via MP2 calculations. They all exhibit a chair-like conformation 
in the TS with allyl azide. On a first-level approximation, given the exothermic 
nature of the reaction, lower activation energies could be expected for an 
earlier TS conformation, in which the C-N distance is larger. This is indeed the 
case for the TS of 3 with allyl azide in which the C-N distance is around 2.19 Å, 
and is more distant in comparison with the 2.10 Å of 1. Also, in the case of allyl 
azide and 3, the azide angle is larger, which means that less N-N-N bending is 
required in order to reach the TS conformation. This latter feature is confirmed by 
the distortion energy of allyl azide (the energy difference between the azide in the 
geometry of the optimized reactant and in the geometry it has in the TS), which 
is 7 kcal/mol lower than that of allyl azide in a TS with 1 (Table 3). However, for 
the also more rapidly reacting compound 4, the TS seems to be later than for 1. 
For example, the C-N distances are around 2.05 Å, which imply a tighter TS than 
found for 1. This corresponds to the larger distortion energy calculated for the allyl 
azide and benzyl azide components reacting with 4 in comparison to reaction with 
1: 26.1 and 27.2 kcal/mol for 4, and 24.8 and 24.4 kcal/mol for 1, respectively. In 
other words, while both 3 and 4 react appreciably faster than 1, the TS of 3 is also 
characterized by a lower distortion energy, while that of 4 is characterized by a 
higher distortion energy than observed for 1. A similar discrepancy is observed 
for compound 2, which also reacts faster than 1 but has a later TS (Figure 5). In 
general, plots of the activation energy versus alkyne or azide distortion energies 
show only a poor correlation for the studied cycloocytnes (see Appendix II Figure S9). 
From these observations it can be concluded that the geometries of the TSs 
and distortion energies of these cyclooctynes cannot be generally correlated 
Table 3. Distortion energies per component (cyclooctyne or azide) for the SPAAC reactions of cyclooctynes 1 - 4, allyl 
azide (A), and benzyl azide (B) (in kcal/mol). 
Compound Edistortion Compound Edistortion
1 (+ A) 3.6 A (+ 1) 24.8
1 (+ B) 3.7 B (+ 1) 24.4
2 (+ A) 1.8 A (+ 2) 24.3
2 (+ B) 1.8 B (+ 2) 24.5
3 (+ A) 3.0 A (+ 3) 17.9
4 (+ A) 5.1 A (+ 4) 26.1
4 (+ B) 4.3 B (+ 4) 27.2
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to activating energies of SPAAC reactions. Also, natural charges on the alkyne 
carbon atoms and the azide nitrogen atoms could not be related to the reactivity 
of the cyclooctynes under study.
4.3.4. LUMO energy levels as predictive tools
Besides efforts to correlate activation energies to geometrical features of the TS, 
interactions between the most-involved molecular orbitals were also studied. This 
revealed a linear correlation between the activation energy Ea and the LUMO 
energy of the cycloalkyne as it is distorted in the TS (Figure 7a; R2 = 0.932), which 
is quite good given the spread of experimental conditions. A lower LUMO energy of 
the cyclooctyne (in the MP2-calculated TS geometry; please note: MP2 provides 
an energy correction on Hartree-Fock level-derived orbitals; as such the LUMO 
energy is a Hartree-Fock energy) consistently corresponded to a more rapidly 
Figure 7. Correlation of the activation energy (Kcal/mol) of the SPAAC transitions states with the LUMO 
energy (in eV) of the cyclooctynes (1 - 10) in the geometry they have (a) in the transition state with allyl 
azide, or (b) in the geometry they have as a fully optimized reactant.
Figure 8. Plot of Logarithm of experimental second-order rate constants for cyclooctynes 1 - 6 versus the 
calculated MP2 LUMO energies (eV) of their geometry in the SPAAC transition state with allyl azide.
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reacting molecule. The HOMO energy of the cyclooctynes could, however, not 
be related to the activation energy in a good linear fashion (Appendix II Figure 
S10). These findings confirm that the SPAAC reaction develops predominantly 
via azide-HOMO and alkyne-LUMO interactions.[12,20,31] However, also the 
azide-HOMO energies could not be related to the SCS-MP2 activation energy 
(R2 = 0.220; Appendix II Figure S11). On the contrary, when cycloocytne LUMO 
values are correlated to the experimental rate constants, a very good regression 
is observed: R2 = 0.960 (Figure 8). This further supports that the reaction is 
cyclooctyne LUMO-driven and that Hartree-Fock LUMO-values are indeed a good 
measure for the reactivity of the cycloocytnes in SPAAC reactions with organic 
azides. Given this success, we wondered whether more simple theoretical tools 
would be available to rapidly predict the order of reactivity of cyclooctynes in strain-
promoted cycloaddition reactions. Therefore, we also plotted the LUMO energy 
of the MP2-optimized cycloalkyne (i.e. full optimization, without presence 
of azide) against the calculated activation energies (Figure 7b). This again 
showed a decent linear correlation (R2 = 0.829), albeit with obviously more 
scatter than the linear correlation of the LUMO values that was obtained for the 
cyclooctynes in the transition state. Even this simplified approach yielded as 
reactivity order 6 > 5 > 4 ≈ 3 ≈ 2 > 1, which closely resembles the experimentally 
observed order 6 > 5 > 4 ≈ 3 > 2 > 1. Even quicker approaches, involving DFT, were 
less successful (R2 = 0.727 and 0.795, for B3LYP and M06-2X, respectively (see 
Appendix II Figures S12 and S13, respectively). Among the employed methods, 
only SCS-MP2 is a uniformly robust method that can yield useful SPAAC reactivity 
predictions. As LUMO energies can be calculated in a straightforward manner 
in a variety of GUI-assisted molecular simulation programs like Gaussview or 
ChemBio3D, this may simplify further experimental optimizations of strain-
promoted cycloaddition reactions, possibly also with other dipoles like nitrones, 
nitrile oxides[18] and other alkynes. A step-by-step standard operating procedure 
for performing these calculations, and thereby giving an indication of the 
reactivity of novel cyclooctynes in SPAAC reactions, can be found in Appendix II.
4.4 Conclusions
It is possible to predict the relative reactivity of strained alkynes in strain-promoted 
azide-alkyne cycloaddition (SPAAC) reactions, via the LUMO energy of the 
alkyne.  The LUMO energy in the TS geometry correlates accurately (R2 = 0.960) 
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with the experimental rate order for a diverse series of cyclooctynes. Even the 
alkyne LUMO energy of the relaxed, fully optimized cyclooctyne yields a good 
indication of relative reactivities. No good correlation between the experimental 
rates and alkyne distortion energies was observed. By comparing experimental 
data with theoretically derived activation energies, it was shown that SCS-MP2 
yielded accurate data, but that – although popular – the DFT methods B3LYP 
and M06-2X did not yield theoretical predictions that correlated favorably 
with experiment. Given the efficiency and accessibility of basic computational 
chemistry on 21th century personal computers, the calculation of LUMO values 
of novel cyclooctynes on these machines is a rapid and easily available method 
to obtain an initial valuable estimate of their reaction kinetics in strain-promoted 
cycloadditions prior to committing to the development of a synthetic route and 
actually preparing them. 
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4.6 Appendix II
Experimental procedure for the synthesis of 1 and allyl azide. Determination of rate 
constants of 1 with benzyl azide. Competition experiment procedure of 1 or 3 with 
benzyl azide and allyl azide. Plots of : Ea (MP2) versus log rate, TS conformation of 9 
and 10, Ea (SCS-MP2) in MeOH versus log rate, Ea (SCS-MP2) versus cyclooctyne 
distortion energies, Ea (SCS-MP2) versus cyclooctyne EHOMO (MP2), Ea (SCS-MP2) 
versus allyl azide EHOMO (MP2),  Ea (SCS-MP2) versus cyclooctyne ELUMO (B3LYP), 
and  ELUMO (M06-2X), (SCS-MP2) versus EHOMO(azide)-EHOMO(cyclooctyne), table with MO 
energies of allyl azide and benzyl azide in the TS with compounds 1 - 10,  step-by-step 
guideline for the calculation of cyclooctyne rate values and complete reference 30.

The influence of copper on GM1os-based CTB detection assays: 
CuAAC vs SPAAC
5
A part of this chapter was subject in a MSc project and documented as 
Synthesis of BCN-modified carbohydrates for surface modification via 
SPAAC reactions, Geert Noordzij, Wageningen University MSc thesis, 2012.
Abstract:
In this Chapter, copper-catalyzed azide-alkyne cycloaddition (CuAAC) 
reactions and strain-promoted azide-alkyne cycloaddtion (SPAAC) reactions 
are directly compared in biological assays. A GM1 oligosaccharide (GM1os)-
bearing compound that presented a hydrophilic spacer and a terminal alkyne 
was immobilized by CuAAC to microtiter plates. Two novel GM1os compounds 
were developed to contain cyclooctynes, one attached via an aliphatic and 
lipophilic undecane spacer and the second compound contained both the 
same aliphatic spacer and an additional hydrophilic hexa-ethyleneoxide 
(EO6) spacer. After the ganglioside derivatives were immobilized on microtiter 
plates by either CuAAC or SPAAC (depending on the nature of the attached 
alkyne), ELISA experiments were performed on the cholera toxin B-subunit 
(CTB). It is shown that when copper ions are added to the SPAAC-immobilized 
carbohydrates their ligand-CTB binding properties increase significantly. The 
most dramatic effect is shown for the EO6-containing compound, and therefore 
employing CuAAC in biological assays in combination with compounds that 
display such hydrophilic moieties is not recommended. These studies give 
significant insight on the effects of copper on carbohydrate-CTB avidity.
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5.1 Introduction
The pentasaccharide fragment of ganglioside GM1 plays a wide variety of 
biological roles, some beneficial, some detrimental.[1] In many of these latter cases, 
GM1 is the targeted entity on cell surfaces. Therefore, it is of general interest 
to synthesize tailor-made GM1 analogues that can be attached to a platform 
of interest for detection purposes. The synthesis and biological evaluation of a 
range of GM1 oligosaccharide (GM1os) fragments are described in Chapter 6. 
In that study, the synthesized fragments were immobilized on a surface via the 
copper-catalyzed alkyne-azide cycloaddition (CuAAC) reaction,[2] and assayed 
for their binding affinity towards a lectin, the cholera toxin B-subunit (CTB),[3] and 
antibodies (Abs) in the sera from patients with Guillain-Barré syndrome (GBS).[4] 
In that study and similar previous studies[5] we observed that in some instances 
the lectins or antibodies showed a significant selective preference for either 
the wild type GM1, which is the natural antigen for both CTB and many GBS-
related Abs, or for the very similar synthetic analogue GM1os. We have previously 
also observed significant differences in binding affinity of GBS Abs towards a 
synthetic GM1 analogue that was equipped with either an aliphatic (C11) or an 
oligo-ethyleneoxide (oligo-EO) aglycone-spacer and immobilized on sepharose 
beads via the CuAAC reaction (unpublished results). The oligo-EO-linked GM1os 
showed a marked lower binding affinity. 
The question therefore arose if, besides the small structural differences, the 
use of copper in the CuAAC ligation reaction, and its possible retention after 
standard washing procedures, might play a role in these observed differences 
in binding affinity. If indeed so, then changing the ligation reaction and omitting 
copper might improve the response of the synthetic GM1 derivatives in our ELISA-
type experiments. To investigate this, we required a facile ligation reaction that 
does not involve copper. Therefore, our attention turned to the strain-promoted 
alkyne-azide cycloaddition (SPAAC) reaction, which can be considered to be the 
copper-free equivalent of the CuAAC reaction. The SPAAC reaction has in recent 
years been successfully applied in a still rapidly increasing number of various 
biological applications.[6] 
Since the initial report by Bertozzi and co-workers in 2004,[7] the application 
of the SPAAC reaction has received a lot of attention.[6] It is especially lauded 
because it makes the use of toxic copper superfluous. The toxicity of copper 
is displayed by its ability to take part in oxidative mechanisms that readily 
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promote the generation of reactive oxygen species (ROS), which are likely to 
lead to biological damage.[8] An example of a disease that reveals the damage 
that copper can cause, through the development of ROS, is Wilson’s disease, 
in which a high copper concentration in the patients’ blood causes severe 
damage to liver and brain tissue.[9] Another commonly known property of copper 
is its ability to be reduced by thiol groups, which are commonly encountered 
in vivo in many proteins in the form of cysteine or methionine residues.[10]
 Importantly, it has also been reported that  polyethyleneglycol (PEG) moieties 
coordinate to copper ions (Figure 1).[11] Besides the use of PEG, or oligo-EO 
moieties as spacers to alter the lipophilicity of organic compounds in biological 
applications,[12] their other most frequent use is to suppress biofouling, which is an 
unwanted process initiated by the deposition of biological components on surfaces 
through aspecific adsorption.[13] Some speculate that copper coordination to the 
PEG spacer reduces the mobility of the spacer and any attached structures like 
antigens.[11] When translated to our investigation, this would mean that the antigen, 
i.e. the GM1os that is equipped with an EO spacers and in the presence of Cu ions, 
may display a lower binding affinity as a result. Because of these drawbacks, it 
becomes clear why there is a need to replace CuAAC as the tool for bioconjugation.
However, to date, only two studies have been published in which SPAAC was 
employed in ELISA-type experiments. First, Heemstra and co-workers recently 
reported an aptamer-based analogue of “sandwich” ELISA experiments, via a 
Figure 1. Illustrative example of an octahedral complex formed by coordination of a PEG spacer to copper(II)
chloride, proposed by Kaczmarek.[11]
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split aptamer approach that employed the SPAAC reaction, using 2-functionalized 
cyclooctyne and aza-dibenzocyclooctyne (DIBAC) and, on the opposite terminus, 
with biotin. The split aptamer approach consists of two DNA strands that only assemble 
in the presence of a small molecule, in this case cocaine.[14] With this approach they 
were able to detect µM-level quantities of cocaine in buffer and human blood serum. 
More recently, Van Hest and co-workers have reported on an assay in which 
the cyclooctyne, 9-hydroxymethylbicyclo[6.1.0]nonyne (BCN) (Figure 2),[15] is used 
to bind an azide-functionalized, citrulline-containing peptide.[16] The employed 
peptide sequence is recognized, and strongly bound, by anticitrulline antibodies 
(ACA’s) that have found medical application as an early diagnosis for the 
autoimmune disease rheumatoid arthritis.[17] In an indirect ELISA experiment, the 
azido-functionalized peptide was immobilized in either terminal alkyne or BCN-
functionalized ELISA wells, employing CuAAC or SPAAC, respectively (Figure 
2). ACA’s were subsequently added to bind to the immobilized peptide after 
which a secondary antibody, conjugated with horse radish peroxidase (HRP), 
was added to bind to the (primary) ACA. Finally, oxidation of the HRP-substrate 
3,3′,5,5′-Tetramethylbenzidine (TMB, Figure 2b) was measured by OD, which is 
indicative for peptide-ACA binding efficiency. It was found that the CuAAC strategy 
showed a high background signal that rendered the test less reliable. This was 
attributed to coordination of the copper catalyst to nitrogen moieties in the peptide 
sequence. Instead, the SPAAC strategy proved successful in its application and 
functioned on a par with a commercially available ELISA test for the ACA antibody.
In the study described in this chapter, we therefore investigate whether using 
the SPAAC reaction to attach carbohydrates with either oligo-EO spacers or 
Figure 2. a) Clickable, alkyne or BCN-terminated, microtiter plates to use for ELISA detection of ACA’s[16] ; b) HRP-
facilitated oxidation of TMB compound A to the oxidized TMB product B. Figure 2a reproduced from reference.[16]
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aliphatic spacers to our assay surfaces would be beneficial, compared to CuAAC, 
for the binding ability of these carbohydrates to CTB. We report the application 
and detailed comparison of SPAAC and CuAAC reactions for the immobilization 
of ganglioside GM1 epitopes in enzyme-linked lectin assay (ELLA) experiments. 
For this comparison, we used the well-documented[18] complementary set of the 
lectin CTB and the ganglioside GM1os (Figure 3). We employed the previously 
reported GM1os derivative 1,[5] which contains a lipophilic spacer and a terminal 
alkyne, and two novel cyclooctyne BCN-containing GM1os derivatives – GM1os 
derivatives, 2 and 3 – that contained a terminal cyclooctyne and were equipped 
without and with an oligo-EO spacer, respectively. The terminal alkyne equivalent 
of compound 3, displaying also an EO-spacer, was not available at the moment 
of testing and therefore not included in these experiments. With these target 
compounds, the effect of adding a hydrophilic EO spacer on the binding to CT 
could also be directly investigated. Additionally, a direct comparison of CuAAC 
versus SPAAC is made and insight is obtained on the influence of copper on the 
compound that contains the hydrophobic EO spacer and its ability to bind CTB.
5.2 Results and discussion
5.2.1 Synthesis 
Initially, the approach of choice was to modify the microtiter plate surfaces with 
alkynes and to use azide-terminated carbohydrates to detect biological agents. This 
approach was also used for the Guillain-Barré syndrome (GBS)-related experiments 
Figure 3: GM1 oligosaccharide-functionalized alkynes 1 - 3 as synthesized and used in ELISA experiments.
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that are described in Chapter 6. In that case, the surfaces were modified by covalently 
linking propargylamine to commercially available activated ester-terminated 
microtiter plates. Biological assays have been performed whilst employing SPAAC 
reactions on BCN-functionalized ELISA plates, vide supra.[16] However, there are 
some notable disadvantages of cyclooctyne-terminated surfaces. One is that 
cyclooctynes, because of their high intrinsic energy, are prone to oxidation and 
other unwanted side-reactions. They are therefore not stable for a long period of 
time and the surfaces need to be used preferably immediately after preparation.[19] 
In addition, an unusually high background signal was observed when we tested 
this BCN-terminated microtiter surface, after ligation with GM1os, for the GM1os-
CTB binding affinity in indirect ELLA experiments. This indicated that the toxin 
interacted with the surface, either chemically or through physisorption. Further 
investigation indicated that an increasing concentration of BCN on the surface 
led to a corresponding linear increase in the toxin absorption (Figure 4), even 
after extensive blocking with bovine serum albumin (BSA) and standard ELISA 
washing procedures. This contrasts observations by Van Hest and co-workers,[16] 
who have conducted ELISA experiments with similar cyclooctyne-modified 
surfaces and do not report having observed this phenomenon. We cannot rule 
out that the binding to the BCN-functionalized surface by this biological agent 
is specific, and only the case, for CTB. Anyway, these results discouraged us 
to further investigate using BCN-terminated surfaces in this manner. When we 
employed a terminal alkyne coating, and applied CuAAC to immobilize azide-
functionalized carbohydrates, a steady and low background signal was measured 
Figure 4: Linear relationship between the concentration of BCN coating applied on ELISA-wells and the 
deposition of CTB (proportional to the OD) on the surface.
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independent of the concentration of the surface coating. Hence, rather than 
applying the alkynes on the surface of the ELISA plates, carbohydrates were 
synthesized to contain the BCN moiety and commercially available ester-
terminated ELISA plates were modified to display azide-functionalized surfaces.
Terminal alkyne-containing 1 (Figure 3) was synthesized as previously 
reported,[5a] and used without further modifications to immobilize it via the CuAAC 
reaction on azide-functionalized surfaces. For the synthesis of compounds 2 
and 10, previously reported azido-terminated 4[5a] and compound 5[20] were 
reduced to amines 6 and 7, respectively. Subsequently, they were attached 
to cyclooctyne BCN 11, to afford BCN-functionalized GM1os compounds 2 
and 3 (Scheme 1A), respectively. The first step was to investigate the optimal 
reaction conditions to reduce the azide functionality of the unprotected 
carbohydrates 4 and 5. Since the GM1os are precious materials, we aimed 
for a reduction methodology that is high-yielding, fast, chemoselective, and 
without byproducts. To prevent unnecessary use of the precious GM1os 
compounds, reduction experiments were performed on the less complex and 
easier to synthesize precursor lactoside 8, which is also discussed in Chapter 6. 
First attempts to reduce the azido-lactoside by employing the Staudinger 
reduction[21] in dioxane, in the presence of PPh3 were moderately successful 
due to complexation of the resulting amine to phosphor species in the 
reaction mixture. After stirring for 4 h in the presence of 0.1 M HCl, more of 
the desired product was formed. However, the triphenylphosphine oxide 
(TPPO) byproduct was hard to remove from the mixture by either liquid-
liquid extraction or flash chromatography. In order to increase the yield of the 
reduction and to circumvent the difficult separation from the TPPO byproduct, 
compound 8 was exposed to polystyrene-bound diphenylphosphine (PS-
Scheme 1: A) Synthesis of BCN-modified GM1os 2 and 3; B) Reduction of test compound 1-O-(11-azido 
undecane)-β-d-lactoside 8; i) Pd/C, 4 bar H2, EtOH, 6 h, 25 °C; ii) 3, Et3N, DMF, 2 h, 25 °C; EO = - CH2CH2O-.
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PPh2).
[22] In this case, as can be expected, TPPO was not observed in the 
final product after filtration. After overnight stirring of the reaction mixture and 
additional overnight dissociation of the phosphazene complex in the presence 
of diluted hydrochloric acid, a still unsatisfactory yield was observed (65%).
At this point, the Staudinger reduction-approach was abandoned, since low 
yields and the formation of by-products rendered the tests not suitable to be 
translated to the GM1os. Also, the use of a strong acid is preferably avoided 
because of the possibility of anomerization[23] and, more importantly, because 
these complex carbohydrates are prone to acid-mediated hydrolysis of glycoside 
bonds after prolonged exposure.[24] Reduction in a suspension of Pd/C in water 
under atmospheric H2-pressure led to even lower yields (max 20%) than those 
observed for the experiments with the Staudinger reduction. When this approach 
was performed in the presence of 0.1 M HCl the desired product was obtained 
almost quantitatively after overnight reaction. However, again, due to possible 
acid-induced hydrolysis of the product, the reaction conditions were found to 
be unsatisfactory for implementation on the valuable GM1 oligosaccharides. 
Subsequently, compound 8 was exposed, in two separate experiments, to 4 
and 10 bar of H2 gas for 6 h in the presence of Pd/C in EtOH. This showed that 
4 bar was already sufficient for the complete reduction of the azide, as shown 
by mass spectrometry. A successful reduction could also be easily observed by 
Figure 5: Part of an HSQC spectrum that indicates the typical chemical shift changes seen for azide reductions.
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heteronuclear single quantum coherence (HSQC) NMR experiments. Typically, 
the carbon adjacent to the non-terminal azide nitrogen can be found around δ 
= 51 ppm (Figure 5, carbon F). After successful reduction, the corresponding 
carbon adjacent to the amine nitrogen is shifted high field to approximately δ = 42 
ppm (Figure 5, carbon F’). After extensive, multistep filtration (see experimental 
section for details) to remove the Pd/C catalyst, the solvent was removed in vacuo. 
The desired product was obtained in excellent yield (95%). Once this suitable 
reduction method was found for the azide-terminated lactoside 8 (Scheme 1B), 
the next step was to reduce the azide-terminated GM1os in a similar fashion 
(Scheme 1A). High-resolution mass spectrometry analyses confirmed that the 
desired amine products had formed, and no residual starting materials were 
observed. Additionally, no degradation products that would imply loss of terminal 
Gal- and/or Neu5Ac moieties were detected either. Both, products 6 and 7 were 
obtained in high yield (> 90%) as white solids and were deemed sufficiently pure 
to be used in subsequent coupling reactions to BCN without further purification.
The synthesis of activated para-nitrophenylcarbonate-BCN (pNP-BCN) 12 (Scheme 
2) proceeded as described in literature.[15] To increase the yield for the first step (from the 
reported 76%[15] to 87%, namely 40% endo-11 and 47% exo-11), instead of diluting the 
reactants with DCM, the cyclization was performed in neat cyclooctadiene.[25] For this 
project, we focussed solely on the slightly more reactive endo-BCN, which was isolated 
pure from a diastereomeric mixture according to literature.[15] BCN-functionalized GM1 
oligosaccharides 2 and 3 were then synthesized by reacting pNP-BCN 12 with amines 
6 and 7 to obtain compounds GM1BCN 2 and GM1EO6BCN 3, respectively (Scheme 
1). The pure compounds were then obtained as white solids by lyophilisation.
5.2.2 Enzyme-linked lectin assay experiments 
Chemical modifications on microtiter plate surfaces are, in general, hard to 
observe. The effectiveness of such modification is therefore typically indirectly 
Scheme 2: Synthesis scheme for pNP-BCN 12.[15] i) 10 (neat), Rh(OAc)4, ethyl 2-diazoacetate, 40 h, 0 °C.
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confirmed after the biological assay experiment is completed. For example, if an 
initial modification was successful, an OD signal is measured through the activity 
of a secondary enzyme. Direct measurement are, however, of course preferred. 
To this aim, we performed infrared (IR) absorbance experiments to confirm that 
the surface of the ELISA plates was indeed azide-functionalized. The bottom part 
of an unmodified well, as provided by the manufacturer, was used as reference, 
and a difference spectrum was recorded for the azide-functionalized ELISA surface 
(Figure 6). A large number of scans (~16,000) was needed to observe a good 
signal, because ELISA plates absorb a quite significant amount of irradiation in 
the IR spectrum, but eventually a sharp signal at σ = 2103 cm-1 appeared in the 
typical region of an asymmetric azide N≡N stretch attached to aliphatic spacers.[26]
Subsequently, the synthetic GM1 derivatives were attached via a CuAAC 
reaction in the case of compound 1, or a SPAAC reaction in the cases of 2 and 
3. To allow for a fair comparison, the compounds were added in similar quantities 
to the wells of different rows on the same plate, and all reactions were allowed 
to run for an equal amount of time, i.e. an overnight reaction. It was assumed 
that an equal amount of each compound was attached to the surfaces of 
the wells prior to the assays. Subsequently, wells of the microtiter plate were 
washed (3 ×) with water to remove unattached compounds and unreacted sites 
were blocked with BSA. The binding experiments were conducted by exposing 
Figure 6. Infrared difference spectrum of terminal azide-functionalized microtiter plate wells. The arrow indicates 
the N≡N azide stretch signal at σ = 2103 cm-1.
106
the surface-bound carbohydrates to a 2-fold dilution series of CTB-HRP-
conjugate. Next, the unbound CTB-HRP was removed by washing and the bound 
CTB-HRP was exposed to ortho-phenylene diamine (OPD). Rather than using 
TMB  – which was also used in the studies that are described in the introduction 
(Figure 2)[14, 16] and in the previously discussed experiments with BCN-modified 
surfaces – OPD was used as substrate for HRP, because it showed a higher 
sensitivity in this system, requiring less GM1os to perform the experiments. 
After 15 min of exposure to the OPD, the oxidation reaction was quenched by 
addition of diluted H2SO4 and the OD was measured immediately (Figure 7).
Figure 7 shows that CuAAC-attached 1 is slightly more responsive towards 
CTB than both the BCN-functionalized carbohydrates 2 and 3 that were bound 
through SPAAC reactions. Clearly, the EO-containing GM1os does not bind as 
well to the CTB as the GM1os derivatives that do not contain a hydrophilic spacer. 
The half-maximum binding values for the three compounds in these experiments 
were determined to be 0.67 µg/ml, 0.59 µg/ml, and 0.35 µg/ml CTB for compounds 
1, 2, and 3, respectively. The binding affinities of 1 and 2 show reasonably good 
similarity. This indicates that the effect of various types of immobilization on a 
similar compound is negligible. Although compound 1 showed a higher response, 
it appeared that the oligosaccharide with the EO-spacer 3 has a lower half-
maximum binding value. This means that it is “recognized” by the CTB earlier, at 
lower concentrations, than the two compounds that have non-hydrophilic spacers. 
A possible reason for this is that in an aqueous environment, in which these 
Figure 7. Binding assay on the surface-bound GM1os to a 2-fold dilution series of CTB-HRP. ● 1, ▲ 2, ♦ 3;
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experiments are performed, the spacer stretches out in the solution whereas the 
hydrophobic spacer has the tendency to adhere to the hydrophobic bottom of the 
well. Hence, the chance of a solvated CTB to encounter the pentasaccharide 
of compound 3, i.e. the opportunity for the GM1 moiety to present itself in the 
optimum orientation towards the CTB active site, is greater than for compounds 
1 and 2, which will reside more towards the bottom of the wells with a lower 
rotational degree of freedom. Nevertheless, the response of the EO-containing 
compound 3 is significantly lower than those for compounds 1 and 2. This 
indicates that – although the CTB “recognizes” the carbohydrate earlier when 
it stretches out in the solution – the hydrophilic spacer upon binding possibly 
prevents ideal positioning of the GM1 to the CTB binding pocket and/ or 
electrostatic interference. The natural inhibitor for CTB, wild-type GM1 (see 
Chapter 1), contains a hydrophobic ceramide moiety which is more closely 
related to the hydrophobic spacers that were used for compounds 1 and 2. 
Figure 8 (left) shows again the binding responses of compounds 1 - 3, but now 
at three specific CTB concentrations that are around their half-maximum binding 
values, i.e. 0.25, 0.50, and 1.0 µg/ml CTB, respectively. In a subsequent experiment 
we studied the influence that copper can have on the binding ability of CTB. The 
three immobilized compounds (including the SPAAC-related compounds) were 
exposed to 50 μl of a 6 μM CuSO4 solution and 50 μl of a 12 μM sodium ascorbate 
solution per well for 1 h (Figure 8 right), and washed extensively afterwards. 
Compound 1 was apparently unaffected by the exposure and showed the same 
response as in the previous experiment. However, a change was noticed in the 
copper-exposed SPAAC compounds. Now, both compounds 2 and 3 showed 
a higher response to the same dose of CTB (at 0.25 and 0.50 μg/ml) than 
compound 1. First of all this confirmed that residual copper ions indeed remains 
on the assay surface even after extensive washing. Furthermore, compound 2 
now appeared to have a higher response at the lower CTB concentrations, which 
would indicate an earlier half-maximum binding. However, the standard error 
of the mean of the experiments increased significantly after the addition of the 
copper. The maximum binding is OD ≈ 1.1, which is, within the error, similar to 
what was observed in the first experiment under standard incubation conditions. 
From this, can only be concluded that the binding abilities of both 1 and 2 were, 
within the error margin, similar to the original experiment in which compound 
2 was not exposed to copper, and 1 was. Surprisingly though, EO-containing 
compound 3 exhibits a higher total response and the ability to bind CTB has 
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apparently improved due to the influence of copper. The effect that copper has 
on this compound is possibly too complex to draw conclusions solely based 
on these experiments. What could be hypothesized from this finding is that 
the EO-spacer coils around the copper ions and thereby rigidifying the system 
(see Figure 1) resulting in a loss of entropy. The spacer is thereby “pulled” to 
the surface and placed in a similar position as the other two compounds that 
are not equipped with the hydrophilic spacer. Then, when CTB “settles down” 
on the surface with a lower rotational entropy, as is the natural operating mode 
of this lectin on cell surfaces, and compound 3 is brought into closer proximity 
of the binding pockets, CTB is bound more strongly. However, this is a rather 
meagre explanation on the matter and it requires more research to clarify further. 
When the compounds were exposed to an even higher, 1 mM, concentration 
of copper prior to the biological assays, the responses, even after extensive 
washing, were prone to high errors and displayed incoherent results that currently 
are challenging to define (Figure 9). The binding responses are very different from 
Figure 8. Left) Response of synthetic GM1 derivatives 1 - 3 under standard ELISA conditions. These responses 
correspond to the curves in Figure 8 between the interval <0.25 - 1.0> µg/ml CTB; Right) Response of synthetic 
GM1 derivatives after being exposed to small amounts of CuSO4 and ascorbate and subsequently washed prior to 
the assay; Error bars indicate the standard error of the mean (SEM) of measurements performed in quadruplicate.
Standard Conditions
0.0
1.0
2.0
0.25 μg/ml 0.50 μg/ml 1.0 μg/ml[CT]  
O
D
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Figure 9. Response of the synthetic GM1 derivatives 1 - 3  that were exposed to 1mM of CuSO4 and ascorbate 
solution prior to the assay; Error bars indicate the SEM of measurements performed in quadruplicate.
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those of the original experiment and, additionally, the average errors of each of the 
in quadruplicate measurements were increased significantly, in some cases, even 
larger than the response. The exaggerated experiment shows to the extreme that 
exposure to (high quantities of) copper leads to unwanted side-effects and large 
error in measurements.
5.3 Conclusions
Microtiter plates were successfully functionalized with BCN and used to attach 
azide-terminated GM1os derivatives. An unprecedented high response of 
background signal in subsequent biological experiments indicated that the BCN 
coating itself yields an unwanted binding of CTB. Therefore, BCN-functionalized 
carbohydrates were synthesized and attached to azide-functionalized ELISA 
surfaces. CuAAC and SPAAC were employed to attach GM1os derivatives 1 - 3 
successfully to the wells and they were subsequently tested on binding affinity 
towards CTB. Binding affinity experiments showed that there was a slightly better 
binding for compound 1, which was attached by CuAAC, but comparable with 
compound 2, which was attached to the surface by SPAAC reactions. The EO-
spacer-containg compound 3 showed a much lower binding affinity to CTB-HRP. 
When also compounds 2 and 3 were exposed to CuSO4 before being exposed to 
CTB, in the subsequent biological assay, especially compound 3 showed a higher 
binding affinity to CTB than in the case of compound 1. Even higher, 1 mM Cu2+ 
concentrations explicitly added to both the CuAAC and SPAAC reaction, led to 
high errors and non-linear results in the subsequent biological binding experiment. 
This indicated that the biological assays were hampered by the addition of 
large amounts of copper, and that this copper was insufficiently removed by the 
standard washing procedure. More importantly, the data from the experiments 
showed that both CuAAC and SPAAC can be successfully employed to perform 
binding affinity experiments on the complementary system of GM1os and CTB.
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5.4 Experimental Section
5.4.1 Synthesis
General experimental information: Compounds 12 (starting from bicyclic 
11),[15] GM1os-derivatives 1, 4, and 5[5a] were synthesized as described in 
literature. Spectral data of these compounds were in agreement with literature 
values. For synthesis and characterization of lactoside 8, the reader is directed 
to compound 3 as described in Chapter 6. Reduction reactions were carried 
out on a Parr multi reactor system. Materials for the ELISA experiments i.e. 
bovine serum albumin (BSA), ortho-phenylenediamine (dihydrochloride salt) 
(OPD), cholera toxin horseradish peroxide (CTB-HRP) conjugate, Tween-20, 
30% H2O2 solution, sodium citrate, and citric acid were purchased at Sigma 
Aldrich and used without further modification, phosphate-buffered saline (PBS) 
10 × concentrate was diluted ten times with demineralized water prior to use. 
Nunc immobilizer aminoTM 96-well microtiter plates were used as purchased 
at Thermo Scientific. The microtiter plates were washed using an automated 
Denville® 2 Microplate Washer. Optical density (OD) was measured between 
1.5 and 0.5 units on a Thermo Labsystems Multiskan Spectrum Reader running 
on Skanit software version 2.4.2. Data analysis and curve fitting of inhibition 
experiments were performed on Prism Graphpad software version 5.04. 
Compound 2: Azido-terminated 4 (10 mg, 7.4 μmol, 1.0 eq) was dissolved in 
EtOH (10 ml), Pd/C (10% Pd; 10 mol%) was added and the reaction mixture was 
exposed to 4 bar H2 gas for the duration of 6 h. After extensive filtration through 
hyflo, microfiber glass filters, and 0.20 µm syringe filters, the solvent was removed 
in vacuo. The desired product, compound 6, was obtained in excellent yield as an 
off-white solid (8.2 mg). MS (HR-ESI-): m/z = 1166.5097 [M], calcd. (C48H86N3O29) 
= 1166.5196; Without further purification, 6 was dissolved in dry DMF (1 ml) and 
Et3N (2 µl, 8.6 µmol, 1.2 eq). The reaction mixture was then added dropwise to 
a solution of pNP-BCN 12 (4.1 mg, 13 µmol, 1.9 eq) in dry DMF (0.5 ml) and 
the solution was stirred for 1 h at room temperature, during which the solution 
turned yellow, indicating the formation of p-nitrophenolate. The desired product 
was observed by MS (ESI-). However, after observation of the presence of minor 
peaks of the starting amine in ESI+ mode, additional pNP-BCN (20 mg, 62 µmol, 
9.0 eq) was added and the reaction was stirred for another hour. Subsequently, 
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the reaction was quenched by drop-wise addition of 0.1 M formic acid, until full 
decolouration of the yellow solution was observed. Water was added (1 ml) and 
the mixture was extracted with toluene (3 × 2 ml) and EtOAc (3 × 2 ml). The 
volume of the water layer was reduced under high vacuum, and, subsequently, 
lyophilized to afford compound 2 as a white solid (7.6 mg, 5.7 mmol, 81 % over 
two steps), remnants of pNP-BCN, or derivatives thereof, were not observed by 
MS (ESI- and ESI+) nor by NMR. 1H-NMR (MeOD/ D2O 9 : 1, 400 MHz) δ (ppm) 
= 4.93 (m, 1H), 4.48 (m, 2H), 4.45 (m, 3H), 4.27 (m, 2H), 4.15 (m, 3H), 4.02 (m, 
2H) 3.93-3.81 (m, 7H) 3.78-3.62 (m, 11H) 3.59-3.35 (m, 9H) 3.22 (m, 2H) 2.86 
(s, 1H) 2.75 (m, 2H), 2.16 (d, 2H, J = 6.8 Hz) 2.00 (m, 6H), 1.66-1.56 (m, 6H), 
1.42-1.24 (m, 17H), 1.17 (m, 2H); selected signals 13C-NMR (MeOD/ D2O 9 : 1, 
100 MHz) δ (ppm) = 105.3, 103.5, 103.0, 102.8, 102.6, 81.6, 80.0, 77.4, 75.0, 
74.8, 70.0, 69.0, 68.1, 61.0, 60.1, 48.1, 37.0, 29.0, 25.9, 22.3, 22.1; Cq were not 
observed; MS (HR-ESI-) m/z = 1343.2749 [M], calcd. (C59H97N3O31) = 1343.6106.
Compound 3: Azido-terminated 5 (10 mg, 6.9 μmol, 1.0 eq) was treated in a similar 
fashion as it is described for compound 4. The desired intermediate 7 was obtained 
in excellent yield as an off-white solid (8.9 mg). MS (HR-ESI-) m/z = 1430.6733 [M-
H]-, calcd. (C60H110N3O35
-) = 1430.6769; Without further purification, the coupling of 
7 to carbonate 12 was performed in a similar fashion as it is described for compound 
6. Compound 3 was obtained as a white solid (7.2 mg, 4.5 μmol, 73% over two 
steps). MS (HR-ESI-) m/z = 1606.7589 [M-H]-, calcd. (C71H120N3O37
-) = 1606.7601.
5.4.2 Enzyme-linked Lectin Assay 
CuAAC Immobilization of compound 1: The following aqueous solutions were 
added to each well in the following order: 50 μl of a 6 μM CuSO4 solution, 100 μl 
of a 3 μM solution of compound 1, 50 μl of a 12 μM sodium ascorbate solution. 
The plate was incubated overnight at room temperature with gentle agitation. The 
wells were then washed with water, 3 × 400 μl per well.
SPAAC Immobilization of compounds 2 and 3: Compounds 2, and 3 were 
dissolved in 20% DMSO in water and 100 μl of this 3 μM solution was added to 
each well, followed by 100 μl of demineralized water. The plate was incubated 
overnight at room temperature with gentle agitation. The wells were then washed 
with water, 3 × 400 μl per well.
Standard procedure for the binding experiments. Each well of the individual 
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96-well microtiter plates, Nunc immobilizer Amino, was treated with 200 μl of a 
10 mM 1-azido-3-amino-propane solution in 0.1 M Na2CO3/ NaHCO 3 aqueous 
buffer (pH 9). The plates were incubated at room temperature for 16 h with gentle 
agitation. The solution was discarded and the wells were washed with water, 3 × 
400 μl per well. The GM1os derivatives (300 pmol/well) were immobilized on the 
surface of the ELISA plates by either CuAAC (compound 1) or SPAAC (compounds 
2 and 3) reactions by methods described below. For every compound, two rows 
on an ELISA plate were reserved, every experiment was performed on two plates. 
Hence, every data point was obtained in quadruplicate. After GM1os immobilization 
(vide infra), the wells were, blocked with 1% BSA PBS for 30 min at 37 °C. Then, 
the plate was washed with PBS (3 × 400 μl per well). Binding experiments were 
performed by addition of a 2-fold dilution series of the CTB-HRP conjugate in 0.1% 
BSA, 0.05% Tween-20 in PBS, along the columns of an ELISA plate, starting from 
5 µg/ml CTB-HRP (100 µl/well). Unattached CTB-HRP was removed by washing 
with 0.1% BSA, 0.05% Tween-20 in PBS (3 × 400 μl per well). 100 μL of a freshly 
prepared OPD solution (25 mg OPD·2HCl, 7.5 mL 0.1 M citric acid, 7.5 mL 0.1 M 
sodium citrate and 6 μL of a 30% H2O2 solution, pH was adjusted to 6.0 with NaOH) 
was added to each well and allowed to react with HRP in the absence of light, at 
room temperature, for 15 min. The oxidation reaction was quenched by addition 
of 50 μL 1 M H2SO4. Within 5 min, the absorbance was measured at λ = 490 nm.
Binding experiments after additional incubation with copper. These 
experiments were performed in a similar fashion as described for the standard 
procedure. However, prior to the exposure of the immobilized carbohydrates to 
CTB, all wells were incubated with 50 μl of a 6 μM CuSO4 solution and 50 μl of 
a 12 μM sodium ascorbate solution for 1 h. Subsequently, the plate was washed 
with water (3 × 400 μl per well) and the assay proceeded as described in the 
standard procedure. For the third set of experiments, 50 μl of a 1 mM CuSO4 and 
50 μl of a 1 mM sodium ascorbate solutions were added to each well and allowed 
to incubate for 1 h. Subsequently, the plates were washed with water (3 × 400 
μl per well) and the assay proceeded as described in the standard procedure.
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Evaluation of synthetic ganglioside-based glycan fragments as 
epitopes for Guillain-Barré syndrome-associated antibodies
This chapter is in preparation for publication.
6
Abstract:
As part of an ongoing investigation, we aim to improve the understanding at the 
molecular level of the antibody (Ab)-ganglioside specificity in the pathogenesis 
of the neuropathological ailment Guillain-Barré syndrome (GBS). Our strategy 
was to test a small library of ganglioside-based glycans on patient sera. We 
synthesized eight mono- and disaccharides that display elements from naturally 
occurring mammalian ganglioside GM1. In addition, these ganglioside fragments 
were designed to contain chemical handles with which they could be covalently 
immobilized to microtiter plates. Once immobilized, they were exposed to GBS 
patient sera that contain anti-ganglioside Abs, and the Ab-carbohydrate binding was 
evaluated. For most patient sera no significant binding was observed, indicating that 
their native ganglioside antigen-Ab response could not be recreated by synthetic 
GM1 fragments or combinations thereof. We did however discover through these 
assays that some anti-ganglioside Abs bind to compounds displaying the simple 
monosaccharide galactose and disaccharide lactose epitopes. Especially sera 
that showed cross-reactivity towards wild type galactocerebroside were shown to 
bind these two simple saccharides. In addition, applying a relatively short oligo-
EO spacer (12 atoms) as a coating on the microtiter plate surfaces had dramatic 
effects for a select number of GBS patient sera on the Abs-ganglioside fragments 
binding affinity. This chemical blocking step was applied in addition to the standard 
blocking step in ELISA with bovine serum albumine. In one case, the Abs-Gal binding 
response was doubled in relation to when this chemical blocking step was not 
performed. These results will contribute to the development of future diagnostics, 
in the form of biosensors, for the rapid detection of certain GBS subtypes.
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6.1 Introduction
Our immune system constantly probes our body for the presence of foreign 
entities. One of many methods it uses for detection is to monitor for non-
indigenous glycan structures, and if identified, to initiate an immune response. 
In rare cases, the antibodies (Abs) that are involved in this immune response 
are cross-reactive with glycans (carbohydrates) that reside on our own cells, 
and thereby initiate an autoimmune response. Guillain-Barré syndrome (GBS) 
is a post-infectious autoimmune disorder that results from such an interaction, 
in which our own carbohydrates (and as a consequence our cells) are 
targeted by our immune system. It is a life-threatening disease and patients 
require immediate hospital treatment. GBS is the leading cause of acute 
paralysis, and worldwide, 1 - 2 persons per 100.000 are annually affected.[1]
The infection preceding GBS may present itself as an upper respiratory tract 
infection, gastro-intestinal infection, influenza-like illness or remain subclinical. 
The main cause of the enteritis that triggers the autoimmune response in 
GBS is the ingestion of Campylobacter jejuni (C. jejuni) bacteria. Chickens 
are considered as the most important source of human infection by C. jejuni, 
which primarily arises from cross-contamination or consumption of not well-baked 
poultry meats.[2] The bacteria is very common in the guts of chickens and ends 
up on meat by contamination from accidental fecal spilling during slaughter.
[3] Other sources of consumption-based infections are, amongst others, bovine 
meat, untreated dairy products, contaminated water sources, and pets.[4] 
The initial symptoms of the bacterial infection can reach their maximum in 
about a week after ingestion of the pathogen (Figure 1). The patients usually 
Figure 1. Guillain-Barré syndrome time-scale concerning limb weakness. Figure adapted from reference.[6b]
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recover from this by the time the main symptoms of GBS, including motor 
dysfunction, present themselves. The first signs of GBS are expressed by 
weakness or numbness, particularly in the limbs. Patients describe tingling 
sensations, followed by paralysis starting from the base progressing all the 
way to the top of the body, and extending to the arms. This ascending paralysis 
increases in intensity and in extreme cases, patients becomes totally paralyzed 
within 2 days.[5] In at least one-fifth of the patients, the nerves innervating the 
respiratory muscle become damaged to such extent that respiratory failure may 
develop and patients need to be ventilated at an intensive care unit. The rapid 
decline of the patient’s health generally reaches its maximum within 4 weeks, but 
many patients have reached their maximal weakness already within 2 weeks.[6] 
The first choice standard treatment for GBS is intravenous immunoglobin 
(IVIg), and the second choice is plasmapheresis. In IVIg, high doses of 
immunoglobulins derived from blood from healthy donors are infused. The 
mechanism of action is unknown but it is believed that IVIg may in part neutralize 
the harmful Abs or their neurotoxic effects. In plasmapheresis, plasma is 
extracorporeally separated from the patients’ other blood components, leaving 
the blood cells to be returned to the body while the plasma that contains the 
malicious Abs is discarded. A major disadvantage of plasmapheresis is 
that patients with GBS may develop life-threatening autonomic dysfunction. 
Despite treatment, about 25% of the patients require respiratory assistance; 
approximately 20% of the patients still experience limb dysfunction after six 
months. Ultimately, 3 - 10% of the patients die,[7] most commonly of heart failure.[8]
On the molecular level, GBS patients are victimized by pathogens that 
display carbohydrates that are in part also indigenous of the human body. 
The terminal parts of the complex bacterial carbohydrates closely resemble 
glycosphingolipids that are part of the host’s peripheral nervous system (PNS) 
tissue (Figure 2) that are subsequently also attacked by the immune system. 
Figure 2B shows the lipooligosaccharide (LOS) that resides on the cell wall of 
C. jejuni.[9] The bacterium LOS contains the terminal tetrasaccharide sequence 
Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1. The same epitope is displayed on the 
ganglioside GM1, which resides on PNS nerve cells (Figure 2A). Abs that are 
formed by the immune system, as a response to the presence of the intruder, 
cross-react to both types of carbohydrates, and thereby causing the autoimmune 
response.[10] These phenomena (including other criteria[11]) make GBS a disease 
that is instigated by molecular mimicry. This mimicry already occurs during 
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the infection period, as the host’s immune system then forms Abs against 
the oligosaccharide structures that are displayed on the intruding pathogen. 
GBS was first described as a single ailment in 1916 by Guillain, Barré and 
Strohl.[12] It is nowadays recognized that the range of symptoms observed in GBS 
patients actually consists of several unique ailments that can be subdivided based 
on their pathogenesis.[13] Depending on the subtype of GBS, patients develop 
Abs against varying human gangliosides that each also result in quite different 
pathogenesis. Patients with acute motor axonal neuropathy (AMAN) predominantly 
display Abs against GM1, GM1b, GD1a, and GalNAc-GD1a (for structures see 
Chapter 1). In axonal forms of GBS, the Abs attack appears directed against 
gangliosides that are displayed on the axon cell membrane and nodes of Ranvier 
(Figure 3B).[14] In acute inflammatory demyelinating polyneuropathy (AIDP), the 
myelin sheath and Schwann cells are targeted by the Abs, rather than the axons 
directly (Figure 3A). Although not always evident, in some cases of AIDP, Abs 
against GM4, GM3, GM2, GT3, and especially GD3 were encountered.[15] In more 
recent studies it is, however, debated if gangliosides actually play a role in the 
pathogenesis of AIDP.[16] It was described that the distinction between the two 
subtypes AIDP and AMAN is difficult and even unreliable, which resulted in 58% 
Figure 2. Molecular mimicry of C. jejuni. The epitope of the bacterium LOS resembles the terminal tetrasaccharide 
sequence Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ of ganglioside GM1 (For chemical structure see Figure 4) 
that resides, amongst others, on PNS nerve cells. Reproduced from reference.[19a]
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of the patients, initially diagnosed with AIDP, to be re-diagnosed with AMAN.[17] The 
question to what antigens are then the target of auto-immune Abs in AIDP was not 
answered and therefore remains to be resolved. However, circumstantial evidence 
for the existence of anti-ganglioside Abs in AIDP is quite strong.[18] Patients with 
Miller-Fisher syndrome (MFS) that cross-react with C. jejuni[19] especially display 
the presence of Abs against multisialylated gangliosides GQ1b, GD3, and GT1a.
Recent studies indicated that some anti-ganglioside Abs that are able to 
bind a certain type of ganglioside, say GM1, are also able to bind a mixture 
of two gangliosides, for example a 1 : 1 combination of GM1 and GD1a. In 
contrast, other Abs show a positive binding towards the pure ganglioside GM1, 
but show no signs of binding when combined with GD1a.[20] These results 
indicate that complexes of gangliosides – complexed through electronic 
interactions, e.g. Van der Waals and H-bonding – are recognized by some Abs 
Figure 3. Depiction of an axon, or nerve cell, that sends synapses to the muscle cell to trigger response. A) In 
AIDP, the myelin sheath is targeted by Abs; B) In AMAN, autoimmune response is caused by Abs that target 
carbohydrates on the nodes of Ranvier.
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rather than the individual gangliosides. This finding underlines the necessity of 
applying pure gangliosides in bioassays.[21] Another study[22] involving saturation 
transfer difference nuclear magnetic resonance (STD-NMR)[23] on two patient 
sera revealed that, in both cases, the main epitope for the anti-ganglioside 
Abs were the terminal Galβ1-3GalNAcβ sequence and the Neu5Acα2 
moiety. Microarrays that included smaller carbohydrate derivatives, basically 
ganglioside fragments, have previously been reported in research on the 
interaction of these ganglioside GM1-related carbohydrates with cholera toxin 
(for a detailed description of the role of ganglioside in cholera toxin-binding 
see Chapter 1).[24] To the best of our knowledge, to this date no study has 
been conducted on synthetic ganglioside fragments to provide more insights 
on which epitopes are responsible for the recognition by GBS-associated Abs. 
In the current study, we aim to improve the understanding of the Abs-ganglioside 
binding in the pathogenesis of GBS by the design and synthesis of a small library 
of ganglioside fragments. Previously, synthetic ganglioside analogues were 
synthesized in our laboratory and used successfully to detect Abs in GBS patient 
sera.[25] These carbohydrates have the advantage that, since they are synthesized, 
they are acquired pure. An additional benefit over isolation from natural sources 
is that the synthesized compounds can be equipped with a handle (e.g. an azide) 
that allows easy bioconjugation or coupling to a surface. In contrast, in current 
standardized assays native gangliosides are used that are extracted from bovine 
brain.[26] These are difficult to purify and are therefore potentially contaminated with 
other glycolipids. Larger bifunctional synthetic ganglioside analogues, presenting 
two similar epitopes, were also successfully used to detect anti-ganglioside Abs 
in sera of GBS patients.[25b] The choice for the fragment approach was based 
on these previous studies and on the additional benefit that fragments are more 
easily accessible due to shorter synthetic pathways. Patients that have contracted 
various GBS subtypes express Abs that are able to distinguish between different 
epitopes, like the multisialylated gangliosides in case of MFS or ganglioside GM1 
in AIDP. By deconstruction of such gangliosides – making them less complex, 
but still providing the epitopes that are essential for binding – we aim to obtain 
new insights into the binding-mode of these Abs. Any insights gained via such 
an approach might eventually also lead to a diagnostic test, in the form of a 
biosensor,  that provides rapid and reliable results for GBS subtype typography.
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6.2 Results and Discussion
6.2.1 Synthesis of ganglioside fragments
The fragment selection and design was based on the carbohydrate sequence of 
ganglioside GM1 derivative 1 that contains an undecane-azido spacer (Figure 
4). The choice for GM1 was made because it is believed to be the most common 
target of Abs in GBS patients in the western world.[27] Additionally, it contains 
almost all epitopes that are also displayed on other gangliosides, except the 
Neu5Acα2-8Neu5Acα2 disaccharide, which is synthetically challenging to 
access. However there are sialyltransferases available that are able to form 
both the α2,3- and α2,8-glycoside bonds on neuraminic acids.[28] Nevertheless,  
the optimization and use of these transferases was beyond the scope of this 
work. Therefore, we focused on a group of mono- and disaccharides that is 
accessible via relatively straightforward synthetic effort. This included the 
monosaccharides Galβ1 2, Neu5Acα2 4, Neu5Acβ2 7, GalNAcβ1 9, the 
non-terminal disaccharide Galβ1-4Glcβ1 (lactoside) 3, Galβ1-3GalNAcβ1 5, 
which represents the carbohydrates at the terminus of the pentasaccharide 
ganglioside GM1, Neu5Acα2-3Galβ1 6, which is ganglioside GM4, and finally 
GalNAcβ1-4Galβ1  8  (Figure 4). All fragments contain the anomeric -O-C11H22N3 
spacer that is also present on the previously synthesized ganglioside GM1 
analogue 1. All compounds have the same stereo- and regiochemistry as the 
carbohydrates present in the wild type ganglioside. However, since neuraminic 
acid is possibly the most important epitope in GBS[29] and in fact an essential 
criterion for a part of a glycosphingolipid to be classified as a ganglioside, we 
also selected the unnatural β-isomer of Neu5Ac (7) for this study. This allowed 
us to assess the effect of a different stereochemistry around the acid moiety. 
The synthesis of glycosides 3 and 2 (Figure 4) started with per-acetylation 
of 10  and 11, respectively, with acetic anhydride in the presence of catalytic 
iodine[30] (for a detailed insight on the mechanism of this reaction see Chapter 
1). After 8 h,  the reaction was diluted with DCM, and an equimolar amount 
of iodine was added to the reaction mixture followed by hexamethyldisilane 
(HMDS).[31] During this reaction, 2 equivalents of iodotrimethylsilane are 
generated in situ.[32] Substitution of the acetate by an iodine moiety yielded 
the α-iodo-anomer 14 in 74% yield, and in 90% in case of compound 15, over 
two steps (Scheme 1). In both cases, only the α-anomers were obtained.
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Activation of donor iodide 15 with iodine, now acting as Lewis acid, and 
subsequent glycosylation in DCM with acceptor 11-azido undecan-1-ol (21) 
Figure 4. Small library of the synthetic analogue of ganglioside GM1, compound 1, and ganglioside fragments 
2 - 9 that were assayed by exposure to anti-ganglioside Abs in sera from GBS patients.
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– which is formed by heating the corresponding 11-bromide analogue 20 with 
sodium azide in DMF[33] – resulted in a 60% yield of beta galactoside 17 (see 
Chapter 1 for mechanistic details on this glycosylation step). This reaction 
yielded both the alpha and the β anomer, in a ratio of 1 : 10, based on 1H 
NMR analysis. The only isolated byproduct was a C-1 hydrolyzed hemiacetal. 
The glycosylation of the α-iodo lactoside (14) yielded 70% of both the α and β 
anomers of 16 in a ratio of 15 : 85. Also 2-deprotected lactoside was isolated 
(20%, α/ β ratio of 9 : 1) as well as the methyl ester of 11-azido-undecan-1-ol. 
The reason for the various (by)products being formed during this glycosylation is 
that various nucleophilic substitution reactions can take place, especially via the 
mechanism involving neighboring group participation (see Chapter 1 for details).
In  an attempt to increase the yield and stereoselectivity of these reactions, 
the glycosylations were repeated with MeCN as solvent. Now only the β-anomer 
was obtained in 62% yield in case of the galactoside 17, and for lactoside 16 
in 70% yield. The acetyl-protected 11-azido-undecane glycosides (16 and 17) 
were subsequently deprotected by the standard Zemplén procedure,[34] namely, 
treatment with NaOMe in MeOH, and subsequent work-up with a H+-resin 
resulted in deprotected 2 and 3 in near quantitative amounts. One-step, SnCl4-
promoted, glycosylation of per-acetyl lactoside 12 or galactoside 13 resulted 
in mixtures of anomers and disappointing yields: 28% for 18, and 20% for 19. 
Galactoside 2 was further modified to function as an glycoside acceptor in the 
glycosylation towards the GalNAcβ1-4Galβ1-O-C11H22N3 fragment 8. Therefore, 
it first needed to be regiospecifically deprotected at the 4-position (Scheme 2). 
To accomplish this, a protective group strategy was required that employs a 
chemoselective deprotection procedure and that keeps the terminal azido moiety 
intact. In the initial design of the strategy towards disaccharide 8, galactoside 2 
was 4,6-protected with a p-methoxybenzyl (PMB) acetal. This route was chosen 
because PMB acetals, and also the corresponding ethers, can be deprotected 
under relatively mild conditions. The electron-deficient DDQ facilitates the mild 
deprotection of PMB ethers[35] by a mechanism of multiple single electron transfers 
(SET) (see Chapter 1 for mechanistic details on this reaction). Additionally, like 
benzylidene acetals, the PMB acetals can also be opened regioselectively to 
form the corresponding 4-O- or 6-O- ether.[36] Galβ1-O-C11H22N3 (2) was therefore 
exposed to p-anisaldehyde dimethylacetal and p-toluenesulphonic acid (PTSA) 
yielding p-methoxybenzylidene acetal 22 (Scheme 2).[35b] When the reaction 
was performed overnight at 50 °C, a high ratio of α-anomer was acquired (α/ 
125
C
hapter 6
Evaluation of synthetic ganglioside-based glycan fragm
ents 
as epitopes for G
uillain-Barré syndrom
e-associated antibodies
β ratio: 3 : 4, at 72% combined yield). Fortunately, both anomers were easily 
separated by flash chromatography. When the reaction was repeated at room 
temperature for 36 h, a significant increase in the desired β-anomer, product 22, 
was observed (65% β) and only trace amounts of the α-anomer could be detected.
The remaining hydroxyl-groups at C-2 and C-3 of compound 22 were PMB-
protected by reacting them with NaH and PMB-Cl, resulting in 69% yield of 
compound 23. The subsequent step was the selective opening of the para-
methoxybenzylidene and concomitant 4-deprotection of the galactoside to obtain 
compound 25. This procedure requires the acetal to be exposed to NaCNBH3 that 
delivers a nucleophilic hydride.[37] After the ring opening is accomplished, an 1 M 
HCl solution in ether is added dropwise to protonate the product and to quench 
the remaining NaCNBH3. In this case, after workup, multiple side products were 
Scheme 1: Iodine-promoted synthesis of fragments 2 and 3. Reagents and conditions: i) Ac2O, I2 (cat.); 
ii) I2, HMDS, MeCN, 5 h (14 74%, 15 90% over two steps); iii) 21, I2, MeCN, 4 Å MS, (16 70%, 17 62%); 
iv) NaOMe, MeOH, 10 min. then H+-resin (2 91%, and 3 quant.); v) SnCl4, 4 Å MS, DCM (18 28%, 19 
20%); vi) NaN3, DMF, 100 °C 16 h; 21 91%; not performed in the direct glycosylation to afford 16 and 17.
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detected that indicated that not only the acetal was opened, but that also the 
2- and 3-deprotected products had formed. Although it was known that the PMB 
ether is acid-labile,[38] it was not expected that the deprotection would already 
be facilitated by addition of minute quantities of acid, and in the presence of a 
reactive species (NaCNBH3) towards protons. This unfortunate reactivity required 
an adjustment in the protective group strategy, and it was decided to synthesize the 
2,3-di-O -acetyl protected compound 26 (Scheme 2) by exposure of 22 to acetic 
anhydride in pyridine. The resulting diacetyl acetal 24 was then regiospecifically 
deprotected to obtain 4-O-deprotected compound 26 in good yield (70%).
Unfortunately, the subsequent glycosylation with a GalNAc donor did not 
yield the desired disaccharide 27. Although, the very similar 2,3-di-O-acetyl 
6-O-benzyl galactoside acceptor has been reported in a successful NIS-promoted 
glycosylation with a thioglycoside donor.[39] Possibly, the reaction temperature 
was too high and therefore, some byproducts with displaced PMB protective 
groups were observed, resulting in a mixture of glycosylation products and 
(partly) deprotected starting materials that were hard to separate. Since the initial 
protective group strategy was not successful, we turned to the more commonly 
used benzyl protective groups as an alternative. Starting from the galactoside 
2 (Scheme 3), 4,6-benzylidene protection was applied to provide compound 
28, followed by benzyl-protection of the 2 and 3-positions (29). Selective ring 
Scheme 2. Protecting group strategies. Reagents and conditions: i) p-anisaldehyde dimethyl acetal, PTSA, MeCN, 
rt, 36 h, 65%; ii) NaH, PMB-Cl, DMF, 18 h, 69%; iii) Ac2O, pyridine, 18 h, 93%; iv) NaCNBH3, 1 M HCl in Et2O, THF, 
3Å MS, 70% 26, compound 25 was not isolated; v) 34, TMSOTf, DCM, 3Å MS -20 °C → 0 °C product not isolated.
127
C
hapter 6
Evaluation of synthetic ganglioside-based glycan fragm
ents 
as epitopes for G
uillain-Barré syndrom
e-associated antibodies
opening of the acetal was achieved, leading to compound 30 in 70% yield. 
The galactosamine donor was synthesized, as described in literature[40], 
by dissolving galactosamine-HCl salt 31 in H2O and reacting it with 
trichloroethyloxycarbonyl (Troc) chloride in the presence of base resulting in 
the Troc carbamate.[41] Subsequent acetylation of the remaining functional sites 
was performed by addition of pyridine and acetic anhydride, resulting in the Troc 
carbamate 32. Specific C-1 deprotection was performed by reaction of 32 with 
hydrazine acetate to acquire 33 in 85% yield. Subsequent reaction of the resulting 
hemiacetal with trichloroacetonitrile and DBU resulted in tricholoroacetimidate, or 
Schmidt imidate,[42] 34 in 75% yield (predominantly α). Alternatively, when CaCO3 
was used in this reaction, the product was obtained in 68% (α/ β ratio: 1 : 2). For 
Scheme 3. Synthesis route of disaccharide 8. Reagents and conditions: i); α,α-dimethoxytoluene, PTSA, 
MeCN, 6 h, 75%; ii) BnCl, NaH, DMF, 1 h, 86%; iii) NaCNBH3, 1 M HCl in Et2O, THF, 3Å MS, 70%; iv) 
K2CO 3, Troc-Cl, H2O, 1 h then pyridine/ Ac2O (1 : 1), 70%; v) hydrazine acetate, DMF, 90 min., 85%; vi) 
trichloroacetonitrile, DBU, DCM, 20 min., 75%; vii) TMSOTf, DCM, 2 h, -40°C, 53%; viii) a) Activated Zn, 
Ac2O, 18 h; b) TMSOTf, Ac2O; 90 min., 70% over two steps; ix) NaOMe, MeOH 10 min. then H
+-resin, 95%.
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this particular compound, a very distinct and characteristic picture arose in the 
mass spectrum (Figure 5), providing a beautiful example of an isotope pattern 
of a compound containing six chlorine atoms. In a similar fashion, also the N-(4-
nitrobenzyl)oxycarbonyl (PNZ) imidate was synthesized as alternative glycosyl 
donor (see §6.4.3 compound 34b for more details). Reaction of the galactoside 
acceptor molecule 30 with the galactosamine imidate 34 in the presence 
of catalytic amounts of TMSOTf resulted in disaccharide 35 in 53% yield. 
 The standard benzyl deprotection procedure,[43] which involves Pd/C-
catalyzed hydrogenation, is not compatible with the azide functionality that is 
later required for the immobilization of the carbohydrates in our biological assays. 
Rather than choosing additional steps – for example, by using an azide transfer 
reagent after the reduction,[44] which would be able to reestablish the azide 
functionality from the amine – a method was chosen that exchanges the benzyl 
protection for acetyl groups after the formation of the disaccharide. Therefore, 
deprotection of the disaccharide started by interchanging the benzyl groups with 
acetyl groups via reaction of compound 35 with TMSOTf in acetic anhydride,[45] 
which was reasonably successful (70% yield). The resulting hexa-acetate 36 
was then easily deprotected to form ganglioside GM1 fragment 8 in 95% yield.
Galactoside 2 was also the starting material in the enzymatic synthesis of 
disaccharide 6 (Scheme 4). This compound contains the disaccharide Neu5Acα2-
3Galβ of ganglioside GM4.[46] The commercially available enzyme sialyl transferase 
II[47] was used to attach its natural substrate, cytidine monophosphate (CMP)-
Neu5Ac 37, to the previously synthesized galactoside 2 to obtain 6 in 77% yield.
Scheme 5 depicts the syntheses of monosaccharide compound 9 and 
disaccharide 5. We attempted to synthesize the galactosamine monosaccharide 
9 by reacting the previously discussed Schmidt imidate 34 (Scheme 3) with 
11-azido-undecan-1-ol (21). However, glycosylation attempts with either 
BF3OEt2 or TMSOTf as promoter did not result in the desired compound. 
Although reactions with galactoside imidate 41 with fairly unreactive alcohols 
and above-mentioned Lewis acids are described in literature,[48] we did not 
isolate the desired galactosamine glycoside in acceptable quantities. The iodine-
promoted glycosylation, which was described earlier in a successful syntheses 
of fragments 2 and 3 (Scheme 1), was unsuccessfully employed in an attempt to 
form an 1-iodo N-Troc-protected galactosamine, or its N-PNZ protected analogue. 
Presumably, the α-iodine does not form in these cases due to steric interference 
of the adjacent bulky carbamate. Ultimately, a microwave-assisted, and H+-silica-
129
C
hapter 6
Evaluation of synthetic ganglioside-based glycan fragm
ents 
as epitopes for G
uillain-Barré syndrom
e-associated antibodies
catalyzed, synthesis was performed,[49] which required the 11-azidoundecan-
1-ol (21) and the per-O-acetylated galactosamine 38 (Scheme 5). Compound 
38 was obtained by reacting the galactosamine hydrochloric acid salt 31 with 
acetic anhydride in pyridine. Generally, a protective group is required on the C-2 
position to prevent formation of the stable oxazoline 38b, in which the acetamide 
carbonyl-group reacts with the C-1 while approaching from the axial position. 
In the microwave-assisted reaction, the oxazoline formation is desired since it 
functions both as a leaving group and prevents approach of a nucleophile, in 
this case 11-azido-undecan-1-ol 21, on the α-position, and thereby stimulates 
β-glycosylation. Performing this MW-assisted reaction at 150 °C ensures opening 
of the oxazoline, reinstating the acetamide on the galactosamine C-2 position and 
forming solely the desired β-product 39 in very good yield (84%). Deprotection 
by the standard Zemplén procedure ensured formation of galactosamine 9. 
Scheme 4. Enzymatic step in the synthesis of disaccharide 6. i) 2, Sialyltransferase II, MnCl2, MgCl2, H2O, 72 h, 77%.
Figure 5. Isotope pattern in a typical ESI+ mass spectrum for 6 Cl-containing compound 34; [M+Na]+ observed.
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Subsequently, galactosamine fragment 9 was selectively 4,6-protected by a 
previously described para-methoxybenzylacetal (see also Scheme 2), forming 
acceptor 40 (Scheme 5). Tricholoracetimidate 41 was synthesized in a similar 
fashion as was described for the GalNAc imidate 34, by selective C-1 deacetylation 
of compound 13, and subsequent reaction with trichloroacetonitrile. Disaccharide 
Galβ1-3GalNAcβ1 5 was then synthesized starting by reaction of 40 with 
galactoside donor 41 to give compound 42. DDQ-facilitated SET-deprotection 
of 42 and subsequent Zemplén deacetylation resulted in disaccharide 5. 
The MW-assisted glycosylation that was successfully employed in the synthesis 
Scheme 5. Synthesis of disaccharide 5. Reagents and conditions: i) Ac2O, pyridine, 18 h, 89%; ii) 21, H+-
silica, DCE, MW, 30 min, 150 °C, 84%; iii) NaOMe, MeOH, 30 min. then H+-resin, quant.; iv) p-anisaldehyde 
dimethylacetal, PTSA, MeCN, rt, 48 h, 86%; v) 41, TMSOTf, -30 °C → 0 °C 8 h, 56%; vi) DDQ, MeCN/ H2O 1 : 
4, 2 h, 58%; vii) NaOMe, MeOH, 10 min then H+-resin, 90%.
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of galactosamine 9 was also applied to form β-Neu5Ac-derivative, fragment 7. 
First, the methyl ester of neuraminic acid 44 was formed by a Fisher esterification, 
followed by protection of the alcohol groups by reaction with pyridine and acetic 
anhydride to provide protected 45.[50] Since the MW-assisted reaction in case of 
the galactosamine 39 proceeded via neighboring group participation by forming the 
oxazoline (38b), formation of the required product was not expected here, because 
the neuraminic acid does not have a neighboring group at the C-3 position that 
can participate. However, mass spectrometry revealed that the target sialoside 
was present. Additionally, some byproducts had formed that showed intramolecular 
cyclization, and these resembled structures that were previously described in 
literature.[51] Target β-compound 46 was obtained in 13% yield after purification. 
Subsequently, by removing the acetyl protecting groups by the Zemplén procedure 
and saponification of the methyl-ester with aqueous KOH, compound 7 was 
obtained in 30% yield (Scheme 6). 
In order to synthesize the required natural α-anomer 4, protected Neu5Ac 45 
was transformed into 2-Cl-Neu5Ac 47 by applying hydrochloric acid gas through 
a solution of 45 in acetyl chloride and diethyl ether.[52] Subsequent Koenigs-Knorr 
glycosylation[53] of chloride 47 with the 11-azidoundecan-1-ol spacer 21 in the 
presence of silver carbonate[54] yielded the acetyl-protected Neu5Acα2, (48) in the 
modest yield of 47%. After deprotection of the acetyl groups and the methyl ester 
compound 4 was obtained quantitatively over two steps (Scheme 7).
NMR techniques showed to be of crucial importance for the unambiguous 
identification of the stereochemistry of the synthesized compounds, which is not 
a trivial task. For glycosyl pyranosides, assignment of the anomeric configuration 
Scheme 6. Reagents and conditions: i) a) H+-resin, MeOH, 4 days; b) pyridine, Ac2O, 0 °C → rt, 18 h, 90% over 
two steps; ii) 21, H+-silica, DCE, MW, 20 min, 150 °C, 13%; iii) a) NaOMe, MeOH, 30 min, then H+-resin; b) KOH, 
MeOH/ H2O 1 : 4, 30% over two steps.
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is, partially based on identification of the coupling constant: 3JH-1,H-2, which hinges 
on the dihedral angles (φ) between H-1 and H-2 for the two anomers.[55] For 
carbohydrates with an equatorial C-2 functional group-configuration as in the 
case of galactose and galactosamine, the α-anomer, φ is close to 60o which 
corresponds to J ≈ 3.5 Hz. Whereas for β- anomers, φ is close to 180o yielding 
J ≈ 8 Hz. This Karplus relation cannot be used for the structural analysis of 
neuraminic acid, because of the absence of an anomeric hydrogen (C-2) in that 
case. Instead, a set of empirical rules has been devised based on chemical 
shift data and coupling constants of various substituted Neu5Ac derivatives.[56] 
On unsubstituted neuraminic acid derivatives, the C-3 protons are expected to 
be found at approximate chemical shifts δ = 1.93 and 2.32 ppm, for H-3ax and 
H-3eq, respectively.[57] Additionally, the α-substituted neuraminic acid supposedly 
shows H-3ax, and H-3eq to reside at δ = 1.73, and 2.72 ppm, respectively. 
The most decisive evidence to determine the anomeric conformation of the 
neuraminic acid derivative is given through 3JC-1,H-3ax, which can be measured 
by the gated-decoupled 13C technique.[57b] The expected value for the hetero-
atomic C-1 → H-3a coupling for β-anomers is 3JC-1,H-3ax < 1 Hz, whereas in the 
case of an α-anomer 3JC-1,H-3ax  = 3 - 6 Hz. Based on these and other criteria,
[56] 
it could be deduced that Neu5Acβ2-O-C11H22N3, compound 7, was formed in the 
MW-assisted reaction. Following these criteria, we were also able to positively 
identify the correct stereochemistry of the Neu5Acα2-O-C11H22N3 compound 4.
6.2.2 Enzyme-linked immunosorbent assays (ELISA)
After the successful synthesis of the ganglioside fragments and completion 
of our library, a set of ELISA experiments was devised to allow for a direct 
comparison of the synthesized compounds 2 - 9 with the previously synthesized 
GM1 analogue 1 with regard to their capacity to function as epitopes for GBS-
associated Abs. These experiments were also compared to assays on native 
Scheme 7. Synthesis route of Neu5Ac-derivative 4. Reagents and conditions: i) AcCl, HCl (g), Et2O, 90%; ii) 21, 
AgCO 3, DCM, 4 Å MS, rt, 30 min, 47%; iii) a) NaOMe, MeOH, 30 min, then H
+-resin; b) KOH, MeOH/ H2O (1 : 4), 
18 h (71% over 2 steps).
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gangliosides, which in some cases were performed in parallel. This allowed 
for a direct comparison between the synthesized compounds that were 
attached to alkyne-terminated ELISA plates via copper-catalyzed azide-alkyne 
cycloaddition (CuAAC) reactions, and the naturally occurring gangliosides that 
were attached to a different type of ELISA plates by hydrophobic interactions.
Prior to exposure of the surface-bound ganglioside GM1 analogue 1 and the 
GM1 fragments 2 - 9 to the sera of GBS patients, they were tested on human 
monoclonal IgM Abs SM1 and HA1. Affinity of these Abs towards gangliosides 
was tested and Figure 6 shows that SM1 preferably binds wild type GM1 and 
asialo-GM1 (AGM1). Surprisingly, also galactocerebroside (GalC) is recognized 
by the SM1 Abs. GalC is a glycosphingolipid that contains a d-galactoside bearing 
a ceramide on its β-1 position, and is the major glycolipid in myelin.[58] GalC is 
also described to play a role in several other neurodegenerative diseases, for 
example, in Krabbe disease[59] and multiple sclerosis (MS).[60] Additionally, 
some sera of GBS patients contain cross reacting Abs against ganglioside 
GM1 and GalC.[61] HA1 specifically binds native multi-sialylated gangliosides in 
the order: GD3 > GD1b >> GQ1b > GT1a  (see §1.2.2 Figure 4 for structures). 
Figure 6 (lower left) shows that the monoclonal HA1 Abs does not recognize the 
synthetic analogue of GM1 1 nor any of the fragments. The initial hypothesis was that 
the HA1 might show some preference for disaccharide 6 since it showed especially 
preference to the wild type gangliosides that contain the terminal Neu5Acα2-3Galβ 
sequence. SM1 showed a comparable response to the chemically immobilized 
GM1 analogue as to the wild type GM1 (Figure 4, GM1), which is in accordance with 
previous findings.[62] From the ganglioside fragment library, the Galβ1-3GalNAcβ 
disaccharide 5 showed a slight response towards SM1 but more importantly, the 
lactoside 3 (Galβ1-4Glcβ) showed a higher response. Both fragments bear the 
terminal β-galactoside moiety. It is safe to assume that that moiety is one of the 
major contributors to the binding of SM1 since also the wild type GM1, AGM1, 
and GalC present this epitope. With this experiment, we confirmed that it is, in 
fact, possible to detect anti-ganglioside Abs by using synthetic glycan fragments.
Next, we explored the effect of presenting combinations of the synthetic 
ganglioside fragments to these two Abs. It was hypothesized that the presence 
of sialic acid moieties in these combinations would increase the response to the 
antibodies, especially in case of HA1, since this particular Ab shows high preference 
for multisialylated gangliosides. Therefore, 1 : 1 combinations of α-, and β-Neu5Ac 
with other fragments were exposed to the SM1 and HA1 antibodies. However, 
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when 1 : 1 combinations of fragments were exposed to the antibodies (Figure 6 
Lower Right), no improvements in binding were observed. This is best indicated by 
the combination of GM1 analogue 1 and Neu5Acα2, fragment 4. The response is 
almost half, in case of the combination of 1 and 4, with respect to the GM1 analogue 
1 when it is not combined. Half the response corresponds to half the concentration 
of compound 1. Therefore it is safe to assume that the Neu5Acα2 fragment (4) is not 
recognized by the Abs. It was to be expected that the full complexity of the native 
ganglioside antigens could not be recreated by combinations of GM1 fragments, 
even though these combinations do contain the moieties that are presumed 
to be the Abs epitopes. This mixed fragment-based approach has not been 
investigated before and therefore this result does contribute to our understanding 
of the ganglioside-Abs interaction. Taking this result into account, we decided 
to conduct the subsequent assays, with patient sera, on single fragments or 1. 
In previously reported studies that were based on the synthetic GM1 analogue 
1[25a] it was established that an amount of 100 pmol 1/well is required to obtain 
Figure 6. Top Left) Response of human Abs SM1 and HA1 to wild type gangliosides, AGM1 and GalC; Lower 
Left) Response of SM1 and HA1 Abs to individual the GM1 analogue 1 and fragments 2 - 9; Lower Right) 
Response of SM1 and HA1 antibodies to 1 : 1 combinations (compound n/compound m). Error bars indicate the 
SEM of triplicate measurements. 
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similar results towards natural Abs as wild type GM1 in standardized ELISA 
experiments.[26] Based on our preliminary fragment experiments, involving 
the SM1 and HA1 Abs, we decided that the fragment concentration should be 
increased 3-fold to match the response of the GM1 analogue. Hence, in the next 
experiments all fragment amounts are tripled, i.e. 300 pmol fragment /well. Also, 
based on the experiments with SM1 and HA1, several fragments were omitted 
from further screening to deal economically with the finite Ab sources, i.e. GBS 
patients’ sera. Hence, fragment 7, Neu5Acβ, was omitted because the natural 
α-anomer 4 is more relevant for the subsequent assays. Only a small quantity of 
compound 6 was acquired via chemoenzymatic synthesis and therefore not used 
in the subsequent reactions unless a high activity towards compound 4 would 
be registered. Fragment 8 suffered from solubility issues in the immobilization 
conditions at the indicated concentration, and was therefore omitted as well. 
Finally, also compound 9 was omitted. Hence, the experiments on GBS patient 
sera were performed on GM1 analogue 1 and fragments 2 - 5. The patient sera 
were coded with either .M or .G, which indicate whether the active components 
(Abs) belong to either the IgM or IgG immunoglobine class, respectively 
(Figure 7). Cholera toxin (CT-Bio.SA) was added to these experiments as a 
standard positive, to give the highest response to ganglioside GM1 analogue 1. 
Figure 7 shows the first set of experiments, together with the blank values. 
Although the background signals were quite high in some cases, they were 
deemed acceptable. However, the blank for PC025.M is exceptionally high. High 
background signals arise from non-specific interaction of serum Abs or other 
serum components with the surface. Deposition of these components leads to 
lower signal-to-noise ratios, thereby lowering the sensitivity of the experiments. 
This issue will be addressed further in §6.2.3. When the blank values are 
subtracted from the binding responses, the actual response Abs-carbohydrate 
binding is shown (Figure 8). PC025.M and F263a.G do not give a noticeable 
response to GM1 mimic 1 nor to any of the fragments, although Abs in both sera 
do show affinity towards the wild type GM1. This could possibly occur because 
hydrophobically coated wild type GM1 presumably forms rather disorganized 
layers and displays random orientation of the glycan part, and may therefore allow 
orientations that are optimally suited to interact with an antibody.[25b] Instead, the 
covalently bound ganglioside analogues are coated in a less random and more 
densely packed order, possibly hampering the availability for Abs interaction. In 
case of PC025.M, the absence of a positive response can also be caused by the 
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diminished sensitivity of the test because of the high background signal. Both 
F225a.M and PFKEY.G show a moderate affinity to the GM1 mimic 1, although 
both sera showed to have high titers of antibodies against wild type GM1. 
The most remarkable response was given by Q122a.G. Whereas it does not 
respond well to ganglioside GM1 nor its synthetic analogue 1, it showed a high 
Figure 8. Net response of the reactivity of human sera from GBS patients to the synthesized ganglioside GM1 analogue 
1 and fragments 2 - 5 displayed in Figure 7. Error bars indicate the mathematical mean of duplicate measurements.
Figure 7. Binding responses of human sera from GBS patients to the synthesized ganglioside GM1 analogue 
1 and fragments 2 - 5. Blank values are not extracted from the OD values in this graph to give an indication of 
the relatively high background signal. Error bars indicate the mathematical mean of duplicate measurements.
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response towards lactoside 3 and also a noticeable response to galactoside 2. This 
gave rise to further testing on additional sera that show GalC cross reactivity. This 
set of sera was tested on 1, fragments 2 - 3 and, in parallel experiments, also on 
wild type GalC-coated hydrophobic plates (Figure 9). Q122a.G showed to contain 
high titers of Abs against GalC. Q122a.G was also used in previous assays and is 
known as a GBS patients’ serum that shows IgG (anti-GalC) cross-reactivity.[61d] 
This assay also proved that the fragment experiment was reproducible because 
again both the lactoside and galactoside showed high responses towards Abs in 
Q122a.G. Also G006.G binds GalC and both the fragments 2 and 3. Serum Q180.G 
shows a higher response to 3 than to GalC, and on the contrary, high titers of 
Abs against GalC are shown in G002.G but not to compound 2 or compound 3. 
A conspicuous result in this assay was that neither of these sera showed a high 
response against 1, although, many of these sera have previously tested positively 
against wild type GM1 (not shown). Additionally, F109.G, Q210.G, Q180.G, Q287.G, 
and Q158.G show to contain titers of Abs that bind 2 and/ or 3 but not GalC. At this 
stage we considered whether this binding occured due to the presence of other Abs 
in these sera that are specifically targeting galactoside and lactoside moieties. It is 
Figure 9. Net response of the reactivity of a second set of human sera from GBS patients, containing also 
GalC-positive samples G002.G, G006.G, and Q122a.G, to the synthesized ganglioside GM1 analogue 1  and 
fragments 2 and 3 displayed in Figure 7. Error bars indicate the mathematical mean of duplicate measurements.
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known that one of the most abundant Abs (termed anti-Gal) in humans makes up 
for approx.1% of all Abs and preferably binds a Gal epitope. However, the natural 
substrate that is targeted by these Abs is the epitope α-Gal, which is present on 
a complex glycosphingolipid structure that is terminated by the sequence: Galα1-
3Galβ1-4GlcNAc-R.[63] Also anti-Lac Abs are known that recognize a lactose moiety 
on the same residue.[64] However, it is debatable whether the effect that is displayed 
in our assays is caused by anti-Gal Abs, since the epitope, in the case of anti-gal 
Abs concerns an α-anomer – which is the opposite configuration as that of our 
fragment 2 –, and because it is attached to a much more complex carbohydrate 
moiety. Therefore, we can neither exclude nor confirm that the Abs binding 
responses that we see towards compounds 2 and 3 are the effect of GBS-related 
Abs that bind these carbohydrates. However, it is likely that the Abs that display anti-
GalC cross reactivity also display binding affinity towards the two carbohydrates 
that display the β-Gal epitope; this is observed in most of our GalC-positive sera. 
A further set of sera was tested for their known activity towards native 
ganglioside GM1 (Figure 10). The results of this assay shows again that the 
sensitivity of wild type GM1 assays is higher than that for the immobilized synthetic 
analogues and that these assays cannot always be translated one-to-one. When, 
for example, F225.M and PC025.M are compared, it shows that the Abs in both 
sera are able to bind to the natural GM1 but not to the synthetic pentasaccharide 
(1). It must be noted that patient PC025.M was treated for a different autoimmune 
disease, which is called neuromuscular multifocal motor neuropathy (MMN). 
Furthermore, most other GM1-positive sera also show a response to 1. 
Additionally, F222.G, and F228.M display relatively high responses to 2 and 3.
6.2.3 Coatings to improve signal-to-noise ratio.
In the experiments that were performed to evaluate Abs-ganglioside binding, 
we observed in some cases relatively high background signals (Figure 7) 
for the covalently immobilized fragments. This leads to lower signal-to-noise 
ratios, thereby lowering the sensitivity of the assays. In an attempt to lower 
the background due to deposition of the serum components, the exposed 
alkyne-termini on the ELISA wells that were not used in the immobilization of 
the synthesized carbohydrates were chemically blocked by reacting them in 
an additional “click” reaction with either a hydrophilic azido tetra-ethyleneoxide 
(EO4N3) or hydrophobic 11-azidoundecan-1-ol 21 (HOC11N3) (Figure 11). 
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In the standard preparation of the microtiter plate surfaces that display 
alkyne-functionalities, azido-functionalized carbohydrates were covalently 
immobilized by applying CuAAC reactions. Subsequently, the surfaces were 
blocked by bovine serum albumin (BSA).[25a] Following this procedure the sites 
on the ELISA plates that did not react with the azido-terminated carbohydrates, 
displayed hydrophobic terminal alkyne moieties. In an attempt to reduce the 
background noise, these “free” alkyne sites were chemically reacted and 
subsequently blocked by BSA. Surface blocking for sera is preferably done 
by employing hydrophilic polyethyleneglycol (PEG)[66] rather than by using 
small chains, but since our antigens are small molecules, the risk existed 
of being overgrown by the PEG. Hence, as a smaller variant, the tetra-
ethyleneoxide was chosen that has the same number of atoms as the linker 
attached the carbohydrates (i.e. 12 atoms, when the anomeric glycoside acetal 
oxygen is counted as part of the linker). Additionally, the more hydrophobic 
linker 21 was also applied as surface coating for a comparative study.
Figure 12 shows the blank values that a select group of patient sera displayed 
when they were deposited on the ELISA wells that were not equipped with any 
Figure 10. Net response of the reactivity of a third set of patient sera with a selected group of carbohydrates, 
GM1 mimic 1, galactoside 2 and lactoside 3, compared to wild type GM1. Error bars indicate the mathematical 
mean of duplicate measurements.
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carbohydrates. Comparing the blank values for the various coatings shows that, 
overall, the changes are not dramatic. In most cases, the chemical blocking 
shows a slight improvement over the standard procedure without chemical 
blocking. However, it seems that in the case of serum PC025.M, which was 
previously already described as suffering from a low signal-to-noise ratio 
(Figure 7), chemical blocking has a significant advantageous effect for both a 
hydrophilic or a hydrophobic surface. This is also the case for PFKEY.M, Neg.M, 
and less prevalent for F292ap.G. In contrast, serum Q122a.G suffers from 
extensive “sticking” to the hydrophobic undecyl spacer as does F152a.G. From 
these experiments we could conclude that blocking with hydrophobic spacers 
does not contribute to a higher signal-to-noise ratio, but applying oligo-EO does 
Figure 11. Left) Schematic representation (not on scale) of the standard approach for the ELISA experiments; 
Right) Chemical blocking of the unreacted free alkyne moieties with hydrophilic oligo-EO spacers. Undecyl 
spacer 21 was also used as hydrophobic coating (not shown). Standard BSA blocking was applied to all ELISA 
experiments described in this chapter.
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improve the results in some cases. Therefore, in subsequent experiments, 
only EO-coating was applied on the free sites on the microtiter plates.
Although the results of the chemically blocked surfaces were not distinctly 
different from those with the surface that present the free alkyne-terminus, the 
question was raised what would the influence of the EO-spacer be on the Abs-
fragment binding. In Figure 13 the results are shown for the background signals 
for a select group of sera that were exposed to carbohydrate-functionalized 
surfaces with only non-covalent blocking (white bars) or both covalent (EO) and 
non-covalent (BSA) blocking steps (grey bars). In all cases, the response of the 
background is slightly increased by applying the hydrophilic EO3 as chemical 
blocking coating. Additionally, Figure 13 shows also the assay results from the 
experiments in which compounds 1 - 5 were exposed to the immunoglobins 
Figure 12. Background measurements: Comparison of patients’ sera blanks, deposited on ELISA alkyne-
terminated surfaces without or with chemical blocking of the free alkyne sites by reacting them with EO3N3 
and HOC11N3. Additional, standard, blocking with BSA was performed in all three cases. Error bars indicate the 
mathematical mean of duplicate measurements.
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without and with EO-blocking, white and grey bars, respectively. Again we notice 
the moderate response to galactoside 2 and the high response to lactoside 3 
that is displayed by Q122a.G (see also the discussion belonging to Figure 9) 
when coated on the alkyne-terminated surface. However, when the free sites 
were blocked with EO, a much higher response of compound 2 was observed. 
When the background is subtracted (Figure 14), it can be seen that there is a 
significant increase and the signal is doubled for the galactoside 2 when the 
free sites in those corresponding wells were EO4-blocked rather than alkyne-
terminated. This is such a significant difference that it cannot be a result from 
the slightly higher background signal of the serum when deposited on the EO4-
coated surface. Furthermore, there is also a large increase in activity of the 
serum F263.G towards GM1 analogue 1 when deposited on the EO4 -blocked 
wells. In previous experiments, only a minor signal was observed for the synthetic 
GM1 analogue 1 (Figure 8). When in the presence of the EO4-coating, F263a.G 
shows a similar response to the wild-type GM1, and the response is more than 
three-fold its original. The nature of the higher response, when using chemical 
EO4-blocking is not fully understood. Possibly, there is a participating effect of 
the coating that mimics the complex formation of the gangliosides. On the other 
Figure 13. Binding results of the Abs in selected patient sera to compounds 1 - 5 with standard alkyne-terminus or 
with chemically block EO4 -surface; B = Blank; Error bars indicate the mathematical mean of duplicate measurements.
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hand, we have seen in Chapter 5 that the influence of copper on EO-spacers 
can be quite drastic and sometimes leads to higher response (but also to higher 
error). In addition, it is not unthinkable that copper also coordinates to the many 
hydroxyl groups presented on the carbohydrates. This can be either in favour 
of the binding by filling up essential coordination positions in the Abs binding 
pockets, but alternatively can also diminish carbohydrate-Abs binding due to 
unfavourable electronic or steric interactions. Therefore, we cannot exclude that 
the phenomena described here involve antigen-copper coordination, or that there 
is a positive interaction of the EO-spacer directly with the Abs. Since the finding 
with the EO4-spacers was interesting but not applicable in all cases, the alkyne-
terminated microtiter plate surfaces are still preferred for general use. However, 
these conspicuous findings might be worth to devote follow-up experiments to. 
For example, changing chain length, chemical appearance (hydrophilicity), as 
well as the use of other immobilization techniques (e.g. SPAAC) may contribute to 
improved signal-to-noise ratio and analysis of the GBS-related Abs in patient sera.
Figure 14. Net binding results of compounds 1 - 5 to immunoglobines with standard alkyne-terminated surface 
or with chemically blocked EO4 -surface; Error bars indicate the mathematical mean of duplicate measurements.
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6.3 Conclusions
As part of an ongoing study to increase the understanding of the pathogenesis 
of GBS on a molecular level, we focused on the binding mode of GBS-related 
anti-ganglioside Abs towards synthetic ganglioside-based glycan fragments. 
Nine compounds were synthesized that are either fragments (2 - 9) or a chemical 
analogue (1) of the ganglioside GM1 pentasaccharide, with the aim to form a 
small library of Abs antigens. All carbohydrates were equipped with an azide 
handle, with which they could be covalently immobilized onto bio-assay surfaces 
via CuAAC reactions. These immobilized compounds were then used in ELISA 
experiments to detect anti-ganglioside Abs in human serum from GBS patients. 
For most sera no significant binding was observed, indicating that their native 
ganglioside antigens cannot be recreated by our synthetic GM1 fragments or 
combinations thereof. We did however discover that some anti-ganglioside Abs 
bind to compounds displaying the galactoside (2) and lactoside (3) epitopes. 
Especially, sera that showed cross-reactivity towards wild type galactocerebroside 
were shown to bind these two simple saccharides as well. As a confirmation 
of a previously performed study,[25b] some Abs showed affinity towards the wild 
type GM1 but not to its chemical analogue 1. To add to the discussion on this 
topic, it cannot be ignored that the ceramide hydroxyl and amide functionalities 
possibly play a role in the assembly, and complex formation, of gangliosides. 
This specific part of the gangliosides has not been incorporated yet in synthetic 
ganglioside analogues, and further studies are required to understand its role in 
anti-ganglioside Abs binding affinity. Finally, in an effort to improve the signal-to-
noise ratio, we applied hydrophobic and hydrophilic coatings onto the microtiter 
(ELISA) surfaces as an additional blocking step. However the effect on the 
ratio was minimal, applying a relatively short oligo-EO spacer (12 atoms) on 
the surface had dramatic effect on the binding affinity of some Abs towards the 
ganglioside fragments. In one case, the Abs-Gal binding response doubled. This 
surprising result is not fully understood and requires more research. Additional 
studies on the use of EO spacers in biological assays can be found in Chapter 5.
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6.4 Experimental section
6.4.1 General information
All solvents and reagents were obtained commercially and used as received unless 
stated otherwise. All moisture sensitive reactions were performed under a N2 or Ar 
atmosphere. Intermediates that required dry conditions for subsequent reactions 
were, prior to use, transferred to a dry round-bottom flask, co-evaporated with, 
EtOAc, Et2O, and, where possible, the solvent that was used in the subsequent 
reaction. The concentrated intermediates were then dried for several hours under 
high vacuum and recovered under Ar atmosphere. Glassware that was used for 
moisture-sensitive reactions was dried in an oven at 120 °C or heat gun-dried, 
and, in both cases, charged with reactants under a N2 or Ar flow prior to use. Dry 
DCM was acquired by distillation over CaH, THF and Et2O were distilled over 
sodium with benzophenone, stored in a Schlenk tube under N2 or Ar atmosphere 
over activated 3 Å molecular sieves (MS). Analytical TLC was performed using 
silica gel plates (Merck 60 F-254 on aluminium) and compounds were visualized, 
according to the functional groups present on the molecules, with UV light (λ 
= 254 nm) and/ or stained with Hanessian’s Ce/ Mo stain, or 10% sulphuric 
acid in EtOH, and subsequent charring. Purifications by gravimetric or flash 
chromatography were performed on Merck silica gel 60 (70 - 230 mesh) using 
a gradient of the described eluent. The term “purification by automated column 
chromatography” typically implies purification on a Biotage Isolera One that is 
running on Spektra software and the ‘TLC method’-program, using Biotage SNAP 
prepacked columns. The applied eluent typically consists of two solvents that 
are the same as the indicated TLC eluent. Microwave (MW)-assisted reactions 
were carried out on a CEM Discover labmate 300 W, running on Chemdriver 
software. MW vials, magnetic stirring bars, and caps were used as provided by 
the supplier. Standard filtration techniques include: Büchner vacuum filtration, 
applying Whatman filters; gravity filtration, applying fluted filters; and filtration 
through hyflo in 3 Å-pore glass filters. NaH was applied as a 60% NaH dispersion 
in mineral oil and was used as purchased. 1H NMR and 13C NMR spectra were 
recorded on Bruker Avance III 400 spectrometer, with signal observation around 
400 and 100 MHz, respectively. Chemical shifts are reported in parts per million 
(ppm), calibrated on the residual peak of the solvent, their values are referred 
to tetramethylsilane (δTMS = 0.0 ppm), as the internal standard, or the signal of 
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the deuterated solvent. Where indicated, NMR signal assignments were made 
using the appropriate 2D NMR experiments. Electrospray ionization (ESI) mass 
analyses were performed on a Finnigan LXQ, while high resolution ESI mass 
analyses were recorded on a Thermo Scientific Q Exactive High-Resolution mass 
spectrometer. Infrared analyses were performed on a Bruker FT-IR spectrometer. 
Nunc F96 Maxisorp 96-well microtiter plates were used as purchased at 
Thermo Scientific. Standard Zemplén conditions typically imply the exposure 
of an acetylated compound – suspended or dissolved in MeOH – to a catalytic 
amount of an 0.5 M NaOMe in MeOH solution, and subsequent neutralization 
by Dowex H+-resin, filtration and concentration by applying reduced pressure.[34]
6.4.2 Enzyme-linked immunosorbent assays
ELISA on wild type gangliosides and serum IgM and IgG anti-ganglioside 
Abs were performed according to the method previously described[67] and 
standardized by the INCAT group.[26] Immobilization of ganglioside GM1 
analogue 1 and fragments 2 - 9 were immobilized on surfaces according to 
the procedure involving CuAAC reactions as is described in Chapter 5.
6.4.3 Synthetic procedures
11-Azido-undecyl-β-d-galactopyranoside 2. Tetra-O-acetyl 17 
600 mg (1.1 mmol, 1.0 eq) was exposed to standard Zemplén 
conditions, until TLC indicated that all starting material was 
consumed. Compound 2 (375 mg, 1.0 mmol, 91%) was obtained as a white 
solid; 1H NMR (400 MHz, MeOD): δ = 4.21 (d, 1H, J = 7.5 Hz, H-1), 3.90 (m, 1H, 
-OCHaHb-), 3.83 (m, 1H, H-4), 3.74 (m, 2H, H-6a+b), 3.55 - 3.50 (m, 3H, H-2, 
H-5, -OCHaHb-), 3.45 (dd, 1H, J = 3.3, 9.7 Hz, H-3), 3.30 (t, 2H, J = 6.7 Hz, 
-CH2N3), 1.64 - 1.62 (m, 4H, -CH2CH2O-, -CH2CH2N3), 1.41 - 1.34 (m, 14H, -CH2-
spacer); 13C NMR (100 MHz, MeOD): δ = 105.0 (C-1), 76.6 (C-5), 75.1 (C-3), 
72.6 (C-2), 70.8 (-OCH2-), 70.4 (C-4), 62.5 (C-6), 51.0 (-CH2N3), 30.8 - 27.1 (9 × 
-CH2-); MS (HR-ESI+) m/z = 376.2491 [M+H]+, calcd. (C17H34N3O6+) = 376.2442.
11-azidoundecyl-β-d-galactopyranosyl-(1→4)-β-d-gluco 
pyranoside 3. Compound 16 (1.0 g, 1.2 mmol, 1.0 eq) was 
exposed to standard Zemplén conditions, until TLC indicated 
that all starting material was consumed, affording compound 3 as a white solid 
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(0.64 g, 1.2 mmol, quant.); 1H NMR (400 MHz, MeOD): δ = 4.33 (d, 1H, J = 7.5, 
HGal-1), 4.24 (d, 1H, J = 7.8, H Glc-1), 3.91 - 3.85 (m, 2H, HGlc-6a, -CGlc-1OCHaHb, 3.83 
(dd, 1H, J = 4.0, 11.0 Hz, HGlc-6b), 3.79 (m, 1H, HGal-4), 3.77 (dd, 1H, J = 7.3, 11.2 
Hz, HGal-6a), 3.69 (m, 1H, HGal-6b), 3.60 - 3.48 (m, 4H, HGal-2, HGlc-4, HGal-5, -CGlc-
1OCHaHb), 3.51 (t, 1H, J = 8.9, HGlc-3), 3.47 (dd, 1H, J = 3.4, 9.8 Hz, HGal-3), 3.42 (m, 
1H, HGlc-5), 3.26 (t, 2H, J = 7.0 Hz, -CH2N3), 3.23 (m, 1H, HGlc-2), 1.51 - 1.53 (m, 4H, 
-CH2CH2O-, -CH2CH2N3), 1.42 - 1.28 (m, 14H, -CH2-spacer); 13C NMR (100 MHz, 
MeOD): δ = 105.7 (CGlc-1), 104.1 (CGal-1), 81.0 (CGlc-4), 77.6 (CGlc-5), 77.2 (CGlc-3),76.0 
(CGal-5), 75.7 (CGlc-2), 73.7 (CGal-3), 73.4 (CGal-3), 71.4 (CGal-2), 70.6 (-OCH2-spacer), 
69.0 (CGal-4), 62.5 (CGlc-6), 62.3 (CGal-6) 52.5 (-CH2N3), 30.5 - 25.0 (9 × -CH2-); MS 
(HR-ESI+) m/z = 536.2921 [M+H]+, calcd. (C23H44N3O11
+) = 536.2970.
11-azido undecanyl 5-acetamido-3,5-dideoxy-α-d-glycero-d-
galacto-2-nonulopyranosonate 4. Deprotection of compound 
48 (100 mg, 140 µmol) started by deacetylation by employing 
the standard Zemplén procedure. After the solvent was removed, the residue was 
dissolved in 10 ml of a 4 : 1 H2O/ MeOH mixture that contained 30 mg/ml KOH. 
The mixture was stirred for 2 days at room temperature after which it was 
neutralized with Dowex-H+ resin, filtered, rinsed with 2 ml water, and 2 ml MeOH. 
By application of a gentle nitrogen flow, MeOH was evaporated from the filtrate 
and the remaining water was removed by lyophilization overnight. The desired 
product, compound 4, was obtained as a white solid (50 mg, 100 µmol, 71%).  1H 
NMR (400 MHz, MeOD) δ = 3.86 - 3.81 (m, 2H, H-8, H-9a), 3.77 (m, 1H, -OCHa-
), 3.73 – 7.69 (m, 2H, H-4, H-5), 3.63 (dd, 1H, J = 5.8, 11.5 Hz, H-9b), 3.56 - 3.52 
(m, 2H, H-6, H-7), 3.42 (m, 1H, -OCHb-), 3.27 (t, 2H, J = 6.9 Hz, -CH2N3), 2.77 
(dd, 1H, J = 3.7, 12.6 Hz, H-3a), 2.01 (s, 3H, -CH3), 1.68 (m, 1H, H-3b), 1.59 - 1.54 
(m, 4H, -OCH2CH2-, N3OCH2CH2-), 1.40 - 1.30 (9 × -CH2-); 13C NMR (100 MHz, 
CDCl3): δ = 174.0 (-NC(O)-), 73.4 (H-6), 71.5 (H-8), 68.8 (H-7), 67.6 (H-4), 63.8 
(-OCH2-), 63.1 (H-9), 52.6 (H-5), 51.1 (-CH2N3), 40.8 (H-3), 29.4 - 52.7 (9 × -CH2-
), 21.2 (-CH3);  MS (ESI-) m/z = 503.2792 [M-H]-, calcd. (C22H39N4O9-) = 503.2723.
11-azidoundecyl-β-d-galactopyranosyl-(1→4)-β-d-2-
acetamido-2-deoxy-galactopyranoside 5. Compound 43 
(50 mg, 86 µmol, 1.0 eq) was exposed to standard Zemplén 
conditions, until TLC indicated that all starting material was consumed, to afford 
compound 5 (45 mg, 77 µmol, 90%) as a white solid. 1H NMR (400 MHz, MeOD): 
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δ = 4.47 (d, 1H, J = 8.4 Hz, HGalNAc-1), 4.32 (d, 1H, J = 7.7 Hz, HGal-1), 4.10 (m, 1H, 
HGalNAc-4), 3.97 (m, 1H, HGalNAc-2), 3.87 (m, 1H, -OCHaHb-); 3.82 (m, 1H, HGalNAc-5), 
3.78 - 3.71 (m, 5H, HGalNAc-3, HGalNAc-6, HGal-6), 3.57 – 3.46 (m, 4H, HGal-2, HGal-4, HGal-5, 
-OCHaHb-), 3.44 (dd, 1H, J = 3.1, 9.7 Hz, HGal-3), 3.27 (t, 2H, J = 6.7 Hz, -CH2N3), 
1.96 (s, 3H, -C(O)CH3), 1.60 - 1.53 (m, 4H, -CH2CH2O-, -CH2CH2N3), 1.40 - 1.28 
(m, 14H, -CH2-spacer); 
13C NMR (100 MHz, MeOD): δ = 174.2 (-NHC(O)-), 106.7 
(CGal-1), 102.7 (CGalNAc-1), 81.6 (CGalNAc-3), 76.8, 76.3, 74.6, 72.5 (CGal-2, CGal-3, CGal-4, 
CGal-5, ), 70.5 (-OCH2-spacer), 70.3 (CGalNAc-5), 69.6 (CGalNAc-4), 62.6, 62.5 (CGalNAc-6, 
CGal-6), 53.3 (CGalNAc-2), 52.5 (-CH2N3), 30.8 - 21.1 (-CH2-spacer), 23.3 (-CH3); 
HRMS (HR-ESI+) m/z = 579.3333 [M+H]+, calcd. (C25H47N4O11+) = 579.3236.
11-azidoundecyl-5-acetamido-3,5-dideoxy-α-d-
glycero-d-galacto-2-nonulopyranosonate(2→3)-β-d-
galactopyranoside 6. To a solution of 6.7 mM galactoside 
2 (5 ml, 34 µmol, 1.0 eq), 10 mM MgCl2, and 10 mM MnCl2 in 50 mM HEPES buffer 
at pH 7.5, a 9.5 mM solution of donor substrate CMP-Neu5Ac 37 (5 ml, 46 µmol, 
1.3 eq) was added. The sialyl transferase II (ST3GalI) (0.5 U) was added to the 
mixture to start the reaction. The reaction was incubated at 37 °C with gentle 
agitation for 72 h. After 24 h more 0.2 U of ST3GalI was added, and after 48 h an 
additional 0.1 U of ST3GalI was added to the reaction mixture. To remove the 
Mn2+, Mg2+ and protein present in the reaction mixture, 1.5 g of Chelex 100 was 
added to the mixture and the solution was incubated for 15 min at room temperature 
while shaking. Then, the mixture was centrifuged at 13000 rpm for 10 min. at room 
temperature and the supernatant was extracted. The Chelex was rinsed and 
centrifuged two times with 1 ml of MeOH. The combined liquid phases were 
concentrated under reduced pressure. The disaccharide was charged on a Waters 
Sep-Pak®Vac C18 column and eluted with MeOH. Fractions containing compound 
6 were combined and concentrated under reduced pressure. Compound 6 was 
dissolved in water and lyophilized to result in a white solid with a yield of 77% (16 
mg, 25 µmol). 1H NMR (400 MHz, D2O) δ = 4.27 (d, 1H, J = 8.0 Hz, HGal-1), 4.20 (m, 
1H, HGal-3), 3.93 (m, 1H, HGal-4), 3.88 (m, 1H, HNeu5Ac-8), 3.84 (m, 1H, HNeu5Ac-9a), 3.77 
- 3.70 (m, 5H, -OCHa-, HGal-6a, HNeu5Ac-4, HNeu5Ac-5, HGal-6b), 3.65 (m ,2H, HNeu5Ac-6, 
HNeu5Ac-9b), 3.60 (m, 1H, HGal-5), 3.58 (m, 1H, HGal-2), 3.52 (m, 1H, HNeu5Ac-7), 3.40 (m, 
1H, -OCHb-), 2.87 (m, 1H, HNeu5Ac-3eq), 2.01 (s, 3H, -CH3); 1.69 (m, 1H, HNeu5Ac-3ax) 
1.64 - 1.55 (m, 4H, -OCH2CH2-, -OCH2CH2N3); 1.42 - 1.32 (m, 4H, -CH2-spacer); 
13C NMR (100 MHz, D2O) δ = 175.0, (CNeu5Ac-1), 174.0 (-NC(O)-), 105.0 (CGal-1), 
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101.1 (CNeu5Ac-2), 77.9 (CGal-3), 76.6 (CGal-5), 75.1 (CNeu5Ac-6), 73.9 (CNeu5Ac-8), 72.9 (CGal-
2), 70.6 (CNeu5Ac-7), 70.4 (CGal-4), 70.3 (CNeu5Ac-4), 64.4 (CNeu5Ac-9), 62.8 (-OCH2-), 62.5 
(CGal-6), 54.1 (CNeu5Ac-5), 52.5 (-CH2N3), 42.4 (CNeu5Ac-3), 30.8 - 27.1 (9 × -CH2-spacer), 
22.6 (-CH3); MS (HR-ESI-) m/z = 665.3345 [M-H]-, calcd. (C28H49N4O14-) = 665.3251.
11-azido-undecanyl-5-acetamido-3,5-dideoxy-β-d-glycero-d-
galacto-2-nonulopyranosonate 7. Compound 46 (113 mg, 0.2, 
mmol, 1.0 eq) was suspended in 10 ml MeOH and 100 μl of a 0.5 
M NaOMe in MeOH solution was added to the stirred mixture. After 1 h, TLC 
indicated that the starting material was not completely consumed and an additional 
100 μl of the NaOMe solution was added to the mixture. After an additional hour, 
TLC indicated full conversion to the deprotected material and the mixture was 
neutralized by addition of Dowex-H+ resin, filtered and the resin was rinsed with 2 
ml of MeOH. The filtrate was concentrated in vacuo and redissolved in 10 ml of a 
4 : 1 H2O/ MeOH mixture that contained 30 mg/ml KOH. The mixture stirred for 2 
days at room temperature after which it was neutralized with Dowex-H+ resin, 
filtered, the resin was rinsed with 2 ml water, and 2 ml MeOH. By application of a 
gentle nitrogen flow, MeOH was evaporated from the filtrate and the remaining 
water was removed by lyophilization overnight. Compound 7 was obtained as a 
white amorphous compound (30 mg, 0.06 mmol, 30%). 1H NMR (400 MHz, CDCl3): 
δ = 4.02 (m, 1H, H-4), 3.86 (m, 2H, H-5, H-6), 3.81 - 3.76 (m, 2H, H-9a, H-7 or H-8) 
3.68 (m, 2H, H-9b, -OCHa-spacer) 3.52 (m, 1H, H-7 or H-8), 3.26 (m, 1H, -OCHb-
spacer), 3.27 (t, 2H, J = 6.8 Hz, -CH2N3), 2.37 (dd, 1H, J = 4.9, 12.9 Hz, H-3eq), 
1.64 - 1.55 (m, 5H, H-3ax, -OCH2CH2-, -OCH2CH2N3); 1.38 - 1.31 (m, 14H, -CH2-
spacer); 13C NMR (100 MHz, D2O) δ = 174.8 (C-1), 173.0 (-NC(O)-), 100.3 (C-2), 
72.3 (C-6), 71.4, 70.2, (C-7 and C-8), 67.9 (C-4), 65.2 (C-9), 64.5 (-OCH2-spacer), 
53.9 (C-5), 52.5 (-CH2N3), 42.0 (C-3), 30.7 - 27.1 (9 × -CH2-spacer), 22.7 (-CH3); 
MS (HR-ESI-) m/z = 503.2721 [M-H]-, calcd. (C22H39N4O9-) = 503.2723.
11-azidoundecyl-β-d-2-acetamido-2-deoxy-galacto 
pyranosyl-(1→4)-β-d-galactopyranoside 8. Hepta-O-ace-
tate 36 was exposed to standard Zemplén conditions, until 
TLC indicated that all starting material was consumed, to afford compound 8 as 
a white solid (55 mg, 95 µmol, 95%). 1H NMR (400 MHz, D2O): δ = 4.50 (d, 1H, J 
= 8.2 Hz, HGalNAc-1), 4.21 (d, 1H, J = 8.0 Hz, HGal-1), 4.15 (m, 1H, HGalNAc-3),  3.98 (m, 
1H), 3.90 (m, 1H, -OCHaHb-), 3.81 (m, 1H, CGalNAc-2), 3.81 - 3.51 (m, 9H), 3.39 (m, 
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1H, HGal-2), 3.27 (t, 2H, J = 6.9 Hz, -CH2N3), 2.00 (s, 3H, -C(O)CH3), 1.69 - 1.62 
(m, 4H, -CH2CH2O-, -CH2CH2N3), 1.40 - 1.31 (m, 14H, -CH2-spacer); 13C NMR 
(100 MHz, D2O): δ = 169.5 (-NC(O)CH3), 104.0 (CGal-1), 103.2 (CGalNAc-1), 77.0, 75.7, 
75.1, 73.2, 70.7 (-OCH2-), 71.9, 71.5, 68.7, 61.0 (C Gal-6), 61.8 (C GalNac-6), 52.5 
(C GalNAc-2), 51.0 (-CH2N3), 23.2 (-NC(O)CH3), 30.5 - 26.8 (9 × -CH2-spacer); MS 
(HR-ESI+) m/z = 579.3241 [M+H]+, calcd. (C25H47N4O11
+) = 579.3236.
11-Azido-undecyl-2-acetamido-2-deoxy-β-d-galactopyranoside 
9. Compound 39 (1.6 g, mmol, 1.0 eq) was exposed to standard 
Zemplén conditions, until TLC indicated that all starting material 
was consumed, to afford 1.3 g (3.0 mmol, quant.) 9 as a white solid. ¹H-NMR 
(400 MHz, MeOD): δ = 4.36 (d, 1H, J = 8.4 Hz, H-1), 3.90 (m, 2H, H-2, -OCHa-
spacer), 3.83 (m, 1H, H-4), 3.74 (m, 2H, H-6a+b), 3.59 (dd, 1H, J = 3.2, 10.7 Hz, 
H-3), 3.47 (m, 2H, -OCHb-spacer, H-5), 3.28 (t, 2H, J = 6.8, -CH2N3), 1.98 (s, 3H, 
CH3), 1.57 (m, 4H), 1.31 (m, 14H); 
13C NMR (100 MHz, MeOD): δ = 174.0 (C=O), 
103.1 (C-1), 76.6 (C-5), 73.3 (C-3), 70.6 (-OCH2-spacer), 69.7 (C-4), 62.5 (C-6), 
54.4 (C-2), 52.5 (-CH2N3), 30.8, 30.73, 30.65, 30.5, 30.3, 29.9, 27.8, 27.2, 23.0; 
MS (ESI+) m/z = 439.2580 [M+Na]+, calcd. (C19H36N4NaO6+) = 439.2527.
2’,3’,4’,6’-tetra-O-acetyl-β-d-galactopyranosyl-(1→4)-
1,2,3,6-tetra-O-acetyl-β-d-glucopyranoside 12. Dry glassware 
was charged with lactose (3.4 g, 10 mmol, 1.0 eq) and acetic 
anhydride (9.4 ml, 10 eq) was added. The suspension was stirred for 5 min. under 
nitrogen flow and warmed to 35 °C. I2 (38 mg, 0.15 mmol, 15 mol%) was added 
and stirring continued for 6 h at 35 °C. Subsequently, the reaction was quenched, 
while cooling in an ice bath, by slow addition of 1 M Na2S2O3. The organic phase 
was then washed with sat. NaHCO3 (3 × 10 ml), brine (1 × 10 ml), dried over 
Na2SO4, filtered, and concentrated in vacuo to afford compound 12 as a white 
amorphous foam (5.0 g, 7.4 mmol, 74%) and an anomeric mixture of α and β. The 
mixture was used in subsequent reactions without further purification. Rf (chex/ 
EtOAc 1 : 2) = 0.52; MS (ESI+) m/z = 679.23 [M+H]+, calcd. (C28H39O19+) = 679.21.
per-O-acetyl-d-galactopyranoside 13. The followed procedure was 
similar to that of compound 12, recrystallization from diethyl ether 
afforded the desired compound as a white solid in 90% yield (19 g, 50 
mmol). The resulting mixture of α and β products was used without further 
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treatment in the next reaction. Rf (chex/ EtOAc 2 : 3) = 0.53, (EtOAc/ nhept 1 : 1) 
= 0.25; MS (ESI+) m/z = 391.23 [M+H]+, calcd. (C16H23O11+) = 391.12.
Iodo-2,3,4,6-tetra-O-acetyl-β-d-galactopyranosyl-(1→4)-2,3,6-
tri-O-acetyl-α-d-glucopyranoside 14. A round-bottom flask was 
charged with lactose (3.4 g, 10 mmol, 1.0 eq), and acetic anhydride 
(9.4 ml, 10 eq) was added. The suspension was stirred for 5 min under nitrogen 
flow and warmed to 35 °C. I2 (38 mg, 0.15 mmol, 15 mol%) was added and 
stirring continued for 6 h at 35 °C. Subsequently, the reaction mixture was diluted 
with dry DCM (10 ml) and equimolar I2 (2.5 g, 10 mmol, 1.0 eq) was added. After 
allowing the reaction to progress overnight, it was quenched, while cooling in an 
ice bath, by slow addition of 1 M Na2S2O3. The organic phase was then washed 
with sat. NaHCO3 (3 × 10 ml), brine (1 × 10 ml), dried over Na2SO4, filtered, and 
concentrated in vacuo to afford compound 14 as an amorphous white foam (5.0 
g, 7.4 mmol, 74%) that was used in subsequent reactions without further 
purification. Rf (nhex/ EtOAc 2 : 3) = 0.49; 1H NMR (400 MHz, CDCl3): δ 6.90 
(1H, d, HGlc-1, J = 4.36 Hz), 5.45 (1H, t, HGlc-3, J = 9.44 Hz), 5.34 (1H, dd, HGal-4, J 
= 3.38 and 0.88 Hz),  5.11 (1H, dd, HGal-2, J = 10.38 and 7.88 Hz),  4.95 (1H, dd, 
HGal-3, J = 10.38 and 3.48 Hz),  4.51 (1H, d, HGal-1, J =  7.88 Hz),  4.47 (1H, dd, 
HGlc-6a, J = 12.35 and 1.96 Hz),  4.22-4.05 (4H, m, HGlc-2, HGlc-6b, HGal-6), 3.98 - 3.92 
(1H, m, HGlc-5), 3.90-3.85 (2H, m, HGlc-4, HGal-5), 2.15 (3H, s, -OC(O)CH3), 2.11 (3H, 
s, -OC(O)CH3), 2.08 (3H, s, -OC(O)CH3), 2.05 (3H, s, -OC(O)CH3), 2.04 (6H, s, 
2 × -OC(O)CH3), 1.95 (3H, s, -OC(O)CH3). 
13C NMR (100 MHz, CDCl3): δ 170.3, 
170.1, 170.1, 170.0, 169.7, 169.2, 168.9 (7 × C=O), 100.8 (CGal-1), 75.7 (CGlc-5), 
74.7 (CGlc-4), 72.6 (CGlc-1), 71.1 (CGlc-3), 71.0 (CGal-3), 70.8 (CGal-5), 70.5 (CGlc-2), 69.1 
(CGal-2), 66.6 (CGal-4), 61.0 (CGlc-6), 60.9 (CGal-6), 20.8, 20.8, 20.7, 20.6, 20.6, 20.6, 
20.5 (7 × CH3). MS (HR-ESI-) m/z = 745.0832 [M-H]- calcd. 745.0835 (C26H35IO17-).
Iodo-2,3,4,6-tetra-O-acetyl-β-d-galactopyranoside 15. The followed 
procedure was similar as that for compound 14. Column chromatography 
afforded 0.75 g of compound 15 (1.6 mmol, 90%) yellowish solid. Rf (hept/ 
EtOAc 1 : 1) = 0.44; ¹H-NMR (400 MHz, CDCl3): δ = 7.09 (d, 1H, J = 4.2, H-1), 5.44 
(m, 1H), 5.24 (dd, 1H, J = 3.3, 10.5 Hz, H-3), 4.31 (dd, 1H, J = 4.2, 10.5 Hz, H-2), 
4.24 - 4.13 (m, 2H), 4.10 - 4.02 (m, 1H); 13C NMR (100 MHz, CDCl 3): δ = 170.4, 
169.8, 169.5, 169.4,  74.7, 72.9, 71.5, 70.0, 66.7, 60.6, 20.5, 20.4, 20.32, 20.26; 
MS (ESI+) m/z = 347.11 [M-I+O]- , calcd. (C14H19IO9) = 458.00, (C14H19O10-) = 347.10.
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11-Azidoundecyl-2,3,4,6-tetra-O-acetyl-β-d-galacto 
pyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-d-glucopyranoside 
16. From 2,3,4,6-tetra-O-acetyl-β-d-galactopyranosyl-
(1→4)-1,2,3,6-tetra-O-acetyl-β-d-glucopyranoside 12: Per-O-acetate 12 (200 mg, 
0.3 mmol, 1.0 eq) and 11-azidoundecan-1-ol compound 21 (800 mg, 0.4 μmol, 
1.2 eq) were dissolved in 10 ml dry DCM, 4 Å MS, and 300 μl (0.3 mmol, 1.0 eq) 
of a 1 M SnCl4 solution in DCM were added to the reaction mixture as subsequently 
stirred for 16 h at room temperature. The reaction mixture was filtered over hyflo, 
washed with sat. NaHCO3 (3 × 5 ml), brine (1 × 5 ml), dried over Na2SO4, filtered, 
and concentrated in vacuo to afford compound 16 (37 mg, 0.05 mmol, 15 %, 
anomeric mixture) as a white amorphous foam. From Iodo 2,3,4,6-tetra-O-acetyl-
β-d-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl-α-d-glucopyranoside 14: Iodide 14 
(1.5 g, 2.0 mmol, 1.0 eq) and 11-azido-1-undecanol compound 21 (0.85 g, 4.0 
mmol, 2.0 eq) were dissolved in dry MeCN (10 ml). Subsequently, the solution 
was stirred under dry N2 for 5 min at 0 °C and I2 (0.76 g, 3 mmol, 1.5 eq) was 
added. The reaction was allowed to warm to room temperature while stirring 
overnight. The reaction was diluted with EtOAc (50 ml), filtered, and the residue 
rinsed. The filtrate was quenched, while cooling in an ice bath, by slow addition of 
1 M Na2S2O3 until the dark brown solution maintained a yellow transparent color. 
The organic phase was washed with sat. NaCl (3 × 50 ml), dried over Na2SO4, 
and concentrated in vacuo. The crude was purified by flash chromatography 
affording compound 16 (1.2 g, 1.4 mmol, 70 %) as a white amorphous foam. Rf 
(EtOAc/ nhept 1 : 2) = 0.50; 1H NMR (400 MHz, CDCl3): δ = 5.34 (dd, 1H, J = 3.3, 
0.8 Hz, HGal-4), 5.18 (t, 1H, J = 9.3 Hz, HGlc-3), 5.10 (dd, 1H, J = 10.4, 7.9 Hz, HGal-2), 
4.95 (dd, 1H, J = 10.4, 3.4 Hz, HGal-3), 4.87 (dd, 1H, J = 9.5, 8.0 Hz, HGlc-2), 4.48 - 
4.43 (m, 3H, HGal-1, HGlc-6a, HGlc-1), 4.15 - 4.05 (m, 3H, HGal-6, HGlc-6b), 3.88 - 3.76 (m, 
3H, HGal-5, -OCHaHb-spacer, HGlc-4), 3.62 - 3.56 (m, 1H, HGlc-5), 3.47 - 3.41 (m, 1H, 
-OCHaHb-spacer), 3.24 (t, 2H, J = 7.0 Hz, -CH2N3), 2.14 (s, 3H, -OC(O)CH3), 2.11 
(s, 3H, -OC(O)CH3), 2.05 (s, 3H, -OC(O)CH3), 2.03 (s, 6H, 2 × -OC(O)CH3), 2.02 
(s, 3H, -OC(O)CH3), 1.95 (s, 3H, -OC(O)CH3), 1.64 - 1.48 (m, 4H, -CH2-spacer), 
1.39 - 1.25 (m, 14H, CH2-spacer); 13C NMR (100 MHz, CDCl3): δ = 170.3, 170.3, 
170.1, 170.0, 170.0, 170.0, 169.0 (7 × C=O), 101.0 (CGal-1), 100.6 (CGlc-1), 76.3 
(CGlc-4), 72.8 (CGlc-3), 72.6 (CGlc-5), 71.7 (CGlc-2), 71.0 (CGal-5), 70.2 (-OCH2-spacer), 
69.1 (CGal-2), 66.6 (CGal-4), 62.1 (CGlc-6), 60.8 (CGal-6), 51.5 (-CH2N3), 29.5, 29.4, 29.4, 
29.4, 29.3, 29.1, 28.8, 26.7 25.8 (9 × CH2), 20.8, 20.8, 20.6, 20.6, 20.6, 20.6, 20.5 
(7 × CH3). MS (HR-ESI-) m/z = 830.3550 [M-H]-, calcd. (C37H57N3O18-) = 830.3556.
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11-Azido-undecyl-2,3,4,6-tetra-O-acetyl-d-galactopyranoside 
17. To round-bottom flask charged with dry MeCN (20 ml) and 4 Å 
MS (0.5 g)  was added compound 15 (2.0 g, 4.3 mmol, 1.0 eq) and 
11-azidoundecan-1-ol 21 (1.8 g, 8.6 mmol, 2.0 eq). The reaction mixture was 
cooled in an ice bath and small portion of iodine (1.0 g, 3.9 mmol, 1.1 eq) were 
added and the reaction mixture was allowed to stir for 18 h while gradually 
warming to room temperature. The reaction was filtered and cooled again in an 
ice bath. Gradually, a 1M Na2S2O3 was added until complete discoloration (turbid 
brown/ red → clear yellow) of the mixture was observed. The mixture was extracted 
with EtOAc (3 × 20 ml). The combined organic layers were washed with brine (3 
× 30 ml), dried over Na2SO4, and concentrated in vacuo. Automated column 
chromatography-purification afforded 1.4 g (2.6 mmol, 62%) of compound 17 as 
a yellowish syrup. Rf (nhex/ EtOAc 1 : 1) = 0.42, ¹H-NMR (CDCl3, 400 MHz): δ 
(ppm) = 5.38 (m, 1H), 5.21 (m, 1H), 5.01 (dd, 1H, J = 3.4, 10.5 Hz),  4.45 (d, 1H, 
J = 8.0, H-1), 4.15 (m, 2H), 3.90 (m, 2H), 3.46 (m, 1H), 3.26 (t, 2H, -CH2N3 ), 2.15 
(s, 3H, -C(O)CH3), 2.05 (s, 3H, -C(O)CH3), 1.99 (s, 3H, -C(O)CH3), 1.58 (m, 4H, 
-CH2CH2O-, -CH2CH2N3), 1.27 (m, 14 H, -CH2-spacer), 13C NMR (100 MHz, 
CDCl3): δ = 101.39 (C-1), 71.0, 70.6, 70.3 (-OCH2-spacer), 69.0, 67.1, 61.3 (C-6), 
51.5 (-CH2N3), 59.54, 59.47, 59.4, 29.3, 29.1, 28.8, 26.7, 25.8, 20.8, 20.7, 20.6; 
MS (ESI+) m/z = 585.27 [M+MeCN+H]+, calcd. (C27H45N4O10+) =  585.31. 
11-Bromo-undecyl-2,3,4,6-tetra-O-acetyl-β-d-galacto 
pyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-d-glucopyranoside 
18. Per-O-acetate 12 (1.0 g, 1.5 mmol, 1.0 eq) and 
11-bromoundecan-1-ol (0.4  g, 1.6 mmol, 1.1 eq) were dissolved in 2 ml dry DCM, 
4 Å MS, and 0.2 ml (1.6 mmol, 1.1 eq) of a 1M SnCl4 solution in DCM were added 
to the reaction mixture as subsequently stirred for 16 h at room temperature. The 
reaction mixture was filtered over hyflo, washed with sat. NaHCO3 (3 × 1 ml), brine 
(1 × 1 ml), dried over Na2SO4, filtered, and concentrated in vacuo. Purification on 
normal-phase silica, eluent: chex/ EtOAc gradient 3 : 2 → 2 : 3, afforded 600 mg 
(0.4 mmol, 28%) 18 as a white solid as a mixture of anomers (α/ β 1 : 4). Rf (chex/ 
EtOAc 2 : 3) = 0.69, 0.67 (α and β, respectively); 1H NMR (400 MHz, CDCl3): δ 5.30 
(1H,  d, HGal-4, J = 3.3 Hz), 5.15 (1H, t, J = 9.3 Hz, HGlc-3), 5.06 (1H, dd, J = 10.4, 7.9 
Hz, HGal-2), 4.92 (1H, dd, J = 10.49, 3.48 Hz, HGal-3), 4.84 (1H, dd, J = 9.52, 8.02 Hz, 
HGlc-2), 4.46 - 4.40 (3H, m, HGal-1, HGlc-6a, HGlc-1), 4.12 - 4.02 (3H, m, HGal-6, HGlc-6b), 3.86 
- 3.73 (3H, m, HGal-5, -OCHaHb-spacer, HGlc-4), 3.58 - 3.54 (1H, m, HGlc-5), 3.44 - 3.39 
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(1H, m, -OCHaHb-spacer), 3.36 (2H, t, J = 6.8 Hz, -CH2Br), 2.11 (3H, s, -OC(O)CH3) 
, 2.07 (3H, s, -OC(O)CH3), 2.02 (3H, s, -OC(O)CH3), 2.00 (6H, s, -OC(O)CH3), 1.99 
(3H, s, -OC(O)CH3), 1.92 (3H, s, -OC(O)CH3), 1.84 - 1.77 (2H, m, CH2-spacer), 
1.59 - 1.43 (2H, m, CH2-spacer), 1.43-1.32 (2H, m, CH2-spacer), 1.32 - 1.17 (12H, 
m, CH2-spacer). 
13C NMR (100 MHz, CDCl3): δ 170.2, 170.2, 170.0, 169.9, 169.7, 
169.4, 168.9 (7 x C=O), 100.9 (CGal-1),  100.5 (CGlc-1), 76.2 (CGlc-4), 72.8 (CGlc-3), 72.5 
(CGlc-5), 71.7 (CGlc-2), 70.9 (CGal-3), 70.6 (CGal-5), 70.1 (-OCH2-spacer), 69.1 (CGal-2), 
66.6 (CGal-4), 62.0 (CGlc-6), 60.7 (CGal-6), 33.9 (-CH2Br), 32.7, 29.4, 29.3, 29.3, 29.3, 
29.1, 28.6, 28.0, 25.7 (9 x CH2), 20.7, 20.7, 20.6, 20.5, 20.5, 20.5, 20.4 (7 x CH3). 
MS (HR-ESI-) m/z = 867.2660 [M-H]-, calcd. (C37H57BrO18-) = 867.2645.
11-Bromo-undecyl-2,3,4,6-tetra-O-acetyl-d-galactopyranoside 
19. Acetyl-protected galactoside 13 (2.0 g, 5.1 mmol, 1.0 eq) and 
1.4 g (5.6 mmol, 1.1 eq) 11-bromo-undecan-1-ol 21 were dissolved 
in dry DCM (2 ml) and stirred in the presence of 4 Å MS for 30 min. Then, 0.66 
ml (5.6 mmol, 1.1 eq) of a 1 M SnCl4 in DCM was added. Stirring continued for 
16 h, and then, filtered over hyflo, rinsed with 5 ml DCM, washed with sat. 
NaHCO3 (3 × 1 ml), and brine (1 × 1 ml), dried over Na2SO4, filtered, and 
concentrated in vacuo. Purification on normal-phase silica, eluent: chex/ EtOAc 
gradient 4 : 1 → 2 : 3, afforded 600 mg (1.0 mmol, 20%, as a mixture of anomers) 
of 19 as a white solid. ¹H-NMR (β) (CDCl3, 400 MHz): δ (ppm) = 5.39 (m, 1H), 
5.20 (m, 1H), 5.02 (m, 1H), 4.45 (d, 1H, J = 7.8 Hz, H-1), 4.24 – 4.13 (m, 2H), 
3.40 (m, 1H), 3.47 (m, 1H), 3.41 (t, 2H, J = 6.7 Hz, -CH2Br), 2.15 (s, 3H, -OC(O)
CH3), 2.05 (s, 6H, 2 × -OC(O)CH3), 1.98 (s, 3H, -OC(O)CH3), 1.85 (m, 2H), 1.61 
(m, 2H), 1.42 (m, 2H), 1.28 (m, 12H); MS (ESI+) m/z = 581.20 [M+H]+ (100%), 
582.20 (30%), 583.20 (95%), 584.20 (25%), Br-pattern observed, calcd. 
(C25H42BrO10
+) = 581.20 (100.0%), 582.20 (27.0%), 583.20 (97.3%), 584.20 
(26.3%), 585.20 (3.4%).
11-Azido-undecan-1-ol 21.[33] To a solution of 11-bromo-
undecan-1-ol (10 g, 39 mmol, 1.0 eq) in DMF (50 ml) was added sodium azide (5.2 g 
80 mmol, 2.1 eq) and the reaction mixture was heated at 100°C for 16 h. The reaction 
mixture was diluted with 50 ml of EtOAc, filtered, washed with brine (3 × 50 ml). 
The organic phase was dried with Na2SO4, filtered and dried in vacuo. Purification 
by flash chromatography, eluent: isocratic chex/ EtOAc 1 : 2, afforded the desired 
compound 21 (7.6 g, 36 mmol, 91%) as a clear and colorless oil. Rf (chex/ EtOAc 1 
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: 2) = 0.60; 1H NMR (CDCl3, 400 MHz): δ (ppm) = 3.49 (t, 2H, J = 6.8 Hz, -CH2OH), 
3.16 (t, 2H, J = 7.0 Hz, -CH2N3), 2.95 (s, 1H), 1.52-1.44 (m, 4H), 1.20 (m, 14H); 
13C 
NMR (CDCl3, 100 MHz): 63.1 (-CH2OH), 51.5 (-CH2N3), 32.8, 29.6, 29.5, 29.4, 29.2, 
28.9, 26.7, 25.8; MS (ESI+) m/z = 214.20 [M+H]+, calcd. (C11H24N3O+) = 214.19.
11-Azido-undecyl-4,6-(4-methoxybenzylidene)-β-d-galacto- 
pyranoside 22. Dry compound 2 (790 mg, 2.1 mmol, 1.0 eq) was 
suspended in 20 ml MeCN. To the stirred suspension, p-anisaldehyde 
dimethyl acetal (0.72 ml, 4.2 mmol, 2.0 eq) was added, followed by 
12 mg (0.06 mmol, 3 mol%) PTSA·H2O, and stirring continued for 36 h at rt. The 
resulting clear, red solution was quenched by neutralization with Et3N, and 
concentrated in vacuo. Purification by automated column chromatography 
yielded the desired beta product 22 in 670 mg (1.4 mmol, 65%) as a yellowish 
oil. β anomer: Rf (EtOAc/ nhept 3 : 1) = 0.18; 1H-NMR (400 MHz, CDCl3): δ = 
7.42 (d, 2H, J = 8.6 Hz); 6.88 (d, 2H, J = 8.6 Hz); 5.50 (s, 1H); 4.30 (m, 1H); 4.25 
(d, 1H, J = 7.5 Hz); 4.17 (m, 1H); 4.05 (dd, 1H, J = 1.7, 12.5 Hz); 3.95 (m, 1H); 
3.79 (s, 3H); 3.72 (m, 1H); 3.67 (m, 1H); 3.50 (m, 1H); 3.43 (m, 1H); 3.24 (t, 2H, 
J = 7.0); 1.68 - 1.56 (m, 4H); 1.39 - 1.27 (m, 16H); 13C NMR (100 MHz, CDCl3): 
δ = 127.8; 113.5; 102.8; 101.3; 75.4; 72.8; 72.7; 71.8; 70.0; 69.2; 51.5; 29.5; 
29.4; 29.1; 28.8; 26.8; 25.9; MS (ESI+) m/z = 494.35 [M+H]+, calcd. (C25H40N3O7+) 
m/z = 494.29. α anomer: Rf (EtOAc/ nhept 3 : 1) = 0.40; 1H NMR (400 MHz, 
CDCl3): δ = 7.39 (d, 2H, J = 8.5 Hz); 6.85 (d, 2H, J = 8.5 Hz); 5.45 (s, 1H); 4.95 
(d, 1H, J = 2.6 Hz); 4.17 (m, 1H); 4.00 (d, 1H); 3.85 (m, 2H); 3.76 (s, 3H); 3.68 
(m, 1H); 3.62 (m, 1H); 3.46 (m, 1H); 3.23 (t, 2H, J = 6.9 Hz); 2.53 (bs, 2H) -OH; 
1.56 (m, 4H); 1.26 (m, 14H); 13C NMR (100 MHz, CDCl3): δ = 127.6; 113.5; 101.3; 
99.1; 69.9; 69.7; 69.3; 68.6; 62.9; 68.6; 51.4; 29.6; 29.5; 29.4; 29.3; 29.1; 28.8; 
26.7; 26.1; MS (ESI+) m/z = 494.28 [M+H]+, calcd. (C25H40N3O7+) = 494.28.
11-Azido-undecyl-4,6-O-benzylidene-2,3-di-O-(4-methoxyben- 
zyl)-β-d-galactopyranoside 23. Compound 22 (100 mg, 203 
µmol, 1.0 eq) was dissolved in DMF (2 ml) under an applied Ar 
flow, and treated with NaH (24 mg, 1.0 mmol, 5.0 eq). After 30 min 
PMB-Cl (0.1 ml, 1.0 mmol, 5.0 eq) was added. The reaction mixture 
was stirred overnight  at rt. TLC analysis indicated that the reaction did not 
progress any further. Subsequently, it was quenched with NH4Cl (1 × 10 ml), 
extracted with EtOAc (3 × 10 ml), the combined organic layers were washed with 
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brine (1 × 10 ml), dried over Na2SO4, filtered, and concentrated in vacuo to obtain 
258 mg of crude orange oil. Purification by automated column chromatography 
yielded 23 (102 mg, 140 µmol, 69%) as a white solid. Rf (EtOAc/ nhept 3 : 1) = 
0.63; 1H NMR (400 MHz, CDCl3): δ = 7.50 (m, 2H, Ph),  7.31 (m, 4H, Ph), 6.87 
(m, 6H, Ph), 5.45 (s, 1H, -CH acetal), 4.87 (d, 1H, J = 10.5, -(C-2)OCHaPh); 4.70 
(m, 3H, -(C-2)OCHbPh, -(C-3)OCH2Ph), 4.36 (d, 1H, J = 7.5 Hz, H-1), 4.27 (m, 
1H, H-6a), 4.06 (m ,1H, H-4), 3.99 (m, 2H, H-6b, -OCHa-spacer), 3.81 (m, 11H, 
H-2, 9 × -CH3), 3.50 (m, 2H, H-3, -OCHb-spacer), 3.26 (m, 2H, H-5, -CH2N3), 1.68 
(m, 2H, -CH2CH2O-), 1.59 (m, 2H, -CH2CH2N3), 1.30 (m, 14H, -CH2-spacer); 13C 
NMR (100 MHz, CDCl3): δ = 160.0 (Cq Ph) 159.2 (Cq Ph), 159.1 (Cq Ph), 131.2 
(Cq Ph), 130.6  (2 × Cq Ph) 129.7 – 127.9 (12 × -CH (Ph)) 113.71 (-CH3), 113.67 
(-CH3), 113.4 (-CH3), 103.8 (C-1), 101.2 (-CH acetal), 78.9 (C-3), 78.3 (C-2), 74.9 
(-(C-2)OCH2Ph), 74.1 (C-4), 71.6 (-(C-3)OCH2Ph), 70.0 (-OCH2-spacer) 69.2 (C-
6), 66.4 (C-5), 55.3 (3 × -CH3), 51.5 (-CH 2 N3), 29.8 – 26.2 (9 × -CH2-spacer); MS 
(ESI+) m/z = 734.38 [M+H]+, calcd. (C41H56N3O9
+) = 734.40.
11-Azido-undecyl-2,3-di-O-acetyl-4,6-O-(4-methoxybenzylid- 
ene)-β-d-galactopyranoside 24. Compound 22 (200 mg, 0.4 
mmol, 1.0 eq) was dissolved in pyridine and cooled to 0 °C. Ac2O 
(0.8 ml, 8.2 mmol, 20 eq) was added drop wise and the reaction 
mixture was allowed to warm to room temperature and stirred overnight. The 
reaction mixture was poured into ice cold water and extracted with EtOAc (3 × 
5 ml). The combined organic layers were washed with 1 M NH4Cl (3 × 5 ml), 
brine (5 ml), dried over Na2SO4, filtered, and concentrated, yielding 214 mg (0.4 
mmol, 93%) 24 as a colourless oil. The material was used in subsequent 
reactions without further purification. 1H NMR (400 MHz, CDCl3): δ = 7.39 (d, 
2H, J = 8.7 Hz, Ph-Ha), 6.83 (d, 2H, J = 8.7 Hz, Ph-Hb), 5.40 (s, 1H, -CH-Ph), 
5.31 (m, 1H), 4.92 (dd, 1H, J = 3.6, 10.4 Hz), 4.43 (d, 1H, J = 8.0 Hz, H-1), 4.30 
(m, 1H), 4.23 (m, 1H), 3.99 (m, 1H), 3.86 (m, 1H), 3.74 (s, 3H, Ph-OCH3), 3.43 
(m, 2H), 3.20 (t, 2H, J = 7.0 Hz, -CH2N3), 2.00 (-C(O)CH3), 1.99 (-C(O)CH3), 
1.58 - 1.48 (m, 4H,-OCH2CH2-, -OCH2CH2N3), 1.31 - 1.24 (m, 14H, -CH2-spacer); 
MS (ESI+) m/z = 600.31 [M+Na]+, calcd. (C29H43N3NaO9+) = 600.29.
11-Azido-undecyl 2,3-di-O-acetyl-6-O-(4-methoxybenzyl)-β-d-
galactopyranoside 26. Galactoside 24 (1.1 g, 1.9 mmol, 1 eq) 
was dissolved in THF (20 ml) in the presence of 4 Å MS. After 10 
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min, NaCNBH3 (1.2 g, 19 mmol, 20 eq) was added and stirring continued for 
another 10 min, after which, 5 drops of HCl (1 M in Et2O) were added while gas 
evacuated. HCl was dropped into the reaction mixture until gas evolution ceased 
and TLC analysis indicated that all starting material was consumed. The 
molecular sieves were filtered off and EtOAc (15 ml) was added. The mixture 
was extracted sat. NaHCO3 (3 × 5 ml) and brine (5 ml), the organic layer was 
dried over MgSO4, filtered and concentrated in vacuo. Purification by automated 
column chromatography yielded compound 26 in 70% yield (0.8 g, 1.3 mmol) as 
a colorless oil; Rf (EtOAc/ toluene 1 : 2) = 0.67; 1H NMR (400 MHz, CDCl3): δ = 
7.22 (d, 2H, J = 8.6 Hz); 6.84 (d, 2H, J = 8.6 Hz); 5.23 (dd, 1H, J = 8.0, 10.3 Hz); 
4.89 (dd, 1H, J = 10.3, 3.3 Hz); 4.48 (m, 2H); 4.40 (d, 1H, J = 8.0 Hz); 4.09 (m, 
1H); 3.85 (m, 1H); 3.77 (s, 3H); 3.70 - 3.62 (m, 3H); 3.45 (m, 1H); 3.22 (t, 2H, J 
= 7.0 Hz); 2.88 (bs, 1H) -OH; 2.05 (s, 3H); 2.01 (s, 3H); 1.60 - 1.49 (m, 4H); 1.36 
- 1.22 (m, 14H) 13C NMR (100 MHz, CDCl3): δ = 170.2; 169.4; 159.3; 129.4; 
101.3, 73.5; 73.3; 73.2; 69.7; 69.5; 68.8; 67.9; 55.2; 51.4; 29.5; 29.4; 29.3; 29.1; 
28.8; 26.7; 25.8; 20.8; 20.7; MS (ESI+) m/z = 602.43 [M+Na]⁺, 1180.96 [2M+Na]+, 
calcd. (C29H45N3NaO9
+) = 602.30, (C58H90N6NaO18
+) = 1181.62.
11-Azido undecyl 4,6-O-benzylidene-β-d-galactopyranoside 28. 
A suspension of β-d-galactopyranoside 2 (1.8 g, 3.4 mmol, 1.0 eq) 
benzaldehyde dimethylacetal (1.0 g, 6.7 mmol, 2.0 eq), and 40 mg 
(0.17 mmol, 5 mol%) camphor-10-sulphonic acid were added and 
the reaction mixture was refluxed for 3 h. Automated column chromatography 
yielded the β-product 28 in 460 mg (1.0 mmol, 30%) as a white solid. The α-anomer 
was obtained in 26% yield (400 mg, 0.86 mmol) as an off-white solid; β anomer: 
Rf (nhex/ EtOAc 1 : 1) = 0.28; 1H NMR (400 MHz, CDCl3): δ = 7.50 (m, 2H, Ph-H), 
7.36 (m, 3H, Ph-H), 5.56 (-CH-Ph), 4.30 (m, 1H, H-6a), 4.28 (d, 1H, J = 7.4 Hz, 
H-1), 4.21 (m, 1H), 4.10 (m, 1H, H-6b), 3.95 (m, 1H, -OCHa-spacer), 3.79 - 3.65 
(m, 2H), 3.51 (m, 1H, -OCHb-spacer), 3.48 (m, 1H), 3.25 (t, 2H, J = 7.0 Hz, 
-CH2N3), 1.65 - 1.59 (m, 4H, -OCH2CH2-, -OCH2CH2N3), 1.36 - 1.30 (m, 14H, 
-CH2-spacer); 
13C NMR (100 MHz, CDCl3): δ = 137.5 (Cq), 129.2, 218.2 (2 ×), 
126.4 (2 ×) (5 × Ph), 102.3 (C-1), 101.5 (-CH-Ph), 75.4, 72.8, 72.0, 70.1 (-OCH2-
spacer), 69.2 (C-6), 66.8, 51.5 (-CH2N3), 29.6 - 26.0 (9 × -CH2-spacer); MS (HR-
ESI+) m/z = 464.27 [M+H]+, calcd. (C24H38N3O6
+) = 464.28; α anomer:  Rf (nhex/ 
EtOAc 1: 1) = 0.28; 1H NMR (400 MHz, CDCl3): δ = 7.50 (m, 2H, Ph-H), 7.37 (m, 
3H, Ph-H), 5.57 (s, 1H, -CH-Ph), 5.04 (d, 1H, J = 2.8 Hz, H-1), 4.30 (m, 2H), 4.16 
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- 4.06 (m, 2H), 3.90 (m, 2H), 3.78 - 3.70 (m, 2H), 2.37 (t, 2H, J = 7.0 Hz, -CH2N3), 
2.35 (bs, 1H, -OH), 2.00 (bs, 1H, -OH), 1.67 - 1.57 (m, 4H, -OCH2CH2-, 
-OCH2CH2N3), 1.40 - 1.28 (m, 14H, -CH2-spacer); 13C NMR (100 MHz, CDCl3): δ 
= 137.6 (Cq), 129.2, 128.3 (2 ×), 126.3 (2 ×) (5 × Ph), 101.3 (-CH-Ph), 99.1 (C-1), 
76.0, 70.2, 69.9, 69.4, 68.7, 62.9, 51.5 (-CH2N3), 29.5 - 26.2 (9 × -CH2-spacer).
11-Azido undecyl 2,3-di-O-benzyl-4,6-O-benzylidene-β-d-
galactopyranoside 29. To a stirred and cooled (0 °C) solution of 
compound 28 (280 mg, 0.6 mmol, 1.0 eq) in DMF (10 ml) was 
added 70 mg NaH (1.8 mmol, 3.0 eq). After 1 h, 0.2 ml (1.8 mmol, 
3.0 eq) BnCl was added drop wise to the solution and stirring continued for an 
additional hour. The reaction was quenched by addition of 10 ml 1 M NH4Cl and 
extracted with EtOAc (3 × 5 ml). The combined organic layers were washed with 
brine (1 × 10 ml), dried over Na2SO4, filtered, and concentrated in vacuo. 
Automated column chromatography yielded 336 mg (0.52 mmol, 86%) of 
compound 29 as a white solid. Rf (EtOAc/ nhex 2 : 3) = 0.41; 1H NMR (400 MHz, 
CDCl3): δ = 7.58 (m, 2H, Ph-H), 7.42 - 7.28 (m, 13H, Ph-H), 5.52 (s, 1H, -CH-
acetal), 4.97 (d, 1H, J = 10.9 Hz, -CHa-Ph), 4.82 - 4.75 (m, 3H, -CHb-Ph, -CH 2-
Ph), 4.40 (d, 1H, J = 7.8 Hz, H-1), 4.31 (d, 1H, J = 1.4, 12.3, H-6a), 4.13 (m, 1H, 
H-4), 4.04 - 4.00 (m, 2H, H-6b, -OCHa-spacer), 3.86 (m, 1H,  H-3), 3.58 (dd, 1H, 
J = 3.7, 9.7 Hz, H-2), 3.52 (m, 1H, -OCHb-spacer), 3.31 (m, 1H, H-5), 3.26 (t, 
2H, J = 7.0 Hz, -CH2N3), 1.72 - 1.57 (m, 4H, -OCH2CH2-, -OCH2CH2N3), 1.44 - 
1.29 (m, 14H, -CH2-spacer); 
13C NMR (100 MHz, CDCl3): δ = 139.1, 138.6, 
138.1 (3 × Cq Ph), 129.0 - 126.6 (15 × Ph), 103.8 (C-1), 101.39 (-CH-Ph), 79.4 
(C-2), 78.6 (C-3), 75.3 (-CH2Ph), 74.1 (C-4), 72.1 (-CH2Ph), 70.0 (-OCH2-
spacer), 69.4 (C-6), 66.5 (C-5), 51.6 (-CH2N3), 29.8 - 26.3 (9 × -CH2-spacer); 
MS (HR-ESI+) m/z = 644.36 [M+H]+, calcd. (C38H50N3O6+) = 644.37.
11-Azido-undecyl 2,3,6-tetra-O-benzyl-β-d-galactopyranoside 
30. Acetal 29 1.4 g (2.1 mmol, 1.0 eq) was dissolved in dry THF 
and stirred under Ar in the presence of 3 Å MS for 1 h. NaCNBH3 
(1.3 g, 21 mmol, 10 eq) was added to the solution and stirred for an additional 
10 min. A 1 M HCl solution in Et2O was added drop wise until evolution of gas 
ceased and TLC indicated that all starting material was consumed. The molecular 
sieves were filtered off and EtOAc (15 ml) was added. The mixture was extracted 
sat. NaHCO3 (3 × 5 ml) and brine (5 ml), the organic layer was dried over MgSO4, 
filtered and concentrated in vacuo. Purification by automated column 
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chromatography yielded compound 29 in 70% yield (1.0 g, 1.5 mmol) as a 
yellowish oil; Rf (toluene/ EtOAc 7 : 1) = 0.38; 1H NMR (400 MHz, CDCl3): δ = 
7.27 - 7.13 (m, 15H, 15 × Bn-H), 4.82 (d, 1H, J = 11.1 Hz, -C-2CHaPh), 4.62 (d, 
1H, J = 11.1 Hz, -(C-2)OCHbPh), 4.58 (s, 2H, -(C-3)OCH3Ph), 4.46 (s, 2H, -(C-6)
OCH3Ph), 4.24 (d, 1H, J = 7.8 Hz), 3.88 - 3.82 (m, 2H, H-4 -OCHa-spacer), 3.68 
(dd, 1H, J = 5.9, 10.0 Hz, H-6a), 3.61 (dd, 1H, J = 6.0, 10.0 Hz, H-6b), 3.55 (m, 
1H, H-2), 3.45 - 3.35 (m, 3H, -OCHa-spacer, H-3, H-5), 3.09 (t, 2H, J = 7.0 Hz, 
-CH2N3), 2.53 (s, 1H, -OH), 1.53 (m, 2H, -CH2CH2O-), 1.45 (m, 2H, -CH2CH2N3), 
1.16 (m, 14H, -CH2-spacer); 
13C NMR (100 MHz, CDCl3): δ = 138.8 (Cq Bn), 
138.2 (Cq Bn), 138.1 (Cq Bn), 128.5 - 127.6 (15 × Bn),  103.8 (C-1), 80.7 (C-3), 
79.1 (C-2), 75.2 (-(C-2)OCH2Ph), 73.7 (-(C-6)OCH2Ph), 73.3 (C-5), 72.4 (-(C-3)
OCH2Ph), 70.0 (-OCH2-spacer), 69.4 (C-6), 67.0 (C-4), 51.5 (-CH2N3), 29.8 
-26.2 (9 × -CH2-spacer). MS (ESI+) m/z = 668.58 [M+Na]+, 1313.11 [2M+Na]+, 
calcd. (C38H51N3NaO6
+) = 668.37, (C76H102N6NaO12
+) = 1313.74.
2,3,4,6-Tetra-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethyloxycarbonyl 
amino)-α/β-d-galactopyranoside 32. A solution of galactosamine 
hydrochloride 31 (2.0 g, 9.3 mmol, 1.0 eq) and 1.9 g (23 mmol, 2.5 eq) 
of K2CO3 in H2O (30 mL) was cooled to at 0 °C. After 10 min, 1.7 mL TrocCl (2.6 
g, 12 mmol, 1.3 eq) was added dropwise. The mixture was allowed to stir for 10 h 
while gradually warming to room temperature. The resulting suspension was 
cooled to 0 °C, and filtered. The residue was rinsed with cold Et2O, and dried in 
vacuo. The residue was then stirred overnight in 50 mL of a mixture of pyridine/ 
Ac2O (1 : 1). The reaction mixture was poured into cold water (200 mL), and 
extracted, while still cold, with EtOAc (3 × 50 mL). The combined organic extracts 
were washed with H2O (3 × 50 mL), 1 M HCl (50 mL), and saturated aqueous 
NaHCO3 (50 mL), dried over Na2SO4, and concentrated in vacuo to afford 3.4 g 
(6.5 mmol, 70%) 32 (mixture of anomers) as a colorless solid. The mixture was 
used in subsequent reactions without further purification. MS (ESI+) m/z = 522.67 
[M+H]+ (100%), 524.67 (95%), 526.67 (30%), Cl 3-pattern observed, calcd. 
(C17H23Cl3NO11
+) m/z = 522.03 (100.0%), 524.03 (95.9%), 526.03 (30.6%).
3,4,6-Tri-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethyloxycarbonyl 
amino)-α/β-d-galactopyranoside 33. Compound 32 (2.3 g, 4.5 mmol, 
1.0 eq) was dissolved in 100 ml DMF and exposed to 0.5 g (5.9 mmol, 
1.3 eq) hydrazine acetate and stirred at room temperature for 1 h. TLC indicated 
that the starting material was still present so additional 0.6 eq hydrazine acetate 
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were added to the solution and stirring continued for 30 min at room temperature. 
Upon completion, the reaction mixture was diluted with 100 ml EtOAc and 
washed with brine (2 × 200 ml), demi water (2 × 200 ml), dried over Na2SO4, 
filtered, and concentrated in vacuo. Automated column chromatography-purification 
afforded 1.3 g (2.7 mmol, 85%) of compound 33 in a mixture of both anomers as a 
white solid. Rf (nhex/ EtOAc 1 : 2) = 0.55 (both anomers); MS (ESI+) m/z = 480.07 
[M+H]+ (100%), 481.07 (15%), 482.08 (95%), 483.07 (15%), 484.06 (30%), 485.08 
(5%), 486.07 (3%), Cl3 isotope pattern observed, calcd. [C15H21Cl3NO10
+] = 480.02 
(100.0%), 481.03 (16.2%), 482.02 (95.9%), 483.02 (15.6%), 484.02 (30.6%), 
485.02 (5.0%), 486.01 (3.3%). Spectral data in agreement with literature values.[40]
3,4,6-Tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonyl 
amino)-α-d-galactopyranosyl trichloroacetimidate 34.[40, 68] A 
solution of hemi-acetal 33 (0.9 g, 1.9 mmol, 1.0 eq), trichloroacetonitrile 
(2.9 g, 19 mmol, 10 eq), and DBU (75 mg, 0.5 mmol, 0.3 eq) in 10 ml 
DCM was stirred at room temperature for 20 minutes and subsequently 
concentrated in vacuo. The residual orange/brown oil was purified by column 
chromatography, eluent: gradient nhex/EtOAc 10 : 1 → 1 : 2, affording 510 mg (0.9 
mmol, 75%) 34 as yellowish oil. Rf (nhex/ EtOAc 1 : 2) = 0.33;  1H NMR (400 MHz, 
CDCl3): δ = 8.78 (s, 1H, -NHCCl3), 6.45 (d, 1H, J = 3.4 Hz, H-1); 5.50 (m, 1H, H-4); 
5.30 (m, 1H, H-3); 4.74 (d, 1H, J = 7.5 Hz, -CHaCCl3),  4.68 (d, 1H, J = 7.5, 
-CHbCCl3); 4.50 (m, 1H, H-2); 4.35 (m, 1H, H-5); 4.15 (m, 1H, H-6a), 4.08 (m, 1H, 
H-6b), 2.17 (s, 3H -C(O)CH3), 2.01 (s, 6H 2 × -C(O)CH3); 
13C NMR (100 MHz, 
CDCl3): δ = 170.7 (C-3OC(O)), 170.2 (C-6OC(O)), 170.0 (C-4OC(O)), 160.4 
(C=NH), 154.3 (-NHC(O)O-); 95.2 (-CCl3), 95.2 (C-1), 90.7 (NHCCl3), 74.6 
(-CH2CCl3); 69.1 (C-5); 67.9 (C-3); 66.8 (C-4); 49.5 (C-2); 20.6 (3 × -C(O)CH3); MS 
(ESI+) m/z = 644.91 [M+Na]+ (51%), 645.92 (10), 646.91 (100%), 647.91 (20%), 
648.91 (81%), 649.91 650.90 (35%), (15%), 651.91 (5%), 652.90  (8%), Cl 6 isotope 
pattern observed., calcd. (C17H20Cl6N2O10Na
+) m/z = 644.91 (52.1%), 645.92 
(9.6%), 646.91 (100.0%), 647.91 (18.4%), 648.91 (79.9%), 649.91 (14.7%), 
650.91 (34.1%), 651.91 (6.3%), 652.90 (8.2%), 653.91 (1.5%), 654.90 (1.0%).
3,4,6-Tri-O-acetyl-2-deoxy-2-N-(4-nitrobenzyloxycarbonyl-
amino)-α-d-galactopyranosyl trichloroacetimidate 34b.[40, 68] A 
solution of 33 (1.0 g, 2.0 mmol, 1.0 eq), trichloroacetonitrile (2 ml, 20 
mmol, 10 eq), and DBU (75 µl, 0.3 mmol, 0.25 eq) in 10 ml DCM was 
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stirred at 0 °C until TLC analysis indicated that all starting material 33 had reacted 
(approx. 1 h). Then, the reaction mixture was concentrated in vacuo to afford 
compound 34b as a white solid in 60% yield (0.5 g, 1.2 mmol). ¹H-NMR (400 MHz, 
CDCl3): δ = 8.75 (s, 1H, -NHCCl3), 8.23 (d, 2H, J = 7.5 Hz, Ph-Ha), 7.51 (d, 2H, J 
= 7.5 Hz, Ph-Hb), 6.44 (d, 1H, 3.8 Hz, H-1), 5.55 (m, 1H, H-4), 5.29 (dd, 1H, J = 
3.1, 11.4 Hz) H-3, 5.20 (s, 2H, -CH2Ph), 4.98 (d, 1H, J = 9.8 Hz, -NHPNZ); 4.50 (m, 
1H, H-2), 4.37 (m, 1H, H-5), 4.23 (m, 2H, H-6a+b), 2.03 (s, 6H, 2 × -OC(O)CH3), 
2.01 (s, 3H, -OC(O)CH3); 
13C NMR (100 MHz, CDCl3): δ = 170.72, 170.68, 169.5, 
155.5, 152.6, 144.8, 125.1, 121.9, 95.4 (C-1), 69.1 (C-5), 68.1 (C-3), 66.6 (C-4), 
65.5 (CH2Ph), 61.1 (C-6), 49.4 (C-2), 20.7, 20.6, 20.5.
3,4,6-Tri-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethyl 
oxycarbonyl amino)-β-d-galactopyranosyl-(1→4)-2,3,6-
tri-O-benzyl-β-d-galactopyranoside 35. GalNAc donor 34 
(438 mg, 0.70 mmol, 1.5 eq) and Gal acceptor 30 (300 mg, 
0.46 mmol, 1.0 eq) were dissolved in DCM (1 ml) in the presence of 3 Å MS and 
cooled to -40 °C. Subsequently, TMSOTf (4.1 µl, 24 µmol, 5 mol%) was added to 
initiate the glycosylation and the mixture was allowed to stir at a constant 
temperature (-40 °C) for 2 h. The reaction mixture was allowed to warm to room 
temperature in 1 h and quenched with three drops of Et3N. The reaction mixture 
was filtered, rinsed with DCM (2 ml), and the filtrate concentrated in vacuo. 
Purification by automated column chromatography afforded disaccharide 35 as 
a white solid (245 mg, 0.24 mmol, 53%). Rf (EtOAc/ nhept 1 : 2) = 0.18, 1H NMR 
(400 MHz, CDCl3) δ = 7.38 - 7.27 (m, 15H, Ph-H), 5.26 (m, 1H, -NH-), 4.93 (m, 
2H), 4.75 - 4.52 (m, 7H), 4.36 (m, 1H), 4.34 (d, 1H, J = 8.0 Hz, HGal-1), 4.11 - 3.89 
(m, 5H), 3.81 - 3.45 (m, 7H), 3.24 (t, 2H, J = 7.0 Hz, -CH2N3), 2.13 (s, 3H, -C(O)
CH3), 1.99 (s, 3H, -C(O)CH3), 1.93 (s, 3H, -C(O)CH3), 1.67 - 1.54 (m, 4H, -CH2N3, 
-OC2HCH2-), 1.38 - 1.26 (m, 14H, -CH2-spacer); 13C NMR (100 MHz, CDCl3): δ = 
170.3, 170.2, 170.1 (3 × -C(O)CH3); 154.3 (-NC(O)O-), 138.2 (2 × Cq Ph), 137.3 
(Cq Ph), 129.0 - 127.6 (15 × Ph), 103.7 (CGal-1), 102.0 (CGalNAc-1), 95.8 (-CCl3), 
81.7, 80.0, 75.7, 75.5, 74.6, 74.3, 73.6, 73.1, 71.9, 70.9, 70.1, 69.1, 66.6, 61.1, 
52.7, 51.5 (-CH2N3), 29.5 - 26.7 (9 × -CH2-spacer), 26.2, 20.64, 20.61, 20.55 (3 
× -OC(O)CH3, -NC(O)CH3) MS (ESI+) m/z = 1107.39 (100%), 1109.39 (95%), 
1111.38 (30%), 1113.38 (5%)  [M+H]+ Cl3 pattern observed, calcd. (C53H70Cl3N4O15
+) 
= 1107.39 (100.0%), 1109.39 (95.9%), 1111.38 (30.6%), 1113.38 (3.3%).
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3,4,6-Tri-O-acetyl-2-deoxy-2-N-acetamido-β-d-galacto 
pyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-d-galactopyranoside 
36. Zn dust activation: To 3 g (46 mmol) powdered Zn was 
added 3 M HCl (30 ml) and stirred for 2 h (gas evolution was no longer observed). 
Subsequently, the suspension was filtered, rinsed with EtOH (20 ml), Et2O (20 ml) 
and concentrated in vacuo. Deprotection: To a solution of disaccharide 35 (120 
mg, 0.11 mmol, 1.0 eq) in Ac2O, was added the previously activated powdered Zn 
(200 mg, 3.2 mmol, 30 eq). The suspension was stirred overnight at room 
temperature. The reaction mixture was then diluted with toluene (2 ml), filtered, the 
residue was rinsed with toluene (2 ml), EtOAc (2 ml), and then concentrated in 
vacuo. Rf (EtOAc/ nhept 3 : 1) = 0.31. A solution of the crude material (200 mg) in 
Ac2O (2 ml) was cooled to -35 °C. A solution of TMSOTf (365 µl, 2.0 mmol) in Ac2O 
(1 ml) was added drop wise. The resulting reaction mixture was stirred overnight 
at -35 °C. Subsequently, the reaction was warmed to 0 °C and quenched by the 
addition of sat. NaHCO3. The mixture was extracted with EtOAc (3 × 2 ml), the 
combined organic layers where washed with sat NaCl (3 × 2 ml), dried over 
Na2SO4, filtered, and concentrated in vacuo. Purification by automated column 
chromatography yielded compound 36 as a white solid in 70% yield (64 mg, 80 
µmol) over two steps; 1H NMR (400 MHz, CDCl3): δ = 5.93 (m, 1H),  5.73 (d, 1H, J 
= 8.0 Hz, -NH-), 5.35 (m, 1H), 5.32 (m, 1H), 5.12 (d, J = 8.5 Hz, HGalNAc-1), 5.00 (dd, 
1H, J = 3.0, 10.5 Hz), 4.60 (d, 1H, J = 8.0 Hz, HGal-1), 4.25 (m, 2H), 4.17 (m, 1H), 
4.05 (m, 2H), 3.92 (m, 1H), 3.73 (m, 2H), 3.34 (m, 2H), 3.26 (t, 2H, J = 6.9 Hz, 
-CH2N3), 2.30 - 2.00 (7 × -C(O)CH2), 1.62 - 1.55 (m, 4H, -OCH2CH2-, -OCH2CH2N3), 
1.34 - 1.26 (m, 14H, -CH2-spacer); 
13C NMR (100 MHz, CDCl3): δ = 170.7, 170.54, 
170.49, 170.0, 169.9, 169.5, 169.1, (7 × -C(O)CH3), 100.5 (CGal-1), 99.0 (CGalNAc-1), 
73.0, 72.5, 70.5, 70.3, 68.7, 68.2, 67.1, 61.1, 63.2, 53.5, 51.5 (-CH2N3), 29.5 - 25.8 
(9 × -CH2-spacer), 25.5, 23.6, 23.5 (2 ×), 21.0, 20.63, 20.59 (7 × -C(O)CH2); MS 
(ESI+) m/z = 853.35 [M+Na]+, calcd. (C37H58N4NaO17
+) = 853.37.
Acetyl 2-acetamido-2-deoxy-3,4,6-tri-acetyl-d-galactopyranoside 
38.[69] To a cooled suspension (0 °C) of 1.0 g (4.6 mmol, 1.0 eq) HCl-salt 
31 in 9.3 ml (115 mmol, 25 eq) pyridine, 13 ml (138 mmol, 30 eq) acetic 
anhydride was added drop wise in 15 min, stirring continued for an additional 48 
h, while warming to room temperature. The reaction mixture was precipitated in 
75 mL cold water (no ice), filtered with a Büchner setup, and the residue was 
rinsed with cold water, and lyophilized, affording 1.6 g (4.1 mmol, 89%) of compound 
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38 as a white solid. The product was sufficiently pure to be used in subsequent 
reactions; MS (ESI+) m/z = 390.20 [M+H]+, calcd. (C16H24NO10+) = 390.14.
11-Azido-undecyl 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-d-
galactopyranoside 39.[49] A mixture of 0.50 g (1.3 mmol, 1.0 eq) 
acetylated 38, 0.33 g (1.5 mmol, 1.2 eq) 11-azido undecan-1-ol 21, 
and 10 mg H2SO4-silica in 3 ml DCE were exposed to MW irradiation (150 W) for 30 
min at 110 °C. The white suspension turned into a clear brown solution during the 
reaction. The reaction mixture was filtered through hyflo, and concentrated in vacuo. 
Purification by column chromatography, eluent: hept/ EtOAc 4 : 1, afforded 0.60 g 
(1.1 mmol, 84%) 39 as yellowish oil. Rf (hept/ EtOAc 4 : 1) = 0.35; ¹H NMR (400 
MHz, CDCl3): δ = 6.43 (d, 1H, J = 8.8, -NH), 5.21 (m, 1H, H-4), 5.15 (m, 1H, H-3), 
4.56 (d, 1H, J = 8.4 Hz, H-1), 4.00 (m, 2H, H-6a+b), 3.82 (m, 2H, H-2, H-5), 3.71 (m, 
1H, -OCHa-spacer), 3.34 (m, 1H, -OCHb-spacer), 3.11 (t, 2H, J = 7.0 Hz, -CH2N3), 
2.00 (s, 3H, -C(O)CH3) 1.90 (s, 3H, -C(O)CH3), 1.84 (s, 3H, -C(O)CH3), 1.80 (s, 3H, 
-NHC(O)CH3), 1.43 (m, 4H, -CH2CH2N3, -CH2CH2O-), 1.13 (m, 14H, -CH2-spacer); 
13C NMR (100 MHz, CDCl3): δ = 170.2 (C=O), 170.1 (C=O), 170.0 (2 × C=O), 100.7 
(C-1), 70.1 (C-5), 69.8 (C-3), 69.5 (-OCH2-spacer), 61.3 (C-6), 51.0 (-CH2N3), 50.9 
(C-2), 29.2, 29.1, 29.0, 28.7, 28.4, 26.3, 25.5, 22.9 (-NHC(O)CH3) 20.3 (3 × -C(O)
CH3); MS (ESI+) m/z = 543.30 [M+H]+, calcd. (C25H43N4O9+) = 543.30.
11-Azido undecyl 2-acetamido-2-deoxy-4,6-O-(4-methoxy 
benzylidene)-β-d-galactopyranoside 40. Compound 9 was dried 
by co-evaporation with EtOAc, Et2O, MeCN and subsequently 
exposed to high vacuum overnight. PTSA·H2O (6 mg, 30 μmol) was 
dissolved in 10 ml dry MeCN under Ar and stirred for 1 h in the presence of 3Å MS. 
Dried 9 (0.90 g, 2.2 mmol, 1.0 eq) was dissolved in 20 ml dry MeCN, while under 
Ar, p-anisaldehyde dimethyl acetal (0.78 g, 4.3 mmol, 2.0 eq) was added and the 
mixture was warmed to 50 °C. To the warmed solution, 2 ml of the freshly prepared 
PTSA-solution was added drop wise and stirring continued for 4 h at 50 °C and 48 
h at room temperature. The resulting pink suspension was filtered on a Büchner 
setup and the residue was rinsed with additional MeCN, affording the desired 
compound 40 as a white solid (0.84 g). Purification by column chromatography of 
the filtrate resulted in additional yield (0.16 g). Combined yield: 1.0 g (1.9 mmol, 
86%) 40 as a white solid. Rf (toluene/acetone 1:4) = 0.47; 1H NMR (400 MHz, 
CDCl3): δ = 7.44 (d, 2H, J = 8.7, Ph-Ha), 6.88 (d, 2H, J = 8.7, Ph-Hb), 5.61 (m, 1H, 
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-NH-), 5.53 (s, 1H, acetal-H), 4.69 (d, 1H, J = 8.3, H-1), 4.32 (m, 1H), 4.19 (m, 1H), 
4.09 (m, 2H), 3.93 (m, 1H), 3.81 (s, 3H, -OMe), 3.70 (m, 1H, H-2), 3.49 (m, 2H), 3.25 
(t, 2H, J = 6.9, -CH2N3), 2.03 (s, 3H, -C(O)CH3), 1.58 (m, 4H, -OCH2CH2-, 
-CH2CH2N3), 1.28 (m, 14H, -CH2-spacer); 13C NMR (100 MHz, CDCl3): δ = 171.7 
(Cq Ph), 160.2 (Cq Ph), 127.8 (Ph-Ha), 113.5 (Ph-Hb), 101.3 (acetal-H), 100.0 (C-1), 
75.1, 70.7, 69.3, 69.1, 66.8, 55.7 (C-2), 55.3 (-OCH3), 51.5 (-CH2N3), 29.5 - 23.7 
(spacer); MS (ESI+) m/z = 535.33 [M+H]+, calcd. (C27H43N4O7+) = 535.31.
11-Azido undecyl 2-acetamido-2-deoxy-3-O-acetyl-4,6-O-(4-
methoxybenzylidene)-β-d-galactopyranoside 40b (used as test 
compound for subsequent DDQ-mediated selective 
4,6-deprotection). Monohydroxy 40 (164 mg, 0.3 mmol, 1.0 eq) was 
dissolved in pyridine (620 μl, 7.7 mmol, 25 eq) and cooled to 0 °C. 
After 10 min, 820 ml (9.2 mmol, 30 eq) Ac2O was added drop wise and stirring 
continued at 0 °C for 16 h. The reaction mixture was poured in 10 ml ice cold 
water (no ice) and the resulting precipitate was recovered by filtration and dried 
overnight in vacuo, resulting in 61 mg (0.1 mmol, 35%) of 40b as a white solid. 
The yield was increased by extracting the water layer with EtOAc (3 × 5 ml), the 
combined organic layers were concentrated in vacuo to obtain an additional 50 
mg (0.08 mmol, 29%) off-white solid, 64% combined yield. Rf (toluene/ acetone 
2:1) = 0.38; 1H NMR (400 MHz, CDCl3): δ = 7.43 (m, 2H, Ph-Ha), 6.88 (m, 2H, 
Ph-Hb), 5.48 (s, 1H, acetal-H), 5.43 (m, 1H, -NH-), 4.92 (d, 1H, J = 8.3 Hz, H-1), 
4.36 (m, 1H), 4.33 (m, 1H), 4.03 (m, 1H), 3.91 (m, 2H), 3.81 (s, 3H, -OMe), 3.50 
(m, 2H), 3.26 (t, 2H, J  = 7.0 Hz, -CH2N3), 2.08 (s, 3H, -C(O)CH 3), 1.95 (s, 3H, 
-C(O)CH 3), 1.59 (m, 4H, -OCH2CH2-, -CH2CH2N3) 1.23 (m, 14H, -CH2-spacer); 
MS (ESI+) m/z = 599.30 [M+Na]+, calcd. (C29H44N4NaO8+) m/z = 599.31.
2,3,4,6-Tetra-O-acetyl-d-galactopyranoside 41a. Per-O-acetate 13 (1.8 
g, 4.5 mmol, 1.0 eq) was dissolved in 100 ml DMF and exposed to 0.5 g 
(5.9 mmol, 1.3 eq) hydrazine acetate and stirred at rt until TLC indicated 
that the starting material had reacted (~ 1 h). Upon completion, the reaction mixture 
was diluted with 100 ml EtOAc and washed with brine (2 × 200 ml), demi water (2 
× 200 ml), dried over Na2SO4, filtered, and concentrated in vacuo. Purification by 
automated column chromatography afforded an anomeric mixture of compound 
41a in 75% (1.2 g, 3.4 mmol) yield as a colorless oil. Rf (EtOAc/ nhept 2 : 1) = 0.39; 
MS (ESI+) m/z = 349.11 [M+H]+, calcd. (C14H21O10+) = 349.11.
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2,3,4,6-Tetra-O-acetyl-α-d-galactopyranosyl-trichloroacetimidate 
41. Hemi-acetal 41a  (300 mg, 0.9 mmol, 1.0 eq) in 10 ml DCM was 
exposed to trichloroacetonitrile (0.7 g, 4.5 mmol, 5 eq), and CaCO3 (27 
mg, 0.3 mmol, 0.3 eq), stirred at room temperature for 20 min, and 
subsequently concentrated in vacuo. The residual orange/brown oil was purified 
by column chromatography, eluent: gradient hept/ EtOAc 10 : 1 → 1 : 2, afforded 
41(α) 91 mg (0.2 mmol, 22%) and the β-imidate in 175 mg (0.4 mmol, 43%). 
Alternatively, when the reaction was performed with DBU, rather than CaCO3, 
predominantly the α-imidate, compound 41, was formed and isolated in 57% 
yield as a white solid. Rf (hept/ EtOAc 1 : 2) = 0.76, 0.68 (α and β, respectively); 
α anomer: 1H NMR (400 MHz, CDCl3): δ = 8.66 (s, 1H, =NH), 6.59 (d, 1H, J = 
3.5 Hz, H-1), 5.56 (dd, 1H, J = 1.1, 3.2 Hz, H-4), 5.36 (dd, 1H, J = 3.1, 10.8 Hz, 
H-3), 5.30 (dd, 1H, J = 3.5, 10.8, H-2), 4.37 (m, 1H, H-5), 4.12 - 4.00 (m, 2H, 
H-6a+b), 2.10 (s, 3H, -C(O)CH3), 1.97 (s, 3H, -C(O)CH3), 1.96 (s, 3H, -C(O)CH3), 
1.95 (s, 3H, -C(O)CH3); 
13C NMR (100 MHz, CDCl3): δ = 170.3 (-C=O), 170.09 
(-C=O), 170.07 (-C=O), 169.67 (-C=O), 160.9 (-C=NH), 93.5 (C-1), 90.8 (-CCl3), 
69.0 (C-5), 67.5 (C-4), 67.3 (C-3), 66.9 (C-2), 61.2 (C-6), 20.7 (-CH3), 20.6 (2 × 
-CH3), 20.5 (-CH3); β anomer: 
1H NMR δ = 8.71 (s, 1H, =NH), 5.82 (d, 1H, J = 
8.2 Hz, H-1), 5.49 (m, 1H, H-2), 5.46 (m, 1H, H-4), 5.11 (dd, 1H, J = 3.6, 10.4 
H-3), 4.18 (m, 1H, H-6), 4.11 (m, 1H H-5), 2.18 (s, 3H, -C(O)CH3), 2.05 (s, 3H, 
-C(O)CH3), 2.03 (s, 3H, -C(O)CH3), 2.01 (s, 3H, -C(O)CH3); 
13C NMR (100 MHz, 
CDCl3): δ = 170.3 (-C=O), 170.2 (-C=O), 170.0 (-C=O), 169.1 (-C=O), 161.0 
(-C=NH), 96.0 (C-1), 90.3 (-CCl 3), 71.7 (C-5), 70.7 (C-3), 67.7 (C-2), 66.7 (C-4), 
60.9 (C-6), 20.7 (4 × -CH3) MS (ESI+) m/z = 514.01 [M+Na]+(100.0%), 515.00 
(15%), 516.00 (95%), 517.01 (15%), 518.00 (30%), 519.00 (5%), Cl3-pattern 
observed, calcd. (C16H20Cl3NNaO10
+) = 514.00 (100.0%), 515.00 (17.3%), 516.00 
(95.9%), 517.00 (16.6%), 517.99 (30.6%), 519.00 (5.3%); (HR-ESI+) m/z = 
331.0265 Corresponds to C-2 → C-1 acetal, calcd. (C14H 19O9
+) = 331.1024.
11-Azido undecyl 2,3,4,6-tetra-O-acetyl-β-d-galacto 
pyranosyl-(1→3)-4,6-(4-methoxybenzylidene) 2-acetamido-
2-deoxy-β-d-galactopyranoside 42. Galactosamine acceptor 
40 (515 mg, 1.0 mmol, 1.0 eq), galactose donor 41 (617 mg, 
1.3 mmol, 1.3 eq), and activated 3 Å MS were dried under 
vacuum for 4 h, then recovered under Ar atmosphere. Dry DCM (10 ml) was 
added to the dried compounds and the reaction mixture was cooled to -30 °C. 
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After 10 min stirring, 13 μl (0.07 mmol, 7 mol%) TMSOTf was added and stirring 
continued for 2 h at -30 °C. TLC indicated only slow conversion, additional drop of 
TMSOTf was added and stirring continued for 16 h while warming up to 0 °C and 
subsequently for 3 h at room temperature. The reaction mixture was quenched by 
addition of a drop of Et3N and concentrated in vacuo. Purification by automated 
column chromatography (toluene/ acetone), resulted in compound 42 as a white 
sold in 56% yield  (465 mg, 0.6 mmol). Rf (acetone/ toluene 1 : 1) = 0.60; 1H NMR 
(400 MHz, CDCl3): δ = 7.46 (d, 2H, J = 8.7 Hz, (Ph-Ha), 6.88 (d, 2H, J = 8.7 Hz, 
(Ph-Hb), 5.69 (d, 1H, J = 5.7 Hz, -NH-), 5.51 (s, 1H, acetal-H), 5.36 (m, 1H), 5.22 
(m, 2H), 5.13 (d, 1H, J = 8.0 Hz, HGalNAc-1),   4.99 (dd, J = 3.4, 10.3 Hz) 4.80 (d, 1H, 
J = 7.9 Hz, HGal-1), 4.73 (dd, J = 3.30, 11.1 Hz, HGalNAc-2), 4.31 – 4.26 (m, 2H), 4.14 
(m, 2H), 4.03 (m, 1H), 3.89 (m, 2H), 3.81  (s, 3H, -OMe), 3.45 (m, 2H, HGalNAc-4, 
HGalNAc-2), 3.25 (t, 2H, J = 7.0 Hz, -CH2N3), 2.14 (s, 3H, -C(O)CH3), 2.04 (s, 6H, 
-C(O)CH3), 1.97 (s, 6H, -C(O)CH3), 1.58 (m, 4H, -OCH2CH2-, -CH2CH2N3), 1.27 (m, 
14H, -CH2-spacer); 
 MS (ESI+) m/z = 866.01 [M+H]⁺, calcd. (C41H61N4O16+) = 865.95.
11-azidoundecyl-2,3,4,6-tetra-O-acetyl-β-d-galacto pyranosyl-
(1→3)-β-d-2-acetamido-2-deoxy-galactopyranoside 43. The 
following procedure was carried out in the dark. The selective 
4,6-deprotection of compound 42 (200 mg, 0.23 mmol, 1.0 eq) was performed 
in MeCN (10 ml) by stirring the starting material at room temperature in the 
presence of DDQ (105 mg, 0.46 mmol, 2.0 eq). After 30 min., H2O (1 ml) was 
added and the reaction mixture was allowed to stir for an additional 90 min., 
after which, TLC analysis indicated that the reaction was complete. The reaction 
mixture was quenched by addition of sat. NaHCO3 (10 ml), the organic phase 
was washed with sat. NaCl (3 × 10 ml), dried over Na2SO4, filtered, and 
concentrated in vacuo. Purification by automated column chromatography 
afforded 100 mg (0.13 mmol, 58%) compound 43 as a white solid. Rf (toluene/ 
acetone 1 : 1) = 0.30; 1H NMR (400 MHz, CDCl3): δ = 5.82 (bs, -NH-), 5.39 (m, 
1H, HGal-4), 5.20 (dd, 1H, J = 7.9, 10.3 Hz, HGal-2), 5.02 (dd, 1H, J = 3.4, 10.4 Hz, 
HGal-3), 4.97 (d, 1H, J = 8.3 Hz, HGalNAc-1), 4.65 (d, 1H, J = 8.0, HGal-1), 4.60 (m, 1H, 
HGalNAc-3), 4.13 - 4.08 (m, 3H, HGalNAc-4, HGalNAc-6), 3.96 (m, 2H, HGalNAc-5, HGal-6a), 
3.86 (m, 2H, -OCHa-spacer, HGal-6b), 3.63 (m, 1H, HGal-5), 3.48 (m, 1H, -OCHb-
spacer), 3.34 (m, 1H, HGalNAc-2), 3.26 (t, J = 7.0 Hz, -CH2N3), 2.17, 2.07 (2 ×), 
1.99, 1.98 (5 × -C(O)CH3), 1.64 - 1.54 (m, 4H, -CH2N3, -OC2HCH2-), 1.39 - 1.28 
(m, 14H, -CH2-spacer); 
13C NMR (100 MHz, CDCl3): δ = 170.8, 170.5, 170.0, 
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169.9, 169.5 (5 × -C(O)CH3), 100.3 (CGal-1), 98.5 (CGalNAc-1), 78.5 (CGalNAc-3), 73.4 
(CGal-5), 71.1 (CGalNAc-5), 70.6 (CGal-3), 69.9 (CGal-5), 68.8 (-OCH2-spacer), 68.4 
(CGalNAc-4), 66.9 (CGal-4), 62.6 (CGal-6), 61.6 (CGalNAc-6), 54.5 (CGalNAc-2), 51.5 (-CH2N3) 
29.5 - 28.8 (9 × -CH2-spacer), 25.9, 20.8, 20.59, 20.57, 20.49 (4 × -OC(O)CH3, 
-NC(O)CH3); MS (ESI+) m/z = 769.36 [M+Na]⁺, calcd. (C33H54N4NaO15+) = 769.35.
5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-didexoy-d-glycero-d-
galacto-2-nonulopyranosonate 45. Compound 45 was synthesized 
from N-acetyl neuraminic acid 44 according to literature procedures.
[52] Compound 45 was obtained as a mixture of anomers as an off-white solid in 90% 
yield over two steps. Spectral data was in agreement with literature values.[52b, 56, 70]
11-Azido undecyl-5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-
didexoy-β-d-glycero-d-galacto-2-nonulopyranosonate 46. 
Similar procedure as described for compound 39. The resulting 
brownish oil was purified by automated column chromatography, eluent: gradient 
hept/ EtOAc, to afford 113 mg (0.2 mmol, 13%) 46 as a white solid. Rf (EtOAc/ 
nhept 4 : 1) = 0.18; 1H NMR (400 MHz, CDCl3): δ = 5.73 (dd, 1H, J = 2.2, 3.3 Hz, 
H-7), 5.32 (d, 1H, J = 10.2 Hz, -NH-), 5.24 (m, 1H, H-4), 5.17 (m, 1H, H-8), 4.77 
(dd, 1H, J = 2.3, 12.4 Hz, H-9a), 4.09 (m, 2H, H-5, H-9b, 3.90 (dd, 1H, J = 2.2, 
10.5 Hz, H-6), 3.77 (s, 3H, -C(O)OCH3), 3.43 (m, 1H, -OCHa-spacer), 3.29 (m, 
1H, -OCHb-spacer), 3.23 (t, 2H, J = 6.8 Hz, -CH2N 3), 2.43 (dd, 1H, J = 4.9, 12.9 
Hz, H-3eq), 2.12, 2.04, 2.00, 1.99, (4 × -OC(O)CH3), 1.85 (m, 4H, -NC(O)CH3, 
H-3ax), 1.61 - 1.52 (m, 4H, -OCH2CH2-, -OCH2CH2N3); 1.32 - 1.36 (m, 14H, -CH2-
spacer); 13C NMR (100 MHz, CDCl3): δ = 171.0, 170.6, 170.4, 170.2, 170.1, (5 × 
-OC(O)CH3, -NC(O)CH3), 167.6 (-C(O)OCH3), 98.5 (C-2), 72.1 (C-8), 71.7 (C-6), 
69.0 (C-4), 68.5 (C-7), 64.2 , 62.4 (C-9), 52.5 (-C(O)OCH3), 51.4 (-CH2N3), 49.4 
(C-5), 37.4 (C-3), 29.6 - 26.0 (9 × -CH2-spacer), 23.1 (-NC(O)CH3), 21.0 - 20.7 (4 × 
-OC(O)CH3); MS (ESI+) m/z = 687.36 [M+H]+, calcd. (C31H51N4O13+) m/z = 687.34.
Chloro 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-d-glycero 
-d-galacto-2-nonulopyranosonate 47. Compound 47 was 
synthesized from 45 according to literature procedures.[52] 
Compound 47 was obtained as a mixture of anomers in 90% yield as an off-
white solid. Spectral data was in agreement with literature values.[52b, 56, 70]
168
11-Azido undecyl-5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-di 
dexoy-α-d-glycero-d-galacto-2-nonulopyranosonate 48. 
Chlorine compound 47 (470 mg, 0.9 mmol, 1.0 eq) and 11-azido-
undecan-1-ol 21 (508 mg, 1.8 mmol, 2.0 eq) were dissolved in 5 ml dry DCM and 
stirred for 30 min. with 4Å MS. AgCO3 (589 mg, 2.8 mmol, 3.0 eq) was added and 
stirring continued overnight in a closed vessel, deprived from light. The reaction 
mixture was filtered through hyflo, rinsed with DCM and concentrated in vacuo. 
The crude yellow oil was purified by automated column chromatography, eluent 
EtOAc/ nhept 10 : 1, to afford 290 mg 48 as a white solid (0.42 mmol, 47%. Rf 
(EtOAc/ nhept 10 : 1) = 0.21; 1H NMR (400 MHz, CDCl3): δ =  5.78 (d, 1H, J = 9.4 
Hz, -NH-), 5.28 (m, 1H, H-8), 5.25 (dd, 1H, J = 1.7, 7.8 Hz), 4.74 (m, 1H, H-4), 4.25 
(dd, 1H, J = 2.4, 12.4 Hz, H-9a), 4.01 (m, 3H, H-5, H-6, H-9b), 3.69 (s, 3H, -C(O)
OCH3), 3.65 (m, 1H, -OCHa-spacer), 3.16 (t, 3H, J = 7.0 Hz, -CH2N3), 3.12 (m, 1H, 
-OCHb-spacer), 2.49 (dd, 1H, J = 4.6, 12.8 Hz, H-3eq), 2.05, 2.04, 1.94, 1.93 (4 × 
-OC(O)CH3), 1.78 (m, 4H, -NC(O)CH3, H-3ax), 1.50 (m, 2H, -CH2N3), 1.43 (m, 2H, 
-OC2HCH2-), 1.26 - 1.19 (m, 14H, -CH2-spacer); 13C NMR (100 MHz, CDCl3): δ = 
170.8, 170.5, 170.2, 170.03, 169.98, (4 × -OC(O)CH3, -NC(O)CH3), 168.5 (-C(O)
OCH3), 98.7 (C-2), 72.5 (C-6), 69.3 (C-4), 69.1 (C-8), 67.4 (C-7), 64.9 (-CH2O-
spacer), 62.3 (C-9), 52.4 (-C(O)OCH3), 51.3 (-CH 2N3), 49.1 (C-5), 38.0 (C-3), 29.4 
- 25.7 (9 × -CH2-spacer), 23.0, 21.0, 20.7 (2×), 20.6 (4 × -OC(O)CH3, -NC(O)CH3); 
MS (HR-ESI+) m/z = 709.3198 [M+Na]⁺, calcd. (C31H50N4NaO13+) = 709.3267.
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7.1 Introduction
In the studies presented in the preceding chapters we used functional glycomics 
in an effort to increase the understanding on biological processes at the molecular 
level. All these studies revolve around the idea to covalently attach functionalized 
synthetic oligosaccharide ligands onto platforms for the detection of cholera and 
Guilliain-Barré syndrome (GBS). Obtaining such a sensor was the overarching 
goal of the Unihealth research program,[1] of which these studies were a part. 
We designed and synthesized relatively small molecules that are similar in 
appearance to natural carbohydrates that occur in the human macromolecular 
glycocalyx, which is on the surface of almost every cell. We applied them on 
multivalent scaffolds that showed very good ligand-protein binding affinities 
and attached them to surfaces via copper-catalyzed azide-alkyne cycloaddition 
(CuAAC) reactions or strain-promoted azide-alkyne cycloaddition (SPAAC)-type 
ligations. A specific computational tool was developed so that novel cyclooctynes 
can be valued for their reactivity with azides in SPAAC reactions before their 
actual time-consuming synthesis. Additionally, very interesting results were 
obtained when synthetic ganglioside GM1 oligosaccharide (GM1os) fragments 
were applied on surfaces and used for the detection of GBS-related anti-
ganglioside antibodies (Abs). In the research presented in this thesis it is clear 
how the combination of several disciplins is fundamental to reach fixed goals. 
Computational chemistry, organic synthesis and biological assays were applied 
in synergy to increase the knowledge of the biological processes involved 
in the diseases cholera and Guillain-Barré syndrome. The sections below, 
provide a general discussion and future prospects for each research chapter. 
These studies show that the past and future of science are only separated 
by the infinitesimally thin present time in which the research is performed.
7.2 Chapters 2 and 3: ‘Getting one-on-one with cholera: 
Picomolar inhibition of cholera toxin by a pentavalent 
ganglioside GM1os-calix[5]arene’ and ‘Nanomolar cholera 
toxin inhibitors based on symmetrical pentavalent 
ganglioside GM1os-sym-corannulenes’
Multivalency is the key factor in the studies presented in these two chapters. A 
single protein-carbohydrate interaction, albeit with high specificity, usually shows 
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weak binding affinities with dissociation constants in the micromolar or millimolar 
range. Enhancement of the protein-ligand binding affinity can be achieved by 
presenting multiple ligands on a multivalent scaffold so that the glycoside cluster 
effect is mimicked to some extend. It has been shown on several occasions that 
compounds bearing multiple copies of the GM1os provide an effective strategy 
for inhibiting the pentameric receptor of the cholera toxin B-subunit (CTB).[2] In 
Chapters 2 and 3, we presented the first examples of pentameric GM1os CTB 
inhibitors. Binding experiments of three corannulene-based compounds presenting 
the GM1os – that was attached to the platforms via spacers with three different 
lengths – with CTB showed that the corannulene compound with the “mid-sized” 
hexa-ethyleneoxide (EO6) spacer was able to inhibit CTB the strongest with IC50 = 
5 nM. The calix[5]arene scaffold that was synthesized to also present five GM1os 
ligands showed an even better inhibitory potency of IC50 = 450 pM, amounting 
to a hundred thousand fold increase in relative inhibitory potency with respect 
to the monovalent control compound. We showed here again that exposing a 
multivalent receptor to a multivalent ligand has a positive synergetic effect on 
the receptor-ligand binding and leads to interactions that are thermodynamically 
and kinetically more favorable than if monovalent ligands would be used.[3]
Our multivalent ligands could be used as diagnostic tools for pathogen 
detection. It would be interesting to functionalize surfaces to present multivalent 
platforms rather than individual molecules so that the structural complexity 
of the glycocalyx on cell surfaces[5] is mimicked. Besides, when multivalent 
ligands are presented, instead of the monovalent counterparts, the overall 
concentration can be reduced to maintain the same binding affinities. This 
Figure 1. A spacer can be attached to the lower rim of a calixarene and equipped with a suitable reactive 
handle to enable covalent immobilization onto surfaces. Reagents and conditions: i) PhtN-(CH2)12Br, 
KHCO3/ CH3CN; ii) CH3CH(CH2)3Br, K2CO3/ CH3CN; iii) H2NNH2/ EtOH. Figure reproduced from reference.
[4]
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is advantageous because high overall concentration can lead to overcrowded 
surfaces on which epitope-movability might be restricted or the epitopes 
might be unavailable for a protein binding pocket due to steric reasons.[6] 
To meet the requirements of being attached to a surface, our current scaffolds 
need to be modified. Whereas, for the corannulene derivatives, this is not really an 
option, due to the lack of reactive functionalities in these compounds, for calix[5]
arenes monofunctionalization on the lower rim can be performed so that they can be 
immobilized on a surface. Figure 1 depicts an example of a possible approach to obtain 
such a calix[5]arene.[4] In that case, they could function as detectors in for example 
a biosensor or also to remove cholera toxin from solutions via a dialysis approach.[7] 
 Spacer length and morphology remain important issues to be further 
investigated.[8] We showed in Chapter 2 that optimizing spacer length is important 
for the binding affinity. In the case of our corannulenes, tuning the spacer 
length led to a factor 100 better binding. Crystallography studies by Hol and 
coworkers[9] on the binding site of CT (bound to ganglioside GM1) revealed that 
the ceramide functionalities clearly do not participate in the protein-carbohydrate 
binding interaction on the cell surface (although it plays a significant role in the 
follow-up steps in the pathogenesis of cholera[10]). So further investigation on 
the ceramide functionalities in order to increase the binding affinity to CTB is 
not relevant for our purpose. However, the ceramide structures are suspected 
to contribute to ganlgioside clustering that is important for the recognition 
by some anti-ganglioside Abs in GBS (this aspect is discussed in §7.5).
An avenue that is worth investigating to reach even more potent CTB inhibitors 
is to use alternative pentameric platforms such as pentacyclen structures 
Figure 2. Pillarenes and pentacyclens are suitable alternatives as carbohydrate-modified pentavalent scaffolds, 
or even decavalent scaffolds in case of the pillarenes; R = suitable spacer and GM1os (or fragments).
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(1,4,7,10,13-pentaazacyclopentadecane) (Figure 2).[11] Fan and coworkers 
synthesized a series of pentavalent CTB inhibitors in which a pentacyclen core 
was conjugated to five linkers, each one ending with a galactose unit.[12] Although 
a single monomeric galactose unit presents a rather low CTB affinity, thanks to 
multivalency the pentavalent galactose compound revealed a CTB-binding that 
was in the same order of magnitude as the inhibition potency of monovalent GM1. 
It showed a 260-fold higher potency compared to the monomeric galactose-
derivative. However, pentacyclens suffer from the same deficiency as the 
corannulene scaffold i.e. a lack of a sixth site to modify for surface immobilization. 
This is imperative for our goal to develop a suitable biosensor, although it 
could be useful for therapeutic purposes since this relatively small scaffold is 
likely to be good water soluble when attached to multiple copies of the GM1os. 
In addition, pillarenes are also worth investigating.[13] Since pillarenes do not 
have chemically distinguishable sides/ sites as equivalents of the calixarene upper 
and lower rims, they can only be functionalized in a decavalent fashion (or a mixture 
of asymmetric compounds). This means that, when equipped with the appropriate 
spacers, they are potentially able to inhibit two toxin proteins simultaneously.
After focusing on purely synthetic small molecule scaffolds, our attention 
recently also turned to multimeric proteins as scaffolds to appropriately 
display the ganglioside GM1 pentasaccharide.[14] We reasoned that the ideal 
pentavalent protein scaffold to bear GM1os would be CTB itself and therefore 
we explored a strategy to achieve this. Tryptophan (Trp) residues in the binding 
pockets of CTB were replaced by glutamic acid (Glu) residues by site-directed 
mutagenesis. This rendered the protein incapable of binding ganglioside GM1. 
Figure 3. A protein-based pentavalent inhibitor of CTB. Figure reproduced from reference.[14]
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This site-specific mutant of CTB was subsequently equipped with suitable 
GM1 analogues at the N-termini (Figure 3). The site-specific modification 
of a protein scaffold, that perfectly matches the target toxin in both size and 
valency provided a convenient route to an effective multivalent inhibitor. This 
synthetic pentavalent neoglycoprotein displayed an IC50 of 104 pM for CTB,
[14] 
which makes it the most potent pentavalent inhibitor for CTB reported thus far.
7.3 Chapter 4: Electronic effects versus distortion energies 
during strain-promoted alkyne-azide cycloadditions: A 
theoretical tool to predict reaction kinetics
Strain-promoted azide-alkyne cycloaddition (SPAAC) reactions are increasingly 
used as the preferred ligation method in biological assays. The high intrinsic 
energy of cyclooctynes and their high reactivity towards azides caught the 
attention of scientists from many disciplines. Therefore, novel cyclooctynes are 
developed on a regular basis. The design of new cyclooctynes might be aimed at 
improving specific characteristics like water solubility that is achieved chemically 
by incorporation of hydrophilic moieties. However, other properties that are of 
interest are less easily predicted like the reactivity of the cyclooctyne towards 
azides. A theoretical exploration of the reactivity of several cyclooctynes towards 
allyl azide and benzyl azide led to the development of a new predictive tool. We 
have used the designed method –  that involves MP2-derived LUMO values as 
a measure for the reactivity of cyclooctynes with azides in the SPAAC reaction 
– to calculate the reactivity of several novel cyclooctynes and related structures 
that have not yet been synthesized. This study confirmed that inducing electron 
deficiency indeed improves the reactivity of the cyclooctynes. Therefore, it is 
definitely worthwhile exploring the design of cyclooctynes, or related strained 
compounds, that carry positive charges within their ring structure. We are 
currently focusing in this direction in the ongoing work on these compounds.
7.4 Chapter 5:  The influence of copper on GM1os-based 
CTB detection assays: CuAAC vs SPAAC
In Chapters 2 and 3 we went “one-on-one” with cholera by strong inhibition of CTB 
with multivalent corannulene and calix[5]arene compounds. These compounds 
were synthesized in a convergent manner by employing the CuAAC reaction to 
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attach five copies of the GM1os to the pentameric scaffolds. In Chapter 4, the 
nature of the high reactivity of cyclooctynes with azides in SPAAC reactions was 
investigated on a quantum mechanical level. In Chapter 5 we then combined 
knowledge gained from the three preceding chapters by directly comparing CuAAC 
and SPAAC in biological assays, while employing again the natural complementary 
system of CTB and the ganglioside GM1os. Three GM1os-bearing compounds 
were immobilized on azide-terminated microtiter plates via either CuAAC or 
SPAAC conditions depending on the nature of the attached alkyne moieties 
(either terminal alkyne or cyclooctyne). From these experiments we learned that 
the influence of residual copper on binding assays may be significantly greater 
than initially expected. Therefore, it can be concluded that ligation techniques that 
do not require metals are preferred to immobilize antigens on a surface. However, 
the solubility of compounds that bear relatively large lipophilic cyclooctynes is 
expected to be limited in the assay conditions. Therefore, hydrophilic spacers 
need to be added. On the other hand, we also saw that the addition of a hydrophilic 
spacer results in lower protein-carbohydrate binding. Perhaps this is because of 
disadvantageous interactions between the hydrophilic spacer and the CTB. Wild 
type gangliosides display a lipophilic aglycon part (ceramide) rather than a polar 
one. This then leads to a specific synthetic proposal: rather than attaching the 
EO directly to the carbohydrate, it should first be attached to an lipophilic part 
that in turn is then attached to an EO spacer suitably functionalized for surface 
attachment (Figure 4) much like the design of our calix[5]arene and corannulene 
compounds. In this way, an amphipathic antigen is created that has increased 
solubility in assay conditions and is therefore better presented in the aqueous 
environment and is expected to be recognized better by the target proteins.
Figure 4. Amphipathic carbohydrate as a potential antigen that does not require metals to be immobilized on a 
surface.
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7.5 Chapter 6: Evaluation of synthetic ganglioside-based 
glycan fragments as epitopes for Guillain-Barré syndrome-
associated antibodies
As part of an ongoing investigation, we aimed to improve the understanding at 
a molecular level of the Abs-ganglioside specificity in Guillain-Barré syndrome 
(GBS). A small library of nine compounds was assembled that included fragments 
of the ganglioside GM1 pentasaccharide or a chemical analogue of it, the GM1os. 
All carbohydrates were equipped with an azide-functionality, with which they were 
covalently immobilized on bioassay surfaces via CuAAC reactions. Previous 
studies by our laboratory[6] showed that improvements for GBS-related Abs 
detection need to be directed to variation of the spacers (length and polarity) and 
to the density of GM1 molecules on the surface. A GM1 surface coverage that is 
too low leads to insufficient gangliosides to bind the Abs strongly, a density that is 
too high on the other hand impairs Abs-carbohydrate interactions because of steric 
reasons. Based on our current study, described in Chapter 6, it cannot be ignored 
that also the ceramide hydroxyl and amide functionalities possibly play a role in 
the assembly, and complex formation, of gangliosides. This specific part of the 
gangliosides has not yet been incorporated in synthetic ganglioside analogues and 
further studies are required to understand its role in ganglioside-Ab binding affinities. 
 It is also required to determined if residual copper on microtiter plates is of 
influence on the Ab binding response towards our synthetic carbohydrates. In 
line with the proposition of Chapter 5 (concerning Figure 4), the influence of 
copper on Ab-fragment interactions can be studied by using carbohydrates that 
are equipped with cyclooctynes. After being immobilized by SPAAC ligations on 
microtiter plates, these compounds can then be compared in an ELISA study with 
carbohydrate analogues that require to be immobilized via the CuAAC reaction. 
It is clear from our research that reducing complexity of the gangliosides 
has only limited success for the detection of GBS-related anti-ganglioside Abs. 
Saturation transfer difference NMR (STD-NMR)[15] studies by Houliston et al. 
indicated that the major contributors to the GM1-Abs binding are the terminal 
Galβ1-3GalNAcβ and Neu5Acα2 epitopes.[16] This, as a stand-alone study, would 
suggest that presenting either of these epitopes would enable significant binding 
to the Abs. However, it is also obvious from our study that the complexity of 
the Ab-ganglioside binding interaction cannot always be mimicked in a one-to-
one fashion by presenting these separate glycan fragments to the Abs. GBS-
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related Abs, in contrast to CTB, have less specifically defined binding sites. 
Their recognition sites are more complex and some Abs are known to recognize 
ganglioside complexes of different ganglioside composition rather than separate 
unique compounds.[17] Thus, mimicking the ganglioside complexes by presenting 
the carbohydrate epitopes on multivalent platforms might drastically increase 
the Ab-carbohydrate binding. In that case, also mixtures of epitopes (such as 
the Galβ1-3GalNAcβ epitope depicted in Figure 4 in combination with a similar 
Neu5Acα2-bearing compound) could be attached to these platforms. This would 
reintroduce some of the complexity of the gangliosides but would still maintain 
the relative ease of synthesizing ganglioside fragments. In line with the future 
prospects of Chapters 2 and 3, also such novel compounds will be fit to be used 
for protein-detection with next generation biosensors, like the Unihealth sensor. 
They eventually should lead to the development of new biosensors that will be 
faster, cheaper and more accurate alternatives for the current detection methods. 
An additional, potential therapeutic, application of our finding is that 
patients that test positive to our galactose and/ or lactose fragments could 
be treated with the unmodified galactose or lactose by IV administration. 
In this approach, the carbohydrates might be able to inhibit the malicious 
Abs and prevent them to target cells. Since these carbohydrates are 
part of our natural diet, unwanted effects are expected to be limited. 
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8.1 SUMMARY
In the studies presented in this dissertation we used functional glycomics in an effort 
to increase the understanding of several biological processes on a molecular level. 
The main goal was to use this knowledge to aid in the development of the Unihealth 
biosensor.[1] These studies focused on the design and synthesis of oligosaccharide-
based antigens with good binding properties for the cholera toxin B-subunit (CTB) 
and Guillain-Barré syndrome (GBS)-related antibodies (Abs). In addition, and 
equally important, we studied the optimal means to attach these antigens onto a 
sensor surface. To achieve these goals it was essential to combine a broad spectrum 
of disciplines e.g. theoretical predictions, biological assays, and organic synthesis.
In Chapters 2 and 3, we presented the first examples of pentameric GM1 
oligosaccharide (GM1os)-displaying CTB inhibitors that are based on two distinct 
pentameric scaffolds. In the pathogenesis of the disease cholera, CTB is used for 
recognition and binding to cell surfaces that display the complex glycan ganglioside 
GM1. It has been shown on several occasions that compounds bearing multiple 
copies of that ligand provide an effective strategy for inhibiting these pentameric 
receptors.[2] However, none of these previously reported compounds simultaneously 
displayed five GM1 pentasaccharides that would match the toxin’s valency.
In Chapter 2, we presented how the pentameric GM1-bearing corannulene 
scaffolds were synthesized to display the GM1os via spacers of three different sizes 
i.e. three, six, or nine ethyleneglycol moieties. Besides resulting in a good nanomolar 
Corannulene Calix[5]arene
Figure 1. A) bowl-like Corannulene scaffold; B) Flexible calix[5]arene scaffold.
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inhibitor of CTB, importantly, it also proved that size does matter, because not the 
compound with the longest spacer, but rather, the intermediate length showed to 
have the best nanomolar inhibitory potency of the three corannulene derivatives.
The studies presented in Chapter 3 showed that also the shape of the platform 
is of importance. A pentameric compound was designed to display five ganglioside 
GM1 oligosaccharides on a calix[5]arene platform. Whereas the corannulene shows 
bowl-like characteristics (Figure 1), with the carbohydrate-bearing spacers directed 
outwards, the calix[5]arene, which is functionalized at the lower rim with methoxy 
groups, presents conformational mobility that allow the five pentasaccharides to 
point also in the same direction adapting itself to the CT structure. The GM1os 
calix[5]arene showed a higher inhibitory potency than any of the corannulenes 
did with an IC50 of 450 pM, this amounted to a hundred thousand-fold increase 
in inhibitory potency with respect to the monovalent control compound. When 
the five terminal galactose moieties from the GM1os were omitted to display 
five GM2 oligosaccharides, the inhibitory potency dropped significantly and a 
much higher half maximal inhibition concentration was measured (IC50 = 9 µM).
Strain-promoted azide-alkyne cycloaddition (SPAAC, Figure 2) reactions are 
increasingly used as the preferred ligation method in bioorthogonal reactions and 
biological assays.[3] As this becomes more important, novel cyclooctynes are 
developed on a regular basis. Synthesis of new cyclooctynes might be aimed at 
improving specific characteristics like water solubility, which is achieved chemically 
by incorporation of hydrophilic moieties. However, other properties that are of 
interest are less easily predicted like the reactivity of the cyclooctyne towards 
azides. Chapter 4 describes a theoretical exploration of cyclooctyne reactivity 
towards allyl azide and benzyl azide that was performed with three types of 
computational methods (B3LYP[4], M06-2X[5] and SCS-MP2[6]). While the DFT-type 
Figure 2. LUMO-driven SPAAC reaction of 9-hydroxymethylbicyclo[6.1.0]non-4-yne (BCN) with allyl azide.
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calculations, B3LYP and M06-2X, did not provide good correlations between an 
extensive set of experimentally observed reaction rates and calculated parameters, 
SCS-MP2 calculations yielded clear, synthetically useful predictions. This allowed 
the discovery of a clear correlation of MP2-derived LUMO energies of the alkynes 
in the geometry they have in the transition state (TS, Figure 2) with the empirical 
reaction rate. In contrast to what has been claimed in literature,[7] no correlation 
between the experimental rates and alkyne distortion energies was established. 
Furthermore, we used these results to develop a tool that can aid synthetic 
chemists to determine SPAAC reaction kinetics of novel cyclooctynes prior to the 
actual synthesis. As a somewhat less accurate but much simpler predictive tool, 
the LUMO energy level of the fully MP2-optimized cyclooctyne reactant can also 
be used instead of the TS LUMO energy. When cyclooctyne TS LUMO values were 
correlated to the experimental rate constants, a good linear regression of R2 = 0.960 
was observed. Our study further supports the idea that the reaction is cyclooctyne 
LUMO-driven and that Hartree-Fock LUMO values are indeed a good measure 
for the reactivity of the cyclooctynes with organic azides in SPAAC reactions.
The SPAAC reaction is a potentially good replacement for the copper azide-
alkyne cycloaddition (CuAAC)[3, 8] reaction in biological assays. One reason for that 
is that copper is suspected to have a negative influence on ligand-protein binding 
measurements. Experiments were devised to investigate the influence of copper 
on such measurements. Therefore in Chapter 5, we combined elements from 
the three previous chapters by directly comparing CuAAC reactions and SPAAC 
reactions in biological assays. A GM1os-bearing compound that presented a 
terminal alkyne[9] was immobilized by CuAAC to microtiter plates. Two novel 
GM1os-bearing compounds were developed to contain cyclooctynes, one was 
attached to an aliphatic and lipophilic undecane spacer and the second compound 
contained both the same aliphatic spacer and an additional hydrophilic spacer. 
The initial assays were performed on the compounds after they had been 
immobilized on azide-terminated microtiter plates via either CuAAC or SPAAC 
conditions depending on the nature of the alkyne. The GM1os-bearing compounds 
were then exposed to CTB in indirect ELISA experiments. Both compounds without 
the EO-spacer were found to be recognized by the CTB protein in an approximate 
equal binding affinity, independent of the used immobilization technique. On the 
other hand, the compound that contained the EO-spacer showed significant lower 
binding affinity towards CTB. In a second set of experiments, the compounds 
were attached to the surface and then exposed to the CuAAC catalyst i.e. a 
190
CuSO4 solution was added to all microtiter wells, including the ones that contained 
the SPAAC-ligated carbohydrates. This was followed by an extensive washing 
procedure in an attempt to remove the residual copper. Within the margin of error, 
the compound that was connected to the surface via CuAAC and the SPAAC-
ligated compound that both contain only the hydrophilic spacer again showed 
similar binding responses, although some changes were noted. On the other 
hand, for the EO-containing compound unprecedented high binding affinities 
were observed. This is undoubtedly a result from coordination of the residual 
copper to the EO spacer as was described previously by Kaczmarek et al.[10] 
Interestingly, the observed binding affinities are thus influenced by copper and, 
specifically in the case of the EO-containing BCN compound, the presence of 
copper boosts the ligand-protein interaction, at least in the case of CTB. The 
exact nature of this phenomenon and its physical manifestation, for example if 
the copper also enters the CTB binding pocket, is unclear at the moment. This 
raises the question whether copper coordination also occurs to the carbohydrate 
epitope. In Chapter 6 we observed that some GBS-related Abs recognize wild 
type ganglioside GM1, but not the very similar synthetic analogue that is attached 
to a microtiter surface via CuAAC (or vice versa). It cannot be excluded that the 
copper is of negative influence here and prevents the epitope from reaching 
the Ab binding pocket, or that the carbohydrate conformation is altered, or its 
movement is restricted in such a way that the Abs do not recognize it anymore. 
Further in Chapter 6, an evaluation is presented of synthetic ganglioside-
based glycan fragments that were used as epitopes for the detection of GBS-
associated Abs. GBS is an autoimmune disorder that results from molecular 
mimicry by complex glycans that are present on the bacterium Campylobacter 
jejuni.[11] Parts of ganglioside epitopes that reside on our cell surfaces can 
also be found in the glycans on the pathogen, and in case of an GBS-related 
autoimmune response the carbohydrate moieties that reside on the surface of 
the bacteria are targeted by anti-ganglioside Abs. These Abs in turn also target 
the structurally similar gangliosides that reside on human nerve cells.[11] As 
part of an ongoing investigation, we aimed to improve the understanding at a 
molecular level of the antibody-ganglioside specificity of GBS. A small library of 
nine compounds was assembled that include fragments of the ganglioside GM1 
pentasaccharide or a synthetic analogue of it, the GM1os. All carbohydrates 
were equipped with a chemical handle i.e. azide-functionality, with which they 
could be covalently immobilized on bio-assay surfaces via CuAAC reactions.
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Saturation transfer difference NMR (STD-NMR)[12] studies by Houliston et al. 
indicated that the major contributors to the GM1-Abs binding are the terminal 
Galβ1-3GalNAcβ and Neu5Acα2 epitopes,[13] which would suggest that either of 
these ganglioside fragments would by themselves also bind the Abs significantly. 
It became obvious from our study that the complexity of the Abs-ganglioside 
binding cannot always be mimicked in a one-to-one fashion by presenting these 
epitopes as smaller synthetic fragments to the Abs. Surprisingly, we discovered 
that some anti-ganglioside Abs bind to compounds displaying the simple 
monosaccharide galactose and disaccharide lactose. Especially sera that show 
cross-reactivity towards wild type galactocerebroside were shown to bind these 
two simple saccharides, which opens up a new line of future investigations. 
Applying a relatively short oligo-EO spacer (12 atoms) on the microtiter 
plate surfaces as chemical blocking agent – next to the immobilized GM1os 
fragments – had a dramatic effect in a select number of GBS patient sera on 
the binding affinity of Abs towards the ganglioside fragments. In one case, the 
Abs-Gal binding response was even doubled in relation to when no chemical 
blocking step was performed. This indicates a positive effect of the increased 
surface polarity towards the Abs-fragment binding affinity. When there is no EO 
coating the carbohydrate epitope will be pulled close to the surface because of 
the hydrophobic nature of the undecane spacer. The EO coating can function as a 
supporting construction for the epitope that allows the epitope to rise further from 
the surface to increase the presentation of the epitope in the solution. This then 
contributes to an increase of the epitope’s degrees of freedom, which also has 
a positive effect on Ab-ligand recognition. On the other hand, we have learned 
from the studies described in Chapter 5 that compounds bearing an EO spacer 
suffer from coordination by residual copper from CuAAC chemistry. This could 
mean that the EO-coated surface contained a higher concentration of residual 
copper than in the cases where no chemical blocking step was performed. 
This higher concentration of residual copper then possibly influences the Abs-
carbohydrate recognition, and in this case also boosts the binding response.
The studies presented in this dissertation show that small tailor-made synthetic 
carbohydrate moieties have the potential to be used in detection methods for 
specific Abs. However, tuning is required to adjust their design to the binding 
pocket characteristics of the proteins. This involves changing (the polarity of) the 
spacers, adjusting the epitope, and creating suitable functionalized surfaces to 
perform inhibitory experiments. Also applying suitable coatings on the surface, 
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in the form of chemical blocking steps, may aid the ligand-protein binding. In 
additon, it is clear from these studies that copper influences measurements in 
biological assays, sometimes beneficial and sometimes detrimental. But the main 
issue remains that it does influence the system. Therefore, to avoid this, it can 
be concluded that ligation techniques that do not require metals are preferred. 
Finally, exploiting multivalent structures achieves binding affinities that are 
multiple orders of magnitude higher than employing monovalent equivalents.
It is clear that there are many tuneable parameters in functional glycomics, and 
optimizing them is one of the challenges for every glycoscientist. These studies show 
the power of custom design and synthesis of tailor-made glycan derivatives to support 
functional glycomics in order to gain knowledge on natural mechanisms. Based on 
the knowledge gained from these studies we formed a precedent to create novel 
pentavalent CTB inhibitors as medicinal drugs, dialysis methods, and biosensors 
that contain GM1-derived carbohydrates for pathogen and antibody detection.
8.2 Samenvatting
Voor de studies die in dit proefschrift worden besproken is functional 
glycomics gebruikt om meer kennis te ontwikkelen over diverse biologische 
processen op moleculair niveau. Het hoofddoel was om deze kennis toe 
te passen op sensoren en daarbij bij te dragen aan de ontwikkeling van de 
Unihealth biosensor.[1] Deze studies draaiden voornamelijk om het ontwerp 
en de synthese van antigenen, gemaakt van oligosachariden, die goede 
bindingseigenschappen vertonen met de cholera toxine B-eenheid (CTB) 
en de antilichamen (Abs) die gerelateerd zijn aan de neuropathologische 
aandoening Guillain-Barré syndrome (GBS). Als toevoeging daarop zijn de 
optimale condities bestudeerd om deze antigenen op sensoroppervlakten 
te immobiliseren. Om deze doelen te behalen was het essentieel om 
een groot scala aan disciplines te combineren waaronder: theoretische 
chemie, biologische experimenten (bioassays) en organische synthese. 
In Hoofdstukken 2 en 3 zijn de eerste voorbeelden beschreven van pentamere 
GM1 oligosacharide-bevattende CTB inhibitoren die gebaseerd zijn op twee 
typische, pentamere platformen. In de pathogenese van de ziekte cholera wordt 
CTB gebruikt voor celherkenning en celbinding. Deze cellen worden herkend 
door de aanwezigheid van een specifiek ligand, de complexe glycan koolhydraat 
ganglioside GM1. Er zijn diverse voorbeelden van synthetische materialen die 
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deze ligand in veelvoud bevatten.[2] Deze studies hebben uitgewezen dat het 
gebruik van multivalente materialen een effectieve strategie behelst voor de 
inhibitie van de pentamere receptor CTB en soortgelijke ziektemakers.[2] 
Echter heeft geen van deze synthetische materialen de fysieke eigenschap 
dat ze vijf GM1 pentasacchariden vertonen, overeenkomstig met de valentie van 
het toxine. In Hoofdstuk 2 wordt de synthese beschreven van het pentamere 
GM1 oligosaccharide-bevattende corannuleen platform. De oligosacchariden 
werden gekoppeld aan het corannuleen platform met ethyleenoxides (EO) van 
drie verschillende lengten, drie, zes of negen EO-eenheden lang. Naast dat 
ze goede, nanomolaire, bindingsaffiniteit vertoonden als inhibitoren van CTB, 
bewijzen deze structuren ook dat de lengte er toch toe doet. Het is namelijk 
zo dat niet het materiaal met de langste “armen” maar het molecuul met de 
intermediaire lengte de beste inhibitiepotentie vertoonde. Uit de studie die in 
Hoofdstuk 3 wordt gepresenteerd kon worden geconcludeerd dat ook de vorm 
van het platform belangrijk is voor de bindingsaffiniteit met CTB. Een calix[5]
areen platform werd voorzien van vijf ganglioside GM1 oligosachariden. Waar 
de corannuleen een komachtige vorm heeft, is dit platform meer bekervormig 
(Figuur 1). Hierdoor zijn bij laatstgenoemde de koolhydraten meer gericht in één 
richting daar komt ook bij dat de onderste rand van de calix[5]areen is voorzien 
van methoxidegroepen waardoor conformationele mobiliteit van het molecuul 
behouden blijft. De GM1os-calix[5]areen vertoonde een betere inhibitiepotentie 
bij de biologische testen met CTB dan de corannulenen. Met een IC50 van 450 pM 
werd een honderdduizend maal betere inhibitiepotentie vastgesteld ten opzicht 
van het monovalente controlemateriaal. Wanneer het calix[5]areen-platform werd 
voorzien van GM2 oligosachariden (waarbij de galactose-eenheid van de GM1os-
terminus is weggelaten) liet de inhibitiepotentie een significant verschil zien en 
verslechterde de half maximale inhibitieconcentratie drastisch naar IC50 = 9 µM.
Strain-promoted azide-alkyne cycloaddition (SPAAC) reacties worden met 
enige voorkeur in toenemende mate gebruikt als ligatiereactie in biologische 
experimenten. Omdat dit soort reacties met deze toepassingen steeds 
belangrijker worden, worden er steeds weer nieuwe cyclooctynen ontwikkeld. 
Synthese van de nieuwe structuren kan gericht zijn op het verbeteren van 
specifieke karaktereigenschappen van bestaande moleculen zoals het verbeteren 
van wateroplosbaarheid dat kan worden bewerkstelligd door het toevoegen 
van hydrofiele eenheden aan het molecuul. Echter is het gebleken dat andere 
intrinsieke eigenschappen van deze moleculen zich lastig laten voorspellen en 
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zijn niet zo eenvoudig te bepalen, zoals de mate van reactiviteit van cyclooctynen 
met azides. Hoofdstuk 4 beschrijft een theoretische verkenning van de reactiviteit 
van cyclooctynen met allyl- en benzylazide in SPAAC reacties. Dit werd berekend 
met drie verschillende typen theoretische methoden (B3LYP[4], M06-2X[5] en 
SCS-MP2[6]). Terwijl de methoden van het DFT-type, B3LYP en M06-2X, geen 
goede correlatie lieten zien voor een uitgebreide set van experimenteel bepaalde 
reactiekinetiek met berekende parameters, gaven SCS-MP2-berkeningen 
daarentegen een heldere voorspelling. Hieruit kwam een goede correlatie 
voort met op MP2-gebasseerde LUMO energieën van de cyclooctynen – in de 
geometrie die de alkynen hebben in de overgangstoestand (TS, Figuur 2) – en 
hun empirische reactiekinetiek. In tegenstelling tot wat in de literatuur[7] wordt 
beweerd hebben we geen relatie kunnen ontdekken tussen empirische data 
en energieën die het alkyn nodig heeft om te vervormen (distortion energy) om 
de overgangstoestand te bereieken. Verder zijn deze resultaten gebruikt om 
een methode te ontwikkelen waarmee het mogelijk is om de reactiekinetiek 
van een cyclooctyn in een SPAAC-reactie te bepalen alvorens het stofje 
daadwerkelijk is gesynthetiseerd. Voor een iets mindere accurate maar veel 
simpelere voorspellingsmethode kunnen ook LUMO-energieën gebruikt worden 
van het reactant waarvan de geometrie volledig is geoptimaliseerd met de MP2 
methode (in plaats van de geometrie van  de TS). Als de cyclooctyn TS LUMO-
waarden gecorreleerd worden met de experimentele reactieconstanten, wordt 
een goede lineaire regressie weergegeven van R2 = 0.960. Tevens onderstreept 
deze studie de theorie dat de SPAAC reacties gedreven worden door LUMO-
energieën en dat Hartree-Fock LUMO-waarden inderdaad een goede maat zijn 
voor de reactiviteit van cyclooctynen met organische azides in SPAAC reacties.
De SPAAC reactie is in potentie een goede vervanger voor de copper 
azide-alkyne cyclooaddtion (CuAAC)[3,8] reactie in biologische testen. Een 
van de redenen is dat koper in potentie een negatieve invloed heeft op 
metingen die betrekking hebben op ligand-proteïne interacties. We hebben 
experimenten bedacht waarbij de invloed van koper op deze bindingen kon 
worden onderzocht. In Hoofdstuk 5 combineren we daarom elementen die 
voorkomen in de voorgaande drie hoofdstukken door een directe vergelijking te 
trekken tussen CuAAC- en SPAAC-reacties in bindingsexperimenten. Reeds 
gesynthetiseerd GM1os materiaal[9] dat was voorzien van een alkynterminus werd 
geïmmobiliseerd op een microtiterplaat. Twee nieuwe materialen, die eveneens 
het GM1os bevatten, zijn zo gemodificeerd dat ze cyclooctynen bevatten. Één 
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daarvan met een verbindingsstuk tussen het koolhydraat en het cyclooctyn 
dat bestond uit een alifatisch, lipofiel undecaangedeelte en een tweede met 
hetzelfde verbindingsstuk en een additioneel hydrofiel EO-verbindingsstuk. 
De eerste set van biologische experimenten werd verricht nadat de materialen 
waren geïmmobiliseerd op microtiterplaten d.m.v. CuAAC of SPAAC, afhankelijk 
van het alkyntype. Beide materialen zonder het EO-verbindingsstuk werden door 
de CTB proteïne in min of meer gelijke mate “herkend”, dus er is in dit geval een 
zekere mate van onafhankelijk van de gebruikte immobilisatietechniek vastgesteld. 
In tegenstelling daartoe werd voor de EO-bevattende stof een significant lagere 
bindingsaffiniteit vastgesteld t.o.v. CTB. Een tweede set experimenten werd 
verricht onder soortgelijke condities, echter werd er in deze set aan alle materialen 
koperkatalysator toegevoegd na de immobilisatiestap (in dezelfde kwantiteit als 
voor de standaard CuAAC-reactie), dus ook aan de cyclooctyne-bevattende 
materialen. Dit werd gevolgd door een uitgebreide wasprocedure in een poging 
om alle residuele koperdeeltjes te verwijderen. Binnen de foutenmarge lieten 
de beide materialen zonder het EO-verbindingsstuk wederom een soortgelijke 
bindingsaffiniteit zien, echter was het verschil dit maal wel aanzienlijk groter 
dan voor de eerste set. Voor het EO-bevattende materiaal werden buitensporig 
hogere waarden waargenomen dan voorheen. Het is onbetwistbaar dat dit het 
resultaat is van coördinatie van residueel koper met het EO-verbindingsstuk 
zoals eerder is beschreven in de literatuur door Kaczmarek et al.[10] 
Interessant genoeg zijn de bindingsaffiniteiten dus beïnvloedbaar door de 
aanwezigheid van (kleine hoeveelheden) koper. Specifiek in het geval van het 
materiaal met het EO-verbindingsstuk, werkt het koper synergetisch op de ligand-
proteïne-interactie. De exacte reden van dit fenomeen is onduidelijk. Het is 
bijvoorbeeld onduidelijk of de koper ook het bindingsdomein van CTB binnendringt 
en of de koper ook coördineert aan het koolhydraatgedeelte en daardoor de interactie 
van het koolhydraat met de proteïne beïnvloed. In de studie die is beschreven in 
Hoofdstuk 6 is waargenomen dat sommige Abs, die zijn gerelateerd aan GBS, 
natuurlijke ganglioside GM1 herkennen maar niet het synthetische, structureel 
vrijwel identieke materiaal dat d.m.v. CuAAC reacties geïmmobiliseerd werd op 
microtiterplaten. Het kan niet worden uitgesloten dat koper een negatief effect heeft 
op deze experimenten en het de koolhydraten bemoeilijkt de bindingsdomeinen van 
de Abs te bereiken of dat de koolhydraatconformatie dusdanig wordt veranderd dat de 
Abs de koolhydraten niet meer herkennen. Verder wordt in Hoofdstuk 6 een evaluatie 
gepresenteerd van synthetische, op ganglioside-gebaseerde glycanfragmenten die 
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gebruikt zijn als liganden voor de detectie van Abs die geassocieerd worden met 
GBS. GBS is een auto-immuunziekte die het resultaat is van moleculaire nabootsing 
(molecular mimicry) van glycans die voorkomen op de celwand van o.a. de bacterie 
Campylobacter jejuni.[11] Gedeelten van structuren van gangliosiden die in het 
menselijke stelsel voorkomen op celwanden kunnen ook teruggevonden worden 
in deze glycans op de bacterie. In het geval van een auto-immuun respons (in 
GBS), worden er Abs gemaakt die deze glycans kunnen herkennen en de bacteriën 
markeren om te worden vernietigd. Echter worden in het menselijk zenuwstelsel 
hierdoor ook gezonde cellen gevlagd die soortgelijke glycanstructuren bevatten en 
eveneens vernietigd.[11] Als onderdeel van een doorlopend onderzoek naar deze 
ziekte pogen wij een beter begrip te vormen van de Abs-ganglioside specificiteit 
op het moleculaire niveau. Een kleine bibliotheek met negen verbindingen werd 
samengesteld en bevatte fragmenten van het ganglioside GM1 pentasacharide 
en een synthetische analoog daarvan. Alle koolhydraten werden voorzien van 
een chemisch handvat d.w.z. een azide-functionaliteit waarmee ze covalent 
geïmmobiliseerd konden worden op microtiterplaten d.m.v. CuAAC reacties. 
Studies die waren gebasseerd op saturation transfer difference NMR (STD-
NMR)[12] door Houliston et al.[13] gaven de indicatie dat de termini Galβ1-3GalNAcβ 
en Neu5Acα2 de koolhydraatstructuren zijn die het meest bijdragen aan de GM1-
Abs-binding. Dit wekt de suggestie dat deze koolhydraten afzonderlijk van elkaar 
een significante bijdrage kunnen leveren aan de GM1-Abs-binding. Het werd echter 
al snel duidelijk in onze experimenten dat dit niet het geval is en dat de complexiteit 
van de bindingen niet altijd één-op-één kan worden nagebootst door (kleinere) 
synthetische fragmenten. Een verassende ontdekking was wel dat sommige 
anti-ganlgioside Abs zich binden aan de simpele galactoside monosacharide en 
lactoside disacharide. Dit zijn in het bijzonder de Abs die voorkomen in patientensera 
die tevens kruisreactiviteit vertonen met natuurlijke galactocerebroside. Deze 
ontdekking heeft een nieuwe richting voor toekomstige onderzoeken geopend.
Het toepassen van relatief korte oligo-EO-materialen, van 12 atomen lang, 
op een microtiterplaat – om te voorkomen dat serumcomponenten ongewild 
adheren aan het oppervlakte – had een dramatisch effect op een select groepje 
GBS patiëntensera op de Abs-ligand-binding. In een enkel geval verdubbelde 
de bindingsrespons t.o.v. experimenten waarin deze vorm van chemisch blokken 
niet werd toegepast. Dit duidde op een positief effect van de verhoogde polariteit 
van het oppervlakte. Bij afwezigheid van de hydrofiele EO-modificatie bevindt het 
ligand zich wellicht dichter op het oppervlakte. Door het hydrofobische karakter 
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van het undecaan verbindingsstuk adheert het aan het eveneens hydrofobe 
oppervlakte. In het geval van de hydrofiele oppervlakte, kan het EO fungeren 
als een ondersteunende structuur die het mogelijk maakt voor het koolhydraat 
om zich verder in de oplossing van de biologische experimenten te bevinden. 
Dit draagt bij aan een toename van de vrijheidsgraden van het ligand en levert 
daarmee een positieve bijdrage aan de Abs-ligand-interactie. Het is uit de studie 
die is beschreven in Hoofdstuk 5 echter ook duidelijk geworden dat EO-materialen 
participeren aan kopercoördinatie en dat dit van invloed kan zijn op de uitkomst 
van een biologisch experiment. Het kan daarom zijn dat de residuele koper in 
het geval van een EO-oppervlakte in het experiment hoger is dan wanneer een 
hydrofoob oppervlakte wordt gebruikt. De hogere bindingsuitkomst zou dus het 
resultaat kunnen zijn van een hogere concentratie koperionen in het systeem.
De studies die in dit proefschrift zijn beschreven bewijzen dat kleine, op-
maat-gemaakte synthetische moleculen de potentie hebben om gebruikt te 
worden als onderdeel van detectiemethoden voor specifieke Abs en toxines. Het 
blijft echter nodig om het ontwerp aan te passen en zo te modeleren naar de 
karakteristieke bindingseigenschappen van de te detecteren proteïnes. Dit houdt 
in dat de (polariteit van de) verbindingsmoleculen en de koolhydraatsamenstelling 
aangepast moeten worden en tevens geschikte, correct gefunctionaliseerde 
oppervlakten ter beschikking moeten zijn voor de inhibitie-experimenten. Het is ook 
duidelijk geworden dat het gebruik van koper van invloed is op de uitkomst van 
de experimenten, soms komt het ten goede aan de binding, soms niet. De meest 
belangrijke conclusie is dat koper het systeem beïnvloed en dat daarom beter 
naar alternatieven gezocht kan worden waarbij het gebruik van metalen overbodig 
is. Tot slot is in dit proefschrift ook multivalentie geëxploiteerd in materialen die 
vijf maal het GM1 ligand vertonen. Deze pentavalente structuren vertoonden 
een bindingaffiniteit die meerdere orden van grootte beter is dan wanneer de 
monovalente equivalenten werden toegepast in proteïne-ligand bindingstudies.
Het is duidelijk dat er veel aanpasbare parameters zijn in functional glycomics en 
dat het optimaliseren daarvan één van de uitdagingen is voor iedere glycochemicus. 
Deze studies laten zien wat de kracht is van handmatig ontwerp en synthese van 
glycanderivaten om de functional glycomics te gebruiken om een beter begrip 
te creëren van biologische mechanismen. De kennis opgedaan in deze studies 
scheppen precedent om nieuwe pentavalente CTB inhibitoren te creëren voor 
medicinaal gebruik, dialysemethoden of het gebruik in nieuwe biosensoren die 
synthetische GM1 derivaten bevatten voor pathogeen- en antilichaamdetectie.
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Appendix I
Chapter 2: Nanomolar cholera toxin inhibitors based on 
symmetrical pentavalent ganglioside GM1os-sym-corannulenes
This Chapter is published as supporting information to:
M. Mattarella,‡ J. Garcia-Hartjes,‡ T. Wennekes, H. Zuilhof, J. S. Siegel, 
Org. Biomol. Chem. 2013, 11, 4333-4339, DOI: 10.1039/c3ob40438b
‡Both authors contributed equally to this work.
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I.1 General notes
Microwave reactions were carried out in a dedicated CEM Discovery microwave 
oven. The microwave power was limited by temperature control once the 
desired temperature was reached. All reagents and solvents were reagent grade 
and were used without further purification unless otherwise specified. Flash 
chromatographic purification was performed using silica gel Merck 60 (particle 
size 0.040 - 0.063 mm); the eluting solvent for each purification was determined 
by thin layer chromatography (TLC). Size exclusion chromatographic purifications 
were performed using Sephadex® G-15 and Sephadex® G-25. Analytical thin-layer 
chromatography was performed using Merck TLC silica gel 60 F254. Solvents for 
chromatography were technical grade and freshly distilled before use. 1H NMR 
spectra were recorded on a Bruker AV2-500 (500 MHz) or Bruker AV2-600 (600 
MHz) spectrometers. Solvent for NMR spectroscopy were purchased from ARMAR 
chemicals, degassed with nitrogen and dried over molecular sieves. Chemical 
shifts are reported in parts per million (ppm) relative to the solvent residual peak: 
CDCl3 = 7.26 ppm, MeOD = 3.31 ppm, D2O = 4.79 ppm. Multiplicities are given 
as: s (singlet), br (broad), d (doublet), t (triplet), q (quadruplet), m (multiplet). 
1H-decoupled 13C NMR spectra were obtained on Bruker AV2-500 (125 MHz) or 
Bruker AV2-600 (150 MHz) spectrometer. 13C NMR chemical shifts are reported 
relative to the solvent residual peak: CDCl3 = 77.2 ppm, d
4-MeOD = 49.00 
ppm. HR-ESI-MS: Finnigan Mat 900 MS. Materials for the ELLA experiments 
i.e. bovine serum albumin (BSA), bovine brain GM1, ortho-phenylenediamine 
(dihydrochloride salt) (OPD), cholera toxin horse-radisch peroxide (CTB-HRP) 
conjugate, Tween-20, 30% H2O2 solution, sodium citrate, and citric acid were 
purchased at Sigma Aldrich and used without further modification, phosphate-
buffered saline (PBS) 10x concentrate was diluted ten times with demi water prior 
to use. Nunc F96 MaxisorpTM 96-wells microtiter plates were used as purchased 
at thermo scientific. The microtiter plates were washed using an automated 
Denville® 2 Microplate Washer. Optical density (OD) was measured between 
1.5 and 0.5 units on a Thermo Labsystems Multiskan Spectrum Reader running 
on Skanit software version 2.4.2. Compounds s1, s2, and s3 were synthesized 
according to literature.S1
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Figure S1. Compounds s1, s2, and s3 were prepared according to literature procedure.
I.2 Synthetic details
Compound 5. A mixture of 3 (15 mg, 29 µmol), s1 (67 mg, 0.18 mmol) and 
copper nanoparticles (12 mg, 0.19 mmol) in DMF (1.5 mL) was loaded in 
a microwave vessel was heated at 60 °C in a microwave reactor for 2 h. The 
mixture was filtrated over Celite® and the solvent evaporated. The crude 
was purified by column chromatography on silica gel (DCM/ MeOH 95 : 5) 
to yield a reddish oil (58 mg, 83%); 1H NMR (500 MHz, CDCl3): δ = 7.64 (s, 
5H), 7.52 (s, 5H), 4.49 (t, 10H, J = 5.5 Hz), 4.18 (s, 10H), 3.82 (t, 10H, J = 
5.5 Hz), 3.66 - 3.45 (m, 50H), 3.26 (t, 10H, J =8.0 Hz), 1.02 (s, 105H); 13C 
NMR (125 MHz, CDCl3): δ = 147.1, 140.4, 134.9, 129.7, 123.0, 122.4, 103.2, 
87.7, 70.5, 70.5, 70.4, 69.7, 68.7, 59.2, 50.2, 33.4, 28.5, 18.6, 11.2; MS (HR-
ESI+) m/z = 1201.2173 [M+2Na]2+, calcd. (C130H205N15Na2O15Si5
2+) = 1201.2185.
Compound 6. A mixture of 3 (9.4 mg, 18 µmol), s2 (83 mg, 0.14 mmol) and 
copper nanoparticles (12 mg, 0.18 mmol) in DMF (1.0 mL) was loaded in a 
microwave vessel and was heated at 80 °C in a microwave reactor for 2 h. The 
reaction mixture was filtrated over Celite® and the solvent evaporated. The crude 
mixture was purified by column chromatography on silica gel (from DCM/ MeOH 
94 : 6 to DCM/ MeOH 9 : 1) to yield a reddish oil (49 mg, 79%); 1H NMR (500 
MHz, CDCl3): δ = 7.69 (s, 5H), 7.64 (s, 5H), 7.53 (s, 5H), 4.62 (s, 10H), 4.48 (q, 
20 H, J = 5.5 Hz), 4.21 (s, 10H), 3.82 (t, 20H, J = 5.0 Hz), 3.69 - 3.47 (m, 90H), 
3.26 (t, 10H, J=8.0 Hz), 1.04 (s, 105H); 13C NMR (125 MHz, CDCl3): δ = 147.1, 
144.8, 140.4, 134.9, 129.7, 123.9, 123.1, 122.5, 103.2, 87.8, 70.6, 70.54 70.51, 
70.47, 69.7, 69.6, 69.5, 68.7, 64.6, 59.3, 50.3, 50.3, 33.4, 28.5, 18.7, 11.2. MS (HR-
ESI+) m/z = 1163.6590 [M+3Na]3+, calcd. (C175H280N30Na3O30Si5
3+) = 1163.6609.
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Compound 7. A mixture of 3 (20 mg, 38 µmol), s3 (296 mg, 0.29 mmol) and 
copper nanoparticles (23.0 mg, 0.36 mmol) in DMF (2.0 mL) was loaded in a 
microwave vessel and was heated at 80 °C in a microwave reactor for 2 h. The 
reaction mixture was filtrated over Celite® and the solvent evaporated. The crude 
mixture was purified by column chromatography on silica gel (DCM:MeOH 9:1) 
to yield a reddish oil (147 mg, 70%); 1H NMR (500 MHz, CDCl3): δ = 7.66 - 7.62 
(m, 15H), 7.56 (s, 5H), 7.47 (s, 5H), 4.56 - 4.52 (m, 30H), 4.43 - 4.38 (m, 40H), 
4.11 (s, 10H), 3.77 - 3.73 (m, 40H), 3.61 - 3.41 (m, 165H), 3.17 (bs, 10H), 0.96 
(s, 105H). 13C NMR (125 MHz, CDCl3): δ = 146.8, 144.5, 140.2, 134.6, 129.5, 
123.7, 122.8, 122.2, 103.0, 87.5, 70.4, 70.34, 70.29, 70.2, 69.4, 69.3, 69.3, 68.5, 
64.4, 64.4, 58.9, 50.07, 50.02, 50.00, 49.96, 49.9, 33.1, 28.2, 18.4, 10.9. MS 
(HR-ESI+) m/z = 794.3097 [M+7H]7+, calcd. (C265H437N60O60Si5
7+) = 794.3114.
Compound 8. A solution of TBAF in THF (1 M, 0.77 mL, 0.77 mmol) was added 
to a solution of 5 (55 mg, 23 µmol) in THF (0.33 mL) and the reaction mixture was 
stirred at rt for 2 h. The solution was then diluted with a saturated aqueous solution 
of NH4Cl and extracted with ethyl acetate. The combined  organic phases were 
dried over Na2SO4 and evaporated to yield the crude product. The crude was then 
heated at 75 °C under high vacuum for 18 h. The product was then purified by column 
chromatography on silica gel (DCM/ MeOH 95 : 5) to yield a reddish oil (15 mg, 40%); 
1H NMR (500 MHz, CDCl3): δ = 7.64 (s, 5H), 7.53 (s, 5H), 4.50 (t, 10H, J = 5.0 Hz), 
4.13 (d, 10H, J = 2.0Hz), 3.82 (t, 10H, J = 5.0 Hz), 3.62 - 3.50 (m, 50H), 3.26 (t, 10H, 
J = 8.0 Hz), 2.40 (t, 5H, J = 2.0 Hz); 13C NMR (125 MHz, CDCl3): δ = 147.1, 140.5, 
134.9, 129.8, 123.1, 122.5, 79.7, 74.8, 70.6, 70.4, 69.7, 69.1, 58.5, 50.3, 33.4, 
28.5. MS (HR-ESI) m/z = 526.2709 [M+2H]2+, calcd. (C85H108N15O152+) 526.2711.
Compound 9. A solution of TBAF in THF (1 M, 1.0 mL, 1.0 mmol) was added 
to a solution of 6 (103 mg, 30 µmol) in THF (1.0 mL) and the reaction mixture 
was stirred at rt for 2 h. The solution was then diluted with a saturated aqueous 
solution of NH4Cl and extracted with ethyl acetate. The collected organic phases 
were dried over Na2SO4 and evaporated to yield the crude product. The crude was 
then heated at 75 °C under high vacuum for 18 h. The product was then purified 
by column chromatography on silica gel (DCM/ MeOH 9 : 1) to yield a reddish oil 
(24 mg, 30%); 1H NMR (500 MHz, CDCl3): δ = 7.70 (s, 5H), 7.64 (s, 5H), 7.53 (s, 
5H), 4.62 (s, 10H), 4.50 - 4.46 (m, 20 H), 4.16 (d, 10H, J = 2.5 Hz), 3.82 (t, 20H, J 
= 5.0 Hz), 3.64 - 3.51 (m, 90H), 3.23 (t, 10H, J = 8.0 Hz), 2.44 (d, 5H, J = 2.5 Hz). 
13C-NMR (125 MHz, CDCl3): δ = 147.1, 144.8, 140.5, 134.9, 129.8, 124.0, 123.1, 
206
122.5, 79.7, 74.9, 70.6, 70.6, 70.5, 69.7, 69.5, 69.1, 64.7, 58.5, 50.3, 50.2, 33.4, 
28.5; MS (HR-ESI+) m/z = 529.2767 [M+5H]5+, calcd. (C130H185N30O305+) 529.2769.
Compound 10. A solution of TBAF in THF (1M, 0.9 mL, 0.9 mmol) was added 
to a solution of 6 (143 mg, 25.7 µmol) in THF (1.0 mL) and the reaction mixture 
was stirred at rt for 2 h. The solution was then diluted with a saturated aqueous 
solution of NH4Cl and extracted with ethyl acetate. The collected organic phases 
were dried over Na2SO4 and evaporated to yield the crude product. The crude 
was then heated at 75 °C under high vacuum for 18 h. The product was then 
purified by column chromatography on silica gel (DCM/ MeOH 9 : 1) to yield a 
reddish oil (81 mg, 66%); 1H NMR (500 MHz, CDCl3): δ = 7.69 - 7.65 (m, 15H), 
7.60 (s, 5H), 7.50 (s, 5H), 4.60 - 4.56 (m, 30H), 4.48 - 4.41 (m, 40H), 4.13 (d, 
10H, J = 2.0 Hz), 3.81 - 3.80 (m, 40H), 3.62 - 3.52 (m, 165H), 3.18 (t br, 10H, J = 
7.5 Hz), 2.41 (s, 5H); 13C NMR (125 MHz, CDCl3): δ = 146.9, 144.7, 140.3, 134.8, 
129.7, 123.8, 123.8, 122.9, 122.3, 79.6, 74.7, 70.47, 70.46, 70.44, 70.42, 70.35, 
69.6, 69.41, 69.39, 69.0, 64.5, 58.4, 50.17, 50.16, 50.12, 50.07, 33.2, 28.4; MS 
(HR-ESI+) m/z = 1216.1057 [M+4Na]4+, calcd. (C220H330N60Na4O60
4+) 1216.1052.
Compound 13. A mixture of 2,3,4,6-tetra-O-acetyl-α-d-galactopyranosyl 
bromide (11, 1.6 g, 4.0 mmol), 2[-2-(2-{2-[2-(2-hydroxyethoxy)-ethoxy]-ethoxy}-
ethoxy)-ethoxy]- ethyl azide (12, 1.7 g, 5.6 mmol) and molecular sieves in dry 
dichloromethane (35 mL) was stirred at rt for 50 min; HgBr2 (1.43 g, 4.0 mmol) 
was added to the reaction and the mixture was stirred at r. t. for 3 days. The 
mixture was then filtrated and the solid washed with dichloromethane, methanol 
and THF. The filtrate was concentrated in vacuo. The product was purified by 
column chromatography on silica gel eluted with AcOEt/ Hexane 1 : 1. The solvent 
was evaporated to yield a yellow syrup (1.4 g, 55%). 1H-NMR (500 MHz, CDCl3): 
δ = 5.36 (d, 1H, J = 3.0 Hz), 5.17 (dd, 1H, J = 8.0, 10.0 Hz), 5.00 (dd, 1H, J = 
3.5, 10.5 Hz), 4.55 (d, 1H 3.5), 4.16 - 4.10 (m, 2H), 3.97 - 3.89 (m, 2H) 3.76 - 
3.62 (m, 23H), 3.39 (t, 2H, J = 5.0 Hz), 2.12 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 
1.99 (s, 3H); 13C NMR (135 MHz, CDCl3): δ = 170.6, 170.4, 170.3, 101.7, 71.1, 
70.9, 70.8, 70.6, 70.5, 70.1, 69.3, 69.1, 67.3, 61.5, 50.9, 21.0, 20.9, 20.9, 20.8; 
MS (HR-ESI+) m/z = 660.2580 [M+Na]+, calcd. (C26H43N3NaO15+) = 660.2586.
Compound 14. A solution of sodium methoxide (3.0 g in 10 mL of methanol) 
was added to a solution of 13 (1.3 g, 2.1 mmol) in methanol (10 mL.) until pH 
12 was reached. The reaction mixture was stirred at r. t. for 2 days. Dowex 50 
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was added to the reaction until pH 6 was reached; the mixture was then filtrated 
and the solvent evaporated. The crude was purified by chromatography (DCM/ 
MeOH 85 : 15). The product is a yellow syrup (560 mg, 58%), 1H NMR (500 
MHz, D2O): δ = 4.44 (d, 1H, J = 8.0 Hz), 4.12 - 4.08 (m, 1H), 3.94 (d, 1H, J = 
3.5), 3.88 - 3.66 (m, 25H), 3.58 - 3.52 (m, 3H); 13C NMR (125 MHz, MeOD): δ 
= 104.3, 76.4, 74.1, 72.1, 71.0, 70.91, 70.87, 70.8, 70.5, 69.9, 69.7, 62.1, 51.4; 
MS (HR-ESI+) m/z = 492.2159 [M+Na]+, calcd. (C18H35N3NaO11+) = 492.2164.
Compound 15. A mixture of 3 (11 mg, 21.5 µmol), 14 (89 mg, 0.19 mmol) and 
copper nanoparticles (12 mg, 0.19 mmol) in DMF (1.0 mL) was loaded in a 
microwave vessel was heated at 80 °C in a microwave reactor for 2 h. The mixture 
was filtrated over Celite® and the solvent evaporated. The crude was purified by 
size exclusion chromatography (Sephadex® G-25, water) to yield a reddish solid 
(147 mg, 47%); 1H NMR (600 MHz, MeOD): δ = 7.83 (s, 5H), 7.71 (s, 5H), 4.54 (t 
br, 10H, J = 5.0 Hz), 4.26 (d, 5H, J = 5.0 Hz), 3.99 - 3.85 (m, 5H), 3.82 - 3.70 (m, 
20H), 3.68 - 3.59 (m, 30H), 3.53 - 3.29 (m, 125H); 13C NMR (150 MHz, MeOD): 
δ = 148.1, 141.7, 135.8, 130.9, 124.7, 124.4, 104.9, 76.7, 74.9, 72.5, 71.4, 
71.31, 71.27, 71.25, 71.24, 71.22, 70.4, 70.3, 69.5, 62.5, 51.3, 34.1, 29.1; MS 
(HR-ESI+) m/z = 737.0824 [M+4Na]4+; calcd. (C130H205N14Na4O55
4+) = 737.0819.
Compound 16. A mixture of 8 (4.5 mg, 2.9 µmol), 14 (11.3 mg, 24.1 µmol) 
and copper nanoparticles (1.5 mg, 24 µmol) in DMF (300 µL) was loaded in a 
microwave vessel and was heated at 80 °C in a microwave reactor for 2 h. The 
mixture was filtrated over Celite® and the solid was washed with water. The 
crude was lyophilized and purified by size exclusion chromatography (Sephadex® 
G-25, water) to yield a reddish solid (5.0 mg, 44%); 1H NMR (500 MHz, D2O/ 
MeOD): δ = 7.81 (s, 5H), 7.57 (s, 5H), 7.52 (s, 5H), 4.41 - 397 (m, 40H), 3.85 
(m, 5H), 3.71 - 2.99 (m, 220H); 13C NMR (125 MHz, D2O/ MeOD): δ = 144.8, 
141.3, 137.4, 126.1, 124.8, 124.4, 103.8, 76.1, 73.7, 71.7, 70.7, 70.5, 70.34, 
70.26, 70.22, 70.18, 69.8, 69.7, 69.6, 69.5, 66.9, 64.0, 61.9, 50.9, 50.8; MS 
(HR-ESI+) m/z = 807.3734 [M+5Na]5+; calcd. (C175H280N30Na5O70) = 807.3747.
Compound 17. A mixture of 9 (8.5 mg, 3.2 µmol), 14 (11 mg, 24 µmol) and copper 
nanoparticles (1.5 mg, 24 µmol) in DMF (300 µL) was loaded in a microwave 
vessel was heated at 80 °C in a microwave reactor for 2 h. The mixture was 
filtrated over Celite® and the solid was washed with water. The crude was 
lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
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water) to yield a reddish solid (9 mg, 57%); 1H NMR (500 MHz, D2O/ MeOD): 
δ = 8.01 (s, 5H), 7.88 (s, 5H), 7.68 (s, 5H), 7.60 (s, 5H), 4.58 - 4.39 (m, 50H), 
4.08 - 4.06 (m, 5H), 3.98 - 3.12 (m, 255H); 13C NMR (125 MHz, D2O/ MeOD): 
δ = 147.9, 144.8, 141.3, 134.8, 130.4, 126.3, 126.1, 124.8 124.2, 103.9, 
76.1, 73.7, 71.7, 70.7, 70.6, 70.5, 70.42, 70.41, 70.35, 70.3, 70.2, 69.9, 69.8, 
69.73, 69.65, 69.6, 69.5, 64.0, 61.9, 50.9, 50.8, 49.5, 34.0, 28.1; MS (HR-
ESI+) m/z = 854.2378 [M+6Na]6+, calcd. (C220H355N45Na6O85
6+) = 854.2366.
Compound 18. A mixture of 10 (16 mg, 3.4 µmol), 14 (14 mg, 29 µmol) and 
copper nanoparticles (1.8 mg, 28 µmol) in DMF (300 µL) was loaded in a 
microwave vessel was heated at 80 °C in a microwave reactor for 2 h. The mixture 
was filtrated over Celite® and the solid was washed with water. The crude was 
lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
water) to yield a reddish solid (10 mg, 43%); 1H NMR (500 MHz, D2O/ MeOD): 
δ = 8.07 (d, 5H, J = 5.0 Hz), 8.02 (d, 5H, J = 5.0 Hz), 7.98 (d, 5H, J = 5.0 Hz), 
7.90 (d, 5H, J=5.0 Hz), 7.89 (d, 5H, J = 5.0 Hz), 7.63 (s, 5H), 4.69 - 4.39 (m, 
90H), 4.08 (m, 5H), 3.96 - 3.16 (m, 345H); 13C NMR (125 MHz, D2O/ MeOD): δ 
= 147.9, 145.0, 141.4, 134.8, 130.3, 126.2, 126.1, 126.0, 125.9, 124.6, 124.1, 
103.8, 99.5, 76.0, 73.7, 71.7, 70.61, 70.58, 70.5, 70.4, 70.3, 70.3, 70.2, 69.9, 
69.59, 69.57, 69.55, 69.5, 64.0, 61.9, 50.89, 50.87, 50.8, 50.7, 32.9, 28.1; MS 
(HR-ESI) m/z = 912.8149 [M+8Na]8+, calcd. (C310H505N75Na8O115
8+) = 912.8139.
Compound 20. A mixture of 8 (0.8 mg, 0.5 µmol), 19 (5.5 mg, 4.6 µmol) and 
copper nanoparticles (0.3 mg, 5.2 µmol) in water (150 µL) was loaded in 
a microwave vessel was heated at 80 °C in a microwave reactor for 2 h. The 
mixture was filtrated over Celite® and the solid was washed with water. The 
crude was lyophilized and purified by size exclusion chromatography (Sephadex® 
G-15, water) to yield a colorless solid (1.8 mg, 45%). 1H-NMR (500 MHz, D2O/ 
MeOD): δ = 7.86 - 7.70 (m, 15H), 4.55 (t, 25H, J = 10.0 Hz), 3.81 (d, 10H, J = 
10.0 Hz), 3.76 (t, 5H, J = 5.0 Hz), 3.85 - 3.79 (m, 15H), 3.75 - 3.59 (m, 40H), 
3.58 - 3.52 (m, 20H), 3.47 - 3.41 (m, 20H), 3.64 - 3.33 (m, 25H), 2.69 (d, 5H, 
J = 10.0 Hz), 1.98 (d, 15H, J = 15.0 Hz), 1.93 - 1.84 (m, 5H), 1.55 - 1.54 (m br, 
5H), 1.47 - 1.37 (m br, 10H), 1.26 - 1.12 (m br, 20H), 1.07 - 0.83 (m br, 30H); 
13C NMR insufficient material was acquired to record an 13C NMR spectrum; 
MS (HR-ESI) m/z =1507.8678 [M-5H]5-, calcd. (C325H515N40O1605-) = 1507.6684.
Compound 21. A mixture of 9 (2.9 mg, 1.1 µmol), 19 (11 mg, 9.3 µmol) and copper 
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nanoparticles (0.8 mg, 12 µmol) in water (300 µL) was loaded in a microwave 
vessel was heated at 80 °C in a microwave reactor for 2 h. The mixture was filtrated 
over Celite® and the solid was washed with water. The crude was lyophilized and 
purified by size exclusion chromatography (Sephadex® G-25, water) to yield a 
colorless solid (4.8 mg, 51%); 1H NMR (500 MHz, D2O/ MeOD): δ = 7.96 - 7.75 
(m, 20H), 4.57 - 4.54 (m, 70H), 4.18 - 4.05 (m, 45H), 3.94 - 3.34 (m, 286H), 
2.70 (d, 5H, J = 10.0 Hz), 2.06 (d, 35H, J = 15.0 Hz), 1.98 - 1.94 (t, 5H, J=10.0 
Hz), 1.62 - 1.45 (m br, 25H), 1.28 - 1.25 (m br, 20H), 1.11 - 0.90 (m br, 75H); 
13C NMR (125 MHz, D2O/ MeOD): δ = 176.0, 175.1, 105.7, 103.6, 103.5, 103.2, 
102.7, 75.8, 75.3, 73.5, 71.7, 70.7, 70.64, 70.62, 70.52, 70.50, 70.48, 70.47, 
70.45, 69.59, 69.57, 61.9, 52.6, 52.1, 51.13, 51.11, 29.7, 26.6, 26.2, 23.6, 23.0; 
MS (HR-ESI-) m/z = 1721.1778 [M-5H]5-, calcd. (C370H590N55O1755-) = 1720.7797.
Compound 22. A mixture of 10 (4.8 mg, 1.0 µmol), 19 (8.4 mg, 7.0 µmol) 
and copper nanoparticles (0.5 mg, 8.0 µmol) in water (300 µL) was loaded in 
a microwave vessel was heated at 80 °C in a microwave reactor for 2 h. The 
mixture was filtrated over Celite® and the solid was washed with water. The crude 
was lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
water) to yield a colorless solid (6.2 mg, 58%); 1H-NMR (500 MHz, D2O/ MeOD): δ 
= 7.91 - 7.67 (m, 25H), 4.47 - 4.35 (m br, 75H), 4,07 (m 20H), 3.98 (t, 10H, J = 5.0 
Hz), 3.88 - 3.15 (m, 280H), 2.60 (d, 5H, J = 10.0 Hz), 1.95 (d, 25H, J = 15.0 Hz), 
1.85 (s, 40H), 1.55 (s br, 10H), 1.40 (s br, 10H), 1.07 - 0.91 (m br, 60H); 13C NMR 
(125 MHz, D2O/ MeOD): δ = 176.0, 175.6, 175.1, 171.9, 144.9, 126.28, 126.25, 
126.20, 126.17, 126.06, 126.05, 125.5, 105.7, 103.6, 103.5, 103.1, 102.7, 81.4, 
79.7, 78.2, 75.8, 75.7, 75.5, 75.3, 75.04, 75.03, 74.07, 74.06, 73.77, 73.76, 73.7, 
73.51, 73.47, 73.2, 71.7, 71.4, 71.0, 70.64, 70.62, 70.59, 70.49, 70.45, 69.91, 
69.87, 69.7, 69.6, 69.0, 68.9, 64.09, 64.06, 63.8, 62.1, 61.9, 61.5, 52.6, 52.1, 51.1, 
50.9, 50.8, 37.9, 30.4, 30.34, 30.33, 30.31, 30.0, 29.89, 29.86, 29.80, 29.79, 29.74, 
29.72, 29.70, 29.68, 29.64, 29.62, 29.2, 26.60, 26.58, 26.18, 26.16, 24.2, 23.6, 
23.0; MS (HR-ESI-) m/z = 2147.2039 [M-5H]5-, calcd. (C460H740N85O2055-) 2147.0024.
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I.3 ELLA experiments
Each well of a 96-well microtiter plate was coated with a 100 μL native GM1 
solution (1.3 µM in ethanol) after which the solvent was evaporated. Unattached 
GM1 was removed by washing with PBS (3 × 450 µL), the remaining free binding 
sites were blocked by incubation with 100 µL of a 1% (w/v) BSA  solution in PBS 
for 30 min at 37 °C. Subsequently, the wells were washed with PBS (3 × 450 µL). 
In separate vials, a logarithmic serial dilution, starting from 2.0 mM, of 150 µL 
saccharide-corannulenes in 0.1% BSA, 0.05% Tween-20 in PBS, mixed with 150 
µL of a 50 ng/mL CTB-HRP solution in the same buffer were incubated. This gave 
an initial inhibitor concentration of 1.0 mM. In the case of potent inhibitors, based 
on the logarithmic experiments, a more accurate, serial dilution of a factor two 
was performed around the expected IC50 values. The inhibitor-toxin mixtures were 
incubated at room temperature for 2 h and then transferred to the coated wells. 
After 30 min of incubation at room temperature, unbound CTB-HRP-corannulene 
complexes were removed from the wells by washing with 0.1% BSA, 0.05% 
Tween-20 in PBS (3 x 500 µL). 100 µL of a freshly prepared OPD solution (25 
mg OPD·2HCl, 7.5 mL 0.1 M citric acid, 7.5 mL 0.1 M sodium citrate and 6 µL of 
a 30% H2O2 solution, pH was adjusted to 6.0 with NaOH) was added to each well 
and allowed to react with HRP in absence of light, at room temperature, for 15 
min. The oxidation reaction was quenched by addition of 50 µL 1M H2SO4. Within 
5 min, the adsorbance was measured at 490 nm. 
I.4 1H-NMR, UV-vis and Emission Spectroscopy Investigation 
on the Aggregation of s4
Figure S2. C5-symmetric galactose conjugated corannulene prepared according to literature procedure.S2
R
R
R
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The thermodynamic behavior of the aggregation process of compound S4 was studied 
by measuring the 1H-NMR chemical shift of the five homotopic hydrogen atoms on the 
corannulene ring at different concentrations and temperatures (Figure S3).
Figure S3. δobs vs. concentration of s4; experimental data and fitting curves at 300 K (black), 310 K(red), 320 K 
(blue), 330 K (green) and 340 K (yellow).
NMR samples were prepared over a range of concentrations and measured at 
different temperatures after 15 minutes equilibration. The association constants 
Ka (Table s1) were calculated based on an equal K model described by Martin
S3 
(eq. s1), where δobs is the observed chemical shift, δmon is the chemical shift of 
monomer, Ka is the association constant, c is the molar concentration of the 
sample, and ∆ is the difference in chemical shift between monomer and dimer. 
The chemical shifts vs concentration data were analyzed by nonlinear least-
squared fitting using Prism 6.0 (GraphPad).
  
δobs = δmon − ∆ 1+ 1− 4Kac +1( )[ ]/2Kac       eq. S1
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Table S1. Association constant of s4 in water at different temperatures.
T (K) Ka (x10
5)
300 2 ± 1
310 0.5 ± 0.2
320 0.6 ± 0.2
330 0.3 ± 0.1
340 0.14 ± 0.03
The aggregation number N, i.e. the number of monomers included in the 
aggregate, was determined by eq. 2, where δobs is the observed chemical shift, 
δmon is the chemical shift of monomer, Ka is the association constant, c is the molar 
concentration of the sample and N is the aggregation number.
  
ln c δmon −δobs( )[ ]= N ln c δobs −δagg( )[ ]+ lnKa + ln N − N −1( )ln δmon −δagg( ) eq. S2
The aggregation number was estimated to 2 assuming that compound s4 is in 
equilibrium between the monomer and the aggregate. S4 The thermodynamic 
parameters ∆H (-13 ± 1 kcal mol-1) and ∆S (-18 ± 4 cal mol-1) for the dimerization 
process were determined based on the van’t Hoff plots revealing that the driving 
force for the aggregation of compound s4 in solution is not the increasing of the 
entropy of the system, like for the most amphiphilic molecules, but the exothermicity 
of the process. UV-vis absorption spectra were recorder for a 10-4 M solution 
of compound s4 at different temperature after 15 minutes equilibration (Figure 
s4). Emission spectra of solutions of compound s4 at different concentration 
were measured at room temperature after excitation at 300 nm (Figure s5). The 
hypsochromic shift in the absorption spectra, upon increasing of the temperature, 
and the quenching of the fluorescence due to the increasing of the concentration 
of compound s4 suggest the formation of H-dimers in solution.S5
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Figure S4. UV-vis spectra of a 10-4 M solution of compound s4 at 280 K (black), 285 K (red), 290 K (yellow), 295 
K (green), 305 K (blue), 315 K (violet), 325 K (white).
Figure S5. Emission spectra of compound S4 at different concentrations: 2.63 x10-3 M (black, solid line), 1.31 
x10-3 M (red, solid line), 6.57 x10-4 M (blue, solid line), 2.42 x10-4 M (green, solid line), 2.31 x10-4 M (yellow, solid 
line), 1.64 x10-4 M (violet, solid line), 8.22 x10-5 M (white, solid line), 4.11 x10-5 (black, dashed line), 2.05 x10-5 
(red, dashed line) and 1.03 x10-5 M (yellow, dashed line).
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Appendix II
Chapter 4: Electronic Effects versus Distortion Energies During 
Strain-Promoted Alkyne-Azide Cycloadditions: 
A Theoretical Tool to Predict Reaction Kinetics
This Chapter is published as supporting information to:
J. Garcia-Hartjes, J. Dommerholt, T. Wennekes, F. L. Van Delft, H. Zuilhof, Eur. J. 
Org. Chem. 2013, 3712-3720. DOI: 10.1002/ejoc.201201627
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II.1 General Methods
Reagents. Unless otherwise stated, reactions were carried out in a small 
glass tube at room temperature, no special conditions/atmosphere were 
needed. Chemicals were purchased from Sigma-Aldrich and used without 
further purification. Solvents CH2Cl2, acetonitrile, THF, Et2O and toluene were 
obtained dry from a MBRAUN SPS-800 solvent purification system. Analytical 
thin layer chromatography (TLC) was performed on silica gel-coated plates 
(Merck 60 F254) with the indicated solvent mixture; visualization was done 
using ultraviolet (UV) irradiation (λ = 260 nm) and/or staining with KMnO4. 
Analytical Methods. New compounds were characterized by 1H NMR and 13C 
NMR (where applicable), IR spectroscopy and HRMS. 1H NMR spectra were 
recorded on a Varian Inova 400 (400 MHz), 13C NMR spectra were recorded on a 
Bruker DMX300 (75 MHz) spectrometer. Infrared spectra were recorded on an ATI 
Mattson Genesis Series FTIR spectrometer. High resolution mass analyses were 
performed using Electrospray Ionization on a JEOL AccuTOF. All 1H NMR spectra 
are reported in parts per million (ppm) downfield of TMS and were measured 
relative to the signals for CHCl3 (7.27 ppm). All 
13C NMR spectra were reported in 
ppm relative to residual CHCl3 (77.2 ppm) and were obtained with 
1H decoupling. 
The pure compounds are estimated to be > 95% pure as determined by 1H NMR.
II.2 Synthesis
Synthesis of allyl azide. To a solution of NaN3 (11 g, 173 mmol) in DMSO (150 ml) 
was added dropwise allyl bromide (7.5 ml, 87 mmol). After stirring for 16 h at room 
temperature the mixture was poured in an ice/water mixture (150 ml). The layers 
were separated; allyl azide was washed with water (2 × 10 mL), and dried (Na2SO4).* 
* There are some dangers that are associated with low molecular weight azides, as well with the 
synthesis of some organic azides. These include explosion hazard. This is particularly true in 
instances where elevated temperatures are required for azide formation.
Synthesis of cyclooctyne. To a solution of cyclooctene (33 ml, 0.25 
mol) in CH2Cl2 (100 ml) was added dropwise at −40 °C a solution of Br2 
(13 mL, 0.25 mol) in CH2Cl2 (12 ml) until the yellow color persisted. The 
reaction mixture was quenched with a 10% Na2S2O3 solution (50 ml), and 
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extracted with CH2Cl2 (2 × 100 ml). The organic layer was dried (Na2SO4) and 
concentrated in vacuo to afford trans-1,2-dibromocyclooctane (66 g, 97%). 
Without further purification the dibromide (66 g, 244 mmol) was dissolved in 
THF (100 ml). A solution of KOtBu (41 g, 370 mmol) in THF (40 mL) was added 
dropwise at 0 °C. The reaction mixture was quenched with a saturated NH4Cl 
solution (100 ml), the THF was evaporated and the remaining water layer was 
extracted with CH2Cl2 (2 × 100 ml). The organic layer was dried (Na2SO4) and 
concentrated in vacuo. The residue was purified by distillation (bp: 73 - 80 
°C/ 10 mbar) yielding 1-bromocyclooctene (37 g, 80%) as a colorless liquid.
To a solution of iPr2NH (11.5 mL, 81 mmol) in THF (30 ml) was added dropwise 
at −25 °C n-BuLi (51 ml, 81 mmol, 1.6 M in hexane). 1-Bromocyclooctene (15 g, 
81 mmol) was added at once to this solution. The temperature of the reaction 
mixture was allowed to rise gradually over a period of 45 min to 15 °C and was 
kept at this level for another 90 min. The mixture was then quenched with a 3 
M HCl-solution (30 ml) and extracted with pentane (5 × 20 ml). The combined 
extracts were washed with water (3 × 20 ml) to remove the THF, dried (Na2SO4) 
and concentrated in vacuo carefully. The residue was purified by distillation 
(bp: 55 - 63 °C/ 30 mbar) giving cyclooctyne (4.8 g, 54%) as a clear liquid.
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II.3 Determination of rate constants of cyclooctyne with 
benzyl azide 
Scheme S1. 1H NMR rate constant determination with benzyl azide.
1H NMR monitoring of cycloaddition of OCT with BnN3 was performed by rapid 
mixing (t = 0) of stock solutions of A and B (0.3 mL each) in an NMR tube 
and immediate insertion into a 400 MHz NMR spectrometer. NMR spectra 
were measured at preset intervals. The experiment was performed in duplo. 
Stock solution A: 1 was dissolved in a mixture of CD3CN and D2O (ratio 3 : 1, 
10 ml) to give a 36 mM solution. Stock solution B: Benzyl azide was dissolved 
in a mixture of CD3CN and D2O (ratio 3 : 1, 10 mL) to give a 54 mM solution. 
Kinetics of the reaction of 1 with benzyl azide was determined by measuring the 
decrease of the integral of the signal caused by benzyl azide methylene protons, 
with the integral of the CD3CN solvent-peak as internal standard. Due to the fact that 
cycloaddition had already proceeded significantly by the time of the first measurement, 
a starting value for the integral of benzyl azide methylene signals was estimated 
based on the average of the summation of signals of benzyl azide and triazole product.
From the conversion plots thus obtained, the second order rate plots were 
calculated according to equation:
   eq. s1
with k = 2nd order rate constant (M-1·s-1), t = reaction time (s), [A]0 = the initial 
concentration of substrate A (mmol/ml), [B]0 = the initial concentration of substrate 
B (mmol/ml) and [P] = the concentration of product (mmol/ml). Calculated rate 
constants were averaged, giving a k = 0.0058 M-1s-1 for cycloaddition of benzyl 
azide and 1.
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Figure S1. Rate plots used for the determination of rate constants of cyclooctyne with benzyl azide.
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II.4 Competition experiments of 1 and 3 with benzyl azide 
and allyl azide
Scheme S2. Competition experiments of OCT with benzyl azide and allyl azide.
Cyclooctyne (OCT, compound 1): Allyl azide (23 μL, 0.25 mmol, 5.0 equiv.) and 
benzyl azide (33 μL, 0.25 mmol, 5.0 equiv.) were dissolved in CD3CN/ D2O (1 : 
1, 10 ml). The 1 : 1 ratio of allyl azide and benzyl azide was corroborated by 1H 
NMR, before addition of cyclooctyne (6.2 μL, 0.05 mmol, 1.0 equiv.). The mixture 
was stirred at room temperature for 16 h, then solvents and excess allyl azide and 
benzyl azide were removed in vacuo. The residue was redissolved in CDCl3 and 
1H 
NMR analysis was used to determine the ratio of allyl- and benzyltriazole adduct.
Bicyclononyne (BCN, compound 3): Allyl azide (23 μL, 0.25 mmol, 5.0 equiv.) and 
benzyl azide (33 μL, 0.25 mmol, 5.0 equiv.) were dissolved in CD3CN/ D2O (1 : 1, 
10 ml). The 1:1 ratio between allyl azide and benzyl azide was corroborated by 
1H NMR, before addition of endo-BCN (7.5 mg, 50 μmol, 1 equiv.). The mixture 
was stirred at room temperature for 16 h, then solvents and excess allyl azide 
and benzyl azide were removed in vacuo. The residue was redissolved in CDCl3 
and 1H NMR analysis was used to determine the ratio of allyl- and benzyltriazole 
adduct.
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Figure S2. 1H NMR spectrum of BnN3 and allylN3 in CD3CN/D2O before addition of 1.
Figure S3. 1H NMR spectrum of mixture of triazole products from OCT in CDCl3.
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Figure S4. 1H NMR spectrum of BnN3 and allylN3 in CD3CN/D2O before addition of compound 3.
Figure S5. 1H NMR spectrum of mixture of triazole products from BCN in CDCl3.
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II.5 Activation energies vs. calculable parameters
Figure S6. MP2 activation energy (kcal/mol) of the TS in the gas phase of cyclooctynes 1 - 6 with allyl azide 
versus the logarithm of the experimental rate.
Figure S7. Transition state conformations of (left) cis-cyclobutyl-substituted cyclooctyne, compound 9 and 
(right) trans-cyclobutyl-substituted compound 10 with allyl azide.
9; Chair-like 
Conformation
10; “Flat” Structure
2.13
2.18
2.07
2.11
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Figure S8. SCS-MP2 activation energy (kcal/mol) of the TS in MeOH of cycclooctynes 1 - 6 with allylazide 
versus the logarithm of the experimental rate.
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Figure S9. SCS-MP2 activation energies (kcal/mol) versus SCS-MP2 cyclooctyne distortion energies (kcal/mol).
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Figure S10. SCS-MP2 activation energies (kcal/mol) versus HOMO energy (eV) values of the distorted 
cyclooctynes 1 – 10 acquired from MP2 calculations.
Figure S11. SCS-MP2 activation energy (kcal/mol) versus HOMO energy  (eV) values of allyl azide acquired 
from MP2 calculations.
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Ea(MP2) vs LUMO (B3LYP)
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Figure S12. SCS-MP2 activation energy (kcal/mol) versus LUMO energies (eV) acquired from B3LYP calculations.
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Figure S13. MP2 activation energies (kcal/mol) versus LUMO energies (eV) acquired from M06-2X calculations.
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Figure S14. SCS-MP2 activation energy (kcal/mol) versus EHOMO(azide)- ELUMO(alkyne) (eV).Table S1. SCS-MP2 MO 
energies of allyl azide (A) and benzyl azide (B) in the TS (with compounds 1 - 10).
Table S1. SCS-MP2 MO energies of allyl azide (A) and benzyl azide (B) in the TS (with compounds 1 - 10).
Azide (cyclooctyne) HOMO-1 (eV) HOMO (eV) LUMO (eV) LUMO+1 (eV)
A (+1) -10.40 -9.78 1.03 1.85
B (+1) -9.34 -9.01 1.05 1.64
A (+2) -10.55 -9.74 1.04 1.86
B (+2) -9.35 -9.02 1.05 1.64
A (+3) -10.57 -9.82 1.35 1.87
B (+3) -9.36 -9.06 1.36 1.64
A (+4) -10.53 -9.69 0.97 1.86
B (+4) -9.26 -8.99 0.92 1.68
A (+5) -10.55 -9.74 1.14 1.86
A (+6) -10.29 -9.92 1.06 1.88
A (+7) -10.56 -9.78 1.21 1.87
B (+7) -9.35 -9.04 1.22 1.64
A (+8) -10.54 -9.74 1.00 1.86
A (+9) -10.56 -9.79 1.24 1.87
A (+10) -10.55 -9.74 1.14 1.86
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Table S2. Calculated LUMO energies for the investigated cyclooctynes (in the state as fully optimized reagents) 
and corresponding activation energies for the SPAAC reaction with allyl amine.
Compound # Abbreviation LUMO (kcal/mol) Ea (kcal/mol)
1 OCT 43.5 10.49
2 DIFO 36.2 6.65
3 BCN 38.2 6.54
4 DIBO 36.1 6.26
5 DIBAC 35.2 3.55
6 BARAC 34.6 2.05
7 diene 38.2 5.73
8 5,6-ene 42.9 8.56
9 trans c-butyl 42.1 9.63
10 cis c-butyl 39.6 7.47
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II.7 Step-by-step manual for minimum energy-calculations 
on MP2 level of theory
1. Start by drawing the envisaged cycloalkyne in ChemDraw and copy (Figure 
S15). 
2. Paste in ChemBio3D.
3. Select “Calculations → GAMESS Interface → Minimize Energy/Geometry” 
(Figure S16).
4. Enter the parameters for the MP2 calculations and press “Run” (Figure S17).
   
   a. Job type:  Minimize (Energy/Geometry)
   b. Method:  MP2
   c. Basis Set:  6-311G
   d. Wave function: R-closed shell
   e. Polarization: 2d,2p
   f. Diffuse:  s
   g. Exponent:  POPN311
   h. Opt. Algorithm:  QA
   i. Move Which: All Atoms
   j. Coord. System:  Cartesian
   k. Spin Multiplicity:  1
   l. Net Charge:  0 (Use Formal Charge)
5. The output file will appear in the “GAMESS Interface” folder, which for 
windows OS is in the “my documents” folder by default.
6. Open the output file “name.out” in a text editor.
7. Search for “Alpha occ. Eigenvalues”, the highest value is the HF LUMO 
value in Hartree.
8. Multiply this value with 627.51, the product is the energy of this orbital in 
kcal/mol.
9. Repeat this procedure for cyclooctyne. [By making one’s own reference to 
cyclooctyne, other, slightly smaller basis sets, can also be used.] 
10. Compare the obtained energy difference of the cycloalkyne of interest to 
cyclooctyne with that calculated for compounds in Table S2.   
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Figure S15: Draw the cyclooctyne in ChemDraw.
Figure S16. Select the GAMESS “Minimize (Energy/Geometry)” option. 
Figure S17. Enter the parameters.
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Dankwoord
Om maar even met een cliché te beginnen: een proefschrift schrijf je niet alleen. 
Hier wil ik dan ook van de gelegenheid gebruik maken om een aantal mensen 
te bedanken die op de één of andere manier bijgedragen hebben aan het 
ontstaan van dit proefschrift en aan mijn persoonlijke ontwikkeling gedurende 
mijn promotie. 
Als traditie begin ik natuurlijk met mijn promotoren, Professor Han Zuilhof, 
promotor van dit proefschrift en ook tijdelijk mijn dagelijkse begeleider: Van 
een promovendus wordt er verwacht dat hij/zij tijdens het promotietraject 
een persoonlijke ontwikkeling ondergaat tot zelfstandig professioneel 
wetenschapper. Ik heb mijn promotie echter ervaren als een uitdaging die zich 
ver buiten het wetenschappelijke uitstrekte, ik heb in de afgelopen paar jaar dan 
ook veel van je geleerd. Daar naast hebben we op wetenschappelijk vlak ook 
leuke resultaten gehaald en wil ik in het bijzonder mijn waardering uiten voor 
de nauwe samenwerking t.b.v. de SPAAC-studie. Ik wil je bedanken voor de 
mogelijkheid die je me hebt geboden om bij ORC te promoveren. 
dr. Tom Wennekes, Tom, co-promotor van dit proefschrift, als vierde dagelijkse 
begeleider heb je nog zeker je stempel op het project weten te drukken. Jouw 
kennis van chemie, in het bijzonder de suikerchemie, was precies wat dit project 
nog nodig had. Ik loof je voor je geduld en de enorme toewijding waarmee 
je mij het laatste anderhalve jaar en voornamelijk met de laatste loodjes hebt 
geholpen. Jij bezit tevens de capaciteit om leven in de (ORC)brouwerij te 
brengen, bedankt voor de gezellige momenten die hiervan het gevolg waren!
dr. Carel Weijers, Carel, na Richard en Han heb jij de supervisie van mijn 
projecten op je genomen, helaas hebben we niet de kans gekregen deze samen 
af te maken. Je achtergrond in de biotechnologie hebben mij een hele andere 
kant van de wetenschap laten zien en ik heb hierdoor veel van je kunnen leren. Ik 
bedank je voor de prettige samenwerking in het bijzonder voor de hoofdstukken 
3 en 6 en het werk dat je hierin hebt gestoken.
dr. Richard Jagt, Richard, ongeveer zes maanden nadat ik aan dit traject ben 
begonnen heb je de vakgroep verlaten. Voor je rol als mijn eerste begeleider/ 
co-promoter wil ik je toch zeer bedanken voor de ondersteuning die je me hebt 
gegeven bij het opstarten van het project en voor het mij wegwijs maken binnen 
de universiteit.
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Professor Hans Tramper, uw ervaring, wijsheid en geduld hebben mij enorm 
geholpen bij het zoeken naar oplossingen voor complexe situaties.
dr. Aart van Amerongen en dr. Truus Posthuma-Trumpie, ik heb aan jullie veel 
kennis te danken met betrekking tot het plannen, opzetten en uitvoeren van 
ELISA experimenten. Bedankt voor de prettige discussies en de samenwerking. 
In het bijzonder wil ik Truus bedanken omdat je mij wegwijs gemaakt hebt in 
het lab bij FBR, mij de details voor het vakkundig uitvoeren van biologische 
experimenten hebt bijgebracht en je met een kritische blik naar de experimenten 
van hoofdstukken 2 en 3 hebt gekeken.
Anne Tio-Gillen, dr. Astrid Heikema, dr. Bart Jacobs: Ik had graag wat meer 
met jullie samengewerkt. Ik heb jullie namelijk leren kennen als zeer prettige 
persoonlijkheden en heb het Guillain-Barré-project, dat is beschreven in 
Hoofdstuk 6, als enorm interessant ervaren. In het bijzonder wil ik Anne bedanken 
voor het uitvoeren van de sera-experimenten die zijn beschreven in Hoofdstuk 6 
maar voornamelijk voor de professionele maar zeer aangename manier waarop 
je me wegwijs hebt gemaakt met de gestandaardiseerde methoden van het 
uitvoeren van ELISA experimenten.
Prof. Jay Siegel and Dr Martin Mattarella, thank you both for the collaboration. 
Together with your expertise of your corannulenes we achieved nice scientific 
results that led to the publication described in Chapter 2. Especially, Martin, 
thanks for the pleasant cooperation and leasure time after work.
Prof. Alessandro Casnati and Dr Francesco Sansone, thank you for sharing your 
(expertise on) calixarenes to achieve the nice scientific results that led to the 
publication described in Chapter 3 and allowing me to work in your department 
on these compounds.
dr. Floris van Delft en Jan Dommerholt, bedankt voor de prettige samenwerking 
t.b.v. de SPAAC-studie, die is beschreven in Hoofdstuk 4.
To all the Unihealth project partners I would like to extend many thanks for 
the inspiring discussions and collaboration that kept us moving forward in this 
interesting project. 
dr. Teris van Beek, Teris, bedankt voor je gezelschap tijdens de ritjes naar 
Duisburg, Nijmegen en Rotterdam, je advies en ondersteuning in het Unihealth 
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Overview of training activities
Discipline specific activities
Courses
Advanced Organic Chemistry I, Wageningen (2009-2010)
Advanced Organic Chemistry II, Wageningen (2010-2012) 
VLAG Summer Course Glycoscience 11th ed., Wageningen (2010)
COST Trainingschool Supramolecular Chemistry in Water, Riccione (2012)
Meetings
NWO Annual Conference, Lunteren (2009-2013)
KNCV eendaagse sectiebijeenkomst, Wageningen (2012)
KNCV Wageningen Symposium on Organic Chemistry, Wageningen (2010)
KNCV Wageningen Symposium on Organic Chemistry, Wageningen (2012)
General courses
PhD-week, Baarlo (2010)
Information literacy and endnote, Wageningen (2010)
Advanced course guide to scientific artwork, Wageningen (2013)
Adobe Indesign, Wageningen (2013)
Optionals
Preparation PhD research proposal, Wageningen (2010)
Group meetings, laboratory of organic chemistry, Wageningen (2009-2014)
Colloquia, laboratory of organic chemistry, Wageningen (2009-2014)
PhD-trip, UK  (2011)
Organization PhD-trip, UK (2011)
PhD representative “group of change”, Wageningen (2011-2013)
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